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 Abstract 
Assessment of disease status in fish is used in the UK Clean Seas Environmental Monitoring 
Programme (CSEMP) as an indicator of the biological effects of contaminants in the marine 
environment. At some UK offshore sites the prevalence of liver tumours in Limanda limanda 
(dab) exceeds 20%. However, the molecular mechanisms of tumour formation and the 
causative agents are not known. The contribution of epigenetic mechanisms such as DNA 
methylation, although well-established in human tumourigenesis, is under-studied in tumours 
of aquatic species used in environmental monitoring or in modeling of human disease. In this 
thesis gene-specific (e.g. bisulfite sequencing PCR, real time-PCR) and high throughput 
techniques (e.g. methylated-DNA immunoprecipitation combined with microarrays or high 
throughput DNA sequencing, triple stage quadrupole tandem mass spectrometry) were used to 
investigate alterations in DNA methylation profiles of tumours of two fish species: the model 
species zebrafish (Danio rerio) with chemically induced liver tumours and the un-sequenced 
marine flatfish dab that develop liver tumours in the wild. The data presented provided a 
comprehensive characterisation of the DNA methylation pattern in zebrafish liver and the first 
evidence of alterations in the DNA methylation profiles of key genes in tumourigenesis 
pathways in any aquatic species. This suggested the possibility of the involvement of DNA 
methylation alterations in dab tumourigenesis. It was then demonstrated a statistically 
significant lower level (1.8 fold) of global DNA methylation in hepatocellular adenoma 
(HCA) and non-cancerous surrounding liver tissue (ST) compared to liver of non-cancer 
bearing dab. Components of the one-carbon cycle, the metabolic pathway involved in 
regulation of DNA methylation, were altered in both HCA and ST compared to healthy dab 
liver samples. In particular, S-adenosylhomocysteine levels, an inhibitor of DNA methylation 
reactions, were statistically significantly increased in HCA and ST compared to healthy dab 
liver samples. Based on the identified changes in the metabolites, methylome and 
transcriptome of ST, our study supports the epigenetic progenitor model of cancer. 
Furthermore, the evidence presented in these chapters suggests that chronic exposure to a 
mixture of pollutants contribute to global DNA hypomethylation followed by further 
epigenetic and genomic changes, especially in the non-genomic and genomic estrogenic 
pathways, leading to the development of tumours in dab. These findings suggest a link 
between the environment, epigenome and cancer in fish tumours in the wild.  
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Chapter 1 
 
General introduction 
 
 
 
The information presented in this chapter contributed towards a review 
article. 
Mirbahai et al., (2011) Epigenetic memory: Its significance in regulation of 
responses to toxicants in aquatic species and potential as a marker of life-time 
exposures, submitted to Environmental Science & Technology. 
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1.1. General introduction 
The involvement of epigenetic mechanisms such as DNA methylation, although well 
established in human tumourigenesis, is relatively under-studied in tumours of aquatic species 
used in environmental monitoring or in the modeling of human disease.  
Assessment of the disease status of the flatfish dab (Limanda limanda) is used in the UK 
Clean Seas Environmental Monitoring Programme (CSEMP), as an indicator of biological 
effects of contaminants in the marine environment. At some UK offshore sites the prevalence 
of liver tumours in dab exceeds 20% of sampled individuals (NMMP, second report, 2004; 
Stentiford et al., 2009; Small et al., 2010; Southam et al., 2008; Lyons et al., 2006); however, 
little research has been conducted to investigate the underlying mechanisms and, in particular, 
possible involvement of epigenetic factors. In addition to this, there is a great need for 
characterisation of DNA methylation changes in emerging human disease models, such as 
zebrafish (Danio rerio). Recent studies comparing hepatic gene expression in human and 
zebrafish tumours demonstrated conservation of gene expression profiles between these two 
species at different stages of tumour aggressiveness (Lam et al., 2006). However, the 
contribution of altered DNA methylation to such changes in zebrafish is unknown.  
In this thesis, state of the art techniques were used to detect differences in the DNA 
methylation profiles of fish liver tumours compared to healthy fish livers. These approaches 
also helped to overcome the technical challenges encountered when working with un-
sequenced species. Combinations of ‘omic’ and gene/metabolite specific techniques at various 
levels of methylome, transcriptome and metabolome have been applied to determine the role 
of DNA methylation as an epigenetic factor in formation of liver tumours in dab and in 
chemically induced hepatocellular carcinoma in zebrafish. The ultimate aim of this project 
was to achieve a better understanding of the molecular mechanisms underlying environmental 
tumourigenesis.  
 
1.2. Epigenetics  
Epigenetics (above genetics, outside conventional genetics) is defined as meiotically and 
mitotically heritable changes in gene expression that are not due to alterations in primary 
DNA sequence (Egger et al., 2004; Jaenisch and Bird, 2003). Such modifications include 
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DNA methylation, post-transcriptional chemical modifications of the N-tail of histones, 
binding of non-histone chromatin proteins to DNA or histone modifications, small interfering 
RNA, nucleosome positioning and higher order organisation (Egger et al., 2004; Turner, 
2007; Chan et al., 2008; Cui et al., 2010; Probst et al., 2009). Moreover, these modifications 
are not isolated events and are closely inter-linked by influencing chromatin structure at 
various levels and by further interactions with the genome (Figure 1.1) (Probst et al., 2009).  
 
Figure 1.1. The three key elements of epigenetic mechanisms (DNA methylation, post-
transcriptional histone modifications and some forms of RNA such as small interfering RNA 
and microRNA) complement, stabilise and interact with each other to regulate transcription of 
genes. Disruption of any of the elements of this interacting system may lead to inappropriate 
regulation of gene expression and development of a range of disorders (Egger et al., 2004). 
 
Normal cells display finely tuned epigenomic equilibrium (Esteller and Herman, 2002). 
Disruption of this equilibrium leads to inappropriate regulation of transcription, hence giving 
rise to diseases and disruption of differentiation and developmental processes (Egger et al., 
2004; Probst et al., 2009). Methylation of DNA at CpG dinucleotides is the most studied 
epigenetic modification (Esteller and Herman, 2002) and is the principal focus of this thesis, 
especially in regards to tumourigenesis in fish.  
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1.3. DNA methylation  
DNA methylation is the most studied epigenetic mechanism associated with regulation of 
gene expression (Esteller, 2007; Pogribny, 2010). To methylate DNA, a methyl group is 
transferred from the universal methyl donor, S-adenosylmethionine (SAM), to the 5
th
 carbon 
position of a cytosine base. This reaction is catalysed by a group of enzymes known as DNA 
methyltransferases (DNMTs) (Figure 1.2). In eukaryotes this modification is predominantly 
observed in cytosine bases located at CpG dinucleotide sequences (Pogribny, 2010; Gronbaek 
et al., 2007). In mammals CpG dinucleotides are not randomly distributed throughout the 
genome. In fact, higher frequency of CpG sites are found within the regions referred to as 
CpG islands (CGI). These sites have distinctive characteristics, including higher frequencies 
of CpG dinucleotides relative to the bulk genome, G+C percentages of greater than 50% and 
average lengths greater than 200bp (Gardiner- Garden and Frommer, 1987). Furthermore, 
CpG dinucleotide sites located in CGIs are mostly un-methylated and are detected within the 
promoter regions and first exons of 40_50% of mammalian genes. The remaining CpG sites 
located at the non-CGIs are mostly methylated in mammals. This means that approximately 
50_70% of all CpG dinucleotides in the mammalian genome are methylated (Karp, 2000; 
Jones and Takai, 2001; Taylor et al., 2007; Suzuki and Bird, 2008; Fang et al., 2008; 
Illingworth and Bird, 2009; Pogribny, 2010). 
 
 
 
Figure 1.2. DNA methylation. Transfer of a methyl group from S-adenosylmethionine (SAM) 
via DNA methyltransferases to cytosine results in formation of 5-methylcytosine and S-
adenosylhomocysteine (SAH). 
 
 
Cytosine 5-methylcytosine 
DNMTs 
SAM SAH 
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1.3.1. DNA methyltransferases; de novo and maintenance DNA methylation 
In mammals, four different DNA methyltransferase (DNMT) members have been identified 
corresponding to two distinct families. The DNMT3 family establishes the DNA methylation 
pattern in previously un-methylated DNA of stem cells and tumour cells. This is known as de 
novo methylation. DNMT1 is responsible for maintenance of the established DNA 
methylation pattern during cell replication in differentiated cells (Figure 1.3). DNMT1, cloned 
by Bestor et al., (1988), utilises the hemi-methylated DNA strand as a template for 
reproducing the exact methylation pattern in the newly synthesised DNA strand, thereby 
ensuring conservation and inheritance of the DNA methylation pattern in the daughter cells 
(Momparler and Bovenzi, 2000; Gronbaek et al., 2007; Lopez et al., 2009; Cheng and 
Blumenthal, 2008). The highest concentrations of DNMT1 are reported during S phase. 
During this stage, DNMT1 interacts with proliferating cell nuclear antigen (PCNA) and 
therefore, its localisation at the replication fork throughout the replication of the DNA is 
ensured (Jones and Liang, 2009).  
 
 
 
Figure 1.3. De novo and maintenance DNA methylation. Methylation of the un-methylated 
DNA in embryonic stem cells and cancer cells, known as de novo methylation, is mainly 
conducted by DNMT3a and 3b. Following each round of replication the maintenance 
methyltransferase, DNMT1, copies the DNA methylation pattern from the parental strand 
onto the newly synthesised strand. M: 5-methylcytosine. Adapted from Gronbaek et al., 
(2007). 
 
Detection of cycles of DNA methylation and de-methylation with corresponding cycles of 
transcription in human cells provided the evidence that DNA methylation may be more plastic 
than previously believed (Kangaspeska et al., 2008). Indeed, at early stages of embryogenesis 
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and gametogenesis the DNA methylation pattern is largely erased, reaching its lowest level 
around implantation time of embryogenesis. Although the precise mechanisms of DNA de-
methylation are not known, it has been suggested that DNA can either passively or actively 
undergo de-methylation (Herceg and Vaissiere, 2011). During passive de-methylation, 5-
methylcytosine is removed in a replication-dependent manner by inhibition of DNMTs while 
active de-methylation depends upon enzymatic removal of 5-methylcytosine. During active 
de-methylation 5-methylcytosine is converted to thymidine. This can occur both 
spontaneously or it can be catalysed by activation-induced cytosine deaminase (AID) protein. 
The generated mismatched T:G can be recognised by the repair machinery and converted 
back to cytosine (Herceg and Vaissiere, 2011). Recently, it has been discovered that 
methylcytosine dioxygenase ten-eleven translocation 1 (TET1) is involved in regulation of 
DNA methylation. TET1 protein catalyses the conversion of 5-methylcytosine to 5-
hydroxymethyl cytosine (5-hmC). 5-hmC sites are poorly recognised by DNMTs. This results 
in a passive replication-dependent loss of DNA methylation. Alternatively, 5-hmC can be 
recognised by the repair machinery and converted to cytosine (Tahiliani et al., 2009; Williams 
et al., 2011; Herceg and Vaissiere, 2011).  
Shortly after, the erased DNA methylation pattern at implantation stage is re-established via 
de novo methyltransferases (Figure 1.4). De novo methylation is mediated by the two active 
members of DNMT3 family namely DNMT3a and DNMT3b, cloned by Okano et al., (1998), 
and one regulatory factor, DNMT3-like protein (DNMT3L). The latter is only identified in 
germ cells and lacks the conserved catalytic domain present in C-terminal of DNMT3a and 
DNMT3b, hence lacks any methyltransferase activity. Nevertheless, it has been shown that 
DNMT3L has a role as a de novo regulatory factor and DNMT3 stabiliser during 
establishment of DNA methylation patterns of sub-set of genes in both male and female germ 
cells (Cheng and Blumenthal, 2008; Goll and Bestor, 2005; Laird and Jaenisch, 1994). 
Although all members of DNMT3 family are mainly associated with de novo methylation, 
they have the same affinity towards both hemi- and un-methylated DNA. Therefore, in 
addition to their role in de novo methylation, they also assist in maintenance of the DNA 
methylation pattern (Gronbaek et al., 2007).  
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Figure 1.4. The two DNA methylation reprogramming events during early embryogenesis and 
gonadal sex determination. During gonadal sex determination, DNA methylation patterns of 
primordial germ cells are erased, then DNA methylation patterns are re-established in the 
developing male (purple line) and female (pink line) germ lines based on paternal and 
maternal-origin of genes (i.e. imprinting), respectively (imprinting is discussed in section 
1.3.4.1). The re-methylation in female germ cells is established at a later stage than in male 
germ cells. Following fertilisation, the paternal genome (lighter purple line) and maternal 
genome (lighter pink line) undergo a second wave of genome-wide de-methylation, reaching 
lowest levels of methylation during implantation. During this round of de-methylation, 
parenteral imprinting markers are protected against de-methylation. Methylation levels are re-
established in blastocysts (Jirtle and Skinner, 2007). 
 
However, it is not clear how certain CGI sites are protected against methylation while other 
sites are methylated during de novo methylation. Two possible models have been proposed:  
1. Non-selective model: In this model it is proposed that DNA is methylated at all CpG 
dinucleotides that are not protected against DNA methylation. CpG islands contain a binding 
site for transcription factor specificity protein 1 (Sp1). Removal of the Sp1 binding site results 
in methylation of CGIs. Therefore, it is possible that Sp1 binding to CGIs provides protection 
against DNA methylation (Jones and Takai, 2001). 
Male 
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Primordial germ cells 
2N 
2N 
2N 
2N 
2N 
2N 
1N 
1N 
2N 
Gametogenesis 
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F
1
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2. Targeted model: This model is based upon the realisation of the complexity of the DNA 
methylation procedure. For DNA methylation to occur interaction of several factors, such as 
chromatin remodelling complexes, histone modifying enzymes and DNA methyltransferases 
are required. Thus absence of any of these components from a CpG site prevents the 
methylation procedure (Jones and Takai, 2001). For example, the absence of chromatin 
remodelling proteins at active regions of DNA prevents structural alterations of chromatin 
which otherwise would have allowed DNMTs to access and methylate DNA (chromatin 
remodelling is discussed in section 1.3.2) (Doerfler, 1983). Lsh (lymphoid specific helicase) 
is a member of the SNF2/helicase family with chromatin-remodelling properties. Interaction 
between this protein and DNMT3a, DNMT3b, heterochromatin protein 1 (HP1) and other 
unknown proteins leads to formation of a remodelling complex. This complex initiates de 
novo DNA methylation and formation of heterochromatin at these regions (Yan et al., 2003; 
Zhu et al., 2006). Disruption of Lsh function during embryogenesis has been linked to 
hypomethylation, alteration in histone H3 methylation and increase in histone H3 and H4 
acetylation. Lsh only contributes to regulation of de novo DNA methylation and it appears not 
to be involved in DNMT1 activity during maintenance methylation (Zhu et al., 2006). 
In addition, a third family of methyltransferases, DNMT2, with high sequence and structural 
homology to the previously described DNMTs has been identified. Due to conservation of the 
sequence of the catalytic motif in DNMT2, this protein was originally classified as DNA 
methyltransferase. However, rather than participating in epigenetic regulation of transcription 
by promoting hypermethylation of DNA sequences, DNMT2 mediates the methylation of  the 
cytosine-38 residue in the anticodon loop of aspartic acid transfer RNA (tRNA). Hence to 
reflect its biological function the name of this protein was changed to tRNA aspartic acid 
methyltransferase 1 (TRDMT1). Although the molecular mechanisms and the biological 
significance of methylation of tRNA by DNMT2 are not entirely established, several studies 
in zebrafish (Danio rerio), Drosophila and mouse (Mus musculus) embryonic fibroblast cells 
have predicted a critical role for DNMT2 throughout the lifespan of the tested species. Indeed, 
morpholino knockdown of this gene in zebrafish results in lethal defects (Cheng and 
Blumenthal, 2008; Goll and Bestor, 2005; Bourchis et al., 2001; Schaefer et al., 2010). In 
addition, recently Schaefer et al., (2010) have identified two additional substrates of DNMT2: 
tRNA
gly-GCC
 and tRNA
val-AAC
. They are both methylated at C38 residue located in the 
anticodon loop. DNMT2-mediated methylation protects the anticodon regions of tRNAs 
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against endonucleolytic cleavage induced under thermal and oxidative stress conditions. This 
protective role of methylation is mediated by methylation-induced structural alterations of the 
tRNA-substrates and by restricting access of endonuclease to the anti-codon regions. 
DNA methylation, although not as well-studied as in humans, occurs in other non-mammalian 
species as demonstrated in zebrafish. Both DNA methyltransferase genes and DNA 
methylation reprogramming that occur during embryogenesis in humans have been detected 
in adult and zebrafish embryos, respectively (Mhanni and McGowan, 2004; MacKay et al., 
2007; Martin et al., 1999). In total eight different DNA methyltransferases have been 
identified in zebrafish (dnmt1-dnmt8). Similar to human DNMT3, two splice variants for 
dnmt5 and 6 have been cloned in zebrafish. However, only the biological functions of dnmt1 
and dnmt7 are known. Dnmt1 protein is found abundantly from the time of fertilisation until 6 
hours post-fertilisation (hpf). As transcription in the embryo starts from 3 hpf (1000 cell), this 
suggests that the origin of the Dnmt1 is maternal. The embryonic expression of dnmt1 gene 
increases in the brain and neural tube at 16 hpf, and reaches its highest levels at 24 hpf in the 
eyes and central nervous system. It is thought that this particular enzyme may be responsible 
for maintenance of DNA methylation. In contrast, Dnmt7 activity has been associated with de 
novo methylation of specific genes, such as the no tail (ntl) gene. As Dnmt7 is detected as 
early as the 4-cell stage, this suggests an initial maternal origin for Dnmt7 (Shimoda, 2007).    
Initially genome-wide embryonic DNA methylation reprogramming was un-detected during 
embryogenesis in zebrafish and thereby considered to be absent in zebrafish (Macleod et al., 
1999). This raised the possibility of overestimating the evolutionary role of DNA methylation 
in differentiation and reprogramming. However recent studies revealed that the zebrafish, 
similar to humans, undergoes extensive DNA hypomethylation during early stages of 
development, reaching its lowest levels at cleavage stage (1.5 hpf), early blastula stage (2 hpf) 
and mid-blastula (3 hpf) stage with DNA re-methylation during late blastula stage (4 hpf). As 
this process occurs at very early stages of development of the embryo and over a short time-
period (4 h), it had previously gone undetected (Mhanni and McGowan, 2004; Mackay et al., 
2007; Martin et al., 1999). Therefore DNA methylation is not restricted to mammals. Indeed 
although limited, several studies have been published on the effect of common environmental 
contaminants on DNA methylation levels of aquatic species, either at gene level or at global 
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level. As environmental contaminants are the key determinants of the health of aquatic 
species, these studies and their main outcomes are summarised in Table 1.1. 
In addition to zebrafish, DNA methylation has been detected throughout the evolutionary tree 
in arthropods, non-arthropod invertebrates and vertebrates (Bird, 1980). Furthermore, DNA 
methyltransferases are extremely well conserved between different species; thus, implying a 
significant role for DNA methylation throughout evolution (Lee et al., 2010).  
However, it is important to mention that DNA methylation patterns and levels vary 
throughout the animal kingdom. For instance, DNA methyltransferases have not been 
detected in the nematode worm Caenorhabditis elegans. As a result its genome lacks any 
detectable methylated cytosines. The differences in the DNA methylation patterns within the 
animal kingdom suggest the potential for different functions for DNA methylation systems in 
some animals (Bird, 2002). Therefore, the role of DNA methylation cannot be generalised for 
all species.  
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Test species Tested compound Targeted organ Investigated 
epigenetic marker  
Main finding Ref 
Adult 
zebrafish  
(Danio rerio) 
EE: 100 ng/L 
Exposure period: 14 
days 
Liver and brain 5' flanking region 
of vtgI 
Hypomethylation of the vtgI gene in the 
liver corresponds with its higher 
expression following treatment with EE. 
Transcriptionally suppressed vtgI in the 
brain was methylated and its methylation 
and transcription did not respond to EE 
treatment. 
Stromqvist et al., 
2010 
Three-spined 
stickleback 
(Gasterosteus 
aculeatus) 
HBCD: 30 and 300 ng/L 
for 30 days, 
E2: 100 ng/L, 
5AdC: 0.5 µg/g body 
weight. 
E2 and 5AdC exposures 
were for 22-23 days 
HBCD: female 
liver,  
E2: Female and 
male liver and 
gonads,  
5Adc: female 
and male gonads 
and liver 
Global DNA 
methylation levels 
Significant hypermethylation of genomic 
DNA in the male gonads following 
treatment with E2 and 5AdC with trends 
of hypermethylation in females. 
Significant global DNA hypomethylation 
of the female liver after treatment with 
5Adc with trends of hypomethylation in 
males. Trends of hypomethylation in the 
female liver following exposure with E2 
with no change detected in males. No 
change was detected in female livers 
following treatment with HBCD. 
Aniagu et al., 
2008 
Goldfish 
(Carassius 
auratus) 
Cu (100 µg/L), Zn (50 
µg/L), Pb (20 µg/L), Cd 
(10 µg/L) and a mixture 
of all four metals. 
Exposure period: 48 h 
Liver Global DNA 
methylation levels 
Significant DNA hypermethylation was 
detected in the liver. This effect was 
more pronounced for Cd and Pb 
compared to Cu and Zn. A concentration-
dependent increase in overall DNA 
methylation levels were detected for the 
mixture. 
Zhou et al., 2001 
Japanese 
medaka  
(Oryzias 
latipes) 
EE: 500 ng/L for 14 days Liver, brain and 
gonads 
Estrogen receptor 
gene and aromatase 
gene 
 
Tissue and gender differences in 
methylation levels before and after 
treatment with EE. However, the CpG 
sites investigated were limited and may 
explain the lack of correlation between 
gene expression and DNA methylation 
Contractor et al., 
2004 
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changes observed following treatment 
with EE. 
Bluegill 
sunfish 
(Lepomis 
macrochirus) 
benzo[α]pyrene: 1  µg/L 
for 40 days 
Liver Global DNA 
methylation levels 
Trends of global hypomethylation from 
day 2 of the exposure. 
Shugart, 1990 
Male  
false kelpfish 
(Sebastiscus 
marmoratus) 
TBT: 1,10 and 100 ng/L, 
TPT: 1, 10 and 100 ng/L, 
mixture of both: 0.5 
ng/L+0.5 ng/L and 5 
ng/L + 5 ng/L, all 
exposures were 
conducted for 48 days 
Liver Global DNA 
methylation levels 
Detection of significant dose-dependent 
DNA hypomethylation after exposure to 
chemicals. 
Wang et al., 
2009 
Water flea 
(Daphnia 
magna) 
Cd (180 µg/L) for 10 
days and 4 days in the 
following generation 
Whole organism Two un-known 
methylated 
fragments 
No change in methylation of the two 
fragments after exposure to Cd. 
Vandegehuchte  
et al., 2009a 
Water flea 
(Daphnia 
magna) 
Zn (388  µg/L), 21 day 
exposures 
Whole organism Global DNA 
methylation levels 
Detection of significant DNA 
hypomethylation in the first generation 
(F1) after the treated group (F0). This 
change did not proceed to the next 
generation (F2) 
Vandegehuchte 
et al., 2009b; 
Vandegehuchte 
et al., 2010a 
Water flea 
(Daphnia 
magna) 
5AC: 2.9 mg/L (F0), 2.3 
mg/L (F1), Genistein: 4.7 
mg/L (F0–F2), 
vinclozolin: 0.54 mg/l 
(F0), 0.45 mg/l (F1), 0.18 
mg/l (F2). 15–17 days 
post exposure 
Whole organism Global DNA 
methylation levels 
Vinclozolin and 5-AC induced 
significant DNA hypomethylation in F0 
groups. The effects of vinclozolin were 
not transferred to non-exposed F1 and F2 
offspring. However, DNA 
hypomethylation induced by 5-AC in F0 
group was transferred to non-exposed F1 
and F2 offspring. 
Vandegehuchte 
et al., 2010b 
Table 1.1. Studies investigating alterations in DNA methylation following treatment with environmentally relevant chemicals in aquatic 
species. Abbreviations; EE: 17α-ethinylestradiol, HBCD: hexabromocyclododecane, E2: 17β-estradiol, 5AdC: 5-aza-2′ deoxycytidine, vtg 
I: vitellogenin I, 5-AC: 5-azacytidine, TBT: tributyltin, TPT: triphenyltin, F(0,1,2): (parental, first, second) filial generation.
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1.3.2. DNA methylation and regulation of gene expression: Crosstalk between DNA 
methylation and histone modifications 
DNA methylation alone, as an epigenetic mechanism, is not sufficient for regulation of 
transcription. Undeniably, this procedure is a complex series of events involving a range of 
epigenetic and non-epigenetic factors and chemical modifications of DNA and histones. 
These changes will lead to chromatin remodelling and subsequently alter DNA-protein 
interactions (Doerfler, 1983; Gronbaek et al., 2007; Li, 2002). The crosstalk between DNA 
methylation, histone modifications and chromatin remodelling proteins is required for 
reinforcing the outcome. However, the precise mechanisms, the order of events and the 
factors linking these epigenetic mechanisms are not entirely known (Butler et al., 2008).  
 
1.3.2.1. DNA methylation as a gene silencing mechanism 
Transcriptional silencing of genes via DNA methylation is divided into two broad categories: 
1. DNA methylation and enhancer blocking activity of insulators. 2. Methyl-CpG binding 
proteins (MeCPs). 
1. DNA methylation and enhancer blocking activity of insulator-binding proteins: Insulators 
are DNA sequence elements that have a significant role in regulation of transcription through 
several mechanisms, such as inhibition of access of enhancers to promoter regions of genes 
(Burgess-Beusse et al., 2002). A number of genes are regulated by the same enhancer 
elements located at a distance from the transcription sites of these genes. Inhibition of 
inappropriate activation of genes under the control of the same enhancer is achieved by 
blocking the access of the enhancer to the promoter region with insulator-binding proteins. 
Insulator-binding proteins recognise and bind to insulator DNA sequences and regulate 
transcription of the genes by positioning themselves between enhancer and the transcription 
start site of the genes (Bell et al., 1999; Hark et al., 2000; Jaenisch and Bird, 2003). 
Methylation of insulator DNA sequences inhibits binding of the insulator-binding proteins to 
these regions, thus allowing access of the enhancer to the promoter region and expression of 
the immediate gene. For example, the imprinted insulin growth factor 2 (IGF2) gene with an 
inactive maternal allele and active paternal allele is regulated by the insulator binding protein, 
CCCTC-binding factor (CTCF). CTCF recognises an insulator sequence element in the 
imprinting control region (ICR) prior to IGF2 gene. The ICR region is un-methylated and 
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methylated in maternal and paternal alleles, respectively. This results in binding of CTCF to 
its recognition site, located between the enhancer and promoter region of the un-methylated 
maternal allele. Therefore, transcription is prevented by blocking access of the enhancer. In 
contrast, as the ICR region is methylated in the paternally inherited allele, binding of CTCF 
and blocking of the enhancer is prevented, thereby resulting in expression of paternal allele of 
IGF2 gene (Hark et al., 2000). 
2.  The methyl-CpG binding proteins (MeCPs). Methylation of the cytosine ring modifies the 
shape and the structure of the major groove, and this directly inhibits the binding of 
transcription factors (TFs) by preventing access to their binding sites (Counts and Goodman, 
1995; Shi et al., 2003; Gronbaek et al., 2007; Momparler and Bovenzi, 2000; Li, 2002). 
However, the predominant mechanism of suppression of transcription via DNA methylation 
relies on selective recognition of methylated CpG dinucleotides by specific proteins that 
contain a methyl-CpG binding domain (MBD). These proteins include, MeCP2 and MBD1_4 
(Li, 2002; Wade, 2001). Although the precise mechanisms and components of the complexes 
formed requires further investigation (Li, 2002), it is thought that MBD-containing proteins 
selectively recognise and bind to methylated cytosine regions, thereby promoting formation of 
a complex comprised of histone deacetylase (HDAC), histone methyltransferases and 
adenosine triphosphate (ATP)-dependent chromatin remodelling proteins. Removal of the 
acetyl groups from the N-tail of histones and remodelling of the chromatin results in the 
wrapping of the DNA around the core histones and formation of condensed transcriptionally 
inactive heterochromatin regions (Li, 2002; Wade, 2001). MeCP2 is the first identified and 
the best characterised member of the MBD family. It contains two functional domains, MBD 
and transcription repression domain (TRD), which promote formation of a suppressive 
complex (Figure 1.5.B). The MBD mediates binding of MeCP2 to methylated cytosine bases 
of the DNA while TRD provides a binding site for the co-repressor proteins known as Sin3a 
and HDACs (Figure 1.5.A) (Wade, 2001; Li, 2002; Hendrich et al., 2001). Figure 1.6, adapted 
from Wade (2001), demonstrates the potential mechanisms of transcription repression 
mediated by MBD containing MeCP2 protein. Although this model (indicated as model 1 in 
Figure 1.6) is certainly the predominant model of DNA methylation mediated transcription 
suppression, there are alternative HDAC-independent MBD mediated suppressive models that 
are not as well characterised, as shown in Figure 1.6. For example MBD can prevent binding 
of TF by directly occupying their binding sites (model 2), promoting remodelling of 
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chromatin architecture (model 3) or inhibiting transcription by binding to general transcription 
factors that are part of the RNA polymerase II pre-initiation complex, such as transcription 
factor IIB (TFIIB) (model 4). It is thought that the chosen mechanism is influenced by the 
type of cell, chromatin architecture and DNA sequence (Wade, 2001).  
The function of the MBD1-3 transcription repression proteins is suppressed in the presence of 
HDACs inhibitors. This indicates the presence of a transcription repression domain (TRD) 
with HDAC-dependent activity in the structure of these proteins (Wade, 2001). Although the 
mammalian MBD3 protein contains a methyl-CpG binding domain, it lacks the capability of 
recognising methylated DNA. Therefore, the transcription repression ability of MBD3 is 
brought about by formation of a nucleosome remodelling and histone deacetylase (NuRD)-
complex. This complex is comprised of histone binding proteins, HDAC and mi-2. The latter 
is an ATP-dependent chromatin remodelling protein which promotes transient changes in the 
architecture of chromatin. Furthermore, HDACs induce DNA condensation and suppress 
transcription through hypoacetylation of DNA (Hendrich et al., 2001; Li, 2002; Wade, 2001).  
In comparison to MeCP2 and MBD3, the biochemistries of the MBD1 and MBD2 are not 
well characterised. However, as both contain TRD and MBD domains, it is thought that their 
transcription repression activities at methylated regions of DNA are due to recruitment of 
HDACs (Wade, 2001; Li, 2002). MBD2, similar to MBD3, interacts with the NuRD complex. 
The MBD2-NuRD complex, which was previously referred to as MeCP1 complex, also 
demonstrates chromatin remodelling properties. In contrast to the transcription suppression 
activity of MBD1-3, MBD4 is a DNA mismatch repair protein with DNA glycosylase activity 
(Li, 2002).  
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Figure 1.5. MeCP2 structure and transcription suppression complex. A. MeCP2 contains two 
functional domains: methyl-CpG binding domain (MBD), which recognises and binds to 
methylated cytosine and transcription repression domain (TRD) which can bind to co-
repressor Sin3a and recruit histone deacetylases. B. MeCP2 selectively recognises methylated 
cytosines and promotes the formation of a complex, containing Sin3a co-repressor and 
HDAC. This will result in histone hypoacetylation and chromatin condensation.  
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Figure 1.6. Potential mechanisms of transcription suppression via MBD containing MeCP2. Model 1. Binding of the MeCP2 to the 
methylated regions of DNA via its MBD binding domain results in recruitment of histone deacetylases (HDAC). HDACs cause the 
hypoacetylation of the chromatin N-tail and chromatin condensation. Model 2. Physical occupation of the transcription factor binding sites 
by MeCP2 inhibits activation of transcription. Model 3. MeCP2 can promote remodelling of chromatin structure and condensation. Model 
4. Some transcription factors can bind to MeCP2 proteins thereby preventing their interaction with their regulatory regions. DNA: blue 
line, core histones: gray circles, MeCP2: is shown by its MBD domain presented by a green circle, HDAC: red circle, TF: red square. This 
figure was modified from Wade, 2001.  
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1.3.2.2. DNA methylation in relation to active transcription  
Transcribed regions are associated with markers commonly indicative of active transcription 
status, such as, un-methylated promoter regions and certain post-transcriptional chemical 
modifications of the histones including acetylation. Transfer of the negatively charged acetyl 
group to the N-tails of the histones via histone acetyltransferases (HATs) results in 
neutralisation of the positive charge of the histones. This reduces the interaction between the 
negatively charged phosphate groups of DNA and positively charged N-tails of the histones, 
resulting in formation of euchromatin regions with relaxed DNA-protein conformations. 
These alterations allow access of transcription factors to the regulatory regions and initiate 
transcription (Figure 1.7) (Jones and Takai, 2001; Gronbeak et al., 2007). In tumourigenesis, 
alterations in methylation of the lysine (mono, di, tri) residues situated at the N-tails of the 
histones are as significant as changes in acetylation of these sites (Tate et al., 2010; Gronbaek 
et al., 2007). However, in contrast to acetylation, which is independent of the location of the 
affected amino acid residue, the influence of the methylation upon gene expression is highly 
dependent on the location of the lysine in the histone tail (Table 1.2) (Gronbaek et al., 2007). 
The crosstalk between histone modification and DNA methylation at the transcribed non-
methylated CGI containing promoter regions is accomplished by a epigenetic marker known 
as, CXXC finger protein 1 (cfp1) (Thomson et al., 2010). This protein with its Cys-rich 
CXXC DNA binding domain selectively binds to methylation-free CpG dinucleotides 
(Thomson et al., 2010; Tate et al., 2010; Butler et al., 2008). This binding will further result in 
recruitment of the Set1A (Set domain containing 1A) and Set1B (Set domain containing 1B) 
histone H3k4 methyltransferase complex. Set1A and Set1B are both mammalian histone 
methyltransferases with non-overlapping, sub-nuclear localisation patterns. They exclusively 
bind to non-methylated, cfp1-attached, and transcriptionally active euchromatin regions and 
catalyse the methylation of H3K4, an epigenetic marker associated with transcriptionally 
active genes. H3K4 methylation results in subsequent interaction of the Set1A or Set1B with 
the RNA polymerase (RNAP) II C-terminal domain and initiation of transcription (Tate et al., 
2010; Butler et al., 2008). In addition to the changes discussed, lysine-specific 
demethyltransferase 2A (KDM2A) catalyses the demethylation of H3K36 at these regions. 
Methylated H3K36 is a chemically modified histone, commonly associated with suppressed 
transcription (Figure 1.8) (Thomson et al., 2010).   
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Based on the mechanisms of suppression and activation of transcription described above, and 
as shown in Figure 1.7, it is clear that histone modifications, DNA methylation and ATP-
dependent chromatin remodelling are interdependent processes. For example, in Arabidopsis, 
heterochromatin protein 1 (HP1) binds to methylated H3-K9 which is an epigenetic marker of 
inactive genes. This results in recruitment of Arabidopsis methyltransferase and initiation of 
methylation of CpNpG sequences (Li, 2002). However, establishing the order of events i.e. 
DNA methylation, promotion of histone modifications and chromatin remodelling  and 
investigating the role of DNA methylation in regulating transcription, requires further 
investigation, especially in complex species such as mammals and plants. However, three 
possible scenarios for the order of interactions between different epigenetic factors have been 
proposed and are shown in Figure 1.9.  
 
 
 
 
 
 
 
 20 
 
Figure 1.7. Chromatin structures of active and inactive promoters. A. Actively transcribed 
open chromatin structure. The CpG sites in the promoter regions are un-methylated, histone 
tails are acetylated and the lysine 4 on histone H3 is trimethylated. B. Transcriptionally 
suppressed closed chromatin regions. The promoter regions are methylated, acetylation of the 
histone tail is removed via histone deacetylases and replaced by two other markers of 
epigenetically suppressed DNA,  histone H3 lysine 9 trimethylation and methyl-CpG-binding-
domain proteins (MBD) (Gronbaek et al., 2007).  
 
Table 1.2. The methylation of the N-tails of histones is used as an epigenetic signature for 
predicting the transcription status of the genes. 
Type of histone modification Symbol Epigenetic marker 
Trimethylation of lysine 9 of N-terminal tail of H3 H3K9me3 Suppressed 
Trimethylation of lysine 27 of N-terminal tail of H3 H3K27me3 Suppressed 
Trimethylation of lysine 36 of N-terminal tail of H3 H3K36me3 Suppressed 
Trimethylation of lysine 20 of N-terminal tail of H4 H4K20m3 Suppressed 
Trimethylation of lysine 4 of N-terminal tail of H3 H3K4me3 Active 
Trimethylation of lysine 79 of N-terminal tail of H3 H3K79me3 Active 
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Figure 1.8. A schematic representation of the key DNA methylation and histone modifications that occur in the promoter region of a 
transcriptionally active gene. KDM2A is a H3K36 demethyltrasferase. C: un-methylated cytosine, red circle: methyl group, blue circle: 
acetyl group, Lys: lysine, HMT: histone methyltransferase.  
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Figure 1.9. The link between DNA methylation, histone modifications and chromatin 
remodelling. DNA methylation and histone modifications are interdependent events 
regulating transcription. Three models have been proposed to explain the possible order of the 
events. Model 1. Model of DNA methylation directing histone methylation. DNA is 
methylated by de novo methyltransferases (DNMT3a and DNMT3b) and the DNA 
methylation pattern is conserved throughout replication by the maintenance 
methyltransferase, DNMT1. Binding of MBD-containing proteins, such as MeCP2, result in 
recruitment of HDACs and chromatin remodelling proteins. This causes deacetylation of 
histones and condensation of the chromatin structure. The chromatin will further attract 
histone methyltransferases (HMT). This leads to methylation of epigenetic markers associated 
with transcriptionally silent genes such as H3-K9.  Model 2. Model of histone methylation 
directing DNA methylation. In this model methylation of histone tails via HMT results in 
recruitment of proteins such as HP1. Binding of HP1 to methylated H3-K9 regions will 
further direct DNMTs to these regions, resulting in methylation of DNA. Model 3. Model of 
chromatin remodelling driving DNA methylation. Remodelling of chromatin via ATP-
dependent remodelling complexes such as Lsh can result in unwinding of DNA. This provides 
access for histone modification enzymes (HMT and HDAC) and DNMTs to these regions, 
leading to transcriptional alterations. This figure was modified from Li, 2002. 
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1.3.2.3. General inverse correlation between gene expression and DNA methylation  
The relationship between gene expression levels and DNA methylation is extremely complex 
and site sensitive. When determining the influence of DNA methylation upon transcription, 
the location of DNA methylation in respect to the transcription start site and other regulatory 
regions (i.e. enhancers and suppressors) is very important (Siegfried and Simon, 2010; Jones, 
1999; Van Vlodrop, 2011; Jones and Takai, 2001). For example, as discussed in section 
1.3.2.1, although the region prior to the TSS of the IGF2 gene is methylated, this gene is 
transcriptionally active. The methylation of this region inhibits the binding of the CTCF 
insulator-binding protein; thereby allowing access to, and binding of the corresponding 
enhancers and activation of transcription (Hark et al., 2000). 
Furthermore, it has become apparent that the methylation levels of specific CpG 
dinucleotides, known as core CpG sites, within the CGIs of a promoter region of a gene are 
key factors in deciding the outcome of DNA methylation upon gene expression. Therefore, 
the methylation levels of these core CpG sites, irrespective of the levels and the direction of 
methylation (hypo- or hyper-methylated) in the remaining CpG sites surrounding the core 
CpG regions, will dictate and regulate transcription. In some cases core CpG sites have been 
narrowed down to a single CpG dinucleotide within a CpG island. This shows that regulation 
of transcription does not require change in methylation of an entire CGI. Indeed, methylation 
of a few key and gene-specific CpG sites can efficiently regulate transcription (Van Vlodrop, 
2011). For example, the tristetraprolin (TTP) gene acts as a tumour suppressor gene by 
destabilising c-myc protein and inducing apoptosis in cells with DNA damage and it is 
commonly suppressed in liver cancers. Recently, transcriptional suppression of this gene has 
been linked to hypermethylation of a single CpG located at the promoter region of this gene. 
Methylation of this particular CpG site allows binding of a transcription suppressor complex 
to the promoter region of this gene and therefore prevents transcription (Sohn et al., 2010). 
The presence of core CpG sites within alternative promoters at intra- and intergenic CpG 
dinucleotides, the regulation of transcription of several genes by one promoter and the 
location of several core CpG sites outside the traditionally defined CGIs can further 
complicate the relationship between regulation of gene expression and DNA methylation 
levels (Van Vlodrop, 2011). Moreover, the level of methylation required for inactivation of 
each gene varies (not a simple case of all or null methylation). Furthermore, these effects can 
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be tissue, cell and cancer type specific. This adds to the complexity and the difficulty of 
interpreting the DNA methylation data in regards to their effect on gene expression (Van 
Vlodrop, 2011).  
 
1.3.3. The one-carbon cycle  
S-adenosylmethionine (SAM) as a universal methyl donor (Pogribny, 2010) is the final and 
immediate source of methyl groups for methylation of a range of substrates including DNA, 
RNA, xenobiotics, phospholipids, hormones and neurotransmitters (Struys et al., 2000) and 
therefore has a vital role in the regulation of crucial biological functions (Krijt et al., 2009). 
SAM is produced as a result of a series of reactions that comprise the one-carbon cycle 
(Herceg and Vaissiere, 2011). A major function of SAM is providing the methyl group 
necessary for methylation of DNA which is catalysed by DNA methyltransferases. In return, 
SAM is converted to S-adenosylhomocysteine (SAH) (Kumar et al., 2008). SAH, due to its 
high binding affinity for the catalytic regions of SAM-dependent methyltransferases, is a 
potent inhibitor of transmethylation reactions (Lu, 2000; Lieber and Packer, 2002; James et 
al., 2002). Therefore, constant removal of SAH from the site of production is necessary for 
continuation of methylation reactions. Removal of SAH is achieved in a reversible reaction 
catalysed by S-adenosylhomocysteine hydrolase (SAHH) protein which results in the 
production of homocysteine (Melnyk et al., 2000; Lu, 2000; Lieber and Packer, 2002) (An 
overview of the one-carbon cycle is presented in Figure 1.10). Changes in concentrations of 
SAH and SAM, result in disruption of SAM/SAH ratio. This ratio is referred to as the 
methylation index. SAH-dependent decrease in the methylation index interferes with and 
inhibits methylation reactions, including DNA methylation (Herceg and Vaissiere, 2011; Krijt 
et al., 2009; Melnyk et al., 2000).  
The produced homocysteine can either be converted to cysteine through a transsulfuration 
reaction or can be converted back to methionine through addition of a methyl group. The 
latter is catalysed by two independent reactions: 1. Folate, vitamin B12-dependent methionine 
synthesis. 2. Betaine-homocysteine methyltransferase (BHMT) reaction. In the first pathway 
the primary source of the methyl group is provided by dietary intake of folate. Folate is 
converted to 5-methyl tetrahydrofolate (5-methyl THF) which subsequently donates a methyl 
group to homocysteine. This results in production of methionine and tetrahydrofolate 
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(Emmert et al., 1996; Herceg and Vaissiere, 2011). In addition, conversion of homocysteine 
to methionine is achieved by BHMT. This results in the transfer of a methyl group from 
betaine, a product of choline oxidation, to homocysteine and generation of dimethylglycine 
and methionine. In contrast to methionine synthesis that occurs in all cells, expression of 
BHMT is mainly restricted to liver tissues in mammals. Nevertheless, both pathways 
contribute equally to regeneration of methionine from homocysteine in the human liver 
(Emmert et al., 1996). Furthermore, conversion of methionine to SAM is catalysed by 
methionine adenosyltransferases (MAT) in the presence of ATP.  
Disruption in the one-carbon cycle by, for example diets deficient in folate and choline, the 
two primary sources of methyl groups for generation of SAM, result in decreased levels of 
SAM. This causes DNA hypomethylation in mouse livers with a subsequent consequence of 
liver tumourigenesis (influence of diet, change in DNA methylation and change in phenotype 
is further discussed in section 1.3.5.2) (Herceg and Vaissiere, 2011; Ghoshal and Farber, 
1984). 
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Figure 1.10. The one-carbon cycle. In this pathway ATP activates methionine which results in 
the generation of the universal methyl donor, SAM. SAM is used in a range of biological 
reactions including methylation of DNA. The one-carbon cycle is highly regulated. Changes 
in components of this pathway can cause decrease in the SAM/SAH ratio which, subsequently 
leads to DNA hypomethylation. For example, reduced levels of essential nutrients, such as 
folate and choline, and accumulation of homocysteine lead to a decreased SAM/SAH ratio. 
Furthermore, sufficient levels of SAM trigger mechanisms that lead to conversion of SAM to 
SAH. For example, 5-methyl THF can inhibit GNMT activity and SAM can regulate GNMT 
activity by inhibiting the synthesis of 5-methyl THF. Therefore, sufficient levels of SAM 
result in SAM-dependent inhibition of 5-methyl THF synthesis which subsequently results in 
GNMT-dependent SAM to SAH conversion and reduction of SAM/SAH ratio.  
Abbreviations: SAM: S-adenosylmethionine, SAH: S-adenosylhomocysteine, DNMT: DNA 
methyltransferase, GNMT: glycine N-methyltransferase, SAHH: S-adenosylhomocysteine 
hydrolase, THF: tetrahydrofolate, MS: methionine synthase, B12: vitamin B12, BHMT: 
betaine-homocysteine methyltransferase, MTHFR: methylenetetrahydrofolate reductase, 
MAT: methionine adenosyltransferases. Green circle: essential nutrients which are mainly 
obtained through diet (Ulrey et al., 2005; Melnyk et al., 2000; Lu, 2000; Herceg and 
Vaissiere, 2011).  
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1.3.4. Epigenetic regulation of normal functions in the cells 
As DNA methylation patterns are maintained post-replication, these modifications contribute 
to the regulation of transcription of normal biological functions of cells such as inactivation of 
the X-chromosome, imprinting, suppression of transcription of parasite sequences, 
differentiation and tissue specific gene expression (Jones and Takai, 2001) which are 
discussed briefly below. In addition, as DNA methylation influences protein-DNA 
interactions and as many pathways are regulated through DNA-protein interactions, the vital 
role of DNA methylation in many biological functions is apparent (Doerfler, 1983).  
 
1.3.4.1. Imprinting 
DNA methylation is involved in imprinting (Gronbaek et al., 2007). Imprinting or parent-of-
origin specific-gene expression is the expression of one of the two alleles of a gene, either the 
maternal or the paternal allele, and complete suppression of the other allele. This causes non-
equivalence between mammalian parents in autosomal genetic material and prevents 
parthenogenesis (Reik and Walter, 2001; Hore et al., 2007). Imprinting has only been 
confirmed in mammals, with approximately 100 imprinted genes identified in humans and 
mice. Imprinted genes are usually located in clusters, partly as a result of a phenomenon 
known as epigenetic spreading (Reik and Walter, 2001).  
In addition to preventing parthenogenesis and possible correction of gene duplications, it is 
hypothesised that imprinting mechanisms have evolved in mammals to prevent conflict 
between offspring and mother over food resources. This is referred to as the “parent conflict 
hypothesis”. Some of the paternal genes increase foetal growth at the expense of the mother, 
whilst it is in the interest of the mother to limit this growth. Therefore, imprinting is a way of 
balancing foetal growth rate. For example in mice IGF2, a growth enhancer, is imprinted in 
the maternal allele while the IGF2 receptor, a growth suppressor, is methylated in the paternal 
allele. However, due to the spreading of the epigenetic changes some of the imprinted genes 
are “innocent bystanders” in this conflict (Hore et al., 2007).  
As mentioned in section 1.3.1, mammalian genomes undergo two extensive epigenetic 
reprogramming events, one during embryogenesis and the other during gametogenesis. In the 
latter epigenetic markers, including DNA methylation and chromatin modifications are re-set 
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in a sex-specific manner in imprinted genes which are protected from the second wave of 
reprogramming during embryogenesis (Hore et al., 2007; Godmann et al., 2009). This results 
in inheritance of imprinted patterns in a parent-of-origin manner in the somatic cells (Reik 
and Walter, 2001). Therefore, as imprinted genes are only represented and expressed 
monoallelically, methylation or deletion of the active allele has serious consequences. For 
example Prader-Willi and Angelman syndrome are both consequence of deletion of the active 
paternal and maternal alleles in the 15q11-13 region of the neuronal tissue, respectively (Hore 
et al., 2007).  
 
1.3.4.2. X-chromosome inactivation 
DNA methylation is involved in X chromosome inactivation (Gronbaek et al., 2007). During 
this process, in order to compensate for the 2-fold higher occurrence of the genes located on 
the X chromosomes in females compared to males, one of the X chromosomes in females is 
inactivated (Xi) (Li, 2002). The X inactivation occurs during embryogenesis after 
implantation, with equal inactivation probabilities for the maternal and paternal X 
chromosome (Avner and Heard, 2001; Li, 2002).  
The inactivation process is initiated by X (inactive)-specific gene (Xist) located at the X 
inactivation centre (XIC). The Xist gene encodes a large non-coding RNA, expressed at a 
background level from both alleles prior to X chromosome inactivation. During inactivation a 
marked increase in expression and accumulation of Xist gene of the allele selected for 
inactivation is observed. This leads to cis coating of the X chromosome with the Xist RNA 
and triggers a cascade of events leading to inactivation of the entire X-chromosome (Avner 
and Heard, 2001).  
X chromosome inactivation is a synergy between DNA methylation, histone deacetylation, 
chromatin remodeling and Xist gene expression. Methylation of the Xist gene of the active X 
chromosome (Xa) prevents its inactivation (Norris et al., 1994). In addition, following 
initiation of the inactivation via Xist, DNA methylation contributes to the inactivation process 
by spreading the inactivation to all CGIs of the housekeeping genes in the X chromosome and 
stabilising and ensuring maintenance of a silence phenotype throughout cell division (Avner 
and Heard, 2001). The significance of the contribution of other epigenetic mechanisms is 
extremely clear. This is because the Xi resembles a highly condensed heterochromatin 
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comprised of CGI regions containing methylated CpG dinucleotides and deacetylated histones 
in the promoters of the house keeping genes (Csankovszki et al., 2001). In addition, it has 
been shown that mutation in DNMT3b gene, without altering the activity of Xist gene, results 
in hypomethylation and activation of several X-linked genes (Li, 2002). 
 
1.3.4.3. Differentiation and tissue specific gene expression  
The DNA sequence of the genetic material is the same for all tissue types, thus it cannot 
directly explain the differences observed in expression patterns and phenotypes of diverse 
categories of tissues. Phenotype-specific gene expression in differentiated cells is achieved 
mainly by altering the proportion and location of hetero- and eu-chromatin regions. As 
epigenetic markers regulate gene expression by altering the protein-DNA interactions and 
DNA packaging, epigenetic mechanisms have been proposed as the key components for 
establishing tissue-specific gene expression profiles (Godmann et al., 2009; Enrlich, 2005; 
Momparler and Bovenzi, 2000). In addition, epigenetic markers in contrast to gene sequences 
are flexible. Therefore, the epigenomes of different cells can differ depending on the 
microenvironment of differentiating cells (Godmann et al., 2009). Indeed, tissue-specific 
expression of genes with altered methylation profiles (hypo- or hyper-methylation) based on 
the tissue type, have been identified in humans (Christensen et al., 2009). For example, testes 
and uterus exclusively express a testis-specific lactate dehydrogenase gene and a 
myometrium-specific oxytocin receptor respectively and these are controlled through 
methylation of their regulatory regions (Enrlich, 2005). Although, it has to be stated that, due 
to the complex nature of the relationship between DNA methylation and gene expression 
(discussed in section 1.3.2.3), the contribution of epigenetic mechanisms is not always clear.  
 
1.3.4.4. Transposons 
Transposons, scattered throughout the genome, comprise more than 40% of the mammalian 
genome (compared to exonic regions comprising <2%) (Jones and Takai, 2001). Due to 
evolution-induced alterations, most transposable elements are inactive. However, the 
remaining small proportions of active transposons are a threat to the genome by inducing 
mutations, chromosome instability, translocations and formation of chimeric mRNAs. 
Nevertheless, generally, little damage is caused by these potentially hazardous elements. This 
 30 
 
has been mainly attributed to DNA methylation-induced inactivation of transposons. This 
theory, known as the genome defence model, corresponds with the CpG dinucleotide richness 
of the promoter regions of transposons (Yoder et al., 1997; Gronbaek et al., 2007; Esteller, 
2008). Indeed, the mammalian genome is found to be globally methylated (Suzuki and Bird, 
2008) with the most highly methylated regions corresponding to transposons (Bird, 2002).  
In contrast to high levels of methylated transposable elements in somatic cells, transposons 
are un-methylated and transcriptionally active in germ cells, where they can cause long-term 
damage compared with somatic cells (Bird, 2002). Therefore, in addition to the genome 
defence model proposed by Yoder et al., (1997), it has been suggested that in general, 
methylation of un-necessary promoters may have evolved as a mechanism to reduce the 
background transcriptional noise (Bird, 2002). 
 
1.3.5. Cancer as an epigenetic disease 
Epigenetic mechanisms are implicated at all stages of tumourigenesis, from initiation to 
metastasis. There is growing certainty that epigenetic mechanisms, including DNA 
methylation, precede genetic changes (Sharma et al., 2010; Herceg and Vaissiere, 2011; 
Moggs et al., 2004; Feinberg et al., 2006; Pogribny, 2010). Indeed, alterations in the 
epigenome trigger tumourigenesis and result in stimulation of a cascade of genetic and 
additional epigenetic changes. Therefore, cancer is as much an epigenetic disease as it is a 
genetic disease (Herceg and Vaissiere, 2011). 
 
1.3.5.1. DNA methylation and cancer 
Distortion of the DNA methylation profile is a key event in tumourigenesis and a known 
hallmark of tumour cells. Detection of abnormal low levels of global methylation in tumours 
was one of the first identified epigenetic events in human cancers. This revealed loss of 
methylation at repetitive DNA sequences, coding and intronic regions (Esteller, 2008). 
Indeed, both global DNA hypomethylation and gene-specific hypermethylation (e.g. genes 
involved in apoptosis, metastasis, adhesion, cell cycle and DNA repair) are observed in all 
investigated human cancers (Lopez et al., 2009; Tischoff and Tannapfel, 2008; Gronbaek et 
al., 2007; Esteller and Herman, 2002; Esteller et al., 2001).  
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It was thought that epigenetic alterations, such as change in DNA methylation of tumours are 
consequences of altered gene expression in tumours (Feinberg, 2001). However, it is now 
known that alterations in epigenome, which can be induced by several factors such as 
chemicals, can initiate changes in gene expression with consequences such as formation of 
tumours. Formation of tumours can further trigger change in the epigenome (Pogribny, 2010). 
Therefore, it should be considered that some epigenetic changes initiate the neoplastic 
transformation (i.e. they are initiated by the agent) and some are characteristic of the formed 
tumour. DNA methylation contributes to the tumourigenesis process through several 
mechanisms as shown in Figure 1.11 (Herceg and Vaissiere, 2011; Esteller and Herman, 
2002; Esteller, 2008; Herrera et al., 2008).  
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Figure 1.11. Biological significance of DNA methylation in normal and tumour cells. This 
figure was modified from Esteller and Herman, 2002. 
 
1.3.5.1.1. DNA hypomethylation  
Large scale de-methylation of the genome was one of the first identified epigenetic 
phenomena in 1983 implicated in tumourigenesis (Gama-Sosa et al., 1983). Since then, it has 
been recognised as a common feature in all tumours (Feinberg et al., 2006). DNA 
hypomethylation promotes tumour development through a number of methods including: 1) 
Activation of oncogenes and genes associated with metastasis and tumour aggression, 2) 
Activation of repetitive sequences, 3) Chromosomal instability, 4) Aneuploidy and 
recombination and 5) Biallelic transcription of imprinted genes (Herceg and Vaissiere, 2011).  
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DNA methylation levels are reduced 20%_60% in cancer cells compared to normal cells. This 
mainly reflects the DNA hypomethylation detected at coding regions and introns of genes and 
the repetitive regions (Esteller and Herman, 2002). Considering that transcription of repetitive 
regions is primarily suppressed through their heavy methylation and the fact that 
approximately half of the human genome is comprised of repetitive regions, including mobile 
transposons and satellites that are dispersed throughout the entire genome, it is not surprising 
that most of the observed DNA hypomethylation in cancers corresponds to these regions 
(Ehrlich, 2009; Herceg and Vaissiere, 2011). Thus hypomethylation of transposable elements 
and pericentromeric repeats results in their activation, followed by instability and 
rearrangement of the chromosomes and aneuploidy (Esteller and Herman, 2002; Strathdee 
and Brown, 2002; Ehrlich, 2009).  
Other than hypomethylation of the whole genome, hypomethylation of specific genes such as 
oncogenes, genes associated with metastasis, and drug resistance genes have been detected in 
mammalian tumours (Ehrlich, 2009). For example the BCL-2 oncogene and the gene 
encoding urokinase-type plasminogen activator (uPA) are hypomethylated and over-
transcribed in human B-cell chronic lymphocytic leukaemia and in breast cancer with 
increased aggressiveness, respectively (Laird and Jaenisch, 1996; Ehrlich, 2009).  
Another consequence of DNA hypomethylation in tumours is loss of imprinting (LOI). LOI 
results in biallelic expression of the previously imprinted genes, hence increasing the 
expression levels of these genes by two-folds (Laird and Jaenisch, 1996). As most of the 
imprinted genes are related to biological functions such as regulation of cell growth, cell 
signalling, cell cycle and transport; their over-expression has major consequences in normal 
development and function of a cell and has been implicated in many human disorders, such as 
cancers (Feinberg et al., 2006). For example LOI of IGF2 gene is correlated with five-fold 
increase in the risk of colorectal cancer and is commonly linked with Wilms’ tumour (Herceg 
and Vaissiere, 2011; Laird and Jaenisch, 1996). 
The mechanism of DNA hypomethylation has been largely unexplored. This is due to the 
nature of hypomethylated regions and their high repetitiveness. However, recent emergence of 
whole genome methylation profiling techniques and discovery of single copy-hypomethylated 
genes in tumours, known as germ cell-specific genes or cancer-germline (CG) genes, has led 
to recognition of DNA hypomethylation in tumours as a selective event rather than a non-
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selective, random procedure (De Smet and Loriot, 2010; De Smet et al., 2004). Thus regions 
between 1kb to several megabases undergo hypomethylation in cancers while other regions 
escape these waves of DNA hypomethylation. This leads to formation of a mosaic DNA 
methylation pattern (De Smet and Loriot, 2010). As a result, DNA hypomethylation patterns 
are tumour-type specific. In fact, activation levels, types of CG genes and some repetitive 
sequences have shown tumour specificity (De Smet and Loriot, 2010; Akers et al., 2010). For 
example the NBL2, a DNA repeat in the acrocentric chromosomes, is hypomethylated in 
neuroblastomas and hepatocellular carcinoma and is hypermethylated in ovarian cancer and 
Wilms’ tumours while showing intermediate methylation levels in normal tissues (De Smet 
and Loriot, 2010).  
So far about 50 CG genes have been identified in humans (De Smet and Loriot, 2010). As 
these genes are hypermethylated in normal somatic cells and hypomethylated in germ cells, 
their expression is restricted to germ cells. Although the functions of all these genes are not 
entirely clear, it is thought that they express tumour-specific antigens and may be involved in 
providing them with stem cell-like properties such as immortality (De Smet and Loriot, 2010; 
Akers et al., 2010; Loriot et al., 2006). In addition, there has been some evidence that CG 
antigens are hallmarks of normal stem cells. This supports the stem cell origin of tumours, as 
tumour cells also express these antigens (this model is explained in section 1.3.5.3). However, 
the role of CG genes in stem cells and provision of the tumours with stem cell-like properties 
is inconclusive and requires further investigation (Akers et al., 2010).  
Several models for mechanisms of DNA hypomethylation in tumours have been proposed. 
One model that seems most likely is the demethylation/remethylation model. This model is 
based on the same principals observed in reprogramming events during embryogenesis. The 
entire genome of a tumour cell undergoes non-selective, active demethylation. This is 
followed by a selective de novo methylation of the genome. This re-methylation only takes 
place at regions that are not protected by transcription factors. Therefore, the selectiveness of 
DNA hypomethylation is based on a protection mechanism against re-methylation (Figure 
1.12) (De Smet and Loriot, 2010). For example, the melanoma antigen-A1 (MAGE-A1) CG 
gene is methylated and in-active in somatic cells while it is hypomethylated and active in 
tumours. Therefore, MAGE-A1 becomes de-methylated and it is protected against re-
methylation by de novo methyltransferases in tumour cells. This protection against DNA 
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methylation is achieved by binding of E-twenty six (ETS)-TF to the regulatory regions of this 
gene, thus inhibiting the access of de novo methyltransferases to these regions. It has been 
shown that removal of ETS transcription factor results in methylation of MAGE-A1 in 
tumour cells (De Smet et al., 2004; De Smet and Loriot, 2010). 
 
Figure 1.12. Demethylation/remethylation model for site specific DNA hypomethylation in 
tumours. Methylation is removed non-selectively from the entire genome. Methylation is 
restored by de novo methyltransferases at the regions that are not protected from re-
methylation by transcription factors. This leads to selective hypomethylation. This model is 
one of the proposed models for DNA hypomethylation in tumours. However, based on current 
evidence, it appears that it is also the most likely model. Red circles: methylated cytosine, 
green oval: transcription factor, blue oval: active demethylase (the nature of these enzymes is 
not known), gray oval; maintenance methyltransferase, yellow oval: de novo 
methyltransferase. This image was modified from De Smet and Loriot, 2010. 
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1.3.5.1.2. DNA hypermethylation and inactivation of tumour suppressor genes 
Methylation of the core CpG dinucleotides located near the transcription start sites of tumour 
suppressor genes (TSG), which are not normally methylated, results in their inactivation. The 
significance of the influence of TSG inactivation in all pathways of tumourigenesis is well 
established (Jones and Takai, 2001; Gronbaek et al., 2007).  
Although the mechanism of suppression of transcription by DNA methylation is becoming 
more evident, the factors that initiate the de novo methylation of TSGs in cancers and the 
preferential methylation of groups of genes based on tumour types, are still poorly understood 
(Herceg and Vaissiere, 2011; Esteller and Herman, 2002). Several hypotheses have been 
proposed, such as over-expression of DNMTs and defects in the mechanisms responsible for 
the protection of CpG dinucleotides against methylation in somatic cells or in stem cells 
(Laird and Jaenisch, 1994; Herceg and Vaissiere, 2011). As discussed, this change in 
methylation of TSGs can arise as early as the differentiation stage in somatic stem cells. It is 
well established that disruption of methylation during stem cell differentiation (epigenetic 
mechanisms are key in this process) can result in abnormal methylation of genes. This results 
in generation of a population of pre-neoplastic progenitor cells with growth and survival 
advantages compared to other cells (Laird and Jaenisch, 1994). This is part of the epigenetic 
progenitor model of tumourigenesis which is described in section 1.3.5.3. 
The list of hypermethylated genes in tumours is continuously growing. Some of the 
hypermethylated genes that are involved in crucial pathways and are known to be altered in 
cancers are shown in Table 1.3. 
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Table 1.3. Examples of identified hypermethylated genes in human cancers associated with 
key pathways in tumourigenesis (Herceg and Vaissiere, 2011; Laird and Jaenisch, 1994; 
Esteller and Herman, 2002; Strathdee and Brown, 2002). In the cases where hypermethylation 
of a gene has been highly associated with a specific tumour type, this has been indicated. 
Abbreviations; CDKN2A: cyclin-dependent kinase inhibitor 2A; CDKN2B: cyclin-dependent 
kinase inhibitor 2B; RB: retinoblastoma; APC: adenomatous polyposis coli; MGMT: O-6-
methylguanine-DNA methyltransferase; MLH1: MutL homolog 1; BRCA1: breast cancer 1, 
early onset; DAPK1: death-associated protein kinase 1; GSTP1: glutathione S-transferase P1; 
GATA4: GATA binding protein 4; GATA5: GATA binding protein 5. 
 
1.3.5.1.3. Increased rate of mutations  
As demonstrated for the first time in the genome of Escherichia coli by Coulondre et al., 
(1978), endogenous and exogenous rates of mutations are increased at 5-methylcytosine sites 
(Weisenberger and Romano, 1999). Deamination occurs at the 4
th
 carbon of both cytosine and 
5-methylcytosine (5-mC). It has been estimated that 100 to 500 cytosine deamination 
reactions occur each day within each cell (De Bont and Van Larebeke, 2004). However, the 
rate of 5-mC deamination compared to cytosine is 3 to 4 times higher. Deamination of 
cytosine results in an unusual base composition of DNA (C to U transition); hence, it is more 
readily recognised and rapidly repaired by the abundant uracil-DNA glycosylase enzyme. 
This enzyme removes the uracil base, resulting in generation of a base-free site which is 
 
 
 
 
Biological function 
 
 
 
 
Gene 
Cell cycle and 
signalling 
P16/CDKN2A (most tumours), P15/CDKN2B (leukaemia,  
gastric cancer, hepatocellular tumours), RB (retinoblastoma), 
APC (Breast, lung, colon, gastric, oesophageal, pancreatic and 
hepatocellular tumours) 
DNA repair 
MGMT (colon, lung, brain, oesophageal and gastric cancer), 
MLH1 (gastric, colon, ovarian and endometrial cancer), BRCA1 
(breast and ovarian cancer) 
Apoptosis and survival DAPK1 (lymphoma and lung cancer) 
Detoxification GSTP1 (prostate, breast and kidney cancer) 
Cellular adhesion 
E-cadherin (leukaemia, breast, lung, colon, gastric and prostate 
cancer), H-cadherin (ranges of tumours, including breast cancer) 
Transcription regulation GATA4, GATA5 
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further repaired. However, 5-mC deamination results in 5mC to T transition which is 
recognised and repaired less effectively and with a slower rate than C to U transition by the 
mismatch repair enzymes (Gronbaek et al., 2007; De Bont and Van Larebeke, 2004). Indeed, 
the higher instability of 5-mC and less effective repair of 5mC:T transitions compared to C:U 
transitions is reflected in the genome base composition as CpG dinucleotides are five-fold 
under-represented in the mammalian genome compared to other dinucleotides (Laird and 
Jaenisch, 1994). In addition, 5mC induced point mutations account for more than 30% of 
disease related mutations, with genes associated with cell growth and survival comprising the 
majority of the identified mutated genes. For example, the cytosine bases at the three main 
CG:TA transition mutation sites of tumor protein 53 (P53), are always found to be methylated 
in normal tissues (Gronbaek et al., 2007). 
Furthermore, 5-mC increases the binding and exogenous mutagenic effect of certain 
chemicals, such as esperamicins A and B and mitomycin C, at the adjacent guanine base. This 
increased targeting of guanine base by chemicals at 5-mC sites has been linked to structural 
alterations and unwinding of DNA at methylated sites. These alterations lead to increased 
accessibility of these regions to carcinogens (Weisenberger and Romano, 1999; Gronbaek et 
al., 2007).  
Finally, the rate of mutations at methylated CpG dinucleotide sites are also increased through 
other epigenetic alterations such as DNA hypermethylation. For example, genes for several 
repair enzymes, such as mismatch repair proteins MLH1 and MSH2, are commonly 
hypermethylated in colorectal cancer. Inactivation of these genes and other repair related 
genes, through hypermethylation or mutations, results in less effective repair of the mutations 
induced by 5-mC deamination; thereby, adding to the cascade of events that contribute to 
tumourigenesis (Gronbaek et al., 2007). 
 
1.3.5.2. Epigenetic mechanisms and cancer: An interface between the environment and 
the genome 
A key question is what causes the change in the phenotype of an individual as a response to 
its environment (i.e. chemical contaminants, diet and stress) which then can cause a higher 
susceptibility to certain diseases? It is becoming evident that, although epigenetic markers are 
stable enough to regulate gene expression, they are also susceptible to environmental signals. 
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This means that the epigenome can change as a response to environmental stimuli which then 
can lead to alteration in the phenotype (Jaenisch and Bird, 2003). In a way, the epigenome 
acts as a link between environmental factors (external and internal factors) and phenotype by 
translating the environmental signals to phenotypic responses through altered gene expression 
profiles. Thereby, environmental agents can affect the phenotype of an individual not only by 
inducing mutations and genetic variations but also by altering the epigenome. This results in 
changes in the expression of the genes without any alterations to DNA sequences (Dolinoy et 
al., 2007; Massicotte et al., 2011). Therefore, epigenetic modifications during critical stages 
of development (i.e. the DNA methylation re-programming stages during embryogenesis and 
gametogenesis) have been recognised, in part, as the factors affecting development of certain 
adulthood phenotypes long after the stimulating factor has been removed. These include 
linkage of various cancers, diabetes, obesity and behavioural and neurodegenerative disorders 
with environmental factors encountered during prenatal and early postnatal periods. This is 
known as “foetal basis or developmental origins of adult-onset of disease” (Jirtle and Skinner, 
2007; Barros and Offenbacher, 2009; Jaenisch and Bird, 2003; Li et al., 2003). In a way, the 
epigenetic markers inflicted upon the genome by environmental factors very early on during 
an individual’s life act as epigenetic memories of the exposures. This epigenetic memory can 
manifest in adults as a pathological phenotype often following a secondary trigger such as 
aging or changes in hormone levels. For example, in 1950s diethylstilbestrol (DES) was used 
during pregnancy to prevent spontaneous abortion. However, DNA methylation changes 
induced by this agent during embryogenesis have been identified as the cause of a range of 
disorders such as increased breast and testicular cancers in adult female and male offspring 
(Prins, 2008). Therefore, the interactions between environmental factors and epigenetic 
mechanisms are extremely important in the development of diseases.  
However, establishing a cause and effect between exposure to environmental factors, change 
in epigenome and disease is challenging. As well as the need to eliminate genetically-induced 
phenotypic changes in response to environmental factors, epigenetic changes as a response to 
environmental factors can appear to be minor. However, these changes to the epigenome can 
accumulate over-time leading to gradual alteration of the phenotype (Baccarelli and Bollati, 
2009). For example, as shown in the viable yellow agouti (A
vy
) mouse model, epigenetic 
changes on a single gene can have a significant impact on an individual’s health and on the 
health of following generations. Furthermore, this model is commonly used to demonstrate 
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the capability of environmental factors in induction of epigenetic alterations in the agouti 
allele at sensitive developmental stages. These changes will subsequently lead to variable 
expression levels of the agouti gene in genetically identical species (Dolinoy et al., 2007). In 
the agouti mouse model the colour of the coat is controlled by the agouti gene. The coat 
colour in the agouti mouse is set in their hair follicles during early stages of development. The 
wild-type agouti gene causes a circular production of phaeomelanin (yellow pigment) and 
eumelanin (black-brown pigment), thus resulting in normal agouti pattern fur. Spontaneous 
insertion of the intracisternal A-particle (IAP) transposable element upstream of the 
transcription start site of the agouti gene gives rise to the A
vy
 allele. The IAP transposable 
element is a metastable epiallele containing a cryptic CpG rich promoter (Dolinoy, 2008; 
Jirtle and Skinner, 2007). Metastable epialleles are expressed at various levels in genetically 
identical individuals. This variation in expression level is due to epigenetic modifications that 
occur during early development (Dolinoy et al., 2007). The expression of the A
vy 
allele 
depends on the methylation levels of the IAP promoter. Maternal nutrients (i.e. methyl 
deficient diet) or environmental exposure at early stages of development alter the extent to 
which the A
vy
 allele is methylated. Unmethylated IAP promoter gives rise to an ectopic and 
ubiquitously expressed agouti gene from the IAP transcription start site (TSS). As the IAP-
induced transcription is not restricted to the hair follicles and it is expressed throughout all 
cells, this gives rise to yellow fur agouti mice with high risk of adult-onset of obesity, diabetes 
and tumourigenesis. In contrast, complete methylation of the IAP promoter results in 
suppression of IAP-induced transcription, which leads to generation of pseudoagouti mice. 
Finally, mosaic methylation leads to formation of the mottled mice phenotype with the IAP-
induced transcription in some but not all cells (Dolinoy, 2008; Jaenisch and Bird, 2003) 
(Figure 1.13).  
The influence of environmental factors such as diet on induction of epigenetic changes at 
early stages of development with subsequent stable changes in gene expression and phenotype 
during adulthood was demonstrated using the viable yellow agouti (Avy) mouse model. 
Dietary methyl donor supplements, such as choline, betaine and folic acid during mice 
pregnancy, resulted in increased methylation of the cryptic CpG rich promoter of the IAP 
transposable element in the offspring. Hence, the coat colour distributions of the offspring 
were changed towards the pseudoagouti phenotype (Jirtle and Skinner, 2007). Similar results 
were observed when genistein at levels comparable to the diet of a human with high soy 
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consumption, was fed to gestating agouti mice. This resulted in methylation of the cryptic 
promoter of the IAP in the developing offspring and shifting the coat colour to pseudoagouti 
phenotype. Moreover, it protected the offspring from adulthood obesity, diabetes and 
tumourigenesis (Dolinoy et al., 2006). In addition, higher proportions of A
vy
 mice are born 
from mothers with yellow A
vy 
phenotype. This indicates that some epigenetic markers are not 
entirely erased during embryonic reprogramming (transgenerational epigenetic inheritance). 
Hence, some epigenetic alterations induced by environmental factors (e.g. diet), not only 
compromise the health of the individual but they can also persist in the following generations 
and impact their health too (Jaenisch and Bird, 2003).  
As epidemiological studies conducted in the past two decades have identified an association 
between the incidence rate of various cancers and certain aspects of diet (Peto, 2001; Dolinoy 
et al., 2007); it is plausible that, accumulation of epigenetic alterations, in part, could explain 
the sensitivity of tumourigenesis to environmental factors (Jaenisch and Bird, 2003). For 
example, folate (methionine precursor) or methionine (SAM precursor) deficient diets and 
induction of genome-wide DNA hypomethylation have been linked to increased risk of 
colorectal cancer in humans (Giovannucci et al., 1993).  
Another example of the influence of environment on the epigenome and subsequent changes 
in gene expression is the response of Arabidopsis to prolonged exposure to cold weather 
(vernalisation). Following prolonged exposure to cold weather flowering locus C, a repressor 
of flowering, becomes epigenetically silenced. This results in coordination of flowering time 
(phenotype) with spring and summer (He et al., 2003; Bastow et al., 2004; Burn et al., 1993). 
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Figure 1.13. The viable yellow agouti (A
vy
) mouse model. A. The methylation status of the 
cryptic CpG rich promoter of the IAP element and the associated phenotype. Methylation of 
the IAP promoter results in restricted expression of the agouti gene in the skin, similar to the 
wildtype allele. Hypomethylation of the IAP promoter results in ubiquitously expressed 
transcript, resulting in yellow coat colour, higher risk of development of tumours and obesity 
(Jaenisch and Bird, 2003). B. Image of genetically identical week 15 A
vy
 mice. This image 
demonstrates the phenotypes (colour and obesity) associated with variation in methylation of 
the A
vy
 allele (Jirtle and Skinner, 2007).   
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The association between environmentally induced subtle but accumulative epigenetic changes 
and increased susceptibility to diseases, such as cancer also correlates with the extensive time 
required for the development of cancers and the late onset of most cancers (Feinberg et al., 
2006). For example, in a study conducted on genetically identical monozygotic (MZ) human 
twins, it was shown that differences in their epigenomic profiles may account for their varying 
phenotype (i.e. disease) in response to environmental factors over time. Indeed, these 
epigenetic differences were more apparent between older twins with extremely different 
lifestyles (i.e. diet, smoking and physical activity). This demonstrates a link between 
accumulation of epigenetic changes over time and altered phenotype (Fraga et al., 2005). In 
another study conducted in MZ human twins, it was shown that the promoter region of the 
AXIN1 gene was significantly hypermethylated in the twin with a caudal duplication 
abnormality compared to the unaffected twin and independent controls. This gene has been 
associated with caudal duplication. Therefore, as no mutation was detected in the AXIN1 gene 
of the affected twin, this also indicated that phenotypic differences can arise as a result of 
epigenetic alterations (Oates et al., 2006). This highlights the importance of epigenetic 
mechanisms in creating diverse phenotypes within human populations (Whitelaw and 
Whitelaw, 2006). 
In addition, the carcinogenicity of some environmental contaminants such as endocrine 
disrupters, nickel, cadmium, chromium and arsenic cannot entirely be explained through 
genetic mechanisms (Martinez-Zamudio and Ha, 2011). Metals can interfere with the activity 
of DNA methyltransferases, either directly or through production of reactive oxygen species. 
This leads to an altered DNA methylation profile and subsequent alterations in gene 
expression (reviewed in Baccarelli and Bollati, 2009). For example, it has been proposed that 
cadmium (Cd)-induced global DNA hypomethylation may be due to Cd interaction with 
DNMTs and subsequent interference with their methylation activity. Detoxification of 
inorganic arsenic (As) is dependent on its enzymatic methylation via the universal methyl 
donor SAM, thus reducing the amount of available SAM for DNA methylation reactions. This 
has been linked to global DNA hypomethylation observed in rat liver epithelial cell lines 
treated with As. In addition, gene-specific hypermethylation (P53, CDKN2A) has been 
reported in blood samples collected from individuals exposed to As. Hypermethylation of the 
DAPK promoter was observed in individuals with bladder cancer in areas with known arsenic 
contamination. Substitution of nickel for magnesium in the DNA triggers chromatin 
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condensation which is further accompanied by initiation of de novo methylation. These 
changes lead to alteration of DNA methylation patterns at these regions (Arita and Costa, 
2009; Baccarelli and Bollati, 2009; Martinez-Zamudio and Ha, 2011). Hence, epigenetically-
induced deregulation of key signalling pathways due to exposure to environmental 
contaminants needs to be taken into consideration when establishing mechanisms of toxicity 
and tumourigenicity (Feinberg et al., 2006; Martinez-Zamudio and Ha, 2011).  
Although it is recognised that the potential for transgenerational epigenetic inheritance is 
somewhat controversial, the concept that some epigenetic markers (imprinted genes and 
metastable epialleles) can escape the DNA methylation reprogramming that occurs during 
embryogenesis means that they can be inherited across generations (Whitelaw and Whitelaw, 
2008). Therefore, environmentally-induced epigenetic alterations in the germ line are 
potentially heritable. This could subsequently lead to inheritance of the environmentally 
acquired phenotypes. This phenomenon is referred to as transgenerational epigenetic 
inheritance or epigenetic basis for inheritance of a trait (Anway and Skinner, 2006). For 
example, several studies have demonstrated that intraperitoneal exposure of gestating outbred 
Harlan Sprague Dawley female rats to the anti-androgenic endocrine disrupter vinclozolin 
(VCZ) (100 mg/kg body weight (bw)/day) during critical stages of sex determination 
(embryonic day (E) 12-E15) induces epigenetically male germ cell transmitted phenotypic 
characteristics up to at least the F3 generation in male rat offspring, such as increased 
spermatogenic cell apoptosis, decreased sperm motility and numbers, prostate abnormalities, 
tumours and renal lesions. The reproducibility and frequency of the VCZ-induced phenotypes 
(i.e. rate of tumours) and identification of genes with altered DNA methylation in the effected 
individuals compared to controls, indicated that mutations are not the most likely cause of this 
abnormality (Anway et al., 2005; Anway et al., 2008a; Anway et al., 2008b; Anway and 
Skinner, 2008; Anway et al., 2006; Stouder and Paoloni-Giacobino, 2010). However, It has 
been demonstrated that the effect and epigenetic inheritance of VCZ is highly dependent on 
dose (Skinner et al., 2010), animal strain (Inawake et al., 2009) and route of exposure 
(Schneider et al., 2008). Oral administration of VCZ (100 mg/kg bw/day) in outbred Wistar 
rats (Schneider et al., 2008) and intraperitoneal injection of VCZ (100 mg/kg bw/day) in 
inbred CD-Sprague Dawley rats (Inawake et al., 2009) during the sex determination stage 
failed to induce inherited phenotypic effects.   
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The environmentally-induced epigenetic modifications have the potential to cause change in 
the expression of genes rather than change in DNA sequences of genes. As a result key genes 
with altered expression as a consequence of response to environmentally-induced epigenetic 
changes can act as epigenetic biomarkers or “fingerprints”, for early detection of disease and 
environmental exposures (this concept is further discussed in Chapter 6) (Jirtle and Skinner, 
2007). However, it has to be noted that this does not mean that genetically-induced 
modifications, caused by environmental factors (i.e. chemical contamination), are not 
important and can be discarded. But rather, both epigenetic and genetic mechanisms and the 
possibility of epigenetic and genetic polymorphisms need to be taken into consideration 
(Bollati and Baccarelli, 2010). Therefore, in the same way that genetic polymorphisms can 
influence the susceptibility of individual organisms to toxicity and disease, differences in the 
epigenome that emerge throughout the life-time of an individual may also have the same 
effects (Christensen et al., 2009) (Figure 1.14). 
 
Figure 1.14. The interactions between environmental factors and the various “-omes”, 
including the epigenome. There is an interactive relationship between the five –omes. 
Environmental factors can directly affect the traditional –omes (genome, transcriptome, 
proteome and metabolome) or induce changes to the epigenome. The epigenome acts as an 
interface between the genome and the environment. Alterations to the epigenome have the 
potential to induce changes in gene expression levels and subsequently alter the phenotype. In 
addition to environmentally-induced changes in responses (e.g. higher risk of disease), both 
genetic and epigenetic susceptibly of an individual should be considered. However, both 
higher genetic and epigenetic susceptibilities of an individual to certain phenotypes (e.g. 
diseases) could have environmentally-induced origins. 
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1.3.5.3. Two models of tumourigenesis: The classic multistep model initiated by 
mutation and the epigenetic progenitor model  
Originally cancer was viewed as a genetic disease initiated by mutations. However, it is now 
known that cancers are a consequence of accumulation of both genetic and epigenetic 
alterations. These events complement each other to promote tumourigenesis by activation and 
inactivation of the genes that are associated with neoplastic transformation (Pogribny, 2010; 
Herceg and Vaissiere, 2011). Furthermore, the need for identifying a common event between 
different types of tumours and establishing the order of events in neoplastic transformation, 
has led to the proposal of various hypotheses and models of cancer development. Below two 
models are briefly described: 1. The multistep model of tumourigenesis, which until recently 
has been the universally accepted model of tumourigenesis 2. The epigenetic progenitor 
model of tumourigenesis. The latter has been proposed in the light of a better understanding 
of the significance of epigenetic mechanisms and the role of epigenetics as an interface 
between environmental factors and genome.  
1. Multistep model of tumourigenesis (initiation, promotion and progression) 
This well-defined classic model is comprised of an initiation step by a genotoxic compound, a 
promotion and a progression step (Weinberg, 1989). During the first step, exposure to a 
genotoxic compound -chemicals that induce cancer by directly damaging the DNA (Mally 
and Chipman, 2002)- leads to formation of an irreversible mutation (Barrett, 1993; Klaunig et 
al., 2000; Moggs et al., 2004). Thus, during DNA replication the modified DNA sequence is 
passed on to the next generation of the cells and becomes permanently fixed in the genome 
(Klaunig et al., 2000). Increased proliferation and inhibition of apoptotic signals results in 
clonal expansion of the initiated cell. Growth advantages of a group of daughter cells due to 
further epigenetic and genetic changes result in their selection over other initiated cells. This 
step is referred to as promotion (Barrett, 1993; Klaunig et al., 2000). Finally, during the 
progression stage, further changes of a sub-section of the promoted cells result in their ability 
to overcome their dependency on the other cells and upon extra-cellular signals. This results 
in metastasis of tumour cells and invasion of other tissues (Figure 1.15) (Moggs et al., 2004; 
Klaunig et al., 2000).  
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The model described above relies on a genotoxic compound or event to initiate 
tumourigenesis by irreversibly damaging and mutating the DNA (Moggs et al., 2004), and 
relies on the participation of non-genotoxic mechanisms only after the initial step. This group 
contributes to tumourigenesis by promoting cell proliferation and inhibiting apoptosis. This 
imbalance between proliferation and apoptosis caused by non-genotoxic compounds, can be 
achieved through different mechanisms, such as alterations of growth signals, gene expression 
and gap junctional intercellular communication (Klaunig et al., 2000).  
 
Figure 1.15. Multistage process of carcinogenesis. Sufficient un-repaired damage to the DNA 
leads to formation of an initiated cell. Further promotion of the initiated cell by mechanisms 
such as increase in proliferation and inhibition of apoptosis results in selective clonal 
expansion of the initiated cell and formation of a cluster of modified cells, known as a “focal 
lesion”. Finally, cell growth and further alterations of the focal lesion lead to formation of a 
fully formed cancer (Klaunig et al., 2000). 
 
2. Epigenetic progenitor model of tumourigenesis 
The basis of tumourigenesis is the irreversible loss of control of a cell in terms of regulation 
of its genetic material, transcription and proliferation levels (Moggs et al., 2004). This results 
in generation of an undifferentiated, stem cell-like, immortal cell with unlimited proliferation 
abilities (Moggs et al., 2004; Sharma, et al., 2010; Herceg and Vaissiere, 2011; Pogribny, 
2010; Feinberg et al., 2006). Better understanding of the function of epigenetic mechanisms 
within a cell and the characteristics of tumour cells led to the knowledge that a stable 
epigenetic change, such as deregulation of the central epigenetic control machinery, could 
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initiate a neoplastic transformation (Moggs et al., 2004; Sharma et al., 2010). Knowing that 
epigenetic mechanisms, such as DNA methylation, can greatly influence gene expression and 
differentiation of the cells has given rise to the epigenetic progenitor/stem cell model of 
tumourigenesis (Feinberg et al., 2006; Moggs et al., 2004). It is important to mention that this 
model does not disagree with the importance of genetic alterations such as mutation in 
gatekeeper genes (gatekeeper genes are genes that can directly regulate tumour growth and 
therefore, are important at early stages of tumour development) and chromosomal 
rearrangement in tumourigenesis. Indeed, mutations in the gatekeeper genes are necessary in 
the early stages of tumour development. For example, mutation in the gatekeeper APC gene 
and translocation and formation of the oncogenic BCR-ABL (break cluster region-V-abl 
Abelson murine leukaemia viral oncogene homolog 1) gene fusion have been recognised as 
key steps in development of colorectal cancer and chronic myelocytic leukaemia, 
respectively. However, chromosomal rearrangement and changes in the expression of 
gatekeeper genes can also be induced by epigenetic mechanisms and have the same effects as 
mutations (Feinberg, 2004; Feinberg et al., 2006).  
The epigenetic progenitor model proposes that cancer is initiated through epigenetic changes 
in progenitor cells much earlier than originally thought.  Three steps have been proposed for 
this model. The first step is the main difference between the two models. 1. Epigenetic 
disruption of the progenitor cells 2. Mutations in gatekeeper genes 3. Genetic and epigenetic 
plasticity (Feinberg et al., 2006). These stages are briefly described below and are shown in 
Figure 1.16. 
1. Epigenetic disruption of progenitor cells. This step involves epigenetic alterations of 
“tumour-progenitor genes” within progenitor cells of a given tissue (somatic stem cells) and 
formation of a cancer-primed population of progenitor cells. Tumour-progenitor genes are 
defined as a group of genes that are responsible for characteristics of stem cells (i.e. genes 
involved in differentiation, intercellular communication, proliferation and genes with wide 
genetic and epigenetic consequences), for example, IGF2, connexins and tumour suppressor 
gene APC which are all known to be epigenetically altered in tumours (Feinberg et al., 2006; 
Moggs et al., 2004). Therefore, the basis of this step relies on two concepts, the stem cell 
origin of cancers and the occurrence of epigenetic changes, with the ability to alter biological 
functions of the cells, prior to genetic alterations.  
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The similar characteristics of somatic stem cells and cancer cells have led to the proposal of 
stem cell origin of cancers (Pardal et al., 2003; Feinberg et al., 2006). Without doubt both cell 
types can self-renew and differentiate, though both actions occur in a more controlled and 
effective manner in somatic stem cells compared with cancer cells. For example, although 
poorly and abnormally differentiated, myeloid leukaemia cells can differentiate to form 
diverse blood cell lineages. Also, medulloblastomas, a type of brain tumour, can differentiate 
to form neuron and glia-like cells. Furthermore, in many tumour types, such as breast cancer, 
glioblastoma and acute myeloid leukaemia, two distinct groups of cells, stem-like and more 
differentiated tumour cells are detectable based on cell surface markers (Pardal et al., 2003), 
therefore giving rise to the stem cell/progenitor origin of cancers.  
As discussed in section 1.3.4.3, epigenetic mechanisms are fundamental in differentiation of 
stem cells. Hence, their disruption can alter the transcription of genes and cause chromosomal 
instability and provide these cells with growth and survival advantages (stem cell properties). 
These changes alter the balance between differentiated, committed cells and progenitor cells. 
In addition, detection of epigenetic abnormalities in normal tissues in the absence of 
mutations and prior to development of tumours, strengthens the concept of involvement of 
epigenetic mechanisms and abnormalities in initiation of cancers (Feinberg et al., 2006; 
Herceg and Vaissiere, 2011). For example, DNA hypomethylation has been detected in 
premalignant stages of gastric carcinoma (Cravo et al., 1996) and it induces aggressive T-cell 
lymphoma in mice (Gaudet et al., 2003). Furthermore, in colorectal cancer DNA 
hypomethylation can precede mutational changes, as it has been detected in normal-appearing 
tissues of patients harboring adenomas prior to neoplastic transformation (Choi and Mason, 
2002). LOI of the IGF2 growth factor has been associated with 5-fold increase in risk of 
colorectal cancer. This modification has also been found throughout the non-cancerous 
colonic epithelium of patients with LOI-associated colorectal cancer (Cui et al., 2003).  
Several other pieces of evidence such as the reversibility of tumour growth at very early 
stages of tumourigenesis and detection of a uniform DNA hypomethylation in all the cells of 
a tumour mass tends to infer that epigenetic changes occur prior to mutations (Feinberg et al., 
2006).  
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2. Initiating mutations in gatekeeper genes. This step is similar to the classic model with the 
exception that genetic changes in gatekeeper genes are not seen as the initiating step and 
occur in primed cells. 
3. Genetic and epigenetic plasticity. Further epigenetic and genetic changes lead to formation 
of a fully formed tumour with the phenotypic characteristics of tumour cells (Feinberg, 2004; 
Feinberg et al., 2006). Epigenetic-induced instability and the role of epigenetics in cancer are 
described in section 1.3.5.1. The epigenetic progenitor model of tumourigenesis is shown in 
Figure 1.16. 
 
 
 
 
 
 
 
 
 
Figure 1.16. Epigenetic progenitor model of tumourigenesis. Cancer is initiated by epigenetic 
disruption of progenitor cells. This results in generation of a tumour-primed, abnormal 
population of progenitor cells that can maintain their stem-cell like properties. This is 
achieved by deregulation of tumour-progenitor genes (TPG). The second step is mutation in 
gatekeeper genes (GKM) which includes oncogenes (ONC) and tumour suppressor genes 
(TSG). Finally, further epigenetic and genetic instabilities lead to formation of fully formed 
tumour cells with features associated with cancer (Feinberg et al., 2006). 
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This affects our understanding of the biology of cancer, the identification of new targets for 
design of antineoplastic drugs (e.g. DNA methyltransferase inhibitors and HDAC inhibitors), 
Progenitor 
cell 
Differentiated  
cells 
Epigenetic 
changes 
Expanded and/or 
epigenetically altered 
progenitor-cell pool 
Benign 
tumour 
Epigenetic and 
genetic plasticity 
Epigenetic 
and genetic 
plasticity 
 
Cancer 
 51 
 
the role of environment in development of disorders (i.e. epigenetic memory) and chemical 
safety assessment (Moggs et al., 2004; Feinberg et al., 2006). This model implies that 
epigenetic changes during tumourigenesis occur at an early stage, prior to the stage that is 
currently recognised as benign pre-neoplastic lesions. Therefore, recognising the early 
reversible epigenetic changes as early biomarkers of prevention or development of cancer are 
extremely valuable (Feinberg et al., 2006).   
 
1.4. DNA methylation and its implication in marine biology 
Although the role of epigenetic mechanisms in regulation of transcription, response to internal 
and external environmental factors and human health are becoming more apparent, this area is 
under-studied in aquatic biology, especially in relation to disease. If chronic exposure to 
environmental contaminants can cause epigenetic changes associated with disease in model 
organisms; there is a high probability that the same mechanisms are implicated in the 
development of disease in aquatic species and are affecting their responses to environmental 
factors. This becomes more important when considering that in current biomonitoring 
protocols and in procedures used for evaluation of health of aquatic species and 
environmental quality, long term exposures to chemical contaminants (especially in the case 
of persistent organic pollutants) and their effects upon epigenetic mechanisms are not 
considered at all. Taking into account that exposures to environmental contaminants can 
induce epigenomic changes in key signalling pathways, it becomes extremely important to 
consider the role of epigenetic mechanisms in the diseases of aquatic species. Furthermore, as 
chemicals can alter the epigenome with subsequent changes in the transcription, it may be 
possible to identify a subset of genes with altered DNA methylation (biomarkers) unique to 
each category of chemicals. Identification of these biomarkers can potentially be used in 
bimonitoring, early detection of exposure to chemical contaminants and chemical risk 
assessments (Moggs et al., 2004; Prins, 2008). However, it has to be noted that some 
epigenetic modifications are reversible and some occur normally. Hence, when identifying 
biomarkers it is important to distinguish between adverse and non-adverse epigenetic signals 
and a change in DNA methylation does not necessarily represent a change in phenotype or 
toxicity (Moggs et al., 2004).  
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1.4.1. Cancer in fish 
1.4.1.1. Use of fish in carcinogenicity studies 
Fish have been used in carcinogenicity studies, as biomonitoring species to provide 
information on the quality of the environment and the health of the population of fish species 
and as alternative non-mammalian cancer models. Indeed, their high sensitivity to a variety of 
classes of carcinogens, tumour promoters, low cost of maintenance and short life cycles 
makes them ideal test species for both environmental monitoring and investigation of 
molecular mechanisms of tumourigenesis (Small et al, 2010; Bailey et al., 1996). In addition, 
although the normal structures of some organs are different between mammals and fish, 
tumours in fish are histopathologically similar to the equivalent tumours in mammals. This 
allows the same tumour type classification in fish as in mammals and their widespread use in 
research (Masahito et al., 1988; Grabher and Look, 2006). For instance, rainbow trout 
(Oncorhynchus mykiss) has been used for biomonitoring of contamination with environmental 
chemical carcinogens for the last four decades. Their low maintenance cost, ultra-sensitivity 
at very early stages of life and sensitivity to different classes of carcinogens, in addition to 
their well characterised tumour pathology, has led to their extensive use in research. As an 
example, investigations into the cause of high rates of liver tumour incidence in rainbow trout 
collected from the Pacific Northwest led to the discovery of aflatoxin B1 (AFB1) as a human 
hepatocarcinogen. Further investigations into AFB1-induced hepatocellular and 
cholangiocellular carcinomas in trout, revealed that the c-ki-ras gene was mutated in these 
tumours, similar to rat liver tumours (Bailey et al., 1996). Another example of species of fish 
used in carcinogenicity studies is medaka (Oryzias latipes). Medaka is commonly used in 
carcinogenicity studies. The effects of more than 30 common carcinogens and their links with 
formation of hepatocellular carcinoma are well characterised in this fish species. A number of 
these carcinogens include AFB1, N-diethylnitrosamine and methylazoxymethanol acetate 
(Bailey et al., 1996). It was also demonstrated that the functional regions of the 
retinoblastoma gene is conserved between humans and medaka and mutations in this gene 
can lead to formation of retinoblastoma. These studies as well as highlighting the importance 
and usefulness of fish species in testing for carcinogenicity, demonstrate the potential use of 
fish as models for studying cancers in humans (Rotchell et al., 2001b).  
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1.4.1.2. Common dab (Limanda limanda) and environmental carcinogenicity studies 
Environmentally-induced tumours in fish collected from their natural habitat are mainly 
observed in bottom-dwelling fish. This has been linked with their high levels of exposure to 
sediment-associated chemical carcinogens (Masahito et al., 1988). For example an unusually 
high prevalence of liver tumours, with some sampling sites exceeding 20%, has been reported 
in the flatfish dab captured from the waters around the UK compared with the frequencies 
considered to represent a background prevalence of the disease (NMMP, second report, 2004; 
Lyons et al., 2006). Other bottom-dwelling flatfish with reported high levels of hepatocellular 
carcinoma and cholangiocarcinoma tumours include English sole (Pleuronectes vetulus) and 
winter flounder (Pleuronectes americanus) sampled from Boston Harbor, USA. Although 
tumours are mainly observed in bottom-dwelling flatfish, they are not restricted to these 
species. For example, tumours have been reported in a wide variety of species including 
brown bullhead (Ictalurus nebulosus) in the rivers entering Lake Erie and also in white perch 
(Morone americana) from Chesapeake Bay (Masahito et al., 1988).  
As a result, monitoring the disease status of dab and Atlantic cod (Gadus morhua) in offshore 
waters and European flounder (Platichthys flesus) in inshore regions and estuaries is now 
established as part of the biomonitoring procedures set up by the International Council for the 
Exploration of the Seas (ICES). These species are monitored for both internal (i.e. foci of 
cellular alterations (FCA) and malignant tumours) and external signs of disease (NMMP, 
second report, 2004). Therefore, the presence of tumours is used as a possible indicator of 
chemical contaminants at levels which cause adverse health effects and serve as indicators of 
the health and quality of the marine environment and fish population (NMMP, second report, 
2004; Masahito et al., 1988). In addition to chemical induction, it is possible that biological 
agents such as viruses are causative of tumours. This was shown in the case of viral-induced 
neurofibromatosis in bicolour damselfish (Stegastes partitus) collected from waters around 
Florida, USA (Schmale et al., 2002).  
Common dab (Figure 1.17) is similar to the other flatfish species living in close proximity to 
the ocean floor. Due to its diet of sediment-dwelling invertebrates it can be exposed to 
relatively high levels of sediment-associated chemicals. It is therefore a useful species for 
monitoring of the bioaccumulation of organic compounds and environmental carcinogenicity 
research. Liver pathology in dab, including cancer and pre-neoplastic lesions, is used as an 
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indicator of the biological effects of contaminants on the marine environment. Recently, 
attention has focussed on dab caught from UK waters as part of the UK Clean Seas 
Environmental Monitoring Programme (CSEMP). This is due to the detection of an unusually 
high prevalence of liver tumours in dab, with some UK sites exceeding 20% (NMMP, second 
report, 2004; Lyons et al., 2006). Lesions seen in livers of flatfish dab can be separated into 5 
main categories; non-specific inflammatory responses, non-neoplastic lesions, FCA, benign 
tumours and malignant tumours. (NMMP, second report, 2004; Stentiford et al., 2009; Small 
et al., 2010; Southam et al., 2008; Lyons et al., 2006). Liver is the main organ used for 
investigation and detection of morphological alterations and detection of tumours in fish 
collected for biomonitoring. Liver and kidney are the two main organs for xenobiotic 
metabolism. Based on studies conducted on the livers of rainbow trout, flatfish and zebrafish 
it has been shown that, similar to humans, fish liver expresses the main phase I and 
biotransformation enzymes, e.g. cytochrome P450s (CYP), required for activation of the pro-
carcinogens and metabolism of compounds and therefore is the main target site for 
chemically-induced adverse effects. Furthermore, first pass metabolism, in addition to high 
levels of CYPs, increases the suitability of the liver as a biomonitoring organ. For example, 
tumours are developed in the liver of rainbow trout in response to exposure to CYP1A-
inducing compounds such as 3-methylcholanthrene. Induction of CYP1A is used as a 
biomarker of exposure to polycyclic aromatic hydrocarbons (PAHs) (Bailey et al., 1996; 
Bragigand et al., 2006; Sheader et al., 2006). However, different types of tissue can be used 
for monitoring of different toxicological endpoints. For example skin and gills in fish are 
extremely useful for monitoring the visible morphological changes as they are directly 
exposed to the environment. In contrast, biofluids offer a less invasive method for 
biomonitoring (Lindesjoo and Thulin, 1994; Ward et al., 2006). 
However, what is most interesting is that the levels of tumours in dab collected from offshore 
regions are higher than the levels of tumours detected in its close relative, the European 
flounder, which is collected from inshore areas. Theoretically, European flounder should be 
exposed to higher levels of contaminants due to their closer proximity to coastal regions and 
sources of anthropogenic pollution. So far the causative agents and the molecular mechanisms 
of these tumours remain unclear, especially in regards to the involvement of environmentally-
induced epigenetic changes and their role in dab tumourigenesis. Better understanding of the 
pathways altered in these tumours and better characterisation of these tumours at molecular 
 55 
 
levels will help to clarify the driving factors behind these tumours. In addition, this may help 
to identify biomarkers for identification of hazardous environments and early indicators of 
health problems in fish. As a result, two recent studies by Small et al., (2010) and Southam et 
al., (2008) attempted to analyse dab liver tumours at the transcriptomic and metabolomic 
levels, respectively. Both studies provided preliminary data in terms of tumour 
characterisation and the identification of pathways that are altered in these tumours (i.e. 
energy pathways, protein synthesis). In the first study, a cDNA microarray designed for the 
close relative of dab, the European flounder, was used. Although this microarray is limited in 
the number of the genes presented on this platform (27,648 features –derived from 13,824 
clones spotted in duplicate. The clones were derived from a redundant flounder cDNA library 
and represent approximately 3336 unique sequences), nevertheless the authors showed that 
genes involved in protein synthesis and vitellogenin, the egg precursor protein, were 
significantly up-regulated in dab tumours in comparison with surrounding non-tumour liver 
tissues. As vitellogenin up-regulation in fish is used as a biomarker of exposure to endocrine 
disrupting chemicals, the authors concluded that these chemicals may be involved in the 
development of these tumours. However they failed to identify a possible 
mechanism/evidence for induction of liver tumours by these chemicals in dab.  
In the second paper (Southam et al., 2008) the authors used one-dimensional 
1
H NMR 
spectroscopy approach for identification of the metabolites whose concentrations were 
significantly altered in dab tumours. One of their findings was that concentrations of two 
metabolites corresponding to choline and betaine were altered in dab tumours. As these 
metabolites are involved in the one-carbon cycle; therefore, they concluded that possibly the 
DNA methylation pathway is disrupted in these tumours. However, this work required further 
investigation of the key metabolites in the one-carbon pathway (SAM and SAH) and required 
evidence of altered DNA methylation at gene levels.  
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Furthermore, both studies mainly focused on characterisation of the tumours and were limited 
to tumours and apparently healthy tissues surrounding these tumours. Including completely 
healthy liver tissues from these fish species as a third category may help to identify the 
involvement of environmental factors and the possibility of higher susceptibility of the 
tumour bearing fish to chemicals. However, considering the challenges of working with non-
model, un-sequenced species; both studies have provided significant insight into the pathways 
that are altered in these tumours.  
 
 
Figure 1.17. A picture of the flatfish dab (Limanda limanda). 
 
1.4.1.3. Zebrafish (Danio rerio) as a laboratory cancer model  
The initial use of zebrafish in developmental biology dates back to a few decades ago. The 
transparency and ex-utero development of zebrafish embryos made this species an ideal 
model for studies on developmental biology. Its use has now expanded to different aspects of 
biosciences, including cancer biology and it is now being recognised as a convenient model 
for studying human tumourigenesis alongside more traditionally used models, such as mice, 
rats and nonhuman primates (Feitsma and Cuppen, 2008; Lawrence et al., 2009). Several 
factors make zebrafish a suitable model for cancer research. These include the sequenced 
genome, sensitivity to a variety of carcinogens, low cost of maintenance, short reproductive 
cycle, possibility of field studies and portability, potential for lifetime bioassays, 
transplantation of fluorescent mammalian cells and ease of forward and reverse screening 
(Bailey et al., 1996; Spitsbergen et al., 2000; Feitsma and Cuppen, 2008). In addition, 
fundamental concepts in development of tumours in humans, such as genome instability, 
tumour invasion and progression, presence of cancer stem cells, tumour suppressor genes and 
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oncogenes have also been recognised in the processes that lead to development of tumours in 
zebrafish (Feitsma and Cuppen, 2008).  
In addition to the significant histopathological similarities between zebrafish tumours and 
corresponding human tumours (Lam and Gong, 2006), recently it has been shown that 
transcription profiles of the tumours between the two phylogenetically distant species are also 
similar (Lam et al., 2006). Indeed, gene expression signatures in chemically-induced liver 
tumours in zebrafish show clear similarities to those in human tumours. Thus, genes involved 
in cell cycle/proliferation, DNA replication and repair, apoptosis and genes with liver-specific 
function were found to be deregulated in both human and zebrafish liver tumours. 
Furthermore, pathways such as Wnt-β-catenin and Ras-MAPK which are commonly distorted 
in human liver cancers, especially in hepatocellular carcinoma (HCC), are also altered in 
zebrafish liver tumours (Cha and DeMatteo, 2005; Lam et al., 2006).  
Finally, although there are many benefits in the use of zebrafish for cancer research, there are 
still many unknown factors associated with the use of zebrafish (Feitsma and Cuppen, 2008) 
or any other fish species both as human cancer models and for environmental carcinogenicity 
studies. The role of epigenetics in fish tumourigenesis and environmentally-induced changes 
is one of these factors. So far no research has been conducted to investigate the involvement 
of epigenetic mechanisms in the development of tumours in fish. Indeed, consideration of 
epigenetic factors as one of the key components involved in human tumourigenesis cannot be 
disregarded in any model that it is currently in use for studying neoplasia in humans. This 
further highlights the need for studying epigenetic mechanisms in these species. 
 
1.5. Aims 
The molecular mechanisms and the reasons for high prevalence of environmentally-induced 
tumours in the flatfish dab are unknown, especially in relation to the balance between 
epigenetic and genetic factors. In addition, previous studies in our laboratory indicated that 
commonly mutated genes in human cancers (e.g. k-ras and h-ras) were not mutated in liver 
tumours of the close relative of dab, the European flounder (Rotchell et al., 2001a; Franklin et 
al., 2000). Therefore, based on the preliminary findings of changes observed in the one-
carbon cycle in tumours of these fish (Southam et al., 2008), the importance of epigenetic 
mechanisms in development of cancers in humans, the role of epigenetics as an interface 
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between environment and genome and the limited information on the significance of 
epigenetic mechanisms in fish tumourigenesis, it was highly appropriate to investigate the 
possibility of involvement of epigenetic mechanisms in induction of and in the features of 
these tumours. However, as dab is not sequenced, conducting DNA methylation studies are 
extremely challenging. As a result, to identify a role for involvement of epigenetic 
mechanisms in fish tumourigenesis we tested the hypothesis that DNA methylation was 
altered in chemically induced fish liver tumours using zebrafish, which lent themselves to 
effective analyses based on genome sequence availability. 
The aims of this project were: 
1. To test the involvement of DNA methylation mechanisms in chemically-induced 
hepatocellular carcinoma (HCC) tumours in zebrafish (Danio rerio). 
2. To overcome the challenges encountered when studying DNA methylation in non-model, 
un-sequenced organisms. 
3. To characterise hepatocellular adenoma (HCA) tumours of dab (Limanda limanda). This 
was investigated at two levels, DNA methylation and gene transcription. These studies were 
conducted with the aim of better understanding of the molecular mechanisms and molecular 
features of these tumours and developing an evidence-based mode-of-action from the original 
hypothesis that epigenetic factors are involved in the high prevalence of naturally occurring 
liver tumours in flatfish dab. 
4. To conduct the first targeted metabolomic study of the one-carbon cycle in fish tumours 
with the aim of testing the premise that this pathway is altered leading to modulation of the 
epigenome in dab HCA tumours. 
The overall aim of this project was to determine if DNA methylation profile was significantly 
altered in fish liver tumours compared to healthy fish liver.  
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Chapter 2 
 
Materials and Methods 
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2.1. Chemicals 
All chemicals were obtained from Sigma-Aldrich Chemical Company (UK) unless otherwise 
stated. 
 
2.2. Test organisms 
2.2.1. Zebrafish (Danio rerio) 
2.2.1.1. Chemical induction of hepatocellular carcinoma in zebrafish liver 
Exposure of zebrafish to carcinogen and extraction of DNA from zebrafish livers were carried 
out by our collaborators at the National University of Singapore. The experimental procedure 
was approved by their Institutional Animal Care and Use Committee (Lam et al., 2006).  
Briefly, three-week post-fertilisation zebrafish fry (100_150) were treated with 7, 12-
dimethylbenz[α]anthracene (DMBA, 0.75 parts per million (ppm)) in dimethyl sulfoxide 
(DMSO) or DMSO (vehicle control) for 24 hours and treatment was repeated once, 2 weeks 
later, for another 24 hours with 1.25 ppm DMBA or DMSO (The chemical concentrations are 
ppm in fish tank water). Treated fish were rinsed three times in fresh water and transferred 
into new tanks for maintenance. Fish were sampled 6_10 months after DMBA exposures. The 
tumour samples used for the present study were all larger than 3 mm in diameter. Liver 
tumours were sampled for histopathological diagnosis (Figure 2.1). In the zebrafish study 
(Chapter 3), healthy male livers from the vehicle control exposure (n=4) and HCC from the 
DMBA exposed group (n=4, male) were used. 
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Figure 2.1. Histopathology images of zebrafish HCC and healthy zebrafish liver.  
A. Zebrafish liver section with hepatocellular carcinoma (HCC) invasion into surrounding 
normal liver tissue. HCC and surrounding normal tissues are labelled. B. Enlarged image of 
the section indicated with a box in image A. This image demonstrates the border between 
HCC and normal tissue. C. Normal control liver section. Normal zebrafish hepatocytes are 
typically organised in two-cell thick plates and are regular throughout the whole liver. 
Carcinomas lose this plate architecture completely and are reorganised in typical patterns, 
such as a trabecular pattern with several-cell thick irregular trabeculae, a glandular pattern 
with a central clear space surrounded by one-cell layer neoplastic hepatocytes, and a large 
sheet of neoplastic cells without any recognisable pattern. Carcinoma cells are cuboidal with 
centrally localised nuclei of variable sizes. 
 
2.2.1.2. DNA extraction from zebrafish liver samples 
Zebrafish liver samples were placed in RNAlater (Ambion, Austin, Texas). DNA samples 
were extracted from the tissue samples using Trizol reagent (Invitrogen, UK) according to the 
manufacturer’s instructions.  
Zebrafish tissues were homogenised in Trizol (1 ml of Trizol/100 mg of tissue) and incubated 
at 30ºC for 5 minutes. Chloroform (200 µl/1ml of Trizol) was added to the samples, mixed by 
vortexing and incubated at 30ºC for 15 minutes. Following incubation samples were 
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centrifuged at 13400 x g for 15 minutes at 4ºC. This resulted in separation of the samples to 
an aqueous layer containing RNA, an interphase layer and an organic layer containing DNA 
and proteins. The aqueous layer was removed for purification of RNA samples. The RNA 
samples were not used in this thesis. Absolute ethanol (300 µl/1ml of Trizol) was added to the 
organic layer containing the DNA sample. Samples were gently mixed, incubated at 30ºC for 
3 minutes followed by centrifugation at 13400 x g for 5 minutes at room temperature. 
Supernatant was removed and the DNA pellet was washed twice with 0.1M sodium citrate 
(1ml sodium citrate/1ml of Trizol). Samples were incubated at 30ºC in wash solution for 20 
minutes with occasional mixing. DNA samples were centrifuged at 13400 x g for 5 minutes at 
room temperature. Supernatant was removed and DNA samples were air dried and stored at -
20ºC for subsequent use in the experiments. The zebrafish exposures, histopathology 
confirmation of types of tumours and extraction of DNA was carried out by our collaborators 
at the National University of Singapore. The complete detail of their experimental approach is 
described in their publication (Lam et al., 2006). 
 
2.2.2. Dab (Limanda limanda) 
2.2.2.1. Collection of dab livers 
As part of the CSEMP, several hundred dab flatfish were captured from sampling sites in the 
Irish Sea, the North Sea and the Bristol Channel (Table 2.1) during June and July 2007, 2008 
and 2009 using 30 minute tows of a standard Granton trawl by the Centre for Environment, 
Fisheries and Aquaculture Science (Cefas, Weymouth, UK). Dab were immediately removed 
from the catch and placed into flow-through tanks containing aerated seawater. Fish were 
assessed for external diseases, sacrificed and livers were visually assessed for the presence of 
macroscopic lesions (nodules). Methods described by Feist et al., (2004) were used for 
dissecting the nodules and the healthy liver tissues. Sections of the collected samples were 
immediately snap frozen in liquid nitrogen and remained frozen at -80ºC for use in DNA 
methylation, transcriptomic and metabolomics studies and the remainder of the samples were 
fixed in 10% neutral buffered formalin for 48 hours for histopathology. Histopathology was 
conducted by Cefas. 
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Fish ID Type of tissue Location Sea Sex Year collected Type of study 
RA09065-830 HCA South Cardigan Bay Irish Sea Female 2009 1, 2, 3, 4 
RA09065-830 ST South Cardigan Bay Irish Sea Female 2009 
1, 2, 3, 4 
RA09065-959 HCA Inner Cardigan Bay Irish Sea Female 2009 
1, 2, 4 
RA09065-959 ST Inner Cardigan Bay Irish Sea Female 2009 
1, 2, 4 
RA08044-302 HCA North Cardigan Bay Irish Sea Female 2008 
1, 2, 4, 5 
RA08044-302 ST North Cardigan Bay Irish Sea Female 2008 
1, 2, 4, 5 
RA08044-289 HCA St Bee's Head Irish Sea Female 2008 
1, 2, 4, 5 
RA08044-289 ST St Bee's Head Irish Sea Female 2008 
1, 2, 4, 5 
RA08045-30 HCA St Bee's Head Irish Sea Female 2008 1, 2, 4, 5 
RA08045-30 ST St Bee's Head Irish Sea Female 2008 
1, 2, 4, 5 
RA09065-1283 HCA St Bee's Head Irish Sea Female 2009 1, 2, 4 
RA09065-1283 ST St Bee's Head Irish Sea Female 2009 1, 2, 4 
RA08044-96 ST Red Wharf Bay Irish Sea Female 2008 
1, 2, 4, 5 
RA08044-96 HCA Red Wharf Bay Irish Sea Female 2008 
1, 2, 4, 5 
RA08045-10 
RA08045-10 
HCA 
ST 
Red Wharf Bay 
Red Wharf Bay 
Irish Sea 
Irish Sea 
Female 
Female 
2008 
2008 
1, 2, 4, 5 
1, 2, 4, 5 
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Continued from previous page 
RA09065-886 HCA South Cardigan Bay Irish Sea Female 2009 
1, 2, 4 
RA09065-886 ST South Cardigan Bay Irish Sea Female 2009 
1, 2, 4 
RA09065-904 HCA South Cardigan Bay Irish Sea Female 2009 1, 2, 4 
RA09065-904 ST South Cardigan Bay Irish Sea Female 2009 
1, 2, 4 
RA09044-381 HCA Lundy Bristol Channel Female 2009 
5 
RA09044-381 ST Lundy Bristol Channel Female 2009 
5 
RA08045-43 HCA Indefatigable Bank North Sea Female 2008 
5 
RA08045-43 ST Indefatigable Bank North Sea Female 2008 
5 
RA08045-49 HCA Indefatigable Bank North Sea Female 2008 
5 
RA08045-49 ST Indefatigable Bank North Sea Female 2008 
5 
RA07045-9 H South Cardigan Bay Irish Sea Female 2007 
1, 2, 4 
RA07045-533 H North Cardigan Bay Irish Sea Female 2007 1, 2, 4 
RA07045-602 H Lundy Bristol Channel Female 2007 
1, 2, 4 
RA07045-607 H Lundy Bristol Channel Female 2007 
1, 2, 4 
RA07045-106 
RA07045-107 
H 
H 
Red Wharf Bay 
Red Wharf Bay 
Irish Sea 
Irish Sea 
Female 
Female 
2007 
2007 
1, 2, 4 
1, 2, 4 
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Table 2.1. Sample information. Cefas code, location of capture, sex and associated liver lesions of dab. Abbreviations; HCA: hepatocellular 
adenoma, ST: surrounding tissue around HCA, H: healthy (non-cancerous) dab liver, 1: bisulfite sequencing PCR (Chapter 4), 2: 
transcriptomic study (Chapter 4), 3: methylated-DNA immunoprecipitation coupled to high-throughput DNA sequencing (Chapter 4), 4: 
targeted metabolomics study (Chapter 5), 5: methylated-DNA immunoprecipitation coupled to cDNA flounder microarray (Chapter 4).  
 
 
Continued from previous page 
RA07045-3 H South Cardigan Bay Irish Sea Female 2007 
1, 2, 4 
RA07045-541 H North Cardigan Bay Irish Sea Female 2007 
1, 2, 4 
RA07045-539 H North Cardigan Bay Irish Sea Female 2007 
1, 2, 4 
RA07045-452 H St Bee's Head Irish Sea Female 2007 
1, 2, 4 
RA07045-455 H St Bee's Head Irish Sea Female 2007 
1, 2, 4 
RA07045-459 H St Bee's Head Irish Sea Female 2007 
1, 2, 4 
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2.2.2.2. Histopathology  
Cefas carried out all subsequent histopathology. Using standard histological protocols, fixed 
samples were processed to wax in a vacuum infiltration processor (Feist et al., 2004). A rotary 
microtome was used to prepare 3_5 µm tissue sections. The prepared sections were mounted 
onto glass slides for haematoxylin and eosin staining. Stained sections were analysed by light 
microscopy (Eclipse E800, Nikon, UK). The type of liver tumour was established based on 
guidelines described by Feist et al., (2004).
 
Lesions were classified as HCA based on a 
combination of distinct morphological criteria, including presence of lesion with relative lack 
of macrophage aggregates, compression of surrounding parenchyma, thickened trabecular 
structure and the relative absence of atypical nuclear and cellular profiles (Feist et al., 2004) 
(Figure 2.2). 
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A. 
B. 
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Figure 2.2. Confirmation of the type of dab liver lesion. Figure A: Normal liver architecture 
exhibiting hepatocytes cords of 2-3 cell thickness between individual blood vessels. The 
arrow shows the presence of macrophage aggregates. Figure B: Large uniform hepatocellular 
adenoma (HCA) exhibiting architectural differences and slight compression (arrow) against 
surrounding normal parenchyma (N). Macrophage aggregates can also be seen at periphery of 
lesion. Figure C: Abnormal cellular architecture within hepatocellular adenoma. Lesion has 
clear trabecular structure with thickening (*) of hepatocytes cords. 
 
2.2.2.3. Sample preparation 
Dab liver tissues provided by Cefas were kept at -80°C until extraction. Each liver was 
homogenised in 10 μl/mg (wet tissue mass) water (Mass spectrometry grade, Fisher 
Scientific, Loughborough, UK) using a Precellys-24 ceramic bead-based homogeniser for two 
bursts of 10 seconds at 3800 x g (Stretton Scientific Ltd, UK). Aliquots of the homogenised 
tissues (no less than 10 mg) were used for RNA and DNA extraction. Separate aliquots of the 
C. 
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homogenised tissues (no less than 5 mg, with ideal amount of 10 mg) were used for 
metabolite extraction. 
 
2.2.2.3.1. DNA and RNA extraction 
To prevent degradation of the RNA samples by RNase, RNase free eppendorfs (Axygen, Inc, 
USA), water and barrier tips were utilised at all times. 
Aliquots of the homogenised tissues (up to 30 mg of tissue) were added to ice cold RLT (600 
μl) and β-mercaptoethanol (6 μl) mixture. Following centrifugation at full speed (16100 x g) 
for 3.5 minutes (Rotofix 32, Hettich Zentrifugen, Germany) and removal of the top lipid 
layer, RNA and DNA were extracted from the same homogenates using the AllPrep 
DNA/RNA kit (Qiagen Ltd, West Sussex, UK) according to manufacturers’ guidelines. This 
kit allowed parallel isolation of DNA and RNA from the same sample using a membrane 
containing silica based resin with a particle size of 100 μm, a large pore size, and high density 
of positively charged diethylaminoethyl groups. Although both DNA and RNA samples are 
negatively charged, due to presence of phosphates of the DNA backbone, they differ on 
charge density and molecule size. DNA has a higher negative charge than RNA molecules; 
therefore, remains tightly bound to the diethylaminoethyl groups over a wide range of salt 
concentrations. RNA, protein, carbohydrates, and small metabolites are washed from Qiagen 
Resin with medium-salt buffers. DNA remains bound until eluted with a high-salt buffer. Salt 
residues are removed with ethanol washes, allowing the elution of the hydrophilic DNA 
samples in water based buffers. 
The homogenate was transferred to Allprep DNA spin column and centrifuged (8000 x g, 30 
seconds). The column was placed at 4°C for later extraction of DNA. To the supernatant 
containing the RNA sample, 70% (v/v) ethanol (350 μl) was added. Samples were mixed by 
pipetting and transferred to the RNeasy spin column placed in a 2 ml collecting tube and 
centrifuged (8000 x g, 15 seconds). Flow-through was discarded and buffer AW1 (700 μl) 
was added to the column and centrifuged (8000 x g, 15 seconds). Buffer RPE (500 μl) was 
added to the column and centrifuged (8000 x g, 15 seconds). Buffer RPE (500 μl) was used 
for washing the column for the second time and centrifuged (2 minutes, 8000 x g). The flow 
through and collecting tube was discarded and the column was placed in a clean collecting 
tube and centrifuged for an additional 1 minutes at full speed. The RNeasy spin column was 
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placed in a 1.5 ml RNase free eppendorf. RNase-free water was added directly to the spin 
column membrane and centrifuged (1 minute, 8000 x g) to elute the RNA.  
The Allprep DNA spin column was removed from 4°C and buffer AW1 (500 μl) was added to 
the column and centrifuged (8000 x g, 15 seconds). Flow-through was discarded and buffer 
AW2 (500 μl) was added and centrifuged for 2 minutes at maximum speed. The Allprep spin 
column was placed in a clean 1.5 ml eppendorf. Care was taken to prevent any ethanol 
carryover. Elution buffer (100 μl) was pipetted directly onto the membrane of the column and 
left at room temperature for 1 minute followed by centrifugation (8000 x g, 1 minute) to elute 
the DNA. The quality of the RNA and DNA samples and the amount of the RNA and DNA 
samples were measured using a NanoDrop ND-1000 UV-VIS Spectrometer version 3.2.1 
(Nanodrop, USA.). The A260/A280 ratio for all the samples ranged from 1.8 to 2.2. This 
indicated absence of protein contamination. RNA and DNA samples were stored at -80ºC and 
-20ºC, respectively until used in transcriptomic and DNA methylation studies. 
 
2.2.2.3.2. Extraction of metabolites 
Metabolites were extracted with a multi-sample ceramic bead-based system (Precellys 24, 
Stretton Scientific Ltd, UK) using a modified version of the protocol described by Southam et 
al., (2008). In the original method liver tissues were homogenised in a mixture of water and 
methanol. However, as in this study DNA, RNA and metabolites were extracted from the 
same sample and the methanol caused interference in RNA extraction, an alteration to the 
established method was made.  
The extraction involved use of chloroform. To avoid any leaching of plasticisers from plastics 
into the extraction mixture via chloroform, any contact of chloroform with plastic was 
avoided. 
Aliquots of the homogenised tissues prepared in section 2.2.2.3 (no less than 50 μl, equivalent 
to 5 mg of tissue, with ideal amount of 10 mg (100 μl)) were transferred to 1.8 ml glass vials 
containing an ice cold methanol: water mixture (40 μl:5.25 μl/mg wet tissue mass, HPLC 
grade methanol, Fisher Scientific) and vortexed (1 minute) at maximum speed. This was 
followed by the addition of ice-cold chloroform (40 μl/mg wet tissue mass, HPLC grade, 
Fisher Scientific, added using a Hamilton syringe, Fisher Scientific), water (20 μl/mg wet 
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tissue mass) and additional vortexing at maximum speed (30 seconds). Samples were placed 
on ice (10 minutes) to allow biphasic separation and then centrifuged at 1500 x g at 4°C for 
10 minutes. Samples were left at room temperature for 5 minutes, leading to a clear separation 
into 3 layers. The upper layer containing water, methanol and polar metabolites, the lower 
phase containing chloroform and non-polar metabolites and lipids separated from each other 
via denatured proteins. Aliquots (50 μl) of the polar phase were transferred to eppendorfs 
using a glass Hamilton syringe and stored at -80°C. The non-polar phase was transferred to a 
glass vial and stored at -80°C. The non-polar layer was not used in the work presented in this 
thesis. Polar extracts were dried using a centrifugal evaporator (Thermo Savant, Holbrook, 
NY) and stored at -80°C until analysis.  
 
2.2.3. European flounder (Platichthys flesus) liver tissue samples and calf (Bos taurus) 
thymus DNA 
The four healthy flounder liver samples used in Chapter 3 were provided by Dr Tim Williams, 
School of Bioscience, the University of Birmingham. These liver samples were dissected 
from immature fish with unknown sex. DNA extraction procedure for these liver samples was 
similar to the methodology used for dab samples described in sections 2.2.2.3.1. DNA from 
calf (Bos taurus) thymus was purchased from Sigma-Aldrich Chemical company (UK). 
 
2.3. Global measurement of DNA methylation levels 
2.3.1. Enzyme-linked immunosorbent assay (ELISA)-based method 
The Methylamp Global DNA Methylation Quantification kit (Epigentek Group Inc, Brooklyn, 
USA) was used according to the manufacture’s guidelines for quantification of global DNA 
methylation. The methylated DNA was immobilised onto the surface of the wells and bound 
via 5-methylcytosine antibody and quantified using ELISA. This method is suitable for 
limited starting materials; however, the variability and accuracy of the method is lower than 
high-performance liquid chromatography (HPLC) and LC-tandem mass spectrometry 
(MS/MS). 
Wells for samples, blank and control were placed in a plate frame included in the kit. GM2 
solution (28 μl) was added to each well followed by addition of 2 μl of sample (1μg DNA/1 
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μl) and mixed. For blank, 30 μl of GM2 and for control 29 μl of GM2 and 1 μl of GM3 was 
added. Wells were placed in the oven at 37°C for 2 hours, and 60°C for 30 minutes for 
complete evaporation of solution. This was followed by the addition of GM4 (150 μl) and 
incubation at 37°C for 45 minutes. Wells were washed 3 times with 150 μl diluted GM1 
(GM1 was diluted at 1:10 ratio with distilled water) and 50 μl of diluted GM5 (GM5 was 
diluted at 1:1000 ratio with diluted GM1) was added to each well and incubated at room 
temperature for 1 hour. Following incubation, wells were washed 4 times with diluted GM1 
(150 μl). Diluted GM6 (50 μl, GM6 was diluted at 1:1000 ratio with diluted GM1) was added 
per well and incubated at room temperature for 30 minutes. Wells were washed 5 times with 
diluted GM1 (150 μl) and GM7 (100 μl) and incubated in the dark for 10 minutes. After 10 
minutes, stopping buffer GM8 (50 μl) was added and the absorbance was read at 450 nm. 
Percentage of methylation was calculated according to the following formula: 
Percentage of methylation= OD (sample-blank) / OD (control-blank) x 100 
 
2.3.2. HPLC and LC-MS/MS 
The sample preparation procedure for both techniques is very similar. RNA contamination is 
eliminated from the DNA samples via enzymatic digestion of RNA. DNA samples are further 
enzymatically digested to form nucleotide monophosphates. 
 
2.3.2.1. Removal of RNA contamination of DNA samples for both HPLC and LC-
MS/MS 
Using TE buffer (10 mM (hydroxymethyl)aminomethane (Tris)-HCl, pH 8.0, 1 mM 
ethylenediaminetetraacetic acid (EDTA)) the total volume of the DNA sample (no less than 1 
µg) was adjusted to 300 μl. RNase A (lyophilised RNase A was dissolved in 10 mM Tris, PH 
7.5, 15 mM NaCl) was added to a final concentration of 100 μg/ml followed by the addition 
of RNase T1 to a final concentration of 2000 units/ml (lyophilised RNase T1 was dissolved in 
20 mM Tris, pH 7.5). The solution was gently mixed and incubated at 37°C for 2 hours. After 
incubation, an equal volume of phenol/chloroform/isoamylalcohol (25/24/1, pH 8.0) was 
added to the sample, mixed and centrifuged at 16000 x g for 2 minutes. The aqueous layer, 
containing DNA, was transferred to a clean eppendorf and DNA was precipitated by the 
addition of 0.1 volume of 3M sodium acetate (pH 5.2), 2.5 volumes of absolute ethanol and 
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centrifugation at maximum speed for 10 minutes. The supernatant containing the hydrolysed 
RNA was discarded. The DNA pellet was washed with 70% (v/v) ethanol and centrifuged at 
maximum speed for 10 minutes. The supernatant was removed and the DNA pellet was air 
dried. 
 
2.3.2.2. DNA hydrolysis prior to HPLC 
Following removal of RNA contamination (2.3.2.1.), DNA was re-suspended in 100 μl 
deoxyribonuclease (DNase) 1 digestion buffer (10 mM Tris-HCl, pH 7.2, 4 mM magnesium 
chloride, 0.1 mM EDTA) and DNase1 was added to the final concentration of 50 μg/ml. 
Samples were incubated at 37°C for 16 hours. The non-specific endonuclease activity of 
DNase I results in cleavage of the phosphodiester bonds of both double- and single-stranded 
DNA. This results in formation of mono and oligonucleotides with 5'-phosphate and a 3'-
hydroxyl groups. Following 16 hours of incubation, 2 volumes of 30 mM sodium acetate (pH 
5.2) and zinc sulfate to a final concentration of 1 mM were added, as nuclease P1 is a zinc 
dependent nuclease. This was followed by the addition of nuclease P1 dissolved in nuclease 
P1 buffer (50 mM Tris HCl, pH 8.0, 10 mM EDTA) with a final concentration of 50 μg/ml 
and incubation at 37°C for 7 hours. This enzyme catalyses the non-specific endonucleolytic 
cleavage of single stranded DNA. This results in the formation of nucleoside 5′-phosphates. 
After incubation, samples were stored at -70°C or directly injected (50μl) into the HPLC. 
 
2.3.2.3. DNA hydrolysis prior to LC-MS/MS 
The DNA pellet prepared in section 2.3.2.1, following removal of RNA contamination, was 
re-suspended in sterile water (50 μl). To denature the DNA, DNA sample was heated (100°C, 
3 minutes) and placed immediately on ice. A solution containing ammonium acetate (1M) and 
zinc chloride (1.25 μl; 45 mM, pH 5.1) was added to the sample. This was followed by the 
addition of nuclease P1 dissolved in nuclease P1 buffer (5 μl; 1 mg nuclease P1 was dissolved 
in 1 ml nuclease P1 buffer; nuclease P1 buffer: 50 mM Tris-HCl, pH 8.0, 10 mM EDTA) and 
incubation at 37°C for 2 hours. Following incubation, Tris (5 μl; 1.5 M, pH 8.0) and alkaline 
phosphatase (5 units; 0.2 units in 1 μl of 100 mM ammonium bicarbonate, pH 8.0) were 
added and the sample was incubated for 2 hours at 37°C. The hydrolysed DNA was filtered 
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using 0.2 μm filter (Millipore, Biomanufacturing and Life Science Research, UK) and syringe 
and stored at -20°C until analysed. 
 
2.3.2.4. Standards 
2'-deoxycytidine 5'-monophosphate (C9H12N3O7P) (dCMP), 5-methyl deoxycytidine 5'-
monophosphate, disodium salt (C10H14N3O7PNa2) (5mdCMP) (Reliable Biopharmaceutical 
Company, Missouri, USA), 2'-deoxythymidine 5'-monophosphate (C10H15N2O8P) (dTMP), 2'-
deoxyguanosine 5' monophosphate (C10H14N5O7P) (dGMP), 2'-deoxyadenosine 5'-
monophosphate (C10H14N5O6P) (dAMP), uridine 5'-monophosphate (C9H13N2O9P) (UMP), 
solutions (1 mg/ml) were prepared in DNase digestion buffer (2 parts nuclease P1 buffer, 1 
part DNase 1 digestion buffer; DNase 1 digestion buffer: 0.01 M Tris-HCl, pH 7.2, 0.1 mM 
EDTA, 4 mM magnesium chloride). Retention times of each of the standards were established 
by injecting 50 μl of each of the prepared solutions. The separation of the bases was 
investigated by the injection of a mixture of the 5 bases. Contamination with RNA was 
monitored using a standard for UMP.   
 
2.3.2.5. Reverse-phase high-performance liquid chromatography 
All the solutions used for HPLC were prepared using HPLC grade solvents. The prepared 
solutions were filtered and de-gassed (Trans sonic T460, CamLab). 
The method described by Ramsahoye (2002) was used for the measurement of global DNA 
methylation levels. A combination of factors, such as type of the column (solid phase), mobile 
phase, temperature and pH will affect the retention time and the observed order of separation 
of the components of a solution. The HPLC systems used were AKTA Explorer 10 with P900 
pump and automatic UV detector (Amersham Biosciences) and Dionex P580 pump (Idstein, 
Germany) with the same column and guard column. The samples were injected onto a column 
containing a non-polar hydrocarbon chemically bonded to the surface of a rigid silica particles 
(solid phase) while an aqueous based mobile phase was running at a constant pressure and 
speed (1 ml/minute) through the column. The components of the injected sample are 
separated and observed in order of their affinity to the mobile phase. At the beginning of each 
run and prior to running the aqueous based mobile phase (50 mM diammonium 
orthophosphate, 50 mM orthophosphoric acid, pH 4.1), the column (APEX C18 column, 250 
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x 4.6 mm internal diameters, 5 μm particle size; Waters: HPLC Ltd, UK, Phenomenex, UK) 
was first washed for 30 minutes with 20% (v/v) methanol followed by HPLC grade water (30 
minutes). After establishing a stable base line with the mobile phase, samples were injected 
(50 μl). At the end of each run the column was washed with water and 20% (v/v) methanol 
and stored in 20% (v/v) ethanol. 
 
2.3.2.6. Nucleotide detection 
Nucleotides were detected using a UV absorbance detector at the wavelength of 280 nm. This 
wavelength was used based on the λmax of dCMP and 5mdCMP (dCMP: 272.7 nm, 5mdCMP: 
278 nm). Unicorn 3.2 and Chromeleon 6.8 software (Dionex, Idstein, Germany) were used to 
calculate the peak area. Molar equivalents (ME) were calculated for 5mdCMP and dCMP 
using the peak areas and the extinction coefficients (dCMP: 9.3x10
3
, 5mdCMP: 11.8x10
3
, 
TMP: 10.2x10
3
, dGMP: 13.7x10
3
, dAMP: 15.3x10
3
). This was followed by calculating the 
percentage of DNA methylation as shown below. 
Molar equivalent (ME) = peak area/extinction coefficient (M
−1
 cm
−1
) 
% of DNA methylation = (ME5mdCMP/(ME5mdCMP + ME dCMP)) x 100 
 
2.3.2.7. LC-MS/MS 
The prepared hydrolysed DNA samples were sent to the Department of Toxicology, 
University of Wurzburg, Germany for measurement of the percentage of methylated DNA via 
LC-MS/MS and by an independent group. 
The hydrolysed DNA samples (1 µg) were diluted with mass spectrometry grade water (49.5 
µl; Fisher Scientific, Loughborough, UK). The diluted samples (10 µl) were injected into the 
LC-MS/MS system. LC-MS/MS analysis was performed using an Agilent 1100 series liquid 
chromatography system coupled to an API 3000 triple quadruple mass spectrometer equipped 
with Turbo ion spray source (Applied Biosystems, Darmstadt, Germany). Separation was 
achieved using a column (Reprosil Pur C18 column, 150 x 2 mm internal diameters, 5 µm 
particle size, Dr Maisch HPLC, Ammerbuch-Entringen, Germany) under a gradient running 
buffer (solvent A: 0.1% formic acid, solvent B: methanol) with the following conditions: 90% 
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A and 10% B (starting condition) followed by an increase to 40% B within the first 3 minutes 
and a liner increase to 100% B in 2.5 minutes with a flow rate of 300 µl/minutes. 
Analytes were detected in the positive ion mode with data acquisition performed as multiple 
reaction monitoring (MRM) of mass transitions of 268.2 mass to charge ratio (m/z) (parent 
compound) to 152.1 m/z (product) for 2-deoxyguanosine and mass transitions of 242.17 m/z 
(parent compound) to 108.95 m/z (product) for 5-methyldeoxycytidine. Quantification of 2-
deoxyguanosine and 5-methyldeoxycytidine was performed by using a serial dilution of 
known amounts of external standards and generation of a standard curve for the two 
compounds of interest. The concentrations of 2-deoxyguanosine represented the total 
concentration of 2-deoxycytidine in the samples. Global DNA methylation was expressed as 
percentage of methylated cytidine in total sample. 
 
2.4. Methylated-DNA immunoprecipitation (MeDIP) 
Methylated fragments of DNA were separated from the un-methylated fragments using 
MagMeDIP kit (Diagenode, Belgium). The optimum starting amount of DNA for each 
MeDIP reaction is 1 µg. The recommended starting amount of DNA prior to MeDIP for DNA 
methylation based microarray experiments is 5 µg. Two options are commonly used by 
research groups: 1. Whole genome amplification of the MeDIP products to generate the 
sufficient starting material for DNA methylation microarrays. However, preferential 
amplification of fragments of DNA can bias the results. 2. MeDIP of five identical aliquots of 
the same DNA sample followed by combining the final immunoprecipitated DNA fragments 
from the five aliquots. As the latter approach remove the complications encountered during 
the first method, this approach was used in the present study. 
DNA samples were dissolved in TE buffer (6 μg in 300 μl) and fragmented to generate 200 
bp_1000 bp products using a sonicator (SONICS Vibra Cell, 100 watt, 3 x 10 seconds with 35 
seconds intervals on ice with 20% amplitude). Lengths of the generated fragments were 
checked on a 1% agarose gel. The final concentration of the sonicated DNA was adjusted to 
0.1 μg/μl. A mastermix containing water (48 μl), magbuffer A (24 μl), magbuffer B (6 μl) was 
prepared. Prepared mixture (65 μl) was added to 10 μl of DNA (0.1 μg/μl, five aliquots of 
each sample), incubated at 95°C for 3 minutes and transferred immediately onto ice. In a 
separate 200 μl tube, 137.5 μl magbuffer A (1): water (5) mix was added to 11 μl of 
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resuspended beads and centrifuged (5 minutes, 230 x g). Supernatant was discarded and beads 
were washed again with 137.5 μl magbuffer A (1): water (5), centrifuged (5 minutes, 230 x g) 
and supernatant was discarded. The washed beads were suspended in 22 μl of the magbuffer 
A (1): water (5) mix and kept on ice until used. In a second 200 μl tube the following mixture 
was prepared per IP reaction and was added to the heated DNA samples prepared earlier: 
antibody (1): water (1) mix (0.3 μl), magbuffer A (0.6 μl), water (2.10 μl), magbuffer C (2 μl). 
Following addition of the resuspend washed beads (20 μl); samples were placed on a rotating 
wheel overnight at 4°C.  
The beads were washed after the overnight incubation. All washing steps were performed in 
the cold room (4°C). IP samples were removed from the rotator, briefly centrifuged in a bench 
top centrifuge in the cold room and placed on a magnetic rack for 1 minute. Supernatant was 
removed, ice cold magwash buffer 1 (100 μl) was added and the beads were resuspended by 
inverting the tube, and then samples were incubated on the rotating wheel (4 minutes, 4°C). 
Following incubation, samples were briefly centrifuged, placed on the magnetic rack for 1 
minute and supernatant was discarded. Beads were washed 3 times with magwash buffer 1 
and once with magwash buffer 2, following the above procedure. Eppendorfs containing the 
washed bead pellets were placed on ice and the remaining work was conducted at room 
temperature with the samples kept on ice. A mixture containing buffer D (360 μl), buffer E 
(40 μl) and buffer F (16 μl) was added to the pellets prior incubation in a thermo-shaker (10 
minutes, 65°C, 230 x g). One volume of phenol/chloroform/isoamyl alcohol (25:24:1) was 
added to the samples. Samples were incubated at room temperature for 10 minutes on a 
rotating wheel prior to centrifugation (2 minutes, room temperature 230 x g). The aqueous 
phase was transferred to a clean eppendorf and 1 volume of chloroform/isoamyl alcohol 
(24:1) was added to the samples and centrifuged (2 minutes, room temperature, 230 x g). The 
aqueous layer was transferred to a clean eppendorf and a mixture containing glycogen (0.02 
mg, Fermentas Life Sciences), co-precipitant (5 μl), precipitant (40 μl) and absolute ethanol (1 
ml) was added to the samples, vortexed and incubated (-80°C, 90 minutes). Following 
incubation, samples were centrifuged (30 minutes, 4°C, 230 x g). Ethanol (70% v/v, 500 μl) 
was added to the supernatant prior to centrifugation for 20 minutes at 230 x g at 4 °C. 
Supernatant was removed, DNA pellets were air dried and stored at -80°C until subsequent 
use. 
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2.5. Microarray experiments 
2.5.1. Pilot study: cDNA flounder microarray 
The flounder cDNA microarray was constructed for European flounder (Platichthys flesus) as 
part of Genomic Tools for Biomonitoring of Pollutant Coastal Impact (GENIPOL) project in 
2006. The procedure for construction of this microarray is described in detail in Williams et 
al., (2006). Briefly, 13,824  PCR amplicon clones derived from flounder cDNA, relating to 
approximately 3336 genes of European flounder (Platichthys flesus) were spotted onto a 
microarray slide (Corning UltraGAPS, Corning Inc., Corning, NY, USA) by an MGII robot 
(Biorobotics, Cambridge, UK) employing a 48 split pin tool. Each clone was spotted twice for 
a total of 27,648 distinct elements per microarray, including control DNA elements. Clones 
had been sequenced and annotated by BLAST against the GenBank database 
(www.blast.ncbi.nlm.nih.gov/Blast.cgi). As the library was redundant, many genes were 
represented by several overlapping clones; therefore, the intensity reading for all the 
overlapping probes representing a gene was averaged prior to data analysis. Sequences that 
were from the same gene that shared no overlapping regions were retained as separate 
identities and could either represent different genetic isoforms or different regions of the same 
gene. 
As sequence homology is sufficiently great between the two closely related flatfish, European 
flounder and dab, the use of this microarray for transcriptional studies in dab is valid (Diab et 
al, 2008; Cohen et al., 2007; Small et al., 2010). Hence, as a pilot study this microarray was 
employed in combination with MeDIP for investigation of DNA methylation alterations 
between dab HCA samples and surrounding tissues. Samples used in this experiment are 
indicated with number 5 in Table 2.1 section 2.2.2.1. An overview of the MeDIP-flounder 
cDNA microarray is given in Figure 2.3. 
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Figure 2.3. Overview of the dab MeDIP-flounder cDNA microarray experiment. DNA from 
dab hepatocellular adenoma (HCA) samples and surrounding liver tissues (ST) were 
sonicated, immunoprecipitated using an antibody against 5-methylcytosine and labelled with 
cyanine-5 labelled deoxycytidine triphosphate (Cy5-dCTP). Sonicated DNA samples from 
both groups of analysis were labelled with cyanine-3 labelled deoxycytidine triphosphate 
without immunoprecipitation (Cy3-dCTP). Cy3-dCTP and Cy5-dCTP labelled samples were 
hybridised to a flounder cDNA microarray.  : methylated cytosine,    : 5-methylcytosine 
antibody attached to a magnetic bead. 
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2.5.1.1. DNA labelling and purification 
Sonicated, MeDIPed DNA fragments from each biological sample were labelled with Cy5-
dCTP and the reference DNA sample was labelled with Cy3-dCTP. As these dyes are light 
sensitive care was taken to minimise their exposure to light. 2.5xRandom priming mix (20 μl) 
(Bioprime DNA labelling kit, Invitrogen, Paisley, UK) was added to the DNA samples and 
the final volume was adjusted to 41 μl using sterile water. To denature the DNA, samples 
were heated (100°C, 10 minutes) and placed immediately on ice. This was followed by the 
addition of 10xdNTPs (5 μl), each at 1.2 mM except dCTP at 0.6 mM (Bioline Ltd., UK), 
Cy3-dCTP or Cy5-dCTP (1 μl; GE Healthcare, Amersham, UK) and Klenow polymerase (1 
μl, equivalent to 40 units; Invitrogen) to the samples while they were on ice. This was 
followed by incubation of the samples in the dark (37°C, 18 hours). Following 18 hours of 
incubation, labelled DNA samples were purified and eluted in Tris-Cl buffer (10 mM, pH 8.5, 
60 μl; also known as elution buffer) using QIAquick spin columns (Qiagen Ltd, West Sussex, 
UK) according to the manufacturer’s protocol. Briefly, 0.1 volume of sodium acetate (3M, 
pH5.2) and 5 volume of PB buffer were added to 1 volume of labelled genomic DNA 
samples. Samples were mixed and transferred to QIAquick spin columns and centrifuged (1 
minute, 5900 x g). Flow through was discarded and buffer PE (750 μl) was added to the 
columns and centrifuged for 1 minute at 5900 x g. After discarding the flow through, columns 
were centrifuged for 1 minute. Columns were placed in 1.5ml eppendorfs and water (60 μl) 
was pipetted directly onto the membrane of the column. To elute the purified labelled DNA 
samples, columns were centrifuged for 1 minute. 
The concentration of labelled DNA samples were measured using a spectrophotometer (for 
Cy3-dCTP labelled samples, an intensity reading of 1 at A550 equated to 0.13 pmoles/μl of 
dye incorporated; for Cy5-dCTP labelled samples, an intensity reading of 1 at A650 equated 
to 0.08 pmoles/μl of dye incorporated). Cy5-dCTP labelled test DNA (60 pmoles) was mixed 
with labelled genomic pool (60 pmoles). The volume was adjusted to 30 μl with water or, if 
required, concentrated using microcon 30 excision filter (Millipore, Biomanufacturing and 
Life Science Research, UK). 
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2.5.1.2. Hybridisation 
For hybridisation 30 μl of 2x hybridisation buffer (50% formamide, 10x sodium citrate 
sodium chloride (SSC), 0.2% sodium dodecyl sulphate (SDS), 1.6 μg/μl poly-A (Alta 
Bioscience, Birmingham, UK) and 4 μg/μl yeast tRNA (Sigma-Aldrich Chemical Company, 
UK)) (Sambrook et al., 1989) was combined with 30 μl of the labelled mixture. Samples were 
heated (2 minutes at 95°C) and centrifuged (30 seconds) followed by pipetting of the mixture 
under a 25 × 60L coverslip (VWR, Lutterworth, UK) placed on a pre-hybridised slide. The 
pre-hybridised slide was located in a hybridisation chamber containing water (20 μl) and 
incubated overnight at 42°C. To prepare the microarray slides for hybridisaition, slides were 
placed in a pre-hybridisation solution (25% formamide, 5x SSC, 0.1% SDS, 10 mg/ml bovine 
serum albumin (BSA)) for 2_10 hours at 42°C. Slides were washed twice with water and once 
with absolute ethanol and dried by centrifugation at 400 x g for 10 minutes (Hettich Rotofix 
32, Hettich Labtechnology, Tuttlingen, Germany). 
 
2.5.1.3. Washing and scanning 
After incubation slides were washed in clean 50 ml centrifuge tubes (Falcon, Becton 
Dickinson Labware, Le Pont De Claix, France) on a Denley Spiramix 5 (Thermo Scientific, 
Langenselbold, Germany) with 2× SSC, 0.1% SDS solution for 5 minutes at 42°C, followed 
by 0.1 × SSC, 0.1% SDS solution for 5 minutes at room temperature, and four washes of 0.1 
× SSC solution for 5 minutes each. Slides were quickly dipped in two water washes, one 
absolute ethanol wash and dried by centrifugation (10 minutes, 400 x g). Slides were placed 
in a slide container and protected from exposure to light. 
Fluorescent signals were detected using an Axon 4000B laser scanner and Genepix software 
(Molecular Devices, Sunnyvale, CA, USA) (Figure2.4). Spots were checked manually and 
spots with poor morphology were excluded from further analyses and labelled as ‘not found’. 
Spot intensity was taken as the median value of all pixels in the spot, minus the median value 
of pixels surrounding the spot. 
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Figure 2.4. Scanned image of a flounder cDNA microarray from MeDIP-cDNA experiment. 
The microarray contains a total of 27,648 elements printed on 48 sub-arrays. Each sub-array 
contains 576 spots and each clone is spotted in duplicate. 
 
2.5.2. CGI (1.5kb downstream to 1kb upstream of TSS) zebrafish tiling microarray 
experiment 
The experimental procedure used is similar to the methodology described in section 2.5.1 for 
MeDIP-cDNA flounder microarray experiment (Figure 2.3). In this experiment 4 male 
zebrafish HCC samples and 4 male zebrafish liver control samples were used.  
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2.5.2.1. Design of the 4x44k format CGI (1.5kb downstream to 1kb upstream of TSS) 
zebrafish tiling microarray 
Probes were designed by Genotypic (Genotypic Technology, Bangalore, India) and printed by 
Agilent (Agilent technologies, Berkshire, UK). The criteria described by Gardiner-Garden and 
Frommer (1987) for prediction of CpG islands in vertebrate were used to predict CpG islands 
in zebrafish, with minor modifications. These criteria were: percentage of C+G >50%, length 
>100 bp and observed/expected ratio >0.6. The zebrafish genome sequence derived from 
Ensembl database (version 56, genome build zv8, genome build date April 2009) was 
employed. Repetitive sequences were masked and the Emboss CpG prediction tool 
(http://www.ebi.ac.uk/Tools/emboss/cpgplot/) identified 9,192 genes containing 14,507 CpG 
islands in the region of 1.5kb upstream to 1kb downstream of transcription start sites (TSS). 
The 5' end of each transcript was used as TSS. From the preliminary list of genes (9,192), 60-
mer probes were designed with an average spacing of 25 bp where possible. Due to probe 
specificity, probes could not be constructed for all predicted CGIs and this also influenced the 
probe spacing. Probes with multiple BLAST hits on the zebrafish genome and with an 
identical 55 bp alignment were removed. Finally, 43,960 probes were designed for 7,903 
CGIs on 6,024 genes. Slides were printed containing 45,220 features; 1,227 Agilent control 
features, 33 blank features and 43,960 probes. The microarray design was named Agilent 
Birmingham D.rerio 025794 45220v1 and its design is available from ArrayExpress under 
accession A-MEXP-1813. Probes were functionally annotated against the zebrafish genome 
and additional gene ontology (GO) terms were found using Blast2GO (Gotz et al., 2008). 
 
2.5.2.2. DNA labelling  
The Agilent Genomic DNA enzymatic labelling kit (Agilent technologies, Berkshire, UK) and 
the protocol provided were used with minor modifications for labelling the MeDIPed test 
DNA and the genomic pool. Immunoprecipitated DNA was dissolved in nuclease free water 
(26 μl), random primers (5μl) were added and samples were mixed by pipetting. This was 
followed by incubation at 95°C for 3 minutes and 5 minutes incubation on ice. A labelling 
mastermix containing 5xbuffer (10μl), cyanine-3 labelled deoxyuridine triphosphate (Cy3-
dUTP) or cyanine-5 labelled deoxyuridine triphosphate (Cy5-dUTP) (1mM, 3μl), Exo-
Klenow fragment (1μl) was prepared on ice and added to the sample. To clean the labelled 
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samples, 1xTE buffer pH 8.0 (430μl) was added to the samples and transferred to a microcon 
30 size exclusion filter (Millipore, Biomanufacturing and Life Science Research, UK) and 
centrifuged at 8000 x g for 10 minutes. After discarding the flow-through 1xTE buffer pH 8.0 
(480 μl) was added and the samples were re-centrifuged for concentrating the samples to a 
final volume of 13 μl. Qualities of the labelled samples were checked using NanoDrop 
spectrophotometer. Samples with a Cy5 pmol/μg yield of >7 and Cy3 pmol/μg yield of >18 
were used. Equal pmol (80 pmol) of Cy3-dUTP and Cy5-dUTP labelled DNA samples were 
mixed and the final volume was adjusted to 22.5 μl using RNase/DNase free distilled water.  
 
2.5.2.3. Hybridisation  
Sample hybridisation was performed using Agilent Oligo aCGH/Chip on chip hybridisation 
kit. 10x blocking agent was prepared by addition of nuclease free water (1250 μl). The 
following components were added in order to a 1.5 ml eppendorf: Cy3-dUTP/Cy5-dUTP 
labelled DNA mixture (22.5 μl), Cot-1 DNA (5 μl; Invitrogen), Agilent 10x blocking solution 
(11 μl), de-ionized formamide (16.5 μl) and Agilent 2x hybridization buffer. The prepared 
mixture was centrifuged, heated (3 minutes, 95°C) and transferred to a circulating water bath 
for 30 minutes. After incubation samples were centrifuged (1 minute, room temperature, 
17900 x g). Samples (100 μl) were loaded into individual wells of a gasket slide held in the 
base of a hybridisation chamber (Agilent technologies, Berkshire, UK). A 4x44k format 
microarray was placed on top of the gasket slide. Chambers were reassembled and clamped 
and placed in an Agilent hybridisation oven (24 hours, 67°C, 3 x g) (Figure 2.5).  
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Figure 2.5. Agilent chamber. A. The individual components and an assembled Agilent 
hybridisation chamber. B. To load the samples gasket was placed in the chamber base and 
each sample was pipetted into the 4 individual wells of the gasket slide. The microarray was 
placed on top of the gasket slide. The chamber cover was placed on top of the microarray 
slide and the chamber base and cover were clamped securely together. 
 
 
2.5.2.4. Washing and scanning 
Following overnight hybridisation, slides were separated from the gasket slides and washed 
using oligo aCGH wash buffer 1 and 2, stabilisation and drying solution (Agilent 
technologies, Berkshire, UK). Slides were dipped in a slide staining dish containing wash 
buffer 1 at room temperature to remove the gasket. Next, they were placed in a second dish 
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containing the wash buffer 1. After placing the slides, the solution was stirred for 5 minutes 
using a magnetic stirrer. After 5 minutes, slides were transferred to a staining dish containing 
wash buffer 2 (37°C, 1 minute) while stirring with a magnetic bar. Slides were immediately 
dipped in acetonitrile followed by dipping in stabilisation and drying solution. The dried 
slides were scanned using an Axon 4000B laser scanner and Genepix software (Molecular 
Devices, Sunnyvale, CA, USA) (Figure 2.6). 
 
 
Figure 2.6. Zebrafish 4x44k tiling microarray. A. Scanned image of a zebrafish 4x44k tiling 
microarray. Each of the four sections contains 43,960 probes and act as an individual 
microarray. B. Enlarged image of a sub-array. The green colour represents lower signal 
intensity from the test sample compared to the reference sample. The red colour represents 
higher signal intensity from the test sample compared to the reference sample. The yellow 
colour indicates equal signal intensity from both samples. 
 
 
  
 
  A. B. 
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2.5.3. Dab MeDIP de novo high-throughput sequencing and transcriptomic profiling 
DNA extracted from a hepatocellular adenoma sample and corresponding surrounding tissue, 
as described in section 2.2.2.3.1, were subjected to immunoprecipitation using 5-
methylcytosine antibody as described in section 2.4. Samples used for this experiment are 
indicated in Table 2.1 section 2.2.2.1. The immunoprecipitated fragments of DNA were 
subject to de novo DNA high-throughput sequencing (HTS) using an Illumina Genome 
Analyser II (Illumina, Inc, USA). This was conducted at Beijing Genomic Institute (BGI), as 
briefly described in section 2.5.3.1. The data achieved from the MeDIP-HTS aided the design 
of a dab specific gene expression microarray. The samples used in this experiment are shown 
in Table 2.1, section 2.2.2.1 and the experimental procedure is explained in section 2.5.3.3. 
An overview of the described experimental procedures is shown in Figure 2.7.  
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Figure 2.7. Overview of the MeDIP, HTS, assembly of contigs, design of the dab microarray and microarray experimental procedure.          
* Dab HCA tumour,       surrounding tissue 
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2.5.3.1. MeDIP de novo high-throughput sequencing  
The MeDIP de novo high-throughput sequencing was conducted at Beijing Genomics 
Institute (BGI, China) based on methods described by Li et al., (2010). Briefly, DNA samples 
extracted from one HCA sample and corresponding surrounding tissue (5 μg) were sonicated. 
Fragmentation was carried out using a Covaris sonication system (16 cycles of duty cycle: 
10%, intensity: 5, cycles/burst: 200, time: 16 minutes; Covaris, Inc, USA) which resulted in 
100-500 bp rich DNA fragments. The Illumina Paired-end library preparation kit (Illumina, 
Inc, USA) and the protocol provided were used to generate adaptor-attached DNA fragments 
for sequencing. During this process the overhangs from fragmentation were converted into 
blunt ends using T4 DNA polymerase and Klenow polymerase. ”A” base was added to the 3' 
end of the blunt end phosphorylated DNA fragments which provided a recognition site for a 
single “T” base overhang containing adaptors. Methylated adaptor ligated DNA fragments 
were separated from the un-methylated fragments using the methodology described in section 
2.4. 
The methylated fractions were purified and eluted in Tris-Cl buffer (10 mM, pH 8.5, 27 μl) 
using ZYMO DNA Clean and Concentrator-5 kit (Zymo Research Corporation, CA, USA), 
following the manufacturer’s instructions. Briefly, 2_7 volumes of DNA binding buffer was 
added to each volume of sample, mixed and transferred to Zymo-Spin column. The column 
was centrifuged (30 seconds, 10000 x g) and the flow through was discarded. Column was 
washed with wash buffer (200 µl), centrifuged (30 seconds, 10000 x g) and the flow through 
was discarded. The column was transferred to a clean eppendorf and the sample was eluted by 
direct addition of Tris-Cl buffer (10 mM, pH 8.5, 27 μl) to the membrane of the column and 
centrifugation at 10000 x g for 30 seconds. The eluted DNA was amplified by adaptor-
mediated PCR in a final reaction volume of 50 μl. The reaction contained purified DNA (23 
μl), Phusion DNA polymerase mix (25 μl) and PCR primers (2 μl). Cycling parameters 
consisted of: 94°C for 30 seconds, 16 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 
72°C for 30 seconds with a final step of 1 minute at 72°C. Products were sequenced using 
Illumina Genome Analyser II (Illumina, Inc, USA). Raw data for both samples, hepatocellular 
adenoma HCA-18-RA09065-830 and healthy surrounding tissue ST-19-RA09065-830, were 
submitted to NCBI database with accession numbers GSE31124 and GSM770685, 
respectively. 
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2.5.3.2. Identification and annotation of differentially methylated regions 
HTS of MeDIP genomic DNA from the HCA sample and ST sample produced 89,925,735 
and 87,826,470 paired-end reads, respectively. The SOAP de novo software (a member of 
Short Oligonucleotide Analysis Package family) was used to assemble the reads with a 25 k-
mer overlap to achieve sets of contiguous sequences (contigs) for both samples. The 
assembled contigs later contributed to microarray design as described in section 2.5.3.3. 
In order to identify differentially methylated regions that contained CGIs in the HCA sample 
compared to ST, a third assembly was generated by combining the reads from both individual 
samples (HCA and ST). Contigs were generated using the list of combined reads from both 
samples and SOAP de novo software. N50 contigs with length <200bp were discarded and the 
remaining N50 contigs were defined as “methylated DNA fragments”. (Note: N50 contig size 
was defined as the length of the smallest contig S in the sorted list of all contigs where the 
cumulative length from the largest contig to contig S was at least 50% of the total length). 
Reads from HCA and ST were aligned to the “methylated DNA fragments” assembled by 
SOAP software. The sequences that were uniquely mapped with <2 bp mismatches were 
retained. This assembly resulted in 264,008 contigs with lengths >200 bases, of which 69,046 
passed the CGI criteria (observed/expected > 0.6 and CG% > 50%), with an average length of 
323.22 bases. As the numbers of short reads contributed by each sample to each contig was 
known, the ratio of enrichment between HCA and ST was calculated to identify candidate 
with differentially methylated CGIs. The identified candidate CGIs (1,693 contigs) were 
annotated using BLASTx versus Genbank non-redundant (nr) protein database employing 
Blast2GO at E-value < 1E-06 (Gotz et at., 2008; Conesa et al., 2005). 
 
2.5.3.3. Design of flatfish dab specific 8x15k oligo microarray based on contigs achieved 
from MeDIP de novo HTS  
The oligonucleotide microarray was designed via Agilent eArray (Agilent technologies, 
Berkshire, UK). The microarray was designed using the 1,693 differentially methylated 
contigs with known protein-coding sequences. The 1,693 contigs were achieved from the 
HTS run, as described in section 2.5.3.1. However, these contigs were supplemented with 
additional data to produce a more comprehensive resource for dab transcriptomics. Eight four 
of the most highly differentially methylated unidentifiable CGIs from the HTS results were 
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included. This necessitated the design of both forward and reverse microarray probes for these 
specific CGIs. Additional putative protein coding sequences were derived from the CGI 
contigs that displayed no differential DNA methylation (7416), the HCA and ST assemblies 
>60 bases that aligned with flatfish expressed sequence tags (ESTs: 1599) and that matched 
with other protein coding sequences (3864) and 5 gene sequences from other flatfish species. 
These were manually curated to reduce duplication of probes for sequences aligning with the 
same orthologs. In total 14,951 sequences were uploaded to Agilent eArray, resulting in the 
successful design of 14,919 60-mer probes. The microarrays were printed in 8x15k format 
with each sub-array including 14,919 experimental spots, 290 empty positions and 77 
negative and 459 positive Agilent control spots (Agilent-031032_8x15k_BhamDab). The 
microarray details and experimental design (Transcription profiling of dab hepatocellular 
adenoma liver) are available from ArrayExpress under accessions A-MEXP-2084 and E-
MTAB-734, respectively.   
 
2.5.3.4. Quality assessment 
In addition to using NanoDrop ND-1000 UV-VIS Spectrometer version 3.2.1 (Nanodrop, 
USA) for the assessment of the quality of RNA samples as described (section 2.2.2.3.1), the 
integrity of the RNA samples and the assessment of contamination of the RNA samples with 
DNA, was evaluated using 2100 Bioanalyzer and a Eukaryote Total RNA Nano assay chip 
and Agilent small RNA kit (Agilent Technologies, Berkshire, UK). Briefly, Gel Matrix (550 
µl) was transferred to the filter columns provided with the kit and centrifuged (10 minutes, 
1500 x g). An aliquot of the filtered Gel Matrix (65 µl) was transferred into an eppendorf and 
the remaining Gel Matrix was stored at 4ºC for later use. Dye (1 µl) was added to the Gel 
Matrix, vortexed and centrifuged at 13000 x g for 10 minutes. The prepared mixture was 
placed on ice in the dark. A chip was placed in the chip priming station. Avoiding any debris 
and air bubbles, the gel-dye mix (9 µl) was pipetted into the well of the chip marked as G with 
a black dot. Plunger was set to 1 ml mark followed by closing of the chip priming station. The 
plunger was pressed down until it reached the chip surface and was held in this position for 30 
seconds and then released. After an additional 5 seconds the plunger was slowly pulled back 
up to the 1 ml mark and the chip was removed from the chip priming station. 
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An additional gel-dye mix (9 µl) was pipetted into the two wells of the chip marked as G with 
grey shading and the remaining mixture was discarded. NanoMarker buffer (5 µl) was 
pipetted into each of the 12 sample wells and the ladder well. To eliminate any secondary 
structures, the RNA samples and the ladder were denatured by heating (2 minutes, 70ºC). The 
heated samples and the heated ladder were briefly centrifuged and 1 µl was loaded into the 
appropriate wells. The chip was vortexed using Agilent Chip Vortexer for 1 minute at 240 
revolutions per minute (rpm) and placed in the 2100 Bioanalyzer. Equipment used are shown 
in Figure 2.8 and examples of Bioanalyzer trace is shown in Figure 2.9.  
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Figure 2.8. Equipment required for assessment of RNA integrity with Agilent 2100 
Bioanalyzer. RNA chip with different sections of the chip, chip priming station, the location 
of the chip in the priming station and an assembled chip, priming station and plunger are 
shown in this figure.  
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Figure 2.9. 2100 Bioanalyzer traces. A. An electropherogram example of a good quality RNA 
sample. Bioanalyzer marker: this is a 25 bp marker to standardise each of the lanes to the 
ladder that is run with each chip. The majority of the total RNA is 18S (2 kilobase pairs (kb)) 
and 28S (5 kb) ribosomal RNA. mRNA samples comprise a small percentage of the total 
RNA (~ <3%) and therefore, it is difficult to assess their quality directly. Thus rRNA quality 
is used as an indicator of the quality of the underlying mRNA population. Clear bands for 18S 
and 28S rRNA is indicative of intact RNA sample. Contamination of RNA samples with 
DNA is shown as a peak in the region indicated with a circle. B. Example of 
electropherogram of a degraded RNA sample. Images were adapted from Agilent website.  
 
 
 
 
 
B. 
A. 
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2.5.3.5. DNase treatment of RNA samples 
RNA samples with genomic DNA contamination, detected by using the 2100 Bioanalyzer, 
were treated with genomic DNA-free kit (Ambion Applied Biosystems, Warrington, UK) in 
order to digest and remove any traces of genomic DNA. 
Water was used to adjust the volume of the RNA samples (5 µg) to 25 µl. DNase I (0.5 µl) 
and DNase I buffer (2.5 µl) were added to the samples followed by incubation at 37ºC for 30 
minutes. After completion of the incubation time, DNase inactivation reagent was vortexed 
and 0.1 volume was added to the samples (with the maximum amount of 2 µl). This was 
followed by incubation of the samples at room temperature for 2 minutes, during which 
samples were mixed at least 3 times. To separate the digested DNA from RNA samples, 
samples were centrifuged (90 seconds, 10000 x g) and the supernatant containing the RNA 
sample was transferred to an RNase free eppendorf. 
 
2.5.3.6. cDNA and cRNA synthesis and labelling 
The Agilent Two Colour Low Input Linear Amplification Kit with Spike-ins (Agilent 
technologies, Berkshire, UK) and the protocol provided, were used for labelling. The total 
RNA from both HCA and ST samples were converted to cDNA, labelled with cyanine-5 
labelled cytidine triphosphate (Cy5-CTP) and converted to complementary RNA (cRNA). 
The reference sample was generated by combining RNA from all samples. The total RNA 
from the reference sample was labelled with cyanine-3 labelled cytidine triphosphate (Cy3-
CTP) and subsequently converted to cRNA.  
Briefly, total RNA (50 ng) dissolved in water (1.5 µl) was supplemented with Agilent two-
colour spike mix, T7 promoter primer (0.8 µl) and the volume was adjusted to 3.5 µl with 
nuclease free water. The sample was denatured by incubating the mixture at 65ºC for 10 
minutes followed by incubation on ice for 5 minutes. During this incubation time, the 5x first 
strand buffer was heated (4 minutes, 80ºC) and a mastermix containing: 0.1 M dithiothreitol 
(DTT, 2 µl), 10 mM dNTP mix (0.5 µl), 5x heated First strand buffer (6 µl) and AffinityScript 
RNase block mix (1.2 µl) was prepared on ice. The prepared mastermix was added to the 
sample, mixed and incubated at 40º for 2 hours, 70ºC for 15 minutes and 5 minutes on ice for 
the synthesis of cDNA.  
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The synthesised cDNA was subsequently labelled and converted to cRNA by addition of a 
mastermix containing nuclease free water (0.75 µl), 5x Transcription buffer (3.2 µl), 0.1 M 
DTT (0.6 µl), NTP mix (1 µl), T7 RNA Polymerase Blend (0.21 µl) and Cy3-CTP or Cy5-
CTP (0.24 µl) depending on the type of sample. Following gentle mixing, samples were 
incubated at 40ºC for 2 hours.  
Any uncoupled Cy3-CTP and Cy5-CTP were removed using the RNeasy mini kit (Qiagen 
Ltd, West Sussex, UK) and the protocol provided. Briefly, nuclease free water (84 µl), buffer 
RT (350 µl) and absolute ethanol (250 µl) were added to the labelled samples and mixed by 
pipetting. Samples were transferred to RNeasy columns and centrifuged (30 seconds, 15700 x 
g). Columns were transferred to clean collecting tubes and washed twice with buffer RPE 
(500 µl) and centrifuged (30 seconds, 15700 x g). Columns were placed in RNase free 
eppendorfs and RNase free water (30 µl) was added directly to the membranes of the 
columns. Samples were incubated at room temperature for 1 minute followed by 
centrifugation (30 seconds, 15700 x g) for eluting the cyanine labelled cRNA samples. 
Labelling efficiency was determined by NanoDrop ND-1000 UV-VIS Spectrophotometer, 
version 3.2.1 (Nanodrop, USA). A yield of 0.825 μg cRNA, and a specific activity (Cy3 and 
Cy5 dye incorporation) of >6 pmol Cy3/μg cRNA was considered sufficient.  
 
2.5.3.7. Hybridisation  
Microarray hybridisation was performed using an Agilent Gene Expression Hybridisation kit 
(Agilent technologies, Berkshire, UK) and according to the manufacturer’s protocol. 10x 
blocking agent was prepared by the addition of nuclease free water (1250 μl). The following 
components were added in order to a 1.5 ml eppendorf: Cy3 labelled cRNA (300 ng), Cy5 
labelled cRNA (300 ng), 10x blocking agent (5 µl), water (to adjust the volume to 24 µl) and 
25x fragmentation buffer (1 µl). Samples were gently mixed and fragmented by incubation at 
60ºC for 30 minutes. The fragmentation reaction was stopped by incubation of the samples on 
ice for 1 minute. 2x GEx hybridisation buffer HI-RPM (25 µl) was added to each sample 
followed by careful pipetting and centrifugation (1 minute, room temperature, 15700 x g). 
Samples were placed on ice and randomly loaded onto 8x15K format slides (Agilent-
031032_8x15k_BhamDab) and hybridised overnight (65°C, 10 rpm). 
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2.5.3.8. Washing and scanning 
Washing steps were similar to the methods described in section 2.5.2.4. The dried slides were 
scanned using an Agilent G2565CA microarray scanner system (Agilent technologies, 
Berkshire, UK). 
 
2.6. Bisulfite sequencing PCR 
2.6.1. Overview of the bisulfite sequencing PCR 
Bisulfite sequencing PCR (BSP) is the ‘gold standard’ methodology for detection of 5-
methylcytosine (5mC). This method provides a detailed analysis of the methylation status of 
individual CpGs within the amplified regions. During prolonged incubation of DNA with 
sodium bisulfite, cytosines in single stranded DNA are deaminated and converted to uracil 
while 5mC is immune to this transformation (Suzuki and Bird, 2008). This allows the 
distinction of methylated cytosines from remaining un-methylated cytosine. The sodium 
bisulfite treated DNA is amplified using BSP specific primers and then sequenced (Figure 
2.10). CpH (H=A, C, T) regions within a sequence are used as internal controls for the 
measurement of efficiency of the sodium bisulfite treatment. Successful sodium bisulfite 
treatment will result in conversion of all cytosines located at these regions to thymine. 
 
 
Figure 2.10. Bisulfite sequencing PCR. During bisulfite treatment, un-methylated cytosine is 
deaminated and converted to uracil. This allows the distinction of methylated cytosines from 
un-methylated cytosines. Green C: un-methylated cytosines, Red C with a star: methylated 
cytosines. 
 
Sodium bisulfite 
treatment 
 PCR amplification 
and sequencing 
5’---GAGTCACCGTTC*GTTAA---3’ 
3’ 
5’---GAGTUAUUGTTC*GTTAA---3’ 
3’ 
5’---GAGTTATTGTTC*GTTAA---3’ 
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2.6.2. Sodium bisulfite treatment 
The EZ DNA Methylation kit (Cambridge Biosciences, UK) was used for bisulfite 
conversion, according to the manufacturer’s protocol. Prior to the start of the experiment, the 
amount of the DNA samples were adjusted to 400 ng and the CT-conversion reagent was 
dissolved in water (750 μl) and M-dilution buffer (210 μl), and then vortexed for 10 minutes 
at room temperature. The CT-conversion reagent is light sensitive; therefore, care was taken 
to minimise its exposure to light. 
M-dilution buffer (5 μl) was added to the DNA samples (400 ng) and the final volumes of the 
samples were adjusted to 50 μl with water. Samples were incubated at 37°C for 15 minutes. 
After incubation, CT-conversion reagent (100 μl) was added to each sample and the samples 
were incubated at 50°C for 16 hours in the dark. Following incubation, samples were placed 
on ice for 10 minutes. During this time M-binding buffer (400 μl) was added to each Zymo-
spin column placed in collecting tubes. After 10 minutes, samples were transferred to the 
columns and mixed with the M-binding buffer by inverting the columns several times and 
then the samples were centrifuged (>10000 x g, 30 seconds). The flow through was discarded, 
M-wash buffer (100 μl) was added to the columns and then the columns were centrifuged for 
30 seconds at full speed. M-desulphonation buffer (200 μl) was added to the columns and 
samples were incubated at room temperature for 20 minutes, and then centrifuged at full 
speed for 30 seconds. Columns were washed twice with M-wash buffer (200 μl) and 
centrifuged twice for 30 seconds. Following the final wash, columns were placed in clean 
eppendorfs and M-elution buffer (10 μl) was added directly onto the membranes, and then 
columns were centrifuged for 30 seconds to elute the bisulfite treated DNA samples. 
 
2.6.3. Design of the bisulfite sequencing PCR primers 
The MethPrimer software was used for identification of CpG islands (CGI) and design of BSP 
primers within a given DNA sequence (Li and Dahiya, 2002) (Figure 2.11). The criteria for 
prediction of CpG islands (CGI) in vertebrates (length >200bp, observed/expected >0.6, CG% 
>50), as described by Gardiner-Garden and Frommer (1987) were used for the identification 
of CGIs. The bisulfite treated DNA was used as a template for the design of the BSP primers. 
The primers were designed at either ends of the CGIs at locations free of CpG dinuclotides. 
This allowed un-biased amplification of both methylated and un-methylated DNA templates. 
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BSP primers only contain three nucleotide types. One primer contains A, G and T nucleotides 
and has an excess of T nucleotide while the other contains A, C and T nucleotides and has an 
excess of A nucleotide. The primers used in this thesis are shown in Tables 2.2 and 2.3.  
 
 
Figure 2.11. The methprimer programme used for identification of CGIs and design of 
bisulfite sequencing PCR primers. As an example, the sequence for the promoter region of the 
coronin, actin binding protein 2ba gene (coro2ba; ENSDARG00000079440) on chromosome 
7 was imported into the methprimer software. The programme was set for design of BSP 
primers around CGIs. The region highlighted in light blue represents a CGI and the location 
of each CpG is shown with a red line.  
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Symbol Chr.no Gene ID Primer 
Annealing 
temp (°C)  
Product 
size (bp) 
gstp1 14 ENSDARG00000005039 
F:  5'-TTATATTTATAGTTTTGGTTGTTTTT-3'  
R: 5'-CTACTCCTAATCTACAATACACTATC-3' 
53.3 230 
Mycb-1 2 ENSDARG00000007241 
F: 5'-TAGAGTTGTTTGTTGGGTTTGTATT-3'  
R: 5'-AAAACTACTTATCATAATATTCTTCC-3' 
53.3 166 
Mycb-2 2 ENSDARG00000007241 
F: 5'-TTTTTTTATTGTTATATTTATGTTTTTATA-3'  
R: 5'-ACTACTTATCATTTACTACAAAATTTC-3' 
53.3 226 
cdh1 7 ENSDARG00000024371 
F: 5'-ATTTATATTTGGAAATTGTGATTAT-3'  
R: 5'-AATTATTACACAAACCATTTAACTC-3' 
51.3 210 
cdk8 24 ENSDARG00000016496 
F: 5'-TTTTTAAATAAAGGGTTAAAATTTA-3'  
R: 5'-AATACAAAATATTATTAAACTAACAATC-3' 
52.3 196 
timp2 3 ENSDARG00000037806 
F: 5'-TAAAATAGATGATGGATATGATGATTAAG-3'  
R: 5'-CCAACACTAACACAAATACAATAAAAAAC-3' 
52.3 242 
hsp90ab1 11 ENSDARG00000029150 
F: 5'-TGTTTAAAGTTGAAAATAAATTTATAAT-3 
R: 5'-ACTACTTTCAACCATTCACTACACC-3' 
52.3 236 
mapk1 5 ENSDARG00000027552 
F: 5'-GAAAAGTTAATTGTTTTTATGGTAT-3'  
R: 5'-ATTAACAAACATATATTTTCTACTAATAAT-3' 
52.3 183 
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Continued from previous page 
tp53 5 ENSDARG00000035559 
F: 5'-GATTTGGATGTAGAAAGTTTATTGGATA-3'  
R: 5'-CCCCTAATTACAAAAAAAACATATAAC-3' 
54.3 244 
msh6 13 ENSDARG00000011666 
F: 5'-TTTTTATTGGTTTATATGTAAATGA-3'  
R: 5'-CTCAAAACTACCCTACAATTATAAC-3' 
53.3 118 
msh2 12 ENSDARG00000018022 
F: 5'-AAGTTTATAATAAGATAGTAATGTTTGT-3'  
R: 5'-TCCATTAATCTTAAAAACCTCTTTAACTAC-3' 
53.3 285 
ntla 19 ENSDARG00000009905 
F: 5'-GGAAATATGTTTGTTTTAAGTTT-3'  
R:5'-ATAACAATCATTTCATTAATAAACTCTTTA-3' 
54.3 179 
dnmt4 23 ENSDARG00000036791 
F: 5'-ATTATTATTTTGAGAAAGGGTTAAATAGT-3'  
R:5'-AAAAATAATCCACTACCAAAATACC-3' 
52.3 230 
rap2c 14 ENSDARG00000015649 
F: 5'-TTGATTATTTAAGAGAGAGAAAATT-3' 
R: 5'-CAAAAAATTTATTAACCACACAAAC-3' 
52.3 222 
cx43 20 ENSDARG00000041799 
F: 5'-TGGTTTAGTTTTTTTATTTATTAGGGTT-3'  
R: 5'-TAAATTTCCTCCACAATCCAAAA-3' 
53.3 197 
coro2ba 
 
7 
 
ENSDARG00000079440 
F: 5'-TGTTGTTATGTGTTTTGTAGATGTTATG-3' 
R: 5'-ACCTATATTTTACCATTAATTTAATATAAA-3' 
53.8 315 
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Table 2.2. Bisulfite sequencing PCR primers used in zebrafish study (Chapter 3). Glutathione S-transferase P1 (gstp1), Transcriptional 
regulator Myc-B (mycb), cadherin 1 (cdh1), Cell division protein kinase 8 (cdk8), TIMP metallopeptidase inhibitor 2 (timp2), Heat shock 
protein HSP 90-beta (hsp90ab1), Mitogen-activated protein kinase 1 (mapk1),  Cellular tumor antigen p53  (Tumor suppressor p53) 
(tp53), MutS homolog 6 (msh6), MutS homolog 2 (msh2), No-tail gene (ntla), DNA (cytosine-5-)-methyltransferase 4 (dnmt4), RAP2C, 
member of RAS oncogene family (rap2c), Gap junction alpha-1 protein (Connexin-43) (cx43), coronin, actin binding protein 2ba 
(coro2ba), insulin-like growth factor binding protein 1b (igfbp1b) and angiopoietin-like 3 (angptl3). F: forward primer, R: reverse primer.
Continued from previous page 
Igfbp1b 2 ENSDARG00000038666 
F: 5'-TAAGTGTAGTTTAAAATATAAGTGTTGAAA-3'  
R: 5'-TATACTCTAACAAAATAACCTCAAC-3' 
53.8 271 
angptl3 6 ENSDARG00000044365 
F: 5'-TGTATAAATTTTTTGAGATTTTGGT-3' 
R: 5'-ATAACTAAACTTATCCACAACAAAC-3' 
53.8 180 
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Table 2.3. Bisulfite sequencing PCR primers used in dab study (Chapter 4). protocadherin 1 gamma 22 (pcdh1g22), microtubule-
associated protein 1aa (map1aa), tubulin tyrosine ligase-like member 7 (ttll7), nidogen 1(nid1). F: forward primer, R: reverse primer. 
Gene symbol Contig ID Primer 
Annealing 
temp (°C) 
Product 
size (bp) 
pcdh1g22 6580896 
F: 5'-GGGTTATTTGGTTATTAAGGTGA-3' 
R: 5'-TCTATAAACAACCTCTAAAAAAAATC-3' 
53.3 183 
map1aa 6176098 
F: 5'-TTTGTGATTTGAATAAAGAGTTGTA-3' 
R: 5'-TCTCAAAAAAACAAATACAAATAAATACTA-3' 
52.4 165 
ttll7 6540261 
F: 5'-TATAGTTTTATATTTAAAATTTGGATTTTT-3' 
R: 5'-ATACTTATCCTTTATTTATTCTACCACTAA-3' 
53.3 283 
nid1 6612046 
F: 5'-TGTTGAGTGGTTTTTAATTTGTTGT-3' 
R: 5'-AAATATTTATATATTCTCTCCTTCC-3' 
52.4 224 
non-coding protein region 6429668 
F’: 5'-GTTTGTGGGATTTATTGTGGATTA-3' 
R: 5'-CACAAAATTTAAATACTTCTACTATC-3' 
53.3 154 
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2.6.4. Amplification of the sodium bisulfite treated DNA 
CpG islands are highly repetitive regions. In addition, treatment with sodium bisulfite further 
increases the receptiveness of these regions by increasing the percentage of T and A bases. 
Hence, specific amplification conditions and DNA polymerase enzyme are required for 
amplification of the sodium bisulfite treated DNA samples. Zymo Taq DNA polymerase 
(Cambridge Biosciences, UK) was used for all the work on bisulfite sequencing PCR 
presented in this thesis.  
A mastermix containing 2x reaction buffer (25 μl), dNTP mix (0.5 μl; each dNTP at 0.25 
mM), bisulfite treated DNA (3 μl) as template, Zymo Taq DNA polymerase (0.4 μl; 2 units/50 
μl), forward primer (10 pmol) and reverse primer (10 pmol) was prepared. The total volume 
was adjusted to 50 μl with water. The samples were amplified using a thermocycler 
(Minicycler™, MJ Research, UK) with the following programme: 95ºC for 10 minutes, 38 
cycles of 95ºC for 30 seconds, variable annealing temperatures for 35 seconds and 72ºC for 
45 seconds. Following completion of the cycling phase, a final extension step was performed 
at 72ºC for 7 minutes. 
Each primer set was optimised and validated prior to use in the experiments. The products 
were checked by running the PCR products on agarose gel. The products were subsequently 
sequenced and compared with the expected sequences.  
 
2.6.5. Generation of artificially methylated and un-methylated genomic DNA 
Genomic DNA can be artificially methylated via treatment with CpG methyltransferase, Sss I, 
in the presence of S-adenosylmethionine (SAM). Following bisulfite treatment, amplification 
of the gene of interest, and sequencing, all CpG dinucleotides should be 100% methylated. In 
addition, un-methylated genomic DNA can be generated by conducting whole genome 
amplification. During amplification the methylation pattern is lost; therefore, following 
bisulfite treatment, amplification of the gene of interest, and sequencing, no methylated 
cytosine should be detected within the sequence. These two controls can be used to monitor 
the effectiveness of immunoprecipitation technique.  
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To generate the artificially methylated genomic DNA, CpG methyltransferase (New England 
Biolabs, USA) was used according to the protocol provided. Briefly, 10xNEBuffer 2 (2 μl), S-
adenosylmethionine (160 μM), genomic DNA (1 μg) and methyltransferase, SssI (40 units/μl; 
New England Biolabs, USA), were mixed in a final volume of 20 μl. The sample was 
incubated at 37°C for 4 hours followed by incubation at 65°C for 20 minutes. The final 
incubation step resulted in inactivation of the enzyme. This resulted in the generation of fully 
methylated genomic DNA.   
To generate the un-methylated genomic DNA samples, DNA samples were sonicated for 
generation of 100-1000 bp fragments (SONICS Vibra Cell, 100 watt, 3 x 10 seconds with 35 
seconds intervals on ice with 20% amplitude). The sonicated DNA samples were amplified 
using GenomePlex Complete Whole Genome Amplification (WGA) Kit (Sigma-Aldrich, 
Poole, Dorset, UK). Briefly, 10x fragmentation buffer (1 μl) was added to sonicated DNA 
samples (10 ng in a final volume of 10 μl) and samples were heated at 95ºC for 4 minutes in a 
thermocycler. Following incubation, samples were immediately placed on ice for 3 minutes 
and consolidated by brief centrifugation. To generate the library, 1x library preparation buffer 
(2 μl) and library stabilisation solution (1 μl) were added to the samples and samples were 
thoroughly vortexed. Samples were heated at 95ºC for 2 minutes and then placed on ice for 3 
minutes. Library preparation enzyme (1 μl) was added to the samples while they were on ice. 
Samples were thoroughly vortexed, briefly centrifuged and then run on a thermocycler 
(Minicycler™, MJ Research, UK) with the following conditions: 16ºC for 20 minutes, 24ºC 
for 20 minutes, 37ºC for 20 minutes and 75ºC for 5 minutes. Following generation of the 
library, samples were placed on ice and a mastermix containing 10xamplification mastermix 
(7.5 μl), nuclease free water (47.5 μl) and WGA DNA polymerase (5 μl) were added to the 
samples. Samples were vortexed, briefly centrifuged then amplified using a thermocycler with 
the following conditions: 3 minutes at 95ºC for the initial denaturation step, 14 cycles of 15 
seconds at 94ºC and 5 minutes at 65ºC.  
Fully methylated and un-methylated DNA samples were purified using QIAquick spin 
columns (Qiagen Ltd, West Sussex, UK), as described in section 2.5.1.1. Purified methylated 
and un-methylated genomic DNA samples were stored at -20ºC until further use in MeDIP 
zebrafish tiling microarray experiments, described in Chapter 3.  
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2.6.6. DNA gel electrophoresis 
DNA gel electrophoresis was used for optimisation of primers and separation of DNA 
molecules based on their size. Depending on the expected size of the products, the percentage 
of the gel varied from 0.6_2.5% (lower percentage gels were used for separation of larger 
DNA fragments while higher percentage gels were used for separation of smaller fragments). 
Agarose powder (Bioline Ltd., UK), according to the required percentage of the gel, was 
added to 1XTBE buffer (89 mM Tris base, 89 mM boric acid and 2 mM EDTA, adjusted to 
pH 8.0) containing ethidium bromide (0.5 µg/ml), and then dissolved by heating. When the 
temperature of the gel reached around 45°C it was poured into the tank and left to set. The gel 
was submerged in ethidium bromide containing 1X TBE Buffer (0.5 µg/ml). DNA samples 
and appropriate DNA molecular weight markers (100 bp, 1 kb; New England Biolabs, USA) 
were mixed with loading dye (6X gel loading dye, blue; New England Biolabs, USA) and 
then loaded into the wells. Electrophoresis was performed at 80 V for 20_45 minutes and the 
gel was visualised by UV transillumination. 
 
2.6.7. Purification of DNA samples and sequencing 
Prior to sequencing, PCR products were purified using QIAquick spin columns (Qiagen Ltd, 
West Sussex, UK), as described in section 2.5.1.1. The purified DNA samples were eluted in 
water, and then sequenced by the Functional Genomics and Proteomics Unit, School of 
Biosciences, University of Birmingham, Birmingham, UK using an ABI3730 DNA analyser 
(Applied Biosystems, UK). Each sequencing reaction was setup using 10 ng of the purified 
DNA samples and 0.4 µl of either reverse or forward primers (10 pmol). The final volume 
was adjusted to 10 µl using sterile water. To analyse the BSP data, the peak areas for C and T 
bases at each CpG site were measured and the methylation level was calculated using the 
formula below: 
% methylated cytosine at each CpG site: ((C peak area)/(C peak area+ T peak area))*100  
 
2.7. Confirmation of the results of the dab oligonucleotide microarray using real-time 
PCR 
To validate the microarray data, real time PCR (RT-PCR) was conducted on selected probes 
that their expression levels significantly varied between HCA and ST or HCA and healthy dab 
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liver samples according to microarray data. The same RNA samples that were used in the 
microarray experiments were also used for the RT-PCR experiment. 
 
2.7.1. Primer design, validation and product sequencing 
Primers were designed using Primer3 (Rozen and Skaletsky, 2000) and synthesised by 
AltaBioscience (Birmingham, UK). Primer sequences are presented in Table 2.4.  
To synthesise cDNA, random hexamers (1 µl; Promega, UK) were added to 500 ng of DNase 
treated RNA samples (for DNase treatment method see section 2.5.3.5). Sample volumes 
were adjusted to 15 µl with RNase free water followed by incubation at 65ºC for 2 minutes. 
The mixture was placed on ice prior to addition of a mastermix containing: 0.1M DTT (2 µl), 
5x first strand buffer (5 µl), Superscript II reverse transcriptase (0.5 µl; Invitrogen, Paisley, 
UK), 25 mM dNTPs (0.5 µl; Fermentas Life Sciences, UK) and RNase free water (2.1 µl). 
The samples were run on a thermocycler with the following programme: 25ºC for 10 minutes, 
42ºC for 90 minutes and 70ºC for 15 minutes. The synthesised cDNA was quantified by 
NanoDrop ND-1000 UV-VIS Spectrometer version 3.2.1. 
Primers were validated using DreamTaq DNA polymerase (Fermentas Life Sciences, UK).  A 
mastermix containing: 10x DreamTaq buffer (5 µl), 5 μl dNTP mix (each dNTP at 0.2 mM), 
forward primer (10 pmol) and reverse primer (10 pmol), cDNA (80 ng), DreamTaq DNA 
polymerase (1.25 units) was prepared. The total volume was adjusted to 50 μl with water. The 
samples were run on a thermocycler with the following programme: 95ºC for 3 minutes, 35 
cycles of 95ºC for 30 seconds, variable annealing temperatures for 30 seconds and 72ºC for 
30 seconds. Following completion of the cycling phase, a final extension step was performed 
at 72ºC for 5 minutes. 
PCR products were examined by agarose gel electrophoresis and products were confirmed by 
sequencing, as described in sections 2.6.6 and 2.6.7. 
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Table 2.4. Primer sequences for real-time PCR used for validation of the dab gene expression microarray results. 
 
 
 
 
 
 
 
Gene name Forward (5'→3') Reverse (5'→3') 
Product size 
(bp) 
vitellogenin b 
vitellogenin c 
S-adenosylhomocysteine 
udp-glucose 6-dehydrogenase 
syntrophin, beta 2  
CTGACCTTCGTGGATATTGAG 
AGTGAGGCAGACATGGTCCT 
TGATCTTCTCTGCTGCGTTC 
AGACCTACGGGATGGGAAAG 
5'-GGCCAGCTCCTGGTTCAC 
ATCTGAGCCTCGGCATTG 
TCTCTGGCGGCTATGAGTCT 
TTCGACAACATGAAGGACGA 
CTTGGTGTTGGCATCGAATA 
AACCAGCCGATGTGTTTGAG 
145 
170 
100 
167 
135 
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2.7.2. Real-time PCR 
RT-PCR was conducted on an ABI Prism 7000 (Applied Biosystems, USA) using SYBR 
Green SensiMix (Quantace, Watford, UK). Five biological replicates, with three technical 
replicates of each were run. Each sample contained: cDNA (80 ng), Sensimix (12.5 µl), 
Sybergreen (0.5 µl), forward and reverse primers (depending on the primer efficiency values 
the amount of primers used ranged from 1 to 5 pmol) and nuclease free water (to adjust the 
final volume to 25 µl). The cycling parameters were: 95ºC for 30 seconds (denaturing step) 
and 60ºC for 30 seconds (combined annealing and extension). Melting curves were plotted 
using the ABI Prism 7000 SDS software to ensure only a single product was amplified and no 
primer dimers were formed. Absolute fluorescence values were used to calculate PCR 
efficiencies for each well (Ramakers et al., 2003). Threshold cycle (CT) values were recorded 
in the linear phase of amplification and the data were analysed using the delta-delta CT 
method of relative quantification (Livak and Schmittgen, 2001). The internal reference gene 
(syntrophin, beta 2) was selected as unvarying during the microarray experiment and was 
used to further normalise the data.  
 
2.8. Targeted quantification of 12 metabolites related to the one-carbon cycle via liquid 
chromatography (LC)-triple stage quadrupole (TSQ) tandem mass spectrometry  
Samples prepared for the targeted metabolomic study, described in section 2.2.2.3.2, were 
resuspended in methanol: water mixture (4 μl: 4 μl, HPLC grade water and methanol, J.T. 
Baker, Netherlands) and vortexed for 30 seconds. To concentrate the samples and increase the 
sensitivity of the detection, five aliquots of the same re-suspended samples were combined. 
The prepared samples were dried using a centrifugal evaporator (Thermo Savant, Holbrook, 
NY) and stored at -80°C until analysed. Prior to analysis, the concentrated samples were re-
suspended in 7.5 μl buffer B (10 mM ammonium formate pH 2.2, 75% acetonitrile: 25% 
water, de-gassed and filtered, HPLC grade water and  mass spectrometry grade acetonitrile, 
J.T. Baker, Netherlands) and 2.5 μl buffer A (10 mM ammonium formate pH 4.2, de-gassed 
and filtered). The re-suspended samples were vortexed and centrifuged for 10 minutes at 
14,000 rpm. Samples (8.7 μl) were transferred to a 96 well plate. S-adenosyl-L-methionine-d3 
(S-methyl-d3) tetra (p-toluenesulfonate) salt (CDN Isotopes, Essex, UK) was dissolved in 
methanol: water mixture (1:1) with a final concentration of 3.125 mmol/ml. The compound 
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was further diluted with buffer B: buffer A mixture (75%: 25%) to a final concentration of 
0.126 mmol/ml. To each prepared sample (8.7 μl), 1 μl of the diluted S-adenosyl-L-
methionine-d3 (S-methyl-d3) tetra (p-toluenesulfonate) salt was added to a final concentration 
of 0.016 mmol/ml. This compound was used as an internal standard. 
The prepared samples were analysed using Dionex UltiMate 3000 liquid chromatography 
system with micropump coupled to a triple stage quadrupole (TSQ) tandem mass 
spectrometer (Thermo Fisher Scientific, Hertfordshire, UK) equipped with Ion Max-S 
atmospheric pressure ionisation (API) spray source (Thermo Fisher Scientific, Hertfordshire, 
UK). For technical replication, samples (1µl injections; acetonitrile was used for injection 
loop) were run in duplicates. Water: acetonitrile mixture (1:1; 1µl injections; acetonitrile was 
used for injection loop) was run in-between each set of biological samples to minimise 
carryover. Furthermore, to correct for background noise, negative controls were run at the 
beginning and at the end of the sample runs. Separation was achieved using a reverse phase 
column with weak anion exchange properties (Acclaim Mixed-Mode WAX column, 250 x 0.3 
mm internal diameter, 5 μm particle size, 120 Aº pore size, Dionex, Idstein, Germany) with 
column oven temperature of 20ºC (minimum and maximum temperature of 18ºC and 22ºC, 
respectively) and under a gradient running buffer, as indicated in Table 2.5 and Figure 2.12. 
Analytes were detected with data acquisition performed as MRM. The masses of the 
precursor ions and the formed product ions, used for detection of the 12 metabolites of 
interest and the internal standard, are mentioned in Table 2.6.  
The retention profiles of the compounds of interest were investigated by combining known 
amounts of the 12 metabolites of interest and the internal standard, S-adenosyl-L-methionine-
d3, and injecting the achieved mixture into the LC-TSQ instruments. A mixture of the 12 
compounds comprised of S-(5’-adenosyl)-L-homocysteine, D-methionine, folic acid, 
adenosine, betaine, sarcosine, DL-homocysteine, S-(5'-adenosyl)-L-methionine p-
toluenesulfonate salt, glycine, N,N-dimethylglycine, choline p-toluenesulfonnate salt, 
stachydrine hydrochloride (Extrasynthese, Genay, France) was prepared in water with each 
compound at a final concentration of 1 mmol/ml. The mixture was further diluted with buffer 
B (75%) and buffer A (25%) at a final concentrations of 0.05 mmol/ml per compound. The 
prepared mixture was spiked with the internal standard, S-adenosyl-L-methionine-d3 at a final 
sample concentration of 0.016 mmol/ml. As well as in combination, each standard was 
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individually directly injected into TSQ for establishment of the fragmentation patterns 
(product m/z) and the exact masses of the precursor ions to aid the identification of the 
compounds, as detailed in Table 2.6. Xcalibur 1.2 software (Thermo Fisher Scientific, 
Hertfordshire, UK) was used for measurement of the peak areas and analysis of the achieved 
data. 
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Table 2.5.  The multi-step gradient used for liquid chromatography. Buffer B: 10 mM 
ammonium formate pH 2.2, 75% acetonitrile: 25% water, Buffer A: 10 mM ammonium 
formate pH 4.2, Buffer C: acetonitrile: water mixture (1:1). 
 
 
 
Figure 2.12. Schematic representation of the multi-step gradient used for liquid 
chromatography. Green: percentage of buffer B, Yellow: percentage of buffer A, Blue: 
Percentage of buffer C, X-axis: time (minutes), Y-axis: % Buffer. 
Steps 
Retention time 
(minutes) 
Flow 
(μl/minutes) 
%B %C %A 
1 0 8 100 0 0 
2 0 8 100 0 0 
3 6 8 100 0 0 
4 12 6 5 0 95 
5 14 6 5 0 95 
6 17 6 0 100 0 
7 18 6 0 100 0 
8 18.01 6 100 0 0 
9 24 8 100 0 0 
10 28 8 100 0 0 
Y axis= µl/min 
X axis= min 
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Compound Formula Ion form Parent mass S-lens 
Collision 
energy (%) 
Product mass 
S-(5'-Adenosyl)-L-homocysteine C14H20N6O5S [M+H]
+
 384.937 106 
37 87.962 
54 118.984 
19 133.95 
20 135.987 
13 232.036 
12 249.982 
12 249.982 
Homocysteine C4H9NO2S [M+H]
+
 135.952 55 
44 45.015 
32 47.033 
19 56.073 
18 73.013 
11 90.023 
5 118.012 
5 118.012 
 
Stachydrine (Proline betaine) 
 
C7H13NO2 
 
[M+H]
+
 
 
143.973 
 
93 
36 42.056 
36 56.045 
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25 58.052 
22 84.04 
20 98.047 
21 102.009 
21 102.009 
Methionine C5H11NO2S [M+H]
+
 149.953 58 
17 56.067 
23 61.022 
17 87.01 
12 102.022 
10 104.031 
6 133.006 
6 133.006 
Folic acid C19H19N7O6 [M+H]
+
 441.941 101 
57 105.964 
45 107.978 
34 119.947 
38 175.968 
20 294.983 
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20 294.983 
Folic acid C19H19N7O6 [M-H]
-
 439.937 128 
46 131.999 
37 175.022 
27 293.035 
23 311.064 
24 396.195 
20 422.143 
20 422.143 
Adenosine C10H13N5O4 [M+H]
+
 267.935 88 
55 66.993 
54 91.976 
38 93.978 
45 118.981 
19 135.993 
33 137.005 
33 137.005 
Betaine C5H12NO2 [M+H]
+
 118 78 
53 42.041 
45 43.049 
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36 56.094 
26 58.045 
19 59.077 
Sarcosine C3H7NO2 [M+H]
+
 89.985 43 
63 28.092 
51 30.103 
25 42.064 
12 44.068 
25 59.037 
S-(5'-Adenosyl)-L-methionine C15H23N6O5S [M+H]
+
 398.944 110 
30 96.953 
24 101.917 
28 136.022 
15 250.014 
15 263.892 
13 298.015 
Glycine C2H5NO2 [M+H]
+
 75.988 41 
62 28.087 
11 30.103 
45 42.009 
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52 45.006 
19 47.016 
Dimethylglycine C4H9NO2 [M+H]
+
 103.992 52 
65 28.113 
29 30.114 
39 42.061 
39 44.072 
24 56.053 
14 58.06 
Choline C5H15NO2 [M+H]
+
 104.028 70 
42 30.109 
51 42.064 
21 45.06 
34 58.066 
22 59.07 
17 60.08 
S-Adenosyl-L-methionine-d3  C15H20D3N6O5S [M+H]
+
 402.063 114 
31 96.998 
25 102.044 
29 136.03 
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Table 2.6. The collision energy, S-lens value or stacked ring ion guide (SRIG) value (this value represents the radio frequency (RF) that 
efficiently captures and focuses the ions into a tight beam for transport of the ions from the source to the mass analyser), parent (precursor) 
masses, product masses, positive or negative ion mode and the chemical formula used for detection of the 13 compounds of interest are 
shown in this table. 
 
15 250.037 
16 267.092 
13 301.055 
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2.9. Statistical analysis 
2.9.1. General statistical approaches used throughout this thesis  
SPSS v16 software was used for statistical analysis of the data. Normal distribution of the 
data and homogeneity of variance was evaluated via Sharipo-Wilks’ test and Levenes’ test, 
respectively. Data that were normally distributed with homogenised variance were analysed 
by one-way ANOVA with a Tukey post-hoc test (comparison of more than two groups with 
one factor) or by 2-tailed independent student’s t-test. Data that did not meet the requirements 
for normal distribution or homogeneity of variance were analysed by non-parametric 
statistics, using a Kruskal-Wallis test (non-parametric test for comparison of more than two 
groups) and Mann-Whitney U test (non-parametric test for comparison of two groups). P-
values <0.05, <0.01 and <0.001 are indicated by *, ** and ***, respectively.  
 
2.9.2. Statistical analysis of microarray data  
Analysis of zebrafish tiling microarray data: 
GeneSpring v7.2 (Agilent) was used for analysing the data. Data flagged as present in at least 
4 of the 10 samples were used for analyses. The Cy5 test signal was divided by the Cy3 
control signal (genomic pool) and each microarray was normalised to the mean of the control 
group. Data with low raw intensity (less than 25) or standard deviation greater than 1.4 
between biological replicates were removed from the analyses. Lists of hypo- and hyper- 
methylated genes were generated using greater than 1.5-fold change cut-off and parametric 
Welch t-tests with assumption of un-equal variance between tumour and healthy groups (P 
<0.05) on the Lowess normalised data. MIAME-compliant raw microarray data were 
submitted to ArrayExpress at EMBL-EBI and can be found under accession E-MTAB-209. 
Analysis of cDNA flounder microarray data: 
GeneSpring v7.2 (Agilent) was used for analysing the data. Data flagged as present in all the 
samples were used for analyses. The Cy5 test signal was divided by the Cy3 control signal 
(genomic pool) and each microarray was normalised to the mean of the control group. Data 
with low raw intensity (less than 20) or standard deviation greater than 1.4 between biological 
replicates were removed from the analyses. Lowess normalised data were imported into 
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MultiExperimental Viewer v4.7. Welch paired t-test with assumption of un-equal variance (P 
<0.05) without multiple testing correction with a fold change cut-off of > 1.5 was used for 
identification of statistically significantly altered regions in HCA samples compared to non-
cancerous surrounding tissues.  
Analysis of the dab gene expression microarray data: 
GeneSpring vGX11 (Agilent, UK) and MultiExperimental Viewer v4.7 were used for 
analysing the data. Agilent feature extraction software (FE) was used for quality control, both 
at sample and gene level. The samples that did not pass the 8 feature extraction values were 
removed from further analysis. In addition, below-background level entities were also 
removed from analysis. Data flagged as present or marginal in at least 3 out of 32 samples 
were used for analysis. Following background correction, log intensity and log ratio 
calculation, data were normalised by Lowess. Data were standardised by calculating the mean 
and standard deviation (SD) for each data point (x) in all samples (standardised value=x-
mean/SD). Statistically differentially expressed genes were identified using Welch paired t-
tests between matching HCA and ST, one way ANOVA between the three groups (HCA, ST 
and healthy liver), and un-paired t-test between HCA and healthy liver (P <0.05) with a fold 
change of greater than 1.5 and Benjamini-Hochberg (B-H) correction (Benjamini and 
Hochberg, 1995). MIAME-compliant raw microarray data were submitted to ArrayExpress at 
EMBL-EBI and can be found under accession A-MEXP-2084.   
 
2.9.3. Ingenuity Pathway Analysis of the microarray data 
The “Core Analysis” function of Ingenuity Pathway Analysis (IPA) 
(htpp://www.ingenuity.com/)
 
was used to aid interpretation of the hypo- and hyper-
methylated genes as well as under- and over-expressed genes (>1.5-fold change). A B-H 
multiple testing correction (FDR <5%) was used to determine significant enrichment of 
annotations with biological functions and canonical pathways amongst these gene sets.  
 
2.9.4. Principal component analysis and hierarchical clustering 
The principal components analysis (PCA) feature embedded in MultiExperimental Viewer 
v4.7 and GeneSpring software were used in order to identify and summarise patterns within 
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gene expression and DNA methylation data. Hierarchical clustering was applied to dab 
transcription data using MultiExperimental Viewer v4.7 to further investigate distinct gene 
expression profiles between dab hepatocellular adenoma samples and ST samples.  
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Chapter 3 
 
Comprehensive profiling of zebrafish 
hepatic proximal promoter CpG island 
methylation and its modification during 
chemical carcinogenesis 
 
 
 
The data presented in this chapter has been published.  
Mirbahai et al., (2011) BMC Genomics, 12 (3): 1-16. 
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3.1. Introduction 
DNA methylation at CpG dinucleotides has a significant role in the regulation of gene 
expression (Rauch et al., 2007), as discussed in Chapter 1. This is achieved through 
modulation of protein-DNA interactions (Jones and Takai, 2001; Pomraning et al., 2009). 
Therefore, aberrant methylation of CGIs in the promoter and exon regions (Weber et al., 
2005; Takai and Jones, 2002), and subsequent changes to gene expression can give rise to a 
range of disorders (Weber et al., 2005; Egger et al., 2004; Rauch et al., 2006).  
Cancer is a complex and multifactorial disorder with more than 100 distinct types and 
subtypes found within specific organs in humans (Pogribny, 2010; Hanahan and Weinberg, 
2000). Clarifying the molecular mechanisms of tumourigenesis and identifying fundamental 
common mechanisms between different types of tumours has been the aim of many 
researchers. Accumulation of both mutations and epigenetic abnormalities in the regulatory 
regions of genes and disruption of cellular signalling pathways contribute to tumour 
development (Tischoff and Tannapfel, 2008; Gronbaek et al., 2007). However, two key 
findings in regards to epigenetics and tumourigenesis have led to substantial interest in this 
field: 1. Reversibility of the epigenetic changes at early stages of tumourigenesis 2. 
Identification of a unifying theme in the development of cancers (the latter and the link 
between environment and epigenetic is explained in Chapter 4). Therefore, epigenomic 
profiling of cancer cells and investigating the involvement of epigenetic mechanisms in the 
development of tumours are amongst the most intensively studied fields in epigenetics in 
relation to human health (Vandegehuchte and Janssen, 2011). However, in contrast to the 
wealth of information available on epigenetic changes and development of cancer in humans; 
this area is substantially understudied in aquatic biology, especially in relation to disease.   
Flatfish dab, used in biomonitoring within the UK waters, have a high prevalence of liver 
tumours with the occurrence at some sites exceeding more than 20% of sampled individuals 
(NMMP, second report, 2004; Stentiford et al., 2009; Small et al., 2010; Southam et al., 2008; 
Lyons et al., 2006). The causative agents and the molecular mechanisms leading to these 
tumours are unclear (discussed in Chapter 1 and 4). As a result, the main aim of this project 
was to investigate the involvement of DNA methylation abnormalities at the gene level and 
whole genome level in these tumours and to provide a testable hypothesis regarding the 
mechanisms involved in dab tumourigenesis. However, as dab’s genome is not sequenced, 
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any comprehensive study at the gene level was challenging. Therefore, the involvement of 
DNA methylation in fish tumours was first investigated using the model fish species, 
zebrafish (Danio rerio). This was the first of such studies on fish tumourigenesis.    
Endogenous and exogenous factors (e.g. chemicals, viruses, radiation) are known to induce 
tumours (Loeb and Harris, 2008; Miller et al., 1970). A range of organic and inorganic 
chemicals in the environment have been shown to initiate and promote tumourigenesis in 
various species and tissues. Therefore, chemical induction of tumours is a useful tool for 
studying molecular mechanisms of tumourigenesis (Miller et al., 1970). In the last few 
decades, alternative models to rodents, such as fish, have been used extensively for studying 
the effects of environmental carcinogens. Several factors, including sensitivity to a variety of 
carcinogens, low cost of maintenance, short reproductive cycle, possibility of field studies, 
portability, potential for lifetime bioassays and the ease of genetic studies have made them 
ideal for initial carcinogenicity studies (Bailey et al., 1996; Spitsbergen et al., 2000). For 
example, rainbow trout (Oncorhynchus mykiss) (Bailey et al., 1996), zebrafish (Danio rerio) 
(Khudoley, 1984), guppy (Poecilia reticulata) (Hawkins et al., 1988), common platyfish 
(Xiphophorus maculatus) (Schwab and Scholl, 1981) and medaka (Oryzias latipes) (Hawkins 
et al., 1988) have been employed in bioassays for carcinogens. Zebrafish are a well-
established model for investigating embryogenesis, organogenesis, and environmental 
carcinogenicity and for modelling human diseases such as cancer (Bailey et al., 1996; Wardle 
et al., 2006; Berghmans et al., 2005; Zon, 2010; Lam and Gong, 2006; Lam et al., 2006). 
Chemically-induced tumours are histopathologically very similar between zebrafish and 
humans (Berghmans et al., 2005; Amatruda et al., 2002) and orthologous TSGs and 
oncogenes in human and fish have been identified (Berghmans et al., 2005). Recent studies 
comparing hepatic gene expression in human and zebrafish tumours have demonstrated 
conservation of gene expression profiles at various stages of tumour aggressiveness between 
these two phylogenetically distant species (Lam et al., 2006). However, the contribution of 
altered DNA methylation to such changes was unknown.  
Although there are reports on global levels of DNA methylation in zebrafish during 
embryogenesis or in adults (MacLeod et al., 1999; MacKay et al., 2007; Martin et al., 1999; 
Mhanni and McGowan, 2004; Jabbari and Bernardi, 2004), the effects of temperature on 
global levels of DNA methylation (Varriale and Bernardi, 2006a), DNA methylation profiling 
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in zebrafish embryo (Fenga et al., 2010), and the roles of chromatin-mediated gene regulation 
during embryogenesis (Wardle et al., 2006), no study had been published on the DNA 
methylation patterns or DNA methylation changes associated with carcinogenesis in 
zebrafish. 
The zebrafish is already extensively employed in environmental carcinogenicity studies, as it 
can be easily raised and treated in a controlled laboratory environment and its genome 
sequence is readily available. Therefore, zebrafish was chosen as a subject for this 
investigation. Hepatocellular carcinoma (HCC) tumours, chemically induced by 7,12-
dimethylbenz[α]anthracene (DMBA) in zebrafish, were used to investigate the differences in 
DNA methylation profiles between fish liver tumours and healthy fish livers. In addition, 
although zebrafish are commonly used for modelling human cancers, there is a lack of 
information on the suitability of zebrafish as an epigenetic model. Therefore, this study could 
also provide background information for future use in zebrafish models of human cancer. 
In the past few years substantial progress has been made in the development of genome-wide 
DNA methylation techniques. In this chapter, a genome-wide approach, known as 
methylated-DNA immunoprecipitation (MeDIP)-microarray, was used for profiling DNA 
methylation alterations in zebrafish liver tumours. This method was initially used in a study 
conducted by Weber et al., (2005) for DNA methylation profiling of human cancer cells. 
MeDIP relies on un-biased enrichment of methylated fragments of DNA which can be 
combined with any type of DNA microarray. In this experiment a novel zebrafish tiling 
microarray was designed covering the regions of 1.5kb upstream to 1kb downstream of the 
transcription start site (TSS) of CpG island-containing genes. This was combined with MeDIP 
to achieve a comprehensive DNA methylation profiling. This study is the first to describe 
MeDIP in combination with a custom-made CGI tiling microarray for establishing normal and 
HCC DNA methylation profiles in the liver of any adult fish species. This microarray, in 
combination with well-established methylated-DNA immunoprecipitation, serves as a 
powerful tool for elucidating comprehensive DNA methylation profiles.    
This work was carried out in collaboration with Professor Zhiyuan Gong’s research group at 
the University of Singapore. The chemically induced zebrafish liver tumour samples were 
provided by our collaborators. 
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3.2. Overview of the experimental approach (Methodological details are described in 
Chapter 2) 
Three different methods; HPLC, LC-MS/MS and an ELISA colourimetric technique, were 
investigated to identify a suitable methodology for measurement of the overall DNA 
methylation levels in fish liver.  
To investigate gene specific DNA methylation changes in fish tumours, chemically induced 
zebrafish HCC samples were used. To induce HCC tumours, three-week-old zebrafish fry 
were treated with DMBA (0.75 ppm in fish tank water) dissolved in dimethyl sulfoxide 
(DMSO, vehicle) or DMSO alone (vehicle control) for 24 hours and the treatment (1.25 ppm 
DMBA or DMSO in fish tank water) was repeated once, 2 weeks later, for another 24 hours. 
Treated fish were rinsed three times in fresh water and transferred into new tanks for 
maintenance. Fish were sampled 6_10 months after DMBA exposure. HCC samples used for 
this study were all confirmed by histopathology studies.  
To investigate differences in DNA methylation profiles in HCC samples compared to control 
samples, a custom-made CGI tiling microarray was developed. DNA samples from both 
groups were sonicated, immunoprecipitated with 5-methylcytosine antibody, labelled with 
different fluorescent dyes and hybridised to the microarray. GeneSpring, Blast2GO and 
Ingenuity Pathway Analysis were used to identify the biological functions that were altered in 
HCC samples compared to controls.   
Bisulfite sequencing PCR was used to confirm the data obtained from the MeDIP-tiling 
microarray experiment. 
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Figure 3.1. Flowchart of the experimental procedures used in Chapter 3. The starting points of 
the diagram are the boxes with borders. The methods used in this chapter are described in 
detail in Chapter 2. In this flowchart, the sections where these methods are described in 
Chapter 2 are shown in brackets. 
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3.3. Results 
3.3.1. Global measurement of genomic DNA methylation 
3.3.1.1. Establishing a method for measuring global genomic DNA methylation levels  
Three different methods; HPLC, LC-MS/MS and ELISA, were compared for accuracy and 
suitability for measuring global genomic DNA methylation levels. In the ELISA method, (as 
described in section 2.3.1) DNA is immobilised to the surface of a plate. 5-methylcytosine 
antibody, detector antibody and a developing solution is added to the DNA. The amount of 
methylated DNA is proportional to the OD intensity. However, in the other two methods (as 
described in section 2.3.2) quantification of the methylated DNA is based on comparison to 
standards.  
To test the three methods, the overall methylation levels in the livers of healthy dab and 
flounder were measured. As shown in Figure 3.2 no significant differences were detected 
between the three methods in both species investigated. However, as indicated by the error 
bars the variation in the colourimetric ELISA-based method was higher than the other two 
methods. This could be due to lack of antibody specificity, slight variation in efficiency of the 
washing steps, variation in the length of time taken to add the developing reagent and to 
measure the fluorescent signal between different samples and substrate availability. The 
HPLC technique used is an established in-house method. However, LC-MS/MS was carried 
out in an external laboratory as described in Chapter 2, section 2.3.2.7. The latter was mainly 
used as an external validation method and to compare the reproducibility and accuracy of the 
global DNA methylation measurements. As shown in Figure 3.2, HPLC and LC-MS/MS data 
were similar with low levels of variation between different samples. Therefore HPLC was 
used as the standard methodology for quantification of global DNA methylation levels 
throughout this project.  
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Figure 3.2. Comparison of HPLC, LC-MS/MS and ELISA methods for measurement of 
global levels of methylation in DNA. The same samples were used for all three techniques. 
Dab liver: n=3 different fish samples ± standard error of the mean (SEM). Flounder liver: n=3 
different fish samples ± SEM. Data are normally distributed with homogenised variance. No 
significant differences were detected between the three techniques as determined by one-way 
ANOVA with Tukey’s post-hoc test. 
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3.3.1.2. Comparison of global genomic DNA methylation in fish and mammals using 
HPLC 
To establish the global levels of cytosine methylation in fish in comparison to mammals, 
HPLC was performed. To establish the retention times and the order of elution, 
mononucleotide standards –dCMP, 5mdCMP, dGMP, dTMP, dAMP- were run individually 
and as a mixture at least three times. The retention times and the order of appearance are 
shown in Figure 3.3.A. 
RNA contamination was enzymatically removed from the samples as described (section 
2.3.2.1). To confirm the absence of RNA contamination, a standard for uridine 
monophosphate (UMP) was used (Figure 3.3.B). DNA extracted from livers of zebrafish, dab, 
flounder and commercially available DNA from calf (Bos taurus) thymus were prepared as 
described (Section 2.3.2.2) and analysed using HPLC. As shown in Figure 3.4, the overall 
DNA methylation levels did not differ between the three fish species investigated with 5-
methylcytosine comprising 8% of the total cytosine in the DNA. However, all three fish 
species had statistically significant ~2-fold higher DNA methylation levels (P<0.05) than as 
found in calf thymus DNA. This is in agreement with previous published data showing higher 
levels of DNA methylation in fish compared to mammals (Jabbari and Bernardi, 2004; 
Aniagu et al., 2008). 
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Figure 3.3.A. Determination of the retention times of five standard mononucleotides using 
HPLC. B. Spiked standard mixture with uridine monophosphate (UMP) for establishing the 
retention time of UMP for monitoring RNA contamination.  
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Figure 3.4.  Measurement of the global percentage of methylated cytosine in calf thymus, 
adult male zebrafish, immature flounder and adult female dab livers using HPLC. No 
differences were detected between fish species investigated. The global percentage of 
methylation was statistically significantly higher (~2 fold) in all fish species compared to calf. 
Data are the mean ± SEM of four independent experiments. ** and * statistically significantly 
different from calf thymus with P<0.01 and <0.05, respectively. P-values were determined 
using a one-way ANOVA with Tukey’s post-hoc test. 
 
 
3.3.2. DNA methylation at gene levels in zebrafish liver tumours 
In this section, differences in methylation levels of genes in DMBA-induced adult zebrafish 
HCC samples were established compared to control zebrafish liver samples. This was 
achieved by combining MeDIP with the custom-made zebrafish DNA tiling microarray.  
 
3.3.2.1. Unbiased enrichment of methylated DNA using methylated-DNA 
immunoprecipitation (MeDIP) 
The immunoprecipitation method as described (Section 2.4) was used for enrichment of 
methylated fragments of DNA extracted from both normal adult zebrafish liver and 
chemically induced HCC samples. DNA samples were extracted from tissue samples and 
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kindly provided by Professor Gong’s research group as described in Chapter 2, section 2.2.1 
and in their publication (Lam et al., 2006). To test the specificity of the immunoprecipitation 
method, CGI regions of 14 genes (15 regions) located 1.5kb upstream to 1kb downstream of 
transcriptional start sites were screened for methylcytosine using bisulfite sequencing PCR. 
These genes included: Transcriptional regulator myc-b (mycb, 2 regions), cadherin 1 (cdh1), 
cell division protein kinase 8 (cdk8), timp metallopeptidase inhibitor 2 (timp2), heat shock 
protein 90-beta (hsp90b1), mitogen-activated protein kinase 1 (mapk1), tumour suppressor 
p53 (p53), muts homolog 6 (msh6), muts homolog 2 (msh2), DNA (cytosine-5-)-
methyltransferase 4 (dnmt4), rap2c, member of ras oncogene family (rap2c), connexin-43 
(cx43), glutathione S-transferase P1 (gstp1) and no-tail a (ntla). 
Following bisulfite treatment and sequencing of the 14 genes, CGIs located at the promoter 
region of the ntla gene were found to be methylated while CGIs at the remaining 13 genes, 
including gstp1, were completely un-methylated (Figures 3.5 and 3.6). The ntla gene and the 
gstp1 gene were thus used as methylated (positive control) and un-methylated (negative 
control) DNA regions for testing the immunoprecipitation enrichment method. This was in 
addition to artificially methylated and un-methylated genomic DNA used as controls in the 
experiment. 
DNA from one zebrafish liver sample was sonicated to generate 200 to 1000 bp enriched 
fragments. Fragmented DNA samples were immunoprecipitated using 5-methylcytosine (5-
mC) antibody and bisulfite-treated. The immunoprecipitation resulted in enrichment of 
methylated fragments of DNA while the bisulfite treatment resulted in distinction of 
methylated cytosines from un-methylated cytosines in the enriched fragments. Equal amounts 
of immunoprecipitated, bisulfite-treated DNA were amplified for the two genes of interest. 
The gel images provided a semi-quantitative indication of enrichment of methylated ntla gene 
in comparison to un-methylated gstp1 gene using 5-methylcytosine antibody (Figure 3.7). 
This was further confirmed by sequencing. 
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A: 
ATCTCGTGCACGCGTGTGGTCATGAATGCAACGACAAACACAATTGCGTGCTCGCGGGGCGCGTGCATGA 
 
B: 
 
 
Figure 3.5. Direct bisulfite sequencing of glutathione S-transferase P1 gene (gstp1). CpG sites investigated were located in a CGI located   
-98 to +19 from the transcriptional start site of gstp1 gene. A. The original sequence (prior to bisulfite treatment) for the region investigated 
for gstp1 with bisulfite sequencing PCR. CpG dinucleotides are shown in red and cytosines located in regions other than CpG dinucleotides 
are shown in green. The latter is used as internal controls for monitoring bisulfite treatment efficiency. B. As shown in this figure all CpG 
sites were un-methylated as all CpG dinucleotides were converted to TpG. Sequencing was performed on 4 independent samples; two 
tumour samples and two control samples. Arrows: thymines located at CpG dinucleotide sites that were converted by bisulfite treatment 
from un-methylated cytosines.  
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A: 
AAATATGTCTGCCTCAAGTCCCGACCAGCGCCTGGATCATCTCCTTAGCGCCGTGGAGAGCGAATTTCAGAAGGGC
AGCGAGAAAGGGGACGCGTCCGAG 
B: 
 
 
 
 
Figure 3.6. Direct bisulfite sequencing of no tail a gene (ntla). CpG sites investigated were located in a CGI situated +44 to +205 from the 
transcriptional start site of ntla gene. A. The original sequence (prior to bisulfite treatment) for the region investigated for ntla with bisulfite 
sequencing PCR. CpG dinucleotides are shown in red and cytosines located in regions other than CpG dinucleotides are shown in green.  
B. As shown in the above figure all CpG sites were methylated or semi-methylated. All remaining CpNs (N=T, A, C) were converted to T 
which served as internal controls for bisulfite treatment efficiency. Sequencing was performed on 4 independent samples; two tumour 
samples and two control samples. Arrows: cytosines located at CpG dinucleotide sites that were methylated and thus protected from 
bisulfite treatment. Blue: C, Red: T. 
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Figure 3.7. Agarose gel electrophoresis image of methylated-DNA immunoprecipitated 
(MeDIP) bisulfite treated ntla and gstp1 genes. The methylated ntla (A) gene is enriched after 
immunoprecipitation compared to un-methylated gstp1 (B) gene. 
 
 
3.3.2.2. Design of the zebrafish CGI tiling microarray and comprehensive mapping of 
adult zebrafish CGI methylation 
Genes with CGIs located 1.5 kb upstream to 1kb downstream of the TSS were identified as 
described (section 2.5.2.1). Probes (43,960) were designed to cover the identified 6,024 
promoters of the genes containing CGIs. A list of genes with predicted CGIs, numbers of 
CGIs for each chromosome and location on the chromosome are presented in Appendix, File 
1. Where possible, overlapping 60–mer probes, with 25 bp spacing, were designed to cover 
the entire length of CGIs (Figure 3.8). The microarray design was named Agilent 
Birmingham D.rerio 025794 45220v1 and is available from ArrayExpress under accession A-
MEXP-1813. The tiling microarray provided a detailed, un-biased approach for studying 
DNA methylation (Mockler and Ecker, 2005).  
Negative and positive controls were used to monitor the success of DNA methylation 
immunoprecipitation. The negative control consisted of PCR amplified whole genomic DNA, 
fragmented, immunoprecipitated and labelled with Cy5. As DNA methylation is removed 
during amplification, as expected, little DNA was precipitated during MeDIP. Therefore, a 
uniform low intensity signal was measured for all probes represented on the tiling microarray. 
This represented non-specific binding of DNA to the 5-methylcytosine antibody. The positive 
control was achieved by treatment of DNA with CpG methyltransferase, Sss I, in the presence 
of S-adenosylmethionine (SAM) prior to MeDIP. This resulted in complete methylation of all 
CGIs and detection of a uniform, high fluorescent signal for all probes (Appendix File 2, 
200 bp
300 bp
BA
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Table 1). The positive control, in addition to serving as a control for the microarray 
experiment, was used to monitor the efficiency of MeDIP (Figure 3.9) 
The CGI tiling microarray provided a comprehensive mapping of the DNA methylation at 
CGIs in healthy adult zebrafish liver between 1.5 kb upstream and 1kb downstream of 
transcription start site of the genes (Figure 3.10). The list of all genes on the tiling microarray 
and their methylation levels are presented in the Appendix (File 2, Table 4. those genes with 
values 2-fold above the median level (higher DNA methylation levels) and 2-fold below the 
median level (lower DNA methylation levels) in control samples are highlighted). Gene 
ontology analysis using Blast2GO identified GO terms significantly (false discovery rate 
(FDR) <5%) over-represented amongst genes that were relatively low and also relatively high 
in DNA methylation levels in healthy zebrafish liver. For genes with lower levels of 
methylation in healthy zebrafish liver, molecular functions associated with biological 
processes related particularly to involvement in regulation of gene expression and 
transcription, cell cycle, negative regulation of apoptosis, intracellular protein transport and 
mitochondrial transport, developmental process, mitochondrial differentiation, cellular 
response to hormone stimulation and sex determination were enriched (due to the size of the 
image and clarity, the complete list of biological processes enriched in lower methylated 
regions are shown in Appendix, File 3 with some of the enriched biological processes shown 
in Figure 3.11). For genes with higher levels of methylation in healthy zebrafish liver, 
molecular functions, such as molecular transducer activity, signalling transducer activity and 
receptor activity associated with the G-protein coupled receptor protein signalling pathway 
were enriched (Figure 3.12).  
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Figure 3.8. Chromosomal mapping of the probes.  A. All probes were mapped onto zebrafish 
chromosomes. As an example, probes for coronin, actin binding protein 2ba gene (coro2ba; 
ENSDARG00000079440) on chromosome 7 are shown. A CGI was predicted at the region 
between 33649014 and 33649398. Colours indicate the intensity of the fluorescent signal 
from the probes (red: hypermethylation, yellow: no change, blue: hypomethylation). B. The 
mean fold changes for all probes representing the coro2ba gene in tumour samples compared 
to healthy zebrafish liver samples.  
Probe no Fold change Chr: probe start - end 
4 3.019 Chr7:33649041-33649100 
5 3.927 chr7:33649050-33649109 
6 4.572 chr7:33649059-33649118 
14 5.473 chr7:33649131-33649190 
15 5.591 chr7:33649140-33649199 
18 3.969 chr7:33649167-33649226 
19 3.541 chr7:33649176-33649235 
20 2.981 chr7:33649185-33649244 
21 3.427 chr7:33649194-33649253 
28 1.895 chr7:33649257-33649316 
29 1.521 chr7:33649266-33649325 
36 1.211 chr7:33649329-33649388 
37 1.074 chr7:33649338-33649397 
Probes 4,5,6 Probes 14,15,18,19,20,21 Probes 28,29 Probes 36,37
[A] 
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Figure 3.9. Generation of artificially methylated genomic DNA. Glutathione S-transferase P1, as explained in Figure 3.5, is un-methylated 
in both tumours and healthy zebrafish livers. Treatment with CpG methyltransferase, SssI, in the presence of S-adenosylmethionine (SAM) 
results in methylation of all CpG dinucleotides. Successful bisulfite treatment of the positive control was established by sequencing and 
observing a single C peak at all CpG dinucleotide positions. 1: gstp1, 2: SssI treated gstp1. Arrows: CpG dinucleotides. 
2
1
1
2
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Figure 3.10. Chromosomal mapping of average methylation levels in tumour samples compared to control samples. Chromosomes are 
numbered 1_25. Each line on the chromosome indicates a probe on the zebrafish microarray. Red: hypermethylation, Blue: 
hypomethylation, yellow: no change. 
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Figure 3.11. Selected gene ontology (GO) terms significantly over-represented in the genes with DNA methylation levels 2-fold below the 
median level in healthy zebrafish liver i.e. genes with lower methylation levels (FDR< 5%). The complete list of biological processes 
enriched in lower-methylated regions is shown in Appendix, File 3.  
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Figure 3.12. Gene ontology (GO) terms significantly over-represented in the genes with DNA methylation levels 2-fold above the median 
level in healthy zebrafish liver i.e. genes with higher methylation levels (FDR< 5%). 
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3.3.2.3. DNA methylation analysis of zebrafish hepatocellular carcinoma and 
comparison to gene expression 
Genomic DNA extracted from zebrafish HCC samples was processed by MeDIP, labelled 
with fluorescent Cy5-dUTP and hybridised to the tiling microarray against input genomic 
DNA that had been labelled with Cy3-dUTP. Following quality checks and normalisation (as 
discussed in Chapter 2, section 2.9.2), probes were mapped onto the chromosomes and two 
lists, containing hypomethylated and hypermethylated regions in comparison to control, were 
generated (>1.5-fold change, P<0.05). MIAME-compliant raw microarray data were 
submitted to ArrayExpress at EMBL-EBI and can be found under accession E-MTAB-209. It 
was apparent that most differentially methylated regions in HCC samples were 
hypomethylated (712 probes) in comparison to 168 hypermethylated regions.  
Blast2GO and Ingenuity Pathway Analysis (IPA) were performed to characterise the 
functional relationships between genes with altered methylation in the regions between -1.5kb 
to +1kb of the TSS in HCC samples compared to control samples. These analyses identified 
significant networks and functions, such as cell-to-cell signalling, cell cycle, cellular growth 
and proliferation, cell death, gene expression, DNA replication, cellular assembly and 
organisation that were enriched in HCC samples compared with control samples. Figures 3.13 
and 3.14 show the biological functions associated with genes with altered methylation levels 
(hyper- and hypo-methylated, respectively) in HCC samples compared to control samples 
(FDR <5%). Table 3.1 illustrates a sub-section of the genes (hypo- and hyper-methylated) 
representing the most relevant biological functions linked to carcinogenesis (the full list of 
genes and gene ontology analyses are presented in Appendix (File 2, Tables 2 and 3). 
Using IPA, cancer was highlighted as the top predicted disorder based on the categories of the 
genes that were hypomethylated (FDR <5%, >1.5-fold change). Figure 3.15 illustrates 
hypomethylated genes in zebrafish tumours (FDR <5%, >1.5-fold change) related to the 
canonical pathway “molecular mechanisms of cancer” in humans, including genes such as c-
jun, shc and p21.   
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Figure 3.13. Biological functions enriched among genes with hypermethylated levels in HCC 
samples compared to control samples. IPA was used to group the genes with altered 
methylation levels based on biological functions. Each section of the pie chart corresponds to 
the number of the genes associated with the mentioned biological function with altered 
methylation levels in HCC samples compared to control samples (>1.5-fold change, FDR 
<5%). 
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Figure 3.14. Biological functions enriched among genes with hypomethylated levels in HCC 
samples compared to control samples. IPA was used to group the genes with altered 
methylation levels based on biological functions. Each section of the pie chart corresponds to 
the number of the genes associated with the mentioned biological function with altered 
methylation levels in HCC samples compared to control samples (>1.5-fold change, FDR 
<5%). 
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Gene name Gene 
symbol 
Gene  
ID  
Chr. 
no 
CGI  
region 
A. Hypomethylated regions proximal to TSS     
     
  Proliferation     
      kruppel-like factor 12b  klf12b ENSDARG00000032197 9 31117162 - 31117483 
      insulin-like growth factor binding protein 5a  igfbp5a ENSDARG00000025348 9 49194032 - 49194791 
      insulin-like growth factor binding protein 2b igfbp2b ENSDARG00000031422 9 49290381 - 49290816 
      insulin-like growth factor binding protein 1b igfbp1b ENSDARG00000038666 2 178184 - 178306 
      insulin-like growth factor-binding protein 2a precursor                                                igfbp2a ENSDARG00000052470 6 22745784 - 22746301 
      estrogen related receptor delta fragment esrrd ENSDARG00000015064 18 48225445 - 48225631 
      Steroid5-alpha-reductase, alpha polypeptide 2a  srd5a2a ENSDARG00000043587 1 51038733 - 51038845 
     
  Stress     
      similar to sh2 domain containing 3C sh2d3ca ENSDARG00000028099 10 14303115 - 14303263 
      PI-3-kinase-related smg-1 smg1 ENSDARG00000054570 3 28544220 - 28544532 
     
  Glycolysis     
      enolase 2 eno2 ENSDARG00000014287 19 4698036 - 4698168 
      hexokinase 1 hk1 ENSDARG00000039452 13 23684991 - 23685203 
     
  Cell cycle, metastasis, adhesion, cell growth, stress     
      c-jun  jun ENSDARG00000043531 20 14274343 - 14274635 
      bcl2-associated athanogene 5 bag5 ENSDARG00000017316 13 17324708 - 17324877 
      angiopoietin-like 3 angptl3 ENSDARG00000044365 6 34165085 - 34165237 
      angiopoietin-1 receptor precursor tek ENSDARG00000028663 5 625275 - 625436  
      ras homolog gene family, member ua rhoua ENSDARG00000019709 13 25136705 - 25136882 
      menage a trois homolog 1 mnat1 ENSDARG00000002077 13 31141636 - 31142019 
      serine/threonine and tyrosine protein kinase dstyk ENSDARG00000000853 22 461194 - 461772 
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Continued from previous page     
DNA binding and regulation of transcription 
    
      DNA (cytosine-5-)-methyltransferase 6 dnmt6 ENSDARG00000015566 17 34759411 - 34759539 
      leucine zipper protein 2 precursor luzp2 ENSDARG00000068247 18 35625841 - 35625986 
      histone h2a h2a ENSDARG00000001915 1 724191 - 724473 
      histone deacetylase 4 hdac4 ENSDARG00000041204 9 46375505 - 46375895 
      homeobox protein hox-b5a hoxb5a ENSDARG00000013057 3 20707021 - 20707754 
      pancreas transcription factor 1 subunit alpha ptf1a ENSDARG00000014479 2 27672474 - 27672641 
      hypothetical protein LOC692291 loc692291 ENSDARG00000012833 17 12689887 - 12690054 
      metastasis associated 1 family, member 2 Mta2 ENSDARG00000013031 7 17243535 - 17244290 
      homeobox protein hox-b4a hoxb4a ENSDARG00000013533 3 20721064 - 20721722 
      lysine-specific demethylase 4a kdm4a ENSDARG00000018782 6 4575451 - 4575994 
      rab11 family interacting protein 4 (class II) a rab11fip4a ENSDARG00000053855 25 13380260 - 13380369 
     
Gene name  Gene ID  Chr. 
no 
CGI region 
B. Hypermethylated  regions proximal to TSS     
     
Anti-angiogenesis     
      hematopoietically-expressed homeobox protein hhex hhex ENSDARG00000074250 12 43558447 - 43558684 
     
Cell-cell adhesion     
      hypothetical protein LOC678612 loc678612 ENSDARG00000069505 21 27963202 - 27963305 
      novel protocadherin protein fragment pcdh7 ENSDARG00000053462 1 55112983 – 55113251 
     
Transporter     
      ATP-binding cassette, sub-family a, member 5 
 
abca5 ENSDARG00000074041 12 38940033 - 38940251 
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Table 3.1. Subsection of the genes with altered DNA methylation levels detected at -1.5kb to +1kb of the TSS in HCC samples compared 
to control samples as measured by CGI-tiling microarray. A. Hypomethylated genes (>1.5-fold change, P<0.05). B. Hypermethylated 
genes (>1.5-fold change, P<0.05).  
 
 
 
 
 
 
 
Continued from previous page 
    
Immune system 
    
      novel protein similar to nuclear factor, IL3 regulated 
      novel protein fragment similar to interleukin 
nfil3 
il 
ENSDARG00000071398 
ENSDARG00000053462 
22 
1 
21400978 - 21401243 
55112983 - 55113251 
      c5a anaphylatoxin chemotactic receptor 
Angiogenesis and oxidative stress protection 
c5ar ENSDARG00000040319 18 45692130 - 45692420 
      vascular endothelial zinc finger 1 vezf1 ENSDARG00000008247 10 35492470 - 35493037 
     
Membrane     
      coronin, actin binding protein 2ba coro2ba ENSDARG00000079440 7 33649014 - 33649398 
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Figure 3.15. Biological network of genes linked to the canonical pathway “molecular 
mechanisms of cancer” that were hypomethylated (>1.5-fold change, P<0.05) in zebrafish 
hepatocellular carcinoma compared to healthy liver. This diagram shows the genes that were 
hypomethylated in zebrafish HCC with grey shading. Additionally, orange outlines indicate 
the molecules associated with the hypomethylated genes via Ingenuity pathways. Direct 
interactions are shown as solid lines and indirect as dashed lines. Biological network analysis 
was performed using Ingenuity Pathway Analysis.  
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3.3.2.4. Principal components analysis 
Using principal components analysis (PCA) scores plot of differentially methylated regions, 
the four groups of HCC, controls, positive and negative controls were separated based on 
treatment along the PC1 and PC2 axes (Figure 3.16). PCA is a statistical multivariate data 
reduction approach used for simplifying complex data sets with several conditions such as 
microarrays (Raychudhuri et al., 2001). PCA converts a number of correlated variables to a 
smaller set of uncorrelated variables or principal components (PC), in order to identify 
patterns within a data set (Yeung and Ruzzo, 2001; Raychudhuri et al., 2001). 
The first PC was the main separation factor for the four different categories investigated. In 
this experiment PC1 accounted for 71.78% of the variance. Negative and positive controls 
were the two extreme conditions in the experiment in which one was fully un-methylated, 
while the other was completely methylated. Indeed, this was reflected in the results of the 
PCA plot, as positive and negative control samples were located at the two ends of the PC1 
axis, with controls (healthy tissue samples) and HCC samples located in between.  
As shown in the PCA plot (Figure 3.16), healthy zebrafish samples (controls) are clustered 
closer together compared to tumour samples. This is not unexpected and several factors may 
contribute to the observed pattern. Control samples are more homogenous in regards to cell 
type. Although tumours are histopathologically confirmed they are usually a mixture of cells 
and are likely heterogenous in terms of progression. 
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Figure 3.16. Principal component analysis (PCA) scores plot of DNA methylation data. 
Zebrafish HCC samples (blue), healthy zebrafish liver samples (red), positive control of 
artificially methylated genomic DNA (purple) and negative control of artificially un-
methylated genomic DNA (green) were separated based on treatment along the PC1 and PC2 
axes. 
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3.3.3. Confirmation of the CGI tiling microarray data using bisulfite sequencing PCR 
Based on the data obtained from the DNA methylation tiling microarray, three genes from the 
2 categories of hypomethylated and hypermethylated genes in HCC samples compared to 
control samples were selected for validation of the microarray data by bisulfite sequencing 
PCR (BSP) (three tumour samples and three control samples). The genes selected for 
additional analysis with BSP were coronin, actin binding protein 2ba (coro2ba) 
(hypermethylated in HCC), insulin-like growth factor binding protein 1b (igfbp1b) 
(hypomethylated in HCC) and angiopoietin-like 3 (angptl3) (hypomethylated in HCC). The 
primers and annealing temperatures used are shown in Chapter 2, section 2.6.3, Table 2.2. 
Measurement of peak areas for C and T bases at a particular CpG site and calculation of the 
percentage of DNA methylation in four-dye trace sequencing data, allowed a semi-
quantitative assessment of the DNA methylation level at the specified site. To compare the 
methylation status of the targeted area by BSP in tumour and control, the total amount of 
methylation for the region was measured and compared. BSP results for igfbp1b, coro2ba and 
angptl3 confirmed the changes observed from the tiling microarray (Figures 3.17 and 3.18).  
The CGI of the gstp1 gene, as shown in Figure 3.5, is un-methylated in both tumour and 
control samples. Following treatment with CpG methyltransferase, SssI, in the presence of 
SAM, it became fully methylated (Figure 3.9). Therefore, this artificially methylated gene 
was used as a positive control in BSP experiments to confirm the semi-quantitative 
measurements of DNA methylation. 
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Figure 3.17. Confirmation of the CGI tiling microarray using bisulfite sequencing PCR. 
Percentage of DNA methylation (combined for all measured CpG dinucleotides) in igfbp1b, 
coro2ba and angptl1 genes showed significant differences between tumour and control 
samples (**P<0.01). (igfbp1b: number of CpG sites in tumours = 15± SEM, number of CpG 
sites in controls = 15± SEM; coro2ba: number of CpG sites in tumours = 51± SEM, number 
of CpG sites in controls = 51 ± SEM; angptl1: number of CpG sites in tumours = 21± SEM, 
number of CpG sites in controls = 21± SEM). Note: number of CpG sites is the sum of all 
CpG sites investigated within and between each replicates. P-value determined by 2-tailed 
Student’s t-test. 
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Figure 3.18. Methylation levels in tumour and control samples for individual CpG sites. A. 
coronin, actin binding protein 2ba (coro2ba) CGI region: -879 to -580, B. insulin-like growth 
factor binding protein 1b (igfbp1b) CGI region: -488 to -259 C. angiopoietin-like 3 (angptl3) 
CGI region: +106 to +258. n= 3 independent controls and 3 independent tumours ± SEM. 
*p<0.05, **p<0.01, p-value determined by 2-tailed Student’s t-test (tumour was compared to 
control for each CpG site). The probes and primers were designed based on version 56, 
genome build zv8, genome build date April 2009. 
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3.3.4. Gene expression and DNA methylation 
In a study published by Lam et al., who also provided the zebrafish DNA samples (Lam et al., 
2006), transcriptional changes in zebrafish HCC samples compared to control adult zebrafish 
liver samples were established. In addition, they compared the statistically significantly 
altered transcripts in zebrafish HCC samples with four different types of tumours found in 
humans (liver, gastric, prostate and lung cancer). Their findings demonstrated that hallmarks 
of cancer in humans were also altered in the zebrafish tumours (e.g. genes associated with cell 
cycle and proliferation, apoptosis, DNA replication and repair, and metastasis). However, 
gene expression signatures in zebrafish liver tumours most significantly correlated with gene 
expression profiles in liver tumours in humans (e.g. changes in Wnt-β-catenin and RAS–MAP 
kinase pathways) (This paper is provided as Appendix File 4).  
The data from this study was used to compare the alterations in gene expression with 
alterations in DNA methylation in HCC samples compared to healthy zebrafish livers. 
Comparisons are limited to the genes represented on the expression microarray that were 
differentially expressed and genes represented on the CGI tiling microarray. Therefore, DNA 
methylation and expression could only be compared for 194 genes. From these 194 genes 
with altered gene expression, 68 genes had CGIs 1.5 kb upstream to 1kb downstream of their 
TSS. Due to the criteria used for the design of the probes, only 49 genes from the previously 
identified 68 genes were represented on the tiling microarray and comparison were made 
between DNA methylation levels and gene expression. In total, 22 genes were identified with 
both significantly altered transcription and methylation (>1.5-fold change) in zebrafish HCC 
samples (Table 3.2, A full list of the 194 genes investigated is presented in Appendix File 5). 
Most of the genes identified were hypomethylated with up-regulated gene expression, such as 
mitogen-activated protein kinase 1 (mapk1), cell division protein kinase 8 (cdk8), RAB2A, 
member ras oncogene family (rab2) and proliferating cell nuclear antigen (pcna). This is not 
un-expected as most of the genes identified in our experiment were hypomethylated. 
Therefore, an extensive proportion of the 22 genes were comprised of hypomethylated genes 
(from the 29 probes (representing 22 genes) significantly altered in DNA methylation (>1.5-
fold change, p<0.05) 20 probes were hypomethylated and 9 probes were hypermethylated). 
IPA was applied to the list of genes that were significantly hypomethylated with up-regulated 
gene expression. The network highlighted in Figure 3.19 contains genes involved in formation 
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of cancer. For example, pcna is involved in formation of the replication fork and directing 
maintenance methyltransferases to the newly synthesised DNA strand. mapk1, capn2 and 
erk1/2 were a few more genes identified in this network with a known role in tumourigenesis. 
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Gene name Symbol Chr. no Expression level 
Methylation 
level 
Gene ID 
matrix metalloproteinase 14 
(membrane-inserted) alpha 
mmp14a 7 ↑ ↓ ENSDARG00000002235 
histidyl-tRNA synthetase hars 14 ↑ ↓ ENSDARG00000003693 
tubulin, alpha 8 like 4 tuba8l4 6 ↑ ↓ ENSDARG00000006260 
e2f transcription factor 6 e2f6 20 ↓ ↓ ENSDARG00000008119 
acetoacetyl-coa synthetase aacs 5 ↑ ↑ ENSDARG00000012468 
nucleophosmin 1 npm1 10 ↑ ↓ ENSDARG00000014329 
cyclin dependent kinase 8 
 (probe 54) 
cdk8 24 ↑ ↓ ENSDARG00000016496 
cyclin dependent kinase 8  
(probes 21, 31) 
cdk8 24 ↑ ↑ ENSDARG00000016496 
hepatoma-derived growth factor-
related protein 2 
hdgfrp2 22 ↑ ↓ ENSDARG00000019530 
rab2a, member ras oncogene family rab2 2 ↑ ↓ ENSDARG00000020261 
lim domain containing preferred 
translocation partner in lipoma 
lpp 6 ↑ ↓ ENSDARG00000023578 
Insulin-like growth factor binding 
protein 5a 
igfbp5b 9 ↓ ↓ ENSDARG00000025348 
mitogen-activated protein kinase 1 mapk1 5 ↑ ↓ ENSDARG00000027552 
cancer susceptibility candidate gene 3 
protein homolog 
casc3 3 ↑ ↑ ENSDARG00000029911 
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Table 3.2. Genes with both significantly altered gene expression levels and DNA methylation levels (>1.5-fold change, p<0.05) (expression 
level: ↑ up regulated, ↓ down regulated; methylation level: ↑ hypermethylated, ↓ hypomethylated). 
 
 
 
Continued from previous page      
hnrpa0l protein hnrpa0l 14 ↑ ↓ ENSDARG00000036161 
cyclin T2 ccnt2 9 ↑ ↓ ENSDARG00000036685 
proliferating cell nuclear antigen pcna 10 ↑ ↓ ENSDARG00000054155 
ret proto-oncogene  (probes 16, 19) ret 13 ↓ ↑ ENSDARG00000055305 
ret proto-oncogene (probes 20, 24) ret 13 ↓ ↓ ENSDARG00000055305 
integrin-linked kinase (probes 8, 1) ilk 10 ↑ ↓ ENSDARG00000056964 
integrin-linked kinase (probes 6) ilk 10 ↑ ↑ ENSDARG00000056964 
novel protein similar to vertebrate 
threonyl-tRNA synthetase 
tars 18 ↑ ↑ ENSDARG00000075429 
ribonuclease inhibitor 1 rnh1 22 ↓ ↓ ENSDARG00000078234 
calpain 2, (m/II) large subunit, like capn2 22 ↑ ↓ ENSDARG00000034211 
synaptopodin-2 synp2 7 ↓ ↑ ENSDARG00000079675 
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Figure 3.19. Ingenuity network predicted for genes that were both hypomethylated and had 
increased expression levels in zebrafish HCC (shaded red). In this diagram genes that are part 
of the canonical pathway “molecular mechanisms of cancer” are indicated with a blue line. 
 
 
 
 
 
 
 
Molecular 
mechanism of cancer 
 160 
 
3.4. Discussion 
The impact of DNA methylation upon the regulation of gene expression and its implications 
in disease has been studied extensively in relation to human health. As a result, the links 
between environmental agents such as chemicals or internal factors such as hormonal 
imbalances, alterations in epigenome and diseases in rodents and humans have become more 
apparent (discussed in Chapter 4). These findings have highlighted the importance of 
considering epigenetic mechanisms in ecotoxicology (Vandegehuchte and Janssen, 2011) and 
aquatic diseases. Therefore, the main aim of this chapter was to provide a starting point and a 
source of information for studying DNA methylation in fish tumours. 
 
3.4.1. Overall DNA methylation levels in fish  
Overall DNA methylation levels vary throughout the animal kingdom with the highest levels 
reported in vertebrates, intermediate levels in non-arthropod invertebrates and the lowest 
levels of DNA methylation in arthropods (Bird, 1980). However, there are some exceptions, 
for example DNA methylation has not been detected in the non-arthropod invertebrate, the 
nematode Caenorhabditis elegans (Simpson et al., 1986). In addition to DNA methylation 
levels, DNA methylation patterns differ throughout the animal kingdom. In invertebrate 
genomes, regions with high levels of methylation are separated by equally large regions of un-
methylated DNA. This gives rise to a pattern referred to as mosaic pattern of DNA 
methylation. In contrast, the genomes of vertebrates have a more globally homogenous 
pattern of methylation. In this case methylated DNA regions are distributed evenly throughout 
most of the genome. This leaves the CGIs located at the promoter regions of the genes as the 
regions that are free from methylation (Bird, 2002; Pogribny, 2010). Vertebrates are further 
divided into two distinct populations based on overall CpG methylation levels. The genomes 
of homeothermic vertebrates have almost two-fold lower methylation levels compared to 
ectothermic vertebrates (Varriale and Bernardi, 2006a). For example 4_5% of all the 
cytosines are methylated in the DNA extracted from the human liver and Bos taurus thymus 
while this value reaches around 7_10% in the DNA extracted from the liver of fish (Aniagu et 
al., 2008). This is in agreement with our findings in which the DNA methylation levels of the 
three fish species (~8%) investigated were two-fold higher than the DNA extracted from the 
thymus of mammalian species, Bos taurus (~4%). Several theories have been proposed for the 
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observed differences in overall DNA methylation levels. Bird (1995) proposed that the 
relatively high levels of DNA methylation in vertebrates is an evolutionary strategy evolved 
to decrease the background transcriptional noise due to increased number of genes in 
vertebrates compared with invertebrates (i.e. increased number/multifunction of genes and 
their products that are essential for development of their complex body). This theory explains 
the differences observed in DNA methylation levels and patterns between vertebrate and 
invertebrate genomes. However as humans compared to fish generally have a more complex 
genome (in regards to regulation, differentiation, interactions and functions), this theory does 
not account for the higher levels of DNA methylation observed in ectotherm genomes 
compared to homeotherm genomes. 
A second set of studies suggest that the changes in overall DNA methylation levels in 
vertebrates inversely relate to body temperature (i.e. methylation level: homeothermic 
vertebrates < tropical fish < temperate fish < polar fish) (Varriable and Bernardi, 2006a; 
Varriable and Bernardi, 2006b; Jabbari and Bernardi, 2004). Increase in body temperature 
results in higher rate of deamination of 5-methylcytosine. This causes an increase in 
5mCpG:TpG transition in homeothermic species, leading to lower levels of DNA methylation 
in homeothermic animals compared to ectothermic animals. Furthermore, transition of 
5mCpG to TpG in homeothermic vertebrate genomes is accompanied by accumulation and 
over-representation of the complementary dinucleotides TpG and CpA in their genome 
(Varriable and Bernardi, 2006a; Bird, 1980; Spontaneous mutation of 5mC is discussed in 
Chapter 1, section 1.3.5.1.3). However, the reason for the observed differences in overall 
DNA methylation levels remains controversial. Nevertheless, what is in agreement is that 
these differences observed in DNA methylation patterns, levels and sites throughout the 
animal kingdom are indicative of the possibility that the function of DNA methylation has 
altered as species have evolved (Lee et al, 2010). Therefore, to understand the role of DNA 
methylation it is important to establish the pattern of DNA methylation (Bird, 2002). 
 
3.4.2. DNA Methylation alterations at gene level in zebrafish HCC samples  
A range of carcinogenic polycyclic aromatic hydrocarbons (PAHs) including DMBA can 
initiate DNA methylation changes, including global DNA hypomethylation. Therefore in 
addition to inducing mutations, these chemicals can initiate and contribute to carcinogenesis 
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process by causing heritable changes in DNA methylation patterns (Wilson et al., 1987). In 
this study, treatment with DMBA was conducted for a short period of time. Following 
chemical exposures, fish were kept for an extensive period of time (6_10 months) in 
chemical-free water. A number of methylation changes are formed as a result of the initial 
chemical exposure (i.e. initiating events). These epigenetic events are maintained as a 
memory of the exposure to the chemical. However, most likely the high proportion of the 
observed changes in DNA methylation profiles are characteristic of the type of formed 
tumour. This is due to the extensive chemical-free period. Nevertheless, studies have 
demonstrated that DNA methylation profiles depend on both the causative agents (memory of 
the exposure) (Pei et al., 2009; Prins, 2008) and the type of tumour (Esteller and Herman, 
2002). In this study DNA methylation modifications were investigated in relation to the 
features associated with tumours rather than the causative agent by using a custom-made 
promoter CGI zebrafish microarray. On this microarray, each CGI was represented by a 
number of probes covering the entire length of the CGI. This provided a comprehensive 
coverage of the CGI. The analyses indicated that DNA methylation levels are not uniformly 
distributed across the regions investigated in the healthy adult zebrafish liver samples. Indeed, 
genes with specific biological functions were enriched or under-methylated compared to the 
average DNA methylation levels of all the investigated regions (Results, section 3.3.2.2). As 
discussed in Chapter 1, DNA methylation is involved in regulation of transcription and tissue-
specific transcription. Therefore, the changes in methylation levels could reflect the 
differences in transcription levels of these genes. Although all somatic cells contain the same 
genetic material, they are phenotypically and functionally diverse. This, in part, has been 
linked to tissue-specific differentially methylated regions which consequently will alter the 
transcription levels of these regions, providing each tissue with a unique phenotype 
(Christensen et al., 2009; Eckhardt et al., 2006). However, this theory requires testing and 
comparing the achieved DNA methylation profile with DNA methylation profiles of other 
adult zebrafish tissues. Therefore at this stage the established normal DNA methylation 
profile can only be used as a measure of background level of DNA methylation for 
comparison with treatment conditions in adult zebrafish liver (i.e. relative changes in DNA 
methylation levels following exposure to chemicals or liver diseases). Therefore DNA 
methylation profiling of healthy adult zebrafish liver has provided: 1. A list of genes with 
CpG islands at their promoter regions 2. A list of genes with different levels of DNA 
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methylation at their promoter regions (relative levels rather than absolute levels of DNA 
methylation). The identified genes can be used in any future studies as suitable target genes to 
test whether their DNA methylation is altered as a response to treatment or whether DNA 
methylation may have a role in regulation of their transcription levels. This bypasses the 
initial screening of the genes that was conducted at the beginning of this study for the 
identification of methylated genes in zebrafish (see results, section 3.3.2.1). Thus although 
this method provided a relative measurement of changes in DNA methylation of HCC tissues 
compared to healthy tissues and relative measurements of the levels of enrichment of 
methylated regions rather than absolute levels of DNA methylation in control samples, this 
did not influence the identification of the categories of genes that were enriched/under-
represented in the analysed groups. Therefore, the data achieved from the MeDIP-tiling 
microarray provided a useful insight into alterations to DNA methylation related to several 
biological functions associated with tumourigenesis, such as regulation of transcription in 
HCC samples.  
Regulation of transcription is a complex procedure. It is modulated and controlled at different 
levels and through various mechanisms. Epigenetic mechanisms are key elements in this 
process with histone-DNA interactions in nucleosomes, covalent modification of the N-
terminal tails of histones, RNA interference (RNAi) and DNA methylation being some of the 
main epigenetic regulatory mechanisms (Momparler and Bovenzi, 2000; Zilberman et al., 
2007; Cui et al., 2010). As shown in Table 3.1A, GO terms associated with DNA binding and 
transcription regulation were significantly over-represented amongst genes hypomethylated in 
HCC samples. For example, methylation of the histone H2A gene was reduced in the HCC 
samples compared to controls. As hypomethylation of genes has been associated with 
increased expression (Lopez et al., 2009; Rauch et al., 2007), it is possible that this change 
could cause increased expression of histone H2A gene. Increase in expression of this gene 
could further affect the composition of nucleosomes and thereby regulation of transcription 
(Turner, 2007). Indeed, histones can cover the transcription start sites and transcription 
termination sites (TTS) of the genes, restricting access of the transcription factors to these 
regions and resulting in altered transcription levels (Cui et al., 2010). In addition to the role of 
globular domains of the histone in regulation of transcription, post-transcriptional chemical 
modifications of the N-terminal tail of histones are extremely important in regulation of gene 
expression and replication (Turner, 2007; Zhou et al., 2000; Turner, 2009). Indeed, the 
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methylation of histone deacetylase 4 and lysine-specific demethylase 4A were reduced in the 
HCC samples compared to controls. The N-terminal acetylation or deacetylation of histones, 
mediated by histone deacetylases and histone acetyltransferases, can decrease and increase the 
positive charge of the histones, respectively, and as a result affect the interaction between 
DNA and histones. This subsequently can permit or restrict the access of transcription factors 
to the regulatory regions of the genes (Zhou et al., 2000; Turner, 2007; Lopez et al., 2009; 
Turner, 2009).  
Methylation profiles of DNA in cancer cells are extensively distorted (Lopez et al., 2009), 
thus mediating changes in most of the key pathways (e.g. cell cycle, apoptosis, proliferation) 
associated with tumourigenesis (Baylin et al., 2001). This is in agreement with our findings 
using Ingenuity Pathway Analysis (IPA). This analysis indicated that the genes with altered 
methylation in zebrafish hepatocellular carcinoma were associated with biological functions 
such as cell death, cell morphology, inflammatory response, DNA repair and replication. The 
changes in methylation levels of these particular genes and pathways could be directly or 
indirectly linked to their altered expression levels during tumourigenesis. 
Most importantly, GO terms associated with genes involved in cell proliferation and 
regulation of cell death were significantly over-represented in the list of hypomethylated 
genes in zebrafish HCC samples. For example our results showed a significant decrease in the 
DNA methylation of a positive regulator of the B-cell lymphoma 2 (Bcl-2) protein, bcl-2 
associated athanogene 5 (bag5) (Yang et al., 2007). It is known that anti-apoptotic genes, 
such as BCL-2, and their regulators, are often over-expressed in human tumours (Yang et al., 
2007; Yang et al., 1997). This finding is particularly relevant since an imbalance between 
regulation of cell proliferation pathways and cell death by apoptosis can promote the 
development of tumours (Sakinah et al., 2007; Klaunig et al., 2000).  
In addition to the observed changes in DNA methylation levels of genes involved in anti-
apoptotic pathways in zebrafish HCC, DNA methylation levels of genes involved in 
proliferation pathways were also altered. Insulin like growth factors (IGF) and insulin like 
growth factor binding proteins (IGFBPs) play important roles in organising cell proliferation, 
apoptosis and differentiation and are commonly deregulated in human tumours (Inman et al., 
2005). In zebrafish HCC samples, genes for several insulin growth factor binding proteins 
such as igfbp2b were significantly hypomethylated. The promoter region of the human 
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IGFBP-2 gene is rich in CpGs and lacks a TATA box (Hoeflich et al., 2001). It is therefore 
plausible that methylation plays an important role in regulating the expression of this gene. 
Multiple complex IGF-dependent and independent biological functions influenced by the 
tissue type and pathological status have been identified for IGFBPs (Inman et al., 2005; 
Hoeflich et al., 2001). An increased level of IGFBP-2 protein has been reported in liver 
tissues and serum during human malignancy (Inman et al., 2005; Hoeflich et al., 2001) with a 
positive correlation to the malignancy status of the tumour (Hoeflich et al., 2001). In contrast 
to its normal role as a negative regulator of growth, increased levels of IGFBPs in tumours 
have been linked to enhanced proliferation, partly as a response to androgens and hypoxia-
inducible factor-1 (HIF-1) protein. Thus, anaerobic conditions can result in increased levels of 
IGFBPs (Kelly et al., 2008).  
A lack of vascular supply at the early stages of tumourigenesis in highly proliferating tumours 
results in hypoxia (Kelly et al., 2008). Under hypoxic circumstances glycolysis becomes the 
dominant pathway for energy production in tumours and glycolytic enzymes are induced. In 
association with this, the HIF-1 protein, expressed in an anaerobic environment, initiates the 
transcription of several genes involved in stress and glycolysis as well as IGFBP2 (Hoeflich 
et al., 2001; Kelly et al., 2008). This is in agreement with the findings from this study in 
which the GO terms related to glycolysis and hypoxia pathways were more prevalent in the 
list of hypomethylated genes in HCC samples. Glycolytic enzymes such as enolase 2 (ENO2) 
and hexokinase 2 showed significant decreases in methylation of their genes in HCC samples, 
indicating a potential increase in expression. Increased expression of enolases such as ENO1 
and 2, as a response to hypoxia and HIF-1, has been reported in human HCC (Hamaguchi et 
al., 2008). As well as its function in energy production, ENO1 has been associated with 
enhanced proliferation in HCC (Hamaguchi et al., 2008). Therefore, based on the functions of 
the genes where methylation was significantly altered in HCC samples, it appears that there is 
a link between induction of IGF, IGFBPs, HIF, anti-apoptotic and glycolytic pathways 
(Hoeflich et al., 2001; Kelly et al., 2008; Feldser et al., 1999). This is similar to the findings 
previously reported on gene expression in human HCC, implying that differential DNA 
methylation is at least partially causative of differential gene expression in HCC. However, it 
has to be noted that some of the observed differences in DNA methylation of the genes in 
HCC samples compared to control samples can be caused by change in the expression levels 
of these genes (this concept is further discussed in Chapter 6).  
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3.4.3. Confirmation of the MeDIP-tiling microarray data using Bisulfite sequencing 
PCR 
Direct sequencing of bisulfite-treated and amplified DNA was used for the measurement of 
average methylation percentage in a population of DNA molecules. Both normal and tumour 
tissues are heterogeneous in terms of molecular alterations and cell populations. As in this 
study DNA was extracted from a tissue with a mixture of cell populations, complete 
homogeneity of the sequenced data was not anticipated. Therefore, the proportion of C/T was 
compared between samples based on well-established methodology previously utilised (Mill 
et al., 2006; Lewin et al., 2004; Paul and Clark, 1996). Hence this method (as well as allowing 
the detection of partial and rare events (Rein et al., 1998)) provided an average percentage of 
DNA methylation at particular CpG sites in a population of DNA molecules. This is in 
contrast to establishment of the methylation status of a CpG in one molecule achieved by 
cloning prior to sequencing (Mill et al., 2006; Lewin et al., 2004; Rein et al., 1998; Paul and 
Clark, 1996). However, it has to be noted that although BSP is the gold-standard method for 
measurement of DNA methylation levels with single base resolution (Suzuki and Bird 2008), 
this method cannot distinguish between 5-mC and 5-hydroxymethylcytosine (5-hmC). The 
latter reacts with bisulfite and yields cytosine 5-methylenesulfonate (CMS). CMS, similar to 
5-mC, does not readily deaminate and therefore it is detected as a cytosine base in the bisulfite 
treated, sequenced data (Huang et al., 2010). Nevertheless, this method has remained as the 
most reliable method for measurement of DNA methylation levels. High density of 5-hmC 
interferes with the activity of DNA polymerase and sequencing of the bisulfite treated DNA 
(Huang et al., 2010). Therefore as no complication was encountered during amplification step 
and due to agreement of BSP data with MeDIP-tiling microarray data, the presence of 5-hmC 
in the investigated genes with BSP seems less likely.  
 
3.4.4. Comparison of gene expression and DNA methylation data 
As distortion of DNA methylation profiles of cells can give rise to altered expression of genes 
commonly implicated in cancers (Momparler and Bovenzi, 2000), the identified genes with 
significantly altered DNA methylation levels in HCC samples were compared with the 
differentially expressed genes from the study of Lam et al., (2006).  
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Although comparison of the genes with statistically significantly altered DNA methylation 
and expression levels were limited to the genes present on both microarrays (49 genes), 22 
genes showed both altered DNA methylation and transcription. These genes were associated 
with biological functions that are commonly implicated in cancers, such as proliferation, 
apoptosis, differentiation, migration, and transcription regulation. For example both cyclin T2 
and cyclin dependent kinase8 (cdk8), involved in transcription regulation and cell-cycle, were 
hypomethylated and over-transcribed in HCC samples (Yang et al., 2004; Firestein et al., 
2008). Most notably, half of the hypomethylated genes over-transcribed in HCC samples were 
identified to be directly or indirectly involved in detachment of cancer cells from surrounding 
tissues and metastasis, such as matrix metalloproteinase14 (mmp14), lim domain containing 
preferred translocation partner in lipoma and calpain2. Metastasis and invasion is one of the 
essential alterations in the physiology of cancer cells that allows growth and spreading of the 
tumour cells (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011).  
MMP14 is involved in activation of MMP2. MMPs are proteolytic enzymes over-expressed in 
many cancers (Clark et al., 2008) and have been found to be activated through 
hypomethylation in pancreatic cancer (Sato et al., 2003). Due to their protein degradation 
activity and breakdown of extracellular matrix, they are important in tumour invasion and 
angiogenesis. Furthermore, their ability to detach IGF from the IGFBPs leads to promotion of 
growth in tumours (Egeblad and Werb, 2002). In addition, calpains, including calpain2, which 
are calcium activated endopeptidases, are also found to be over-expressed in cancers and have 
been associated with invasion of cancer cells as well as apoptosis and proliferation (Mamoune 
et al., 2003; Nakagawa and Yuan, 2000). It has been discovered that over-expression of 
calpain2 in prostate cancer is regulated through epigenetic mechanisms (Mamoune et al., 
2003), which agrees with hypomethylation of the calpain2 promoter in this study.  
Lam et al., (2006) reported that expression of Wnt/β-catenin and Ras-MAPK (mitogen-
activated protein kinase) pathways were altered in zebrafish HCC samples. The data from this 
study also showed that genes involved in these two pathways were altered at the methylation 
level in these samples. erk1 involved in the ERK pathway (extracellular-signal-regulated 
kinases), an evolutionary conserved MAPK pathway, was hypomethylated and over-
transcribed in HCC samples. From the Wnt/β-catenin pathway, frizzled homologs 8a and 8b, 
secreted frizzled-related protein 2 (sfrp2) and c-jun, a target gene for β-catenin and ERK 
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pathway, were hypomethylated in zebrafish HCC samples. Both pathways are associated with 
proliferation, apoptosis, differentiation and migration in cancers and are commonly 
deregulated in human liver cancers (Dhillon et al., 2007; Firestein et al., 2008; Bikkavilli and 
Malbon, 2009; Lam et al., 2006).  
However, regulation of gene expression through CGI methylation is extremely complex. For 
example, the data presented in this chapter (Table 3.2) demonstrated that methylation and 
expression levels of several genes were altered in the same direction (e.g. cancer 
susceptibility candidate gene 3 protein homolog was hypermethylated and over-transcribed in 
HCC samples) or in the case of suppressed ret proto oncogene, two regions of the CGI were 
hypomethylated while two other sections were hypermethylated. As discussed (Chapter 1, 
section 1.3.2.3) the relationship between gene expression and DNA methylation is complex 
and several factors affect the relationship between them.  
Although the methylation level of an entire CGI located around the TSS of a gene could be 
altered, the methylations of particular CpG sites known as core regions are of key importance 
in determining the effects of methylation upon transcription. These core regions could be as 
short as single CpG dinucleotides. For example, methylation of a single CpG site in the TSS 
region of tristetraprolin gene (TTP), a negative post transcriptional regulator of c-MYC, 
results in transcriptional silencing of this gene in liver cancers (Van Vlodrop, 2011). In 
addition, the presence of transcriptional enhancers and suppressors, alternative promoters at 
intra- and intergenic CpG dinucleotides, regulation of transcription of several genes by one 
promoter, activity of more distal response elements and location of several CpGs outside the 
traditionally defined CGIs can influence the outcome in terms of gene expression and thus 
interpretation of the data (Siegfried and Simon, 2010; Jones, 1999; Van Vlodrop, 2011). 
Therefore establishing a relationship between gene expression and DNA methylation data 
without structural and mechanistic analysis and identification of core CpG regions is not 
entirely possible.  
 
3.4.5. Comparison between DNA methylation profiles of HCC and healthy liver in 
zebrafish and in human  
Lam et al., (2006) demonstrated that the changes in the expression of key genes involved in 
promotion of tumours are conserved in the phylogenetically distant species, zebrafish and 
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human. This emphasised the importance of these genes in cellular responses and strengthened 
the suitability of fish as models for carcinogenesis research. To further investigate the 
possibility of conservation of DNA methylation profiles between zebrafish and human 
healthy livers and HCC tumours, the data achieved from this study were compared with a 
study by Archer et al., (2010), focusing on DNA methylation profiling of human HCC 
tumours. This study was selected based on their experimental approach, comprehensive 
analysis and design. In this study an Illumina Golden Gate methylation bead microarray was 
used to investigate the methylation of 1,505 CGIs (807 genes) in 76 patients (20 hepatitis C 
virus (HCV) induced HCC tissues, 20 adjacent non-tumourous samples from HCC containing 
livers, 16 HCV cirrhotic tissues from patients without HCC, 20 normal liver tissues). As well 
as high numbers of genes and patients investigated in this study, the effect of several factors 
in their experimental design was considered, such as examination of both surrounding tissues 
and liver samples from healthy individuals (DNA methylation differences in surrounding 
tissue and non-tumour containing tissue is covered in Chapter 4), analysis of samples with 
similar age groups and most importantly, HCC samples with same underlying cirrhosis 
etiology (HCV induced HCC) were used in their experiment. The latter is important as it has 
been shown that HCV induced HCC and hepatitis B virus (HBV) induced HCC samples have 
different methylation profiles (Pei et al., 2009).  
In this study, non-tumour containing livers from zebrafish and HCC tumour samples were 
used. In order to match the experimental conditions as best as possible between the human 
DNA methylation study conducted by Archer et al., (2010) and the zebrafish study presented 
in this chapter, comparisons between human and zebrafish methylation profiles were 
restricted to human DNA methylation data obtained from healthy liver and HCC samples 
from humans. Therefore in these comparisons the human data obtained from adjacent non-
tumourous samples from HCC containing livers were not used. A low correlation was 
detected between the methylation pattern of hepatic genes in healthy human liver presented by 
Archer et al. (2010) and healthy zebrafish liver in this study (r= 0.187). A poor correlation 
was also identified between HCV induced liver tumours in humans and HCC tumours in 
zebrafish (r=0.166). This implied that the methylation patterns between human and zebrafish 
at individual gene levels in both healthy liver and HCC samples are not conserved (The list of 
genes common between the two studies are presented in Appendix File 6). This could be 
partly explained due the nature of the zebrafish genome. Zebrafish often have more members 
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of multigene families than humans (Postlethwait et al., 1998) and that their exact functions 
have not been well-studied. Although different at gene level, comparisons with the literature 
showed that in zebrafish and human HCC tumours similar families of genes and genes 
involved in shared pathways are altered in terms of methylation. For example, zebrafish HCC 
samples showed methylation changes in genes involved in proliferation, cell cycle, metastasis, 
apoptosis, energy production, adhesion, stress, DNA binding and regulation of transcription. 
Methylation pattern of genes involved in similar biological processes in human HCC were 
also altered (Tischoff and Tannapfel, 2008; Archer et al., 2010). Several other genes from 
families, such as ATP-binding cassette, sub-family A, DEAD-box helicases, potassium 
channel tetramerisation domain containing gene family and epidermal growth factor family 
were found to be hypermethylated in both zebrafish and human HCC (Gao et al., 2008). 
However, this work is preliminary. A more comprehensive study with same tumour causative 
agents in both species is required. 
 
3.4.6. Conclusions 
In this study development of a zebrafish CGI tiling microarray was described. It was 
demonstrated that in combination with the MeDIP technique, it can be used to detect and 
profile the methylation status of specific genes. This method was used to achieve a 
comprehensive profiling of DNA methylation in zebrafish liver as well as establishing the 
DNA methylation changes observed in HCC samples. Furthermore, the detected alterations in 
DNA methylation can help to explain some of the changes detected in gene expression in 
HCC samples. However, further functional studies are required to identify key CpG sites that 
are crucial in regulating gene expression. Nevertheless, striking similarities between the 
pathways disrupted by aberrant gene expression and DNA methylation were detected, both 
within and between human and zebrafish HCC. 
Finally, achieving a better understanding of genetic and epigenetic regulation of transcription 
in zebrafish will increase the level of confidence in using zebrafish as a convenient model for 
investigating human diseases. Most importantly, this study has provided evidence of 
disruption of DNA methylation in critical pathways of tumourigenesis in fish.  
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DNA methylation in liver tumourigenesis 
in dab (Limanda limanda) from the 
environment 
 
 
 
The data presented in this chapter has been published.  
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4.1. Introduction 
Traditionally cancer was considered as a multistep genetic disease driven and initiated by 
mutations (Vogelstein and Kinzler, 2004; Hanahan and Weinberg, 2000). However, data 
collected in the past decade demonstrate that both epigenetic and genetic changes interact and 
complement each other to enable the development of tumours (Gronbaek et al., 2007; Sharma 
et al., 2010; Feinberg, 2004).  
The relationships between DNA methylation, chromatin modification and gene expression are 
complex. Several factors such as presence of transcriptional enhancers and suppressors, and 
their locations on the promoter, can subsequently influence the outcome (Siegfried and 
Simon, 2010; Jones 1999; see Chapter 1, section 1.3.2.3 and Chapter 3, section 3.4.4). In 
addition, the association between transcription and DNA methylation of the regulatory 
regions is further complicated by methylation of the coding regions of the genes. Genes that 
are moderately transcribed with no methylation in promoters have highly methylated coding 
regions compared to highly transcribed genes. This methylation has been linked to inhibition 
of transcription from cryptic sites located in the coding regions of the genes during 
transcription elongation (Suzuki and Bird, 2008; Zilberman et al., 2007). This suggests a 
higher susceptibility of the moderately transcribed genes to transcription interference 
(Zilberman et al., 2007). Nevertheless, irrespective of the specific influences of DNA 
methylation upon gene expression, distortion of the DNA methylation profile is a key event 
and a known hallmark of neoplastic cells with both global DNA hypomethylation and gene 
specific DNA hypermethylation (e.g. genes involved in apoptosis, metastasis, adhesion, cell 
cycle and DNA repair) reported in all cancers investigated (Lopez et al., 2009; Tischoff and 
Tannapfel, 2008; Gronbaek et al., 2007; Esteller and Herman, 2002; Esteller et al., 2001). 
Evidence is emerging that epigenetic changes, including alterations in DNA methylation, 
occur at early stages of tumourigenesis, potentially preceding mutational changes (Lopez et 
al., 2009; Pogribny, 2010; Reamon-Buthner et al., 2008; Feinberg et al., 2006; Sharma et al., 
2010).  
Environmental factors play a key role in the development of complex diseases. Exposures to 
natural and artificial chemicals and physical agents have been recognised as major 
contributors to the risk of development of cancers in humans (Parkin et al., 2002; Armstrong 
and Doll, 1975; for review see Wild, 2009). Previously, carcinogenic effects of chemicals 
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were mainly associated with the ability of the chemicals to interact with DNA and induce 
mutations (genotoxic chemicals). However non-genotoxic carcinogens have been identified as 
a second category that induce tumourigenesis but are not directly mutagenic. These chemicals 
modulate cell growth and proliferation through alteration of signalling pathways, including 
changes in DNA methylation; hence, resulting in changes to gene expression (Klaunig et al., 
2000). Growing amount of experimental and epidemiological data demonstrate that 
accumulation of epigenetic modifications over time due to environmental insults (e.g. 
environmental stressors, including sub-lethal concentrations of chemicals), increases the 
individual’s susceptibility to disease and development of disorders such as cancer (Reamon-
Buthner et al., 2008; Wild, 2009; Bollati and Baccarelli, 2010; Baccarelli and Bollati, 2009; 
Feinberg et al., 2006). This correlates with the considerable time required for development of 
different types of tumours (Baccarelli and Bollati, 2009; Feinberg at al., 2006). For example, 
both rodent and epidemiological studies on exposure to metals (e.g. nickel, cadmium, 
chromium, arsenic), air pollutants and endocrine disruptors have clearly demonstrated a link 
between environment, epigenome and cancer (for reviews see Skinner et al., 2010; Arita and 
Costa, 2009; Baccarelli and Bollati, 2009; Chapter 1, section 1.3.5.2).     
However, in contrast to the wealth of information available on environmental factors, change 
in the epigenome and development of cancer in humans, this area is substantially 
understudied in aquatic biology. A few studies have investigated the effects of chemical 
exposures on DNA methylation levels at either global level or on selected genes in aquatic 
species. These are; hypomethylation of the vitellogenin 1 promoter in adult zebrafish liver 
(Danio rerio) following exposure to 17α-ethinylestradiol (EE) (Stromqvist et al., 2010), 
global DNA hypermethylation in male gonads of three-spined stickleback (Gasterosteus 
aculeatus) after exposure to 17β-estradiol (E2) (Aniagu et al., 2008), global DNA 
hypermethylation in the liver of goldfish (Carassius auratus) following exposure to heavy 
metals (Zhou et al., 2001), changes in methylation of aromatase and estrogen receptor (ER) 
promoters in Japanese medaka (Oryzia latipes) following exposure to EE (Contractor et al., 
2004), genome-wide methylation profiling of adult zebrafish hepatocellular carcinoma 
tumours induced by DMBA (our own study, Mirbahai et al., 2011, Chapter 3), global DNA 
methylation studies in Daphnia magna following exposure to several chemicals 
(Vandegehuchte et al., 2009a, Vandegehuchte et al., 2009b, Vandegehuchte et al., 2010a; 
Vandegehuchte et al., 2010b) and global DNA methylation studies in the liver of bluegill 
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sunfish (Lepomis macrochirus) and kelpfish (Sebastiscus marmoratus) following exposure to 
benzo[α]pyrene, tributyltin and triphenyltin (Shugart et al., 1990; Wang et al., 2009) (for more 
details on each study see Chapter 1, section 1.3.1, Table 1.1). As a result, it is becoming more 
apparent that epigenetic mechanisms in both aquatic species and mammals are affected by 
model environmental pollutants. This highlights the importance of investigating the influence 
of environmental factors upon the epigenome and determining its role in diseases of marine 
species. However, so far there have been no studies of marine species investigating epigenetic 
changes in relation to carcinogenesis, partly due to the difficulties of studying non-model 
organisms and the availability of tumour samples from wild species. 
Common dab (Limanda limanda) is a flatfish caught from UK waters as part of the UK Clean 
Seas Environmental Monitoring Programme (CSEMP). Liver pathology in dab, including 
cancer and pre-neoplastic lesions, is used as an indicator of the biological effects of 
contaminants on the marine environment. Due to their living habits and close proximity to the 
ocean floor they can be exposed to relatively high levels of sediment-associated chemicals. 
This makes them ideal species for biomonitoring and environmental carcinogenicity research. 
An unusually high prevalence of liver tumours has been reported in dab, with some UK sites 
exceeding 20% of sampled individuals (NMMP, second report, 2004; Stentiford et al., 2009; 
Small et al., 2010; Southam et al., 2008; Lyons et al., 2006). However, the causative factors of 
these tumours and the molecular mechanisms involved, especially in relation to the balance 
between epigenetic and genetic factors, is unclear. Previous studies in our laboratory indicated 
that mutation profiles of oncogenes and tumour-suppressor genes within tumours were 
markedly different in frequency between fish species and humans (Rotchell et al., 2001a; 
Franklin et al., 2000). In Chapter 3 and in our publication (Mirbahai et al., 2011) we 
demonstrated that pathways with differentially methylated genes in chemically induced 
zebrafish (D. rerio) hepatocellular carcinoma (HCC) are similar to the pathways altered in 
human HCC. This highlighted the importance of DNA methylation alterations in the 
development of fish tumours and suggested the involvement of epigenetic factors in the 
formation of dab tumours.  
Therefore, having confirmed the alteration of DNA methylation in fish tumours, based on the 
results of Chapter 3, the aims of this study were to identify differentially methylated regions 
of the genome as well as differentially expressed genes in dab hepatocellular adenoma (HCA) 
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compared to healthy dab liver. In addition, using pathway analysis techniques we aimed to 
determine if methylation and expression of genes in specific pathways were altered in 
tumours compared to healthy control samples. The ultimate goal was to elucidate possible 
molecular mechanisms behind these tumours and determine if a link could be established 
between environmental contaminants, epigenetic changes and dab liver tumours.  
Dab is an un-sequenced species, therefore using traditional techniques for gene-specific 
studies in dab is challenging. Hence, to overcome this problem and to identify genome-wide 
methylation changes we combined MeDIP with de novo high-throughput DNA sequencing 
for the first time. Based on this data, we designed the first dab-specific gene expression 
microarray. Finally, this data demonstrates the suitability and power of these methods for 
studying DNA methylation in un-sequenced species.   
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4.2. Overview of the experimental approach (Methodological details are described in 
Chapter 2) 
The HPLC method, established in Chapter 3, was used for measurement of global DNA 
methylation levels in three different categories of interest, dab hepatocellular adenoma 
(HCA), healthy tissue surrounding HCA samples (ST) and dab healthy liver. Samples 
(healthy liver, ST and HCA) used for this study were all confirmed by histopathology studies. 
MeDIP combined first with a cDNA microarray as a pilot experiment, then with high-
throughput sequencing (HTS) were used to investigate alterations in DNA methylation in 
HCA samples compared to non-cancerous surrounding tissue (MeDIP-HTS was carried out 
by Beijing Genomics Institute (BGI)). In addition, bisulfite sequencing PCR was used to 
confirm the observed changes in DNA methylation. 
A dab-specific 8x15k gene expression microarray was constructed based on the sequences 
achieved from the HTS of a HCA sample and corresponding ST. This microarray was used 
for transcriptomic profiling of the three sample categories of interest. Real time-PCR was 
used for validation of the data achieved from the transcriptomic study. 
GeneSpring, multiexperiment viewer (MeV), Blast2GO, Ingenuity Pathway Analysis and 
PCA were used to analyse and identify the biological functions that were altered in HCA 
samples compared to ST and healthy dab liver.  
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Figure 4. 1. Flowchart of the experimental procedures used in Chapter 4. The starting points 
of the diagram are the boxes with borders. The methods used in this chapter are described in 
detail in Chapter 2. In this flowchart, the sections where these methods are described in 
Chapter 2 are shown in brackets. 
 
 
 
 
Labelled with  
Cy5-CTP 
 
RNA aliquot of combined 
HCA, ST and healthy dab liver 
Labelled with  
Cy3-CTP 
Custom-made dab gene 
expression microarray 
(section 2.5.3.3) 
HCA and ST from 9 other fish 
+ 12 non-cancerous dab livers 
HCA and ST from one fish 
(section 2.2.2.1 for sampling 
locations) 
DNA extraction 
(section 2.2.2.3.1) 
MeDIP-HTS 
(section 2.5.3.1) 
Bisulfite sequencing PCR 
n=32 samples, 5 genes 
(section 2.6) 
DNA extraction 
(section 2.2.2.3.1) 
RNA extraction 
n=32 samples 
(section 2.2.2.3.1) 
RT-PCR 
n=5 per category of samples, 4 
genes 
(section 2.7.2) 
HPLC 
n=5 
(section 2.3.2.5) 
Pilot study: MeDIP-
flounder cDNA microarray 
n=8 
(sections 2.4 and 2.5.1) 
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4.3. Results 
4.3.1. Global measurement of genomic DNA methylation 
To establish the global levels of cytosine methylation in the three tissue categories of interest 
(healthy dab liver, HCA and apparently healthy surrounding tissue of tumour containing dab 
liver (ST)) HPLC was performed (number of replicates for each category=5). Absence of 
RNA contamination was confirmed as previously described (Chapter 3, section 3.3.1.2). As 
shown in Figure 4.2 a statistically significant 1.8-fold DNA hypomethylation was detected 
between healthy dab liver and tissue surrounding HCA tumours (ST) and between healthy dab 
liver and HCA (P<0.01). However, no significant differences were detected in overall 
cytosine methylation levels between ST and HCA. The level of cytosine methylation in 
healthy dab liver (Figure 4.2) was 8%. This is in agreement with previous published data 
demonstrating a 2-fold higher DNA methylation level in fish liver compared to the liver of 
mammals (Aniagu et al., 2008). 
 
 
 
 
 
 179 
 
Figure 4.2. Measurement of global percentage of methylated cytosine. Overall DNA 
methylation levels were measured in healthy dab liver, hepatocellular adenoma (HCA) and 
tissue surrounding HCA tumours in dab liver (ST) using HPLC. Overall methylation levels of 
HCA and ST differed significantly from healthy liver. No significant difference was detected 
in overall DNA methylation levels between HCA and ST. This was investigated using one-
way ANOVA Tukey’s post-hoc test. ** Significantly different from healthy liver (P<0.01). 
Data are shown as mean ± SEM of five independent samples.  
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4.3.2. DNA methylation at gene levels in dab liver 
4.3.2.1. Pilot study using MeDIP coupled with flounder cDNA microarray 
Although no differences was detected in overall cytosine methylation levels between ST and 
HCA, to investigate further the possibility of differentially methylated regions between HCA 
and ST at the gene level, MeDIP was combined with a flatfish European flounder (Platichthys 
flesus) cDNA microarray as described previously (Chapter 2, section 2.5.1). DNA samples 
were extracted from 8 HCA and corresponding surrounding tissue (ST) of female dab and 
sonicated (sample details are described in Chapter 2, section 2.2.2.1) then immunoprecipitated 
as described previously (Chapter 2, section 2.4) and labelled with Cy5-dCTP. These samples 
were hybridised to a flounder cDNA microarray against a reference sample comprised of 
sonicated genomic DNA pool labelled with Cy3-dCTP. 
The flounder cDNA microarray was constructed as part of the Genomic Tools for 
Biomonitoring of Pollutant Coastal Impact (GENIPOL) project in 2006 (Williams et al., 
2006) containing 12,738 clones spotted in duplicate (either expressed sequenced tags (ESTs) 
or cloned regions of genes) relating to approximately 3336 unique coding sequences from the 
European flounder. Sequence homology is sufficiently great between the two closely related 
flatfish; therefore, the use of this microarray for transcriptional studies in dab is valid (Diab et 
al, 2008; Cohen et al., 2007; Small et al., 2010).  
Two fish samples were excluded from the analysis. One HCA and matching ST sample were 
removed from the analysis as the microarray slide containing the HCA sample (sample code: 
RA08045-43) broke prior to scanning of the slide. The second set was removed during sample 
quality checks (sample code: RA08045-10). The HCA sample showed poor hybridisation to 
the microarray probes and therefore along with the matching ST was excluded during data 
analysis. This reduced the sample numbers to 6 pairs of HCA and ST.  
Following quality checks and normalisation, the data were analysed using Welch paired t-test 
with assumption of un-equal variance (P<0.05) as described previously (Chapter 2, section 
2.9.2). This approach resulted in identification of 78 clones (15 hypomethylated and 63 
hypermethylated) that were statistically significantly altered in HCA samples compared to the 
non-cancerous ST with 16 clones (3 hypomethylated and 13 hypermethylated) showing 
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altered methylation levels of greater than 1.5-fold (Table 4.1; complete list of all potentially 
differentially methylated clones are presented in Appendix File 7). 
Due to several reasons, explained in the discussion, this study resulted in identification of 
small numbers of differentially methylated clones in HCA compared to ST (>1.5-fold 
change). The data achieved from this pilot study were only used as a qualitative approach for 
investigating the possibility of alteration in DNA methylation at gene level between HCA and 
ST rather than a comprehensive quantitative study. 
 
4.3.2.1.1. Principal components analysis 
From the two categories of interest, all the genes that differed with disease status were 
subjected to PCA scores plot (Figure 4.3). HCA and ST samples were separated based on 
treatment with PC1 and PC2 accounting for 84.25% and 6.25% of the variations observed, 
respectively. 
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Function Common name Fold change P-value 
Antioxidant activity glutathione peroxidase 1 -1.59 0.03 
Antioxidant activity peroxiredoxin 6 -1.43 0.03 
Protein synthesis 60S acidic ribosomal protein P0 (L10E) 1.28 0.045 
Protein synthesis mitochondrial ribosomal protein S18C 1.37 0.019 
Protein synthesis ribosomal protein L19 1.27 0.039 
Drug transporter multidrug resistance protein (mdr gene) 1.38 0.045 
Energy and metabolism aldolase B 1.40 0.041 
Amino Sugar metabolism N-acylglucosamine 2-epimerase 1.41 0.024 
Anti-proliferation activity retinoic acid receptor responder 1.60 0.006 
Viral transcription reverse transcriptase-like protein 1.52 0.006 
Virus related gene (fish disease) viral hemorrhagic septicemia-induced protein-5 1.34 0.037 
Angiogenesis vascular endothelial growth factor 1.32 0.017 
Migration and growth ras homolog gene family, member A 1.48 0.016 
Protein degradation proteasome (prosome, macropain) 26S subunit , 12 -1.28 0.002 
Protein degradation chymotrypsinogen 1 -1.15 0.015 
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Table 4.1. Subsection of the identified clones with potentially altered methylation levels in dab HCA samples compared to ST determined 
by MeDIP-cDNA flounder microarray. The biological function, common name, fold change (tumour versus ST) and the P-value 
corresponding to each clone are shown in this table.   
Continued from previous page    
Lipid metabolism apolipoprotein AI -1.28 0.029 
Structural role protein transport protein Sec61 alpha subunit -1.77 0.04 
Structural role actin 1.30 0.046 
Structural role collagen, type XII, alpha 1 1.72 0.021 
Apoptosis B-cell receptor-asociated protein 31 1.39 0.045 
Immune system, inflammation myeloid/lymphoid or mixed-lineage leukaemia protein 4 1.37 0.012 
Immune system, inflammation CD3G antigen, gamma polypeptide (TIT3 complex) 1.33 0.013 
Immune system, inflammation T-cell leukaemia translocation altered gene (TCTA) 1.27 0.039 
Immune system, stem cell regeneration, 
inflammation 
mesenchymal stem cell protein DSCD75 1.56 0.006 
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Figure 4.3. Principal component analysis (PCA) scores plot for all the genes that were 
differentially methylated in the HCA samples compared to ST in MeDIP-cDNA microarray 
data. Dab HCA samples (red) and surrounding tissue samples (blue) were separated based on 
treatment along the PC1 and PC2 axes. One ST sample is grouped with the HCA samples. 
Numbers 1-6 represent 6 individual fish. Matching numbers are ST and HCA samples from 
the same fish. Sampling sites for each fish is also shown. N: North Cardigan Bay, B: St Bee’s 
Head, R; Red Wharf Bay, L: Lundy, IF: Indefatigable Bank. 
  
 
 
 
 
 
1-R 
1-R 
2-IF 
2-IF 
3-B 
3-B 
4-N 
4-N 
5-B 
5-B 
6-L 
6-L 
X axis=1, Y axis=2 
HCA 
ST 
 185 
 
4.3.2.2. Comprehensive DNA methylation profiling of dab HCA tumours 
4.3.2.2.1. De novo high-throughput sequencing analysis of MeDIPed DNA 
The pilot study using MeDIP coupled with a flounder cDNA microarray provided a 
reasonable level of confidence that DNA methylation at gene level varied between HCA and 
ST samples collected from the livers of flatfish dab. Therefore to achieve a comprehensive, 
dab sequence-specific study and to overcome the complications encountered in the pilot 
study, (see discussion), de novo high-throughput sequencing (HTS) was combined with 
MeDIP, for the first time, as described in Chapter 2, section 2.5.3.1. The genome-wide DNA 
methylation profiling of HCA and corresponding ST was performed by first generating 
MeDIP enriched DNA libraries. Immunoprecipitated fragments were subjected to high-
throughput sequencing using an Illumina Genome Analyser II to obtain a comprehensive 
DNA methylation map (Raw data for both samples, hepatocellular adenoma HCA-18-
RA09065-830 and healthy surrounding tissue ST-19-RA09065-830, were submitted to NCBI 
database and can be found under accession numbers GSE31124 and GSM770685, 
respectively). The 89,925,735 and 87,826,470 44-base paired-end reads for HCA and ST 
respectively, were combined and assembled. This resulted in identification of 264,008 contigs 
with lengths greater than or equal to 200 bp. From the identified contigs, the ones that did not 
match the criteria for prediction of CGIs in vertebrates, (criteria for prediction of CGI: length 
>200bp, O/E >0.6, CG% >50) as described by Gardiner-Garden and Frommer (Gardiner-
Garden and Frommer, 1987), were excluded (Table 4.2).  
 
 
 
 
 
 
 
 
 
 
 
 186 
 
 
Table 4.2. CpG island discovery. The reads obtained from MeDIP high-throughput 
sequencing of HCA and corresponding surrounding tissue were combined. The criteria 
described by Gardiner-Garden and Frommer (1987) were used to obtain 69,046 CGI-
containing contigs for further analysis and identification of differentially methylated regions 
between HCA and surrounding tissue.  
 
In order to classify each segment as hyper-, hypo-, or non-differentially methylated, the 
number of MeDIP-reads comprising each contig in tumour were divided by the number of 
MeDIP-reads that comprised the same contig in corresponding ST. Hypo- and hyper-
methylated regions in HCA compared to ST were defined arbitrarily as 1.5-fold or greater 
decrease and increase in the calculated ratio, respectively. As dab is an un-sequenced species, 
the identified candidate hypo- and hyper-methylated contigs were annotated against the 
Genbank non-redundant (nr) protein database (E-value cut-off <10
-6
). This resulted in 
identification of 1,693 differentially methylated sequences containing CGI regions in tumour 
compared to control (Figure 4.4; a complete list of identified contigs (1,693), annotations and 
fold changes are shown in Appendix File 8). To identify potentially differentially methylated 
CGI-containing promoter regions in dab HCA compared to ST, the identified contigs (69,046) 
were mapped onto pufferfish (Takifugu rubripes) genome available from UCSC genome 
browser website. Pufferfish was selected for contig mapping due to its higher sequence 
homology to dab compared with other fully sequenced fish species (zebrafish, stickleback, 
medaka and Atlantic salmon (Salmo salar)). This was decided based on the initial annotation 
that was conducted against the Genbank nr protein database. This resulted in identification of 
60 hypo- and 51 hyper-methylated (>1.5-fold change, Figure 4.4) CGIs that could be aligned 
with the pufferfish genome between 1.5 kb upstream and 1 kb downstream of the predicted 
transcription start sites. One of the key genes identified in this list was DNA (cytosine-5-)-
methyltransferase 3 beta which was hypomethylated in HCA compared to ST.  
Contigs criteria Total number Total  length Average length Maximum length 
Length > 200bp 264,008 78,492,996 297 2,283 
Length >200bp, 
O/E >0.6,CG% >50 
69,046 22,317,135 323 2,283 
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Figure 4.4. Identification of differentially methylated contigs in dab HCA compared to 
surrounding tissue. Combined blue and red sections: 899 hypomethylated and 794 
hypermethylated CGIs in dab HCA compared to ST that could be annotated against Genbank 
nr protein database (>1.5-fold change, E-value cut-off <10
-6
). Red sections: 60 
hypomethylated and 51 hypermethylated CGIs identified from dab that aligned to 1.5 kb 
upstream to 1 kb downstream of the predicted transcription start sites (TSS) in pufferfish 
genome (>1.5-fold change; the list of 111 hypo- and hyper-methylated regions in TSS are 
shown in Appendix, File 9). 
 
4.3.2.2.2. Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA) was performed to characterise the functional relationships 
between genes with altered methylation in HCA compared to ST. The most significant 
networks and functions included cell-to-cell signalling, cell cycle, DNA replication and 
cellular assembly and organisation as well as canonical pathways including Wnt/β-catenin 
signalling, growth hormone signalling and apoptosis signalling. Figure 4.5 represents the IPA 
biological functions associated with genes with altered methylation levels in HCA (FDR 
<5%). Table 4.3 illustrates a sub-section of the genes (hypo- and hyper-methylated) 
possessing biological functions linked to carcinogenesis. 
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Figure 4.5. Biological functions enriched among genes with altered methylation levels (hypo- 
and hyper-methylated) in HCA. IPA was used to group the genes with altered methylation 
levels based on biological functions (>1.5-fold change, FDR <5%). The numbers of genes 
associated with each biological function are shown. 
 
Cell Death, 323
Protein Degradation, 
47
Cellular Growth and 
Proliferation, 277
Vitamin and Mineral 
Metabolism, 51
Cell-To-Cell 
Signaling and 
Interaction, 210
Cellular Compromise, 
48
Gene 
Expression, 
233
Protein Trafficking 
and Degradation, 39
Cellular Assembly 
and Organization, 228
Cellular Function and 
Maintenance, 50
Cellular Movement, 
253
Cell Morphology, 210
Lipid Metabolism, 34
Cellular 
Development, 276
Post-Translational 
Modification, 162
Amino Acid 
Metabolism, 77
Cell Signaling, 138
Small Molecule 
Biochemistry, 113
Molecular Transport, 
93 Protein Synthesis, 90
 189 
 
Biological function Methylation level in HCA compared to ST 
Cell death  
(cell death, apoptosis, 
survival of cells) 
caspase 6 (casp6,↑), cell death-inducing dffa-like effector b (cideb,↓), dedicator of cytokinesis 1 (dock1,↑), 
apoptosis-associated tyrosine kinase (aatk,↓), angiopoietin-related protein 4 precursor (angptl4,↓), synovial 
apoptosis inhibitor synoviolin (syvn,↑), signal transducer and activator of transcription 5 (stat5a,↓), jagged 1 
(jag1,↓),  jagged 2 (jag2,↓), rho-associated protein kinase 1 (rock1,↑), cyclin-dependent kinase 6 (cdk6,↑) 
Cell growth and 
proliferation 
fibroblast growth factor receptor 3 (fgfr3,↓), insulin-like growth factor 1 receptor (igf1r,↓), jagged 1 
(jag1,↓),  jagged 2 (jag2,↓), transcription factor e2f7 (e2f7,↓), DNA (cytosine-5-)-methyltransferase 3b 
(dnmt3b,↓), signal transducer and activator of transcription 5 (stat5a,↓), glucose-6-phosphate 1-
dehydrogenase (g6pd,↓), discs, large homolog 1 (dlg1,↓), peroxisome proliferator-activated receptor beta 
(pparb,↓) 
Cell-to-cell signalling 
and interaction 
jagged 1 (jag1,↓),  jagged 2 (jag2,↓), signal transducer and activator of transcription 5 (stat5a,↓), cadherin 
22 (cdh22,↓), integrin, alpha 3a (itga3,↑), integrin beta l subunit (itgb1,↑), integrin alpha 9 (itga9,↑), 
protocadherin 1 gamma 22 (pcdh1g22,↓) 
Gene expression cAMP responsive element binding protein 1 (crem,↑), notch homolog 2 (notch2,↓), aryl hydrocarbon 
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Continued from previous page 
Gene expression receptor nuclear translocator-like protein 1(arntl,↑), hematopietic transcription factor gata-1 (gata1,↑),             
mitogen-activated protein kinase kinase kinase kinase 4-like isoform 3 (mapk4k3,↑), mitogen-activated 
protein kinase 12 (mapk12,↓), mitogen-activated protein kinase 8 interacting protein 3 (mapk8ip3,↑), 
mitogen-activated protein kinase 11 (mapk11,↓), mitogen-activated protein kinase 1 (mapk1,↑) 
 
Table 4.3. Subsection of the genes with altered methylation associated with development of tumours (FDR <5%) in HCA compared to ST. 
↑ hypermethylated and ↓ hypomethylated in HCA compared to ST. The complete list of the biological functions and associated genes are 
presented in Appendix File 10. 
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4.3.2.2.3. Confirmation of the MeDIP de novo high-throughput sequencing data using 
BSP and comparability of the data to additional individuals 
To validate the data achieved from MeDIP de novo HTS, five differentially methylated genes 
were selected with a fold change of greater than 2-fold, including both hypomethylated and 
hypermethylated groups of genes and an unidentified sequence. Direct bisulfite sequencing 
PCR (see Chapter 3, section 3.3.3) was carried out on the original samples used for MeDIP de 
novo HTS, as previously described. Cytosines located at CpH (H=A,T,C) sites were used to 
monitor the efficiency of bisulfite treatment and sequencing. Efficient bisulfite treatment 
should result in 100% conversion of the cytosine base to T at these regions. The data for the 5 
genes investigated, protocadherin 1 gamma 22 (pcdh1g22), microtubule-associated protein 
1aa (map1aa), tubulin tyrosine ligase-like member 7 (ttll7), nidogen 1 (nid1) and an 
unidentified sequence, are shown in Figure 4.6. For all the genes investigated the BSP data 
were in complete agreement with the data from MeDIP high-throughput sequencing. 
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Figure 4.6. Direct bisulfite sequencing PCR data for A. protocadherin 1 gamma 22 
(pcdh1g22, -2.08), B. microtubule-associated protein 1aa (map1aa, -7.69), C. an unidentified 
sequence (+4.17), D. tubulin tyrosine ligase-like member 7 (ttll7, +3.05) and E. nidogen 
1(nid1, +2.01). To validate the MeDIP high-throughput sequencing data the same HCA and 
corresponding ST were used for direct BSP. The numbers in front of the gene symbols in the 
brackets demonstrate the fold change in DNA methylation level detected by MeDIP HTS for 
the mentioned gene for the same region investigated with direct BSP. +: hypermethylation,     
-: hypomethylation, numbers on the x-axis: represent CpG sites. (x axis label added). Absence 
of a bar indicates unmethylated CpG sites. 
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4.3.2.2.4. Comparison of the BSP data  
In addition, the levels of variation and comparability of the DNA methylation data achieved 
from MeDIP de novo HTS and BSP of the one fish described in section 4.3.2.2.3, to HCA and 
corresponding ST from 10 individual dab collected from five different sampling sites in the 
Irish Sea and Bristol Channel were investigated using BSP (sampling details are shown in 
Chapter 2, section 2.2.2.1). To achieve this, BSP was conducted for the same five genes 
mentioned in section 4.3.2.2.3 on 10 HCA, 10 corresponding ST and 12 healthy tissues 
(Figure 4.7). To clarify the figures, the data for healthy fish liver samples are presented as 
heat maps. However, as the main focus is on tumour and ST samples the data for these 
samples are presented as individual graphs.  
The same trends in methylation levels were observed between HCA and surrounding tissue 
samples for most genes and fish investigated. However, inter-individual variation was 
observed, especially between HCA samples of different fish. The lowest level of variation in 
DNA methylation profile was observed between different healthy dab livers. The observed 
variation was not surprising as these were wild fish, exposed to different environmental 
conditions, such as different levels of contaminants. Furthermore, from the pathology data for 
these samples it is evident that these tumours are heterogeneous in their stage of development 
and other underlying conditions (pathology data are presented in Appendix File 11). For 
example, different HCA samples demonstrated various stages of hepatic hydropic vacuolation 
(HydVac). This condition is characterised by cells with large non-staining vacuoles and small 
peripheral nuclei. In certain fish species including flatfish, such as winter flounder 
(Pseudopleuronectes americanus) this condition has been associated with exposure to 
xenobiotics (e.g. polychlorinated biphenyls (PCBs) and polycyclic aromatic hydrocarbons 
(PAHs)) and neoplasia (Moore et al., 1997; Stehr et al., 1998).  
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Figure 4.7. BSP was used to compare the methylation levels of protocadherin 1 gamma 22, 
microtubule-associated protein 1aa, an unidentified sequence, tubulin tyrosine ligase-like 
member 7 and nidogen 1 in dab collected from five different sampling sites in the Irish Sea 
and the Bristol Channel. Each page shows the result for one gene as indicated by the name of 
the gene at the top of the page.  
Section A of each page: Methylation levels of CpG sites (x-axis) in 10 individual fish (10 
HCA and 10 corresponding ST). Sampling sites: 1, 6, 9: South Cardigan Bay; 2: Inner 
Cardigan Bay; 3, 8: Red Wharf Bay; 4: North Cardigan Bay; 5, 10: St Bee’s Head. Each 
graph represents one fish.  
Section B of each page: Heat map of methylation levels for the same CpG sites in 12 healthy 
dab livers. For every analysed matrix each row represents one fish and each column represent 
a CpG site. Fish are labelled based on their sampling locations. The bar below the heat map 
represents the scale of methylation levels with green closest to lowest level of methylation, 
red closest to highest level of methylation and black for the CpG sites with median level of 
methylation.   
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4.3.2.3. Transcription profiling of dab tumours 
4.3.2.3.1. Design of 8x15k gene expression microarray and gene expression analysis of 
dab hepatocellular adenoma  
Dab DNA contigs derived from the MeDIP-HTS were annotated against the Genbank nr 
protein database for identification of coding sequences. The annotated sequences were used to 
design an Agilent custom-made dab specific 8x15k 60-mer oligonucleotide gene expression 
microarray as previously described (Chapter 2, section 2.5.3.3). Both the details of the 
designed microarray (name of the microarray: Agilent-031032_8x15k_BhamDab) and the 
experimental design (name of the experimental design: transcription profiling of dab 
hepatocellular adenoma liver) are available from ArrayExpress under accessions A-MEXP-
2084 and E-MTAB-734, respectively.    
RNA extracted from the 3 groups of interest whose DNA samples were used in the direct BSP 
experiment (HCA, ST and healthy dab liver) were labelled with fluorescent Cy5-CTP and 
hybridised to the dab custom-made gene expression microarray against a Cy3-CTP labelled 
RNA reference pool made from all samples. Following quality checks and normalisation, 
genes differentially expressed between the 3 groups investigated were identified (>1.5-fold 
change, FDR <15%, MIAME-compliant raw microarray data were submitted to ArrayExpress 
at EMBL-EBI and can be found under accession E-MTAB-734). During the final incubation 
of the slides in the oven, the hybridisation mixture on one of the slides containing an HCA 
sample evaporated. This was a manufacture’s fault as the rubber seal between the chamber 
slide and the microarray slide was loose. Therefore, the data achieved from the HCA sample 
in question did not pass the initial quality checks and with its corresponding ST was removed 
from the analysis. Most differentially expressed genes were observed between HCA and ST 
with 520 genes statistically significantly altered in expression between HCA and ST samples 
(208 genes repressed and 312 genes induced in HCA compared to ST, paired t-test, >1.5-fold 
change, FDR <15%). This finding was not un-expected. Each pair of HCA and ST samples 
was dissected from the same fish. This reduced the levels of inter-individual variation that 
was observed when comparing liver tissues from healthy fish with HCA or ST samples from 
different fish. Therefore the main focus has been on the observed differences between HCA 
and ST. We found 91 genes to be statistically significantly altered in expression between 
HCA and healthy tissue with 73 and 18 induced and repressed in HCA compared to healthy 
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dab liver, respectively (>1.5-fold change, FDR <15%, unpaired t-test, Appendix File 12). 
Furthermore, there were apparent differences between ST and healthy dab liver. However, 
due to inter-individual variation they did not pass the FDR cut-off.  
 
4.3.2.3.2. Principal components analysis 
All the genes from the three categories of interest (i.e. disease) that were differentially 
expressed were subjected to principal component analysis (Figures 4.8, 4.9 and 4.10).  
In all the PCA plots, samples were separated based on disease status with the clearest 
separations identified when comparing two sample groups at a time (Figures 4.8 and 4.9). As 
shown in Figure 4.8, PC1 and PC2 resulted in clear separation of HCA samples from ST 
samples with the first and second components accounting for 54.66% and 10.04% of variance, 
respectively. While PC1 and PC2 accounted for 58.14% and 7.3% of the variance, 
respectively in PCA plot of HCA and healthy dab liver samples.  
In addition, within each condition samples were further clustered based on sampling sites. As 
shown in Figure 4.8, HCA and ST samples collected from Cardigan Bay were separated from 
other sampling sites along the PC1 axis. This demonstrates the influence of environmental 
factors upon the main condition (i.e. disease). 
 
4.3.2.3.3. Hierarchical clustering 
Hierarchical clustering (HAC) resulted in identification of distinct transcription profiles for 
HCA and ST and validated the PCA results (Figure 4.11).  Hierarchical clustering, similar to 
PCA, is a statistical approach for identification of similar features within a data set. However, 
in contrast to the data reduction approach used in PCA, HAC relies on grouping of the similar 
features and generating a tree with all the data points present (Raychudhuri et al., 2001). As 
shown in Figure 4.11, a gene tree was generated in which genes with similar expression 
profiles and samples with similar transcription profiles were clustered together.  
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Figure 4.8.  Principal component analysis (PCA) scores plot for all the genes that responded 
to the disease status of dab tissue samples. These genes were identified by the gene expression 
microarrays generated for HCA and ST. The plot shows separation of dab HCA samples (red) 
from dab ST (blue) samples based on treatment along the PC1 and PC2 axes. There is some 
level of separation based on sampling sites. Cardigan Bay is separated from the remaining 
sampling sites mainly along the PC1 axis. Numbers 1_9 represent 9 individual fish. Matching 
numbers are ST and HCA samples from the same fish. Sampling sites for each fish are also 
shown. I: Inner Cardigan Bay, S: South Cardigan Bay, B: St Bee’s Head, R; Red Wharf Bay. 
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Figure 4.9.  PCA scores plot for all the genes that responded to the disease status of dab tissue 
samples. These genes were identified by the gene expression microarrays generated for HCA 
and healthy tissue. The plot shows separation of the dab HCA samples (red) from healthy dab 
liver samples (green) based on treatment and along the PC1 and PC2 axes. In addition, there 
was clear clustering of samples based on sampling sites within each treatment group along the 
PC1 and PC2 axes. Dab healthy liver and HCA samples are represented based on their 
sampling sites. I: Inner Cardigan Bay, S: South Cardigan Bay, N: North Cardigan Bay, B: St 
Bee’s Head, R; Red Wharf Bay, L: Lundy.    
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Figure 4.10.  PCA scores plot for all the genes that responded to the disease status of dab 
tissue samples. These genes were identified by the gene expression microarrays generated for 
HCA, ST and healthy tissue. The plot shows a relatively good separation of dab HCA samples 
(red) from healthy dab liver samples (green) and ST samples (blue) based on treatment along 
the PC2 (10.04%) and PC3 (6.57%) axes. However no clear clustering of samples was 
observed based on sampling sites. Numbers 1_9 for HCA and ST represent 9 individual fish. 
Matching numbers are ST and HCA samples from the same fish. Sampling sites for each fish 
are also shown. I: Inner Cardigan Bay, S: South Cardigan Bay, N: North Cardigan Bay, B: St 
Bee’s Head, R; Red Wharf Bay, L: Lundy.   
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Figure 4.11. Hierarchical clustering tree generated using Pearson correlation showing 
relationships between differentially transcribed genes and disease status (HCA and ST). The 
tree is coloured based on a gradient with respect to transcription levels for each feature, with 
red indicating over-transcribed and green under-transcribed. Each column represents a 
specific sample and each row represents a specific gene. Blue bar: ST, Red bar: HCA. For 
clarity, individual genes have not been labelled. 
 
 
 
HCA ST 
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4.3.2.3.4. Ingenuity Pathway Analysis 
IPA was performed to characterise the functional relationships between genes with altered 
expression in HCA compared to healthy dab liver samples, as well as HCA and ST samples. 
IPA identified that the most significant networks and most enriched functions were commonly 
associated with cancer in both comparisons of HCA to ST and HCA to healthy dab liver. 
Networks and functions including cell death, cell cycle, cellular growth and proliferation, cell 
morphology, cell signalling, amino acid synthesis and gene expression and canonical 
pathways including molecular mechanisms of cancer, Wnt/β-catenin signalling, aryl 
hydrocarbon receptor signalling and regulation of eIF4 and eIF2 signalling were associated 
with the differentially expressed genes for each comparison analysed (FDR <5%) as shown in 
Figures 4.12 and 4.13. In both sets of analysis (HCA and ST; HCA and healthy dab liver) 
cancer was highlighted as the top predicted disorder based on categories of the genes with 
altered transcription (FDR <5%, >1.5-fold change). As an example Table 4.4 shows a sub-
section of the genes (under- and over-expressed) associated with cancer derived from 
comparison of HCA to ST. The list of all the genes with altered transcription levels and their 
associated biological functions (FDR <5%) in both groups is shown in Appendix File 13. 
Figure 4.14 illustrates genes with altered expression levels in dab HCA compared to ST 
(>1.5-fold change, FDR <5%) related to the canonical pathway “molecular mechanisms of 
cancer” in human, including v-akt murine thymoma viral oncogene homolog 1 (akt1), cyclin 
d2 (ccnd2) and mitogen-activated protein kinase 10 (mapk10). 
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Figure 4.12. Biological functions enriched among genes with altered transcription levels 
(over- and under-expressed) in HCA compared to ST. IPA was used to group the genes with 
altered transcription levels based on biological functions (>1.5-fold change, FDR <5%). The 
numbers of genes associated with each biological function are shown. 
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Figure 4.13. Biological functions enriched among genes with altered transcription levels 
(over- and under-expressed) in HCA compared to healthy dab liver. IPA was used to group 
the genes with altered transcription levels based on biological functions (>1.5-fold change, 
FDR <5%). The numbers of genes associated with each biological function are shown.  
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Table 4.4. Subsection of the genes with altered gene expression in HCA compared to ST. These genes are associated with the most relevant 
biological functions altered in tumours (FDR <5%, >1.5-fold change). ↑ and ↓ over- and under-expressed in HCA compared to ST, 
respectively. A complete list of the biological functions and associated genes is presented in Appendix File 13. 
Biological function Gene expression level in HCA compared to ST 
Cell death  mitogen-activated protein kinase kinase kinase 10 (map3k10,↑), ras-like protein 1 (ras,↑), histone de-acetylase 
1 (hdac1,↓), retinoid x receptor beta (rxrb,↑), cyclin D2 (ccnd2,↑), v-myc myelocytomatosis viral oncogene-like 
protein (myc,↑), dnaJ (hsp40) homolog, subfamily B, member 1 (dnajb1,↑) 
Cellular growth and 
proliferation 
S-adenosylhomocysteine hydrolase (ahcy,↑), retinoid x receptor beta (rxrb,↑), histone de-acetylase 1 (hdac1,↓), 
ras-like protein 1 (ras,↑), myc-associated zinc finger protein (maz,↑), cyclin d2 (ccnd2,↑), 26s protease 
regulatory subunit 8 (psmc5,↑), DnaJ (hsp40) homolog, subfamily B, member 1 (dnajb1,↑), suppression of 
tumorigenicity 14 (st14,↓) 
Cell cycle cell cycle regulator mat89bb homolog (m89bb,↓), mediator of RNA polymerase ii transcription subunit 29 
(med29,↑), retinoid x receptor beta (rxrb,↑), histone de-acetylase 1 (hdac1,↓), cyclin d2 (ccnd2,↑) 
Protein and lipid 
synthesis and 
reproduction 
vitellogenin b (vtgb,↑), vitellogenin a (vtga,↑), 60s ribosomal protein l9 (rpl9,↑), 60s ribosomal protein l19 
(rpl19,↑), 60s ribosomal protein l28 (rpl28,↑), aldehyde dehydrogenase 8 member a1 (aldh8a1,↑), Similar to 
human cytochrome P450, family 2, subfamily J, polypeptide 2 (cyp2j2,↑), eukaryotic translation initiation 
factor subunit 3 isoform cra_d (eif3,↑), methionine aminopeptidase 2 (metap2,↑) 
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Figure 4.14. Biological network of genes linked to the canonical pathway “molecular 
mechanisms of cancer” with altered gene expression levels in dab HCA compared to ST 
(>1.5-fold change, FDR <5%). Green: under-expressed, red: over-expressed in HCA 
compared to ST. 
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4.3.2.3.5. Confirmation of the gene expression data using RT-PCR 
Microarrays are extremely useful for achieving a comprehensive transcription profiling and 
identifying subset of genes with altered transcription between different experimental 
conditions. However, the experimental procedure is complex and the data can be influenced 
by each step. Hence, a second approach is commonly used to validate the data achieved from 
microarray experiments. Real time-PCR is recognised as an accurate and reproducible method 
for confirmation of the gene expression microarray data (Rajeevan et al., 2001). Therefore 
based on microarray data, four genes with statistically significantly altered transcription levels 
and acceptable primer efficiencies were selected for RT-PCR analysis. These genes included: 
udp-glucose 6-dehydrogenase (ugdh), vitellogenin c (vtgc), vitellogenin b (vtgb), S-
adenosylhomocysteine hydrolase (sahh) and syntrophin, beta 2 (sntb2). As shown in Table 
4.5 the gene expression data achieved from microarray and RT-PCR were in agreement. A 
statistically significant positive correlation was observed between microarray data and RT-
PCR (P< 0.05, Pearson’s correlation coefficient=0. 97).  
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Table 4.5. Comparison of fold change in gene expression for the selected genes by RT-PCR and microarray analysis. The same mRNA was 
used for both RT-PCR and microarray analysis. syntrophin, beta 2 (sntb2) gene was used as a reference gene. Five biological and four 
technical replicates were used. (H: healthy dab liver, **
 
P<0.01, * P<0.05, P-value determined by 2-tailed Student’s t-test following 
establishment of normal distribution of data and homogeneity of variance by Shapiro-Wilk test and Levenes’ test, respectively). 
 
 
Gene Grouping 
RT-PCR             
fold change 
Microarray fold change                                  
(FDR <15%,  >1.5-fold change) 
vitellogenin b HCA and H 3.17** 2.13
 
vitellogenin c HCA and ST 7.89* 8.5 
S-adenosylhomocysteine hydrolase HCA and ST 2.3* 1.78 
udp-glucose 6-dehydrogenase HCA and ST 2.51** 3.24 
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4.4. Discussion 
4.4.1. Global DNA methylation 
Despite the observed differences in methylation levels of specific genes in HCA compared to 
the surrounding liver tissues, one of the most important findings of this study was the 
detection of similarly lower levels of global DNA methylation in both ST and HCA samples. 
A significant 1.8-fold global DNA hypomethylation was detected in HCA compared to liver 
from non-cancer bearing dab. A similar level of significant DNA hypomethylation was also 
identified when comparing “apparently healthy” liver (ST) surrounding the HCA tumours 
with liver from non-cancer bearing dab (Figure 4.2). Surprisingly, there were no detectable 
differences in global DNA methylation levels between ST and HCA dissected from the same 
liver.  
There is evidence that global DNA hypomethylation and gene specific hypermethylation can 
occur during early stages of tumourigenesis, this has been reported in apparently normal 
tissues prior to mutational changes in patients who later developed cancer (Feinberg et al., 
2006; Pogribny, 2010). It has been suggested, as part of the “progenitor model of 
tumourigenesis”, that epigenetic changes arise as early as progenitor cells. DNA 
hypomethylation and other gene specific epigenetic changes can lead to genome instability, 
chromosomal rearrangement, loss of imprinting and activation of germ line specific genes and 
transposons, therefore making gatekeeper genes more susceptible to mutations and increasing 
the risk of tumourigenesis (Gronbaek et al., 2007; Feinberg et al., 2006; Sharma et al., 2010; 
Pogribny, 2010; De Smet and Loriot, 2010). Mutations in gatekeeper genes of the pre-
neoplastic cells and further epigenetic and genetic changes can ultimately lead to fully formed 
tumours (Sharma et al., 2010; Feinberg et al., 2006). Hence DNA hypomethylation is a 
striking feature and a common early mechanism in carcinogenesis (Feinberg et al., 2006). 
This is in agreement with our findings of DNA hypomethylation in apparently healthy 
portions of tumour-bearing dab livers (the epigenetic progenitor model of tumourigenesis and 
examples of detection of epigenetic alterations at early stages of tumourigenesis are described 
in Chapter 1, section 1.3.5.3).  
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4.4.2. Pilot study indicated change in the methylation of DNA samples extracted from 
HCA samples compared to ST at gene level 
Based on the epigenetic model of tumourigenesis, it was anticipated that the “epigenetically 
primed” liver tissues would undergo further epigenetic and genetic changes, leading to 
formation of HCA tumours with specific methylation changes at individual genes (Sharma et 
al., 2010; Feinberg et al., 2006). Indeed the results of the pilot study, using MeDIP combined 
with a flounder cDNA microarray, showed that DNA methylation profiles of the investigated 
HCA samples differed from those of ST for specific genes. However, due to several reasons 
this study was only used as a preliminary experiment to test whether DNA methylation 
alterations could be detected at the gene level in HCA samples, and thereby justifying the 
need for a comprehensive DNA methylation study. 
Due to sufficient levels of sequence homology between the two flatfish species, dab and 
flounder, the use of the flounder microarray has been successful for dab (Diab et al, 2008; 
Small et al., 2010; Cohen et al., 2007). However, a limited number of genes (3,336) were 
represented on this microarray, the probes were variable in length and targeted towards the 3’ 
end of the genes. This excludes the epigenetically important control regions, such as the gene 
promoter regions near the transcription start sites and exon one regions. Thus, although this 
platform is useful for transcriptomic studies, it has limited use for comprehensive DNA 
methylation studies. Hence to compensate for this, longer DNA fragments were generated 
prior to MeDIP with the aim of detecting overlaps between long MeDIP fragments, 
potentially including gene promoters and the coding sequence amplicon microarray probes.  
Nevertheless, due to the design of this microarray methylated fragments towards the 3’ end 
were more represented on the microarray compared to the fragments located towards the 5’ 
end of a gene. Therefore, the methylation status of the CpG dinucleotides located around the 
TSS and exon one, which are predicted to include the promoter regions and regulatory regions 
(Suzuki and Bird, 2008), are most likely under-represented in the results achieved from this 
cDNA microarray. Furthermore, as the methylation levels between different sections of a 
gene vary, it is important that each gene is represented with more than one probe tiling the 
entire region of interest. The latter will provide detailed information regarding the methylation 
profile of each section of the gene. In addition, dab samples used in this study were captured 
from different sampling sites located in the Irish Sea, North Sea and Bristol Channel. The 
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variability between different fish may be high due to different sampling sites. This can 
negatively impact the study by deflecting attention from the changes caused due to formation 
of tumours. Therefore to overcome this issue in the main study, in addition to increasing the 
number of samples, only liver samples from fish collected from the Irish Sea and Bristol 
Channel were used.  
Regardless of the limitations of this pilot study, the PCA plot and the identified genes 
presented in Table 4.1 indicated that at the gene level HCA and ST samples differed in their 
methylation levels. For example, genes with biological functions such as angiogenesis, 
inflammation, antioxidant activity, metabolism, protein synthesis and drug transporters were 
identified to potentially have altered methylation levels in HCA samples compared to ST 
samples.  
 
4.4.3. Overview of the DNA methylation changes 
Based on the success of the pilot study, to achieve a comprehensive DNA methylation and 
transcriptomic profile for the un-sequenced flatfish dab, we successfully combined MeDIP 
with de novo HTS and designed a gene expression microarray based on the contigs achieved. 
As demonstrated for the first time by Down et al., (2008), MeDIP-HTS is a powerful, 
unbiased and quantitative technique for establishing whole genome methylation profiles in 
model organisms. However, this technique has never before been attempted for studying 
DNA methylation alterations in un-sequenced species.  
Combining MeDIP with high-throughput sequencing resulted in considerable numbers of 
overlapping reads for construction of contigs, 34% of which were hypo- or hyper-methylated 
(>1.5-fold change) in tumour samples compared to control and could be annotated based on 
homology between protein-coding regions. This method is not without limitations. As the data 
are assembled based on conserved regions and homolog sequences, most of the identified 
regions corresponded to the CGIs located within exons, and only a fraction of the data 
focussed on promoter regions. Therefore the main outcome of this study was identification of 
genes and pathways with altered DNA methylation in HCA compared to ST irrespective of 
the position of the changes observed. Nevertheless, this approach resulted in identification of 
a substantial number of genes and pathways with altered methylation in HCA samples, as 
shown in Appendix Files 8, 9 and 10. Most importantly the data confirmed our hypothesis by 
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which we proposed that although similar in terms of global DNA methylation levels, HCA 
samples differ in DNA methylation at the gene level compared to primed surrounding tissue. 
Our finding that methylation of exons was different in the tumour samples, is in agreement 
with previous findings in humans (Liang et al., 1998). Furthermore, in tumourigenesis 
identifying DNA methylation alterations is more important than the absolute levels of DNA 
methylation (Liang et al., 1998). In humans, aberrant DNA methylation mediates changes in 
most of the key pathways associated with cancer, resulting in loss of cell cycle control, cell-
to-cell signalling, apoptosis signalling, altered receptor and transcription factor functions as 
well as genomic instability (Baylin et al., 2001). Our study identified expression and DNA 
methylation changes in key genes of the same biological pathways in dab HCA samples. 
DNA methylation is therefore an important factor in tumourigenesis in the wild flatfish dab. 
 
4.4.4. DNA methylation and transcriptional changes associated with tumourigenesis in 
dab HCA 
Comparison of the gene expression data from the microarray experiment and DNA 
methylation data from the MeDIP-HTS experiment showed no significant overall inverse 
correlation between gene expression and DNA methylation levels (This data is presented in 
Appendix File 14). As discussed in Chapter 1 (section 1.3.2.3) and Chapter 3 (section 3.4.4) 
this is not un-expected. However, similar pathways were affected both in terms of DNA 
methylation and gene expression. For example, IPA identified changes in DNA methylation 
of genes involved in the Wnt/β-catenin signalling pathway. Activation of this pathway has 
been associated with development of cancer mediated by stabilisation of β-catenin and 
inappropriate activation of β-catenin target genes such as c-MYC and c-JUN in humans 
(Polakis, 2000; Mann et al., 1999). Our data showed that methylation of genes such as 
dishevelled, dsh homolog 2 (dvl2) acting as a positive mediator of Wnt signalling,  frizzled 
gene responsible for encoding Wnt receptors, tumour suppressor gene adenomatous polyposis 
coli (apc) and c-myc were altered in HCA compared to ST. In addition, transcription of c-myc 
and frizzled homolog 7a were induced and frizzled homolg 10 and 7b were suppressed in 
HCA samples. 
Changes in methylation of genes involved in the apoptosis signalling pathway, involved in 
release of mitochondrial cytochrome c and activation of a range of caspases, were detected in 
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HCA samples. These genes included; diablo which is associated with neutralisation of 
members of inhibitory proteins (IPs) and release of cytochrome c (Adrian et al., 2001; Kohli 
et al., 2004), caspase activator rock1 (Tsai and Wei, 2010; Coleman et al., 2001) and pro- and 
anti-apoptotic nf-κb (Hu et al., 2000).  
Based on transcriptional changes, the canonical pathway “molecular mechanism of cancer” 
and “cancer” as a disease annotation term were enriched among differentially expressed genes 
in HCA compared to ST and healthy liver. Genes involved in different aspects of 
tumourigenesis were significantly enriched in dab HCA samples compared to ST samples. 
For example, genes involved in cell cycle, proliferation and cell death (e.g. cyclin d2 (ccnd2), 
cyclin d binding protein 1 (ccndbp1), ras and MAP kinases (mapk3k9, mapk10)) were 
significantly over-expressed in tumours while genes related to repair mechanisms, such as 
excision repair cross-complementing rodent repair deficiency, complementation group 6 
(ercc6) and suppression of tumourigenesis 14 (st14) were significantly down regulated. Genes 
associated with energy production and ribosomal protein synthesis were significantly over-
expressed in tumours. This finding is not unexpected as both functions, like other parameters 
relating to proliferation/apoptosis as discussed above, are features likely to give tumour cells a 
selective advantage for clonal expansion and are required for highly proliferating tumour cells 
(Small et al., 2010).  
 
4.4.5. Methionine cycle and DNA methylation 
Changes detected in the expression levels of the genes involved in the methionine cycle 
between the three tissue categories of interest are suggestive of distortion of this pathway in 
dab HCA samples. During this cycle (Figure 4.15), methionine adenosyltransferase (MAT) 
catalyses the production of S-adenosylmethionine (SAM) from methionine. S-
adenosylmethionine (SAM) acts as a universal methyl donor for a range of transmethylation 
reactions of biological significance, including regulation of gene expression by means of 
DNA methylation (Lieber and Packer, 2002). DNA methylation is catalysed by DNMTs.  In 
this reaction a methyl group is transferred by DNMTs from SAM to the 5
th
 carbon position of 
a cytosine base within the CpG dinucleotide, resulting in conversion of SAM to S-
adenosylhomocysteine (SAH) (Gronbaek et al., 2007). In dab DNA methyltransferase 3b (-1.7 
fold, matching the pufferfish dnmt3b gene from bases 6-116), DNA methyltransferase 4 (-
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2.55), DNA methyltransferase 12 (-1.73) and sam dependent methyltransferase (-1.76) were 
hypomethylated in the tumour sample compared to ST. These changes suggest possible 
alterations in the expression of dnmts, the SAM to SAH metabolic pathway and subsequent 
change in DNA methylation.  
Hyper- and hypo-methylated regions of DNA coexist in tumour cells. The possible 
mechanism behind this is explained in the demethylation-remethylation model and depends 
upon changes in the levels of DNMTs. As discussed in Chapter 1, section 1.3.5.1.1 and Figure 
1.12, tumourigenesis involves an early transient phase of demethylation which will result in 
global DNA hypomethylation (Loriot et al., 2006). Several studies have shown that lower 
expression of DNMT1 and DNMT3b causes severe DNA hypomethylation contributing to 
tumourigenesis as demonstrated in aggressive T-cell lymphomas in mice (Gaudet et al., 2003) 
and in human colorectal cancer cell line (Rhee et al., 2002). This is followed by a 
remethylation phase. In this stage, binding of transcription factors to un-methylated regions 
prevents them from becoming re-methylated. The newly established, lower DNA methylation 
level is maintained in tumour cells (Loriot et al., 2006; De Smet and Loriot, 2010). In fully 
formed tumours it has been shown that the expression levels of most DNMTs reach a similar 
or even higher level than in normal tissue as detected in various human cancers such as HCC 
and breast cancers (Girault et al., 2003; Sun et al., 1997; Laird and Jaenisch, 1994; Momparler 
and Bovenzi, 2000; Robertson et al., 1999). However, the contribution of different DNMTs to 
the maintenance of DNA methylation profile in different cancer cells vary and are highly 
dependent upon the relative abundance of different DNMTs in different tissue and cell types 
(Loriot et al., 2006). Therefore, it is possible that the expression profile of different DNMTs 
differs according to the type of tumour.  
In addition, the S-adenosylhomocysteine hydrolase (sahh) gene was significantly over-
expressed in dab tumour samples compared to ST. The conversion of SAH to homocysteine is 
catalysed by SAHH. SAH, due to its high binding affinity for the catalytic regions of SAM-
dependent methyltransferases, is a potent inhibitor of transmethylation reactions (Lu, 2000; 
Lieber and Packer, 2002; James et al., 2002). SAH accumulation has been associated with 
global DNA hypomethylation and alterations in the expression of specific genes. Therefore 
constant hydrolysis of SAH via SAHH is necessary for maintaining transmethylation 
reactions (James et al., 2002). The observed difference in the expression level of the sahh 
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gene in dab tumour samples compared to ST samples indicates the possibility of alterations to 
the levels of SAH and homocysteine metabolites in dab HCA samples compared to ST 
samples. 
The changes observed in the methylation and transcription of genes encoding enzymes of the 
methionine cycle led to the hypothesis that this pathway is affected during dab 
tumourigenesis. As a result, changes in the levels of the metabolites involved in the one-
carbon cycle between the three categories of samples were investigated using LC-TSQ as 
shown in Chapter 5. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15. The methionine cycle. An illustration of the generation of the universal methyl 
donor, SAM from methionine. Transcriptional and DNA methylation alterations observed in 
this pathway in HCA samples compared to ST samples are indicated in this diagram. 
Abbreviations: SAM: S-adenosylmethionine; SAH: S-adenosylhomocysteine; Dnmt: DNA 
methyltransferase; SAHH: S-adenosylhomocysteine hydrolase; BMHT: betaine-homocysteine 
methyltransferase; MAT: methionine adenosyltransferase. Both folate and choline cycles are 
linked closely to this pathway via the site indicated by *. Folate donates one-carbon units for 
the production of methionine. Choline is located up-stream of betaine which is also used for 
the synthesis of methionine. Reduced levels of folate and choline inhibit the production of 
methionine and subsequently SAM (The one-carbon pathway is described in details in 
Chapter 1, section 1.3.3). 
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4.4.6. A link between environmental contaminants, changes in DNA methylation and 
transcription, and dab liver tumours 
Statistically significant inductions in the expression of the egg yolk precursor proteins, 
vitellogenins (vtga, vtgb and vtgc), were observed in HCA compared to healthy liver. As this 
induction was also observed when comparing HCA to ST of the same fish, inter-individual 
variability, such as female reproductive cycle was not responsible. During oocytogenesis, 
vitellogenin proteins are transferred from the liver via the plasma to the growing oocyte where 
they are cleaved to form lipovitellin and phosvitin which serve as food reserves for growing 
embryos of most oviparous species (Zhang et al., 2011; Sumpter and Jobling, 1995). In 
contrast to high levels of vitellogenin in female fish during seasonal reproduction, very little 
vitellogenin is observed in male fish and juvenile female fish (Sumpter and Jobling, 1995). 
Expression of vitellogenin in the liver is controlled mainly through binding of estrogen 
receptors to estrogen response elements. Therefore, exposure to estrogen mimicking 
chemicals (endocrine disrupting chemicals (EDCs)) can elevate the expression of vitellogenin 
in fish, which can indicate feminisation of male fish. Hence, induction of vitellogenin in male 
fish and signs of intersex are used as biomarkers of exposure to EDC (Scott et al., 2007). Our 
findings agree with previous studies demonstrating induction of vtg in female and male dab 
and intersex in male dab (Small et al., 2010; Stentiford and Feist, 2005; Scott et al., 2007). 
Different types of PCBs, polybrominated diphenyl ethers (PBDEs) and heavy metals such as 
cadmium (Cd) and lead (Pb) were detected in dab tissue. The concentrations of these 
chemicals, as shown in Appendix File 15, varied at different sampling sites with Cardigan 
Bay, specifically South Cardigan Bay, identified as the most polluted site in regards to PCBs 
and PBDEs investigated in dab liver tissues (Chemical measurements were conducted by the 
Centre for Environment, Fisheries and Aquaculture Science (Cefas, Weymouth, UK)). For 
example, from the seven non-planar PCBs recommended for monitoring by the International 
Council for the Exploration of the Sea (ICES), the concentration of PCB118 in dab liver at 
South Cardigan Bay was higher than the recommended hazardous ecotoxicological 
assessment criteria (EAC). This indicates the possibility of chronic exposure of dab to this 
chemical which is in agreement with the data reported by the Department for Environment 
Food and Rural Affairs (DEFRA) (UK marine monitoring and assessment strategy 
community (UKMMAS), Charting Progress 2 Feeder report, 2010). The differences between 
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sampling sites based on chemical data were also reflected in the PCA plots of gene expression 
data. As shown in Figures 4.8 and 4.9, samples in each disease category were further clustered 
based on sampling sites. Previous chemical exposure studies in European flounder, conducted 
in our laboratory, demonstrated that gene expression profiles alter distinctively following 
exposure to environmentally relevant concentrations of chemical contaminants, including 
cadmium and 17β-estradiol (Williams et al., 2006; Williams et al., 2007). It is therefore 
possible that environmental contaminants are similarly influencing transcriptional profiles of 
flatfish dab. In addition, it has been reported that vitellogenin levels in male dab collected at 
different sampling sites varies, with fish collected from Cardigan Bay having the highest 
levels of vitellogenin compared to fish collected from other sampling sites investigated in this 
study (St Bee’s Head, Red Wharf Bay and Lundy) (Scott et al., 2007). Furthermore, a study 
by Lyons et al., (2006) reported that dab collected from Cardigan Bay, specifically South 
Cardigan Bay, have higher tumour prevalence compared to dab collected from Red Wharf 
Bay. As the levels of environmental contaminants vary between sampling sites, it is plausible 
that environmentally driven epigenomic changes are responsible for different levels of 
susceptibilities of these fish. The main estrogenic compounds from the sewage treatment (i.e. 
the synthetic hormone 17α-ethinylestradiol used in contraceptive pills and 17β-estradiol) are 
short-lived and unlikely to reach so far off shore. Thus it is un-likely that these compounds 
would reach fish populations in offshore waters and cause adverse health effects such as 
elevated VTG levels (Scott et al., 2007). Hence, it is hypothesised that a widespread mixture 
of weak but persistent lipophilic estrogenic chemicals such as PCBs, PBDEs and some of 
their metabolites (Siddiqi et al., 2003) are responsible for the observed increase in expression 
of vitellogenin and potentially contribute to formation of these tumours (Scott et al., 2007). 
A link between exposure to chemicals such as EDCs (PCB, EE2, E2) and heavy metals (e.g. 
As, Cd), changes in DNA methylation (Vandegehuchte and Janssen, 2011) and 
tumourigenesis in rodents and humans has been established (Arita and Costa, 2009; Li et al., 
2003; Lo and Sukumar, 2008; Skinner et al., 2010; Baccarelli and Bollati, 2009). For 
example, Cd can bind to DNA methyltransferases and inhibit their DNA methylation activity. 
This leads to hypomethylation and activation of genes, such as oncogenes and can lead to 
carcinogenesis (Baccarelli and Bollati, 2009). Although recent studies have demonstrated that 
EDCs can cause changes in DNA methylation in aquatic species (Stromqvist et al., 2010; 
Aniagu et al., 2008), with separate studies suggesting that EDCs can cause tumours in fish 
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liver (Tilton et al., 2006), this connection between exposure to EDCs, change in DNA 
methylation and tumourigenesis has not been established in fish.   
Methylation and/or expression of several genes in both non-genomic and genomic (estrogen 
response element (ERE)-dependent and ERE-independent) estrogenic pathways were altered 
in HCA samples compared to healthy liver and ST samples. These genes are involved in 
biological functions such as proliferation and growth, differentiation, cell cycle, apoptosis and 
oncogenesis (Obrero et al., 2002; Safe and Kim, 2008; for a review see Bjornstrom and 
Sjoberg, 2005). The methylation and/or expression of several genes controlled through the 
ERE-dependent pathway that are commonly implicated in cancers were altered in this study. 
For example, induction in transcription of c-myc oncogene, vtg a and vtg b, reduced 
transcription of protease cathepsin (cts) with change in methylation of c-myc and cts were 
identified in HCA compared to ST (Obrero et al., 2002; Bjornstrom and Sjoberg, 2005). The 
estrogen-estrogen receptor (E-ER) complex can also modulate transcription of a range of 
genes without directly binding to DNA. This ERE-independent mechanism occurs in the 
nucleus and through protein-protein interaction with other DNA binding transcription factors 
(TF) and subsequent binding of TFs to their recognition sites in the promoter regions 
(Bjornstrom and Sjoberg, 2005). Furthermore, methylation/expression of several transcription 
factors that bind to ER and their target genes were altered in HCA compared to ST, such as 
specificity protein 1 (Sp1) involved in crucial biological processes (such as differentiation, 
proliferation, apoptosis) which is regularly over-expressed in tumours (Safe and Kim, 2008), 
signal transducer and activator of transcription (stat) 5, activating transcription factor 2 (atf-
2) and nuclear factor nf-κb associated with inflammation and oncogenesis (Dolcet et al., 
2005) and their target genes such as c-myc, vtgs and cyclin d1 (Bjornstrom and Sjoberg, 
2005). In addition to the changes observed in ERE-dependent and independent pathways, 
methylation and/or expression of several genes involved in the non-genomic estrogenic 
mechanism of action and development of cancer were also changed. For example, insulin 
growth factor-1 receptor (igf1r), known to be altered in terms of DNA methylation and 
expression in various cancers (Mirbahai et al., 2011), several different MAP kinases and 
oncogene Akt kinase, involved in cell proliferation and survival of tumour cells (Rosen and 
She, 2006), were altered in HCA samples. In the non-genomic pathway of estrogenic 
compounds, estrogen binds to the ER located at the cytoplasmic membrane and in 
combination with several other signalling molecules activates MAP kinases. Activated 
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kinases regulate transcription factors associated with ER (such as SP1, ATF2, STAT5 and 
NF-κB) as well as the nuclear ER through phosphorylation (Bjornstrom and Sjoberg, 2005). 
Figure 4.16, adapted from Bjornstrom and Sjoberg (2005), demonstrates the 3 main estrogen 
receptor pathways and the changes detected in dab HCA samples.  
 
 
 
     
Figure 4.16. DNA methylation and transcription changes in genomic and non-genomic 
estrogenic pathway in HCA samples. 1. The classical genomic ERE-dependent pathway. 2. 
Genomic ERE-independent pathway. ER modulates the transcription of genes through other 
transcription factors such as SP1, ATF1, STAT5 and NF-κB. 3. Nongenomic pathway. 
Activation of the cytoplasmic ER subsequently leads to activation of kinases which regulate 
the function of TFs (e.g. SP1, STAT5 and NF-κB) and estrogen receptor through 
phosphorylation. Therefore all pathways are linked and influenced by each other. Many of the 
targeted genes are involved in key functions such as proliferation and cell cycle. Blue: genes 
with altered methylation in HCA compared to ST. ↑↓: genes with altered transcription 
(induced, repressed) in HCA compared to ST or healthy dab liver. P: Phosphorylation. E: 
estrogen or estrogen mimicking compounds. Adapted from original figure of Bjornstrom and 
Sjoberg (2005). 
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4.4.7. Hypothesis 
Based on the evidence discussed above (chemical data and vitellogenin induction), one 
possible hypothesis is that chronic exposure to a mixture of contaminants such as endocrine 
disrupting chemicals (e.g. PCBs, PBDE) or metals (e.g. Cd) causes the initial changes in 
overall DNA methylation levels seen in the entire liver of tumour bearing dab. Indeed, 
inhibition of the activity of DNA methyltransferases is a reported effect of Cd (Baccarelli and 
Bollati, 2009). Exposure to EDCs and metals, especially during critical stages such as 
embryogenesis and gametogenesis, as well as increasing the individual’s susceptibility to 
disease, can cause heritable epigenetic changes (Baccarelli and Bollati, 2009). It is plausible 
that these chemicals further affect the ERE-dependent and independent genomic and non-
genomic estrogen response pathways. Changes in the methylation of genes in this pathway 
can alter the expression of genes involved in proliferation and cell cycle (Figure 4.16). It is 
postulated that additional epigenetic and genetic changes of the primed pre-neoplastic cells, 
and genome instability caused by global DNA hypomethylation, could lead to development of 
these tumours (Figure 4.17, adapted from Feinberg et al., 2006). 
Although the combined data on gene expression, DNA methylation, chemical exposures and 
evidence available in the literature are in agreement with this interpretation, it is also possible 
that altered DNA methylation and disturbance of estrogen signalling pathway in ST is a 
secondary change due to proximity of this tissue to HCA in the organ. However, there is no 
evidence in relation to fish tumours to support this possible explanation. Further support for a 
direct environmental influence on DNA methylation changes and to test for tissue specificity 
might come from analysis of additional tissues in animals with modified DNA methylation in 
the liver. 
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Figure 4.17. A possible mechanism of tumourigenesis in dab. Chronic exposure to a mixture of contaminants, such as weak estrogenic 
chemicals causes the initial global DNA hypomethylation. Over time, a fraction of the primed cells will further undergo epigenetic and 
genetic changes which may lead to formation of tumours. This hypothesis is based on the observed changes in DNA methylation, gene 
expression and chemical data. However, as their environment is complex most certainly there are other factors (chemical and biological) 
involved in the formation of these tumours. : Healthy cell; : “Primed cell”;  : tumour cell 
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4.4.8. Conclusions 
In this study we demonstrated the suitability of MeDIP- de novo HTS for studying DNA 
methylation in un-sequenced species. We also showed for the first time, a link between DNA 
methylation abnormalities and liver tumours in wild fish. In addition, we proposed a 
mechanism to explain formation of dab liver tumours that arise in wild fish chronically-
exposed to contaminants, such as EDCs. It was shown that DNA methylation and 
transcription of cancer-related pathways were altered, with inter-individual variation, in HCA 
compared to ST samples as demonstrated by BSP. Our data support the epigenetic model of 
tumourigenesis in which DNA methylation changes initiate tumourigenesis and therefore 
have the potential to be used for identification of tumour bearing livers, possibly even prior to 
manifestation of microscopic tumours. In particular, global DNA hypomethylation and the 
methylation status of DNA methyltransferases and the genes associated with the non-genomic 
and genomic estrogenic pathways have the potential to be used as early biomarkers of 
environmentally-induced epigenetic change, thus acting as indicators for identification of 
potential tumour inducing, hazardous environments for marine species. However, further 
studies are required to investigate if the observed transcription and DNA methylation changes 
are consequences or causes of these tumours. It is recognised that the epigenetic changes seen 
in ST are likely to be in association with potential genetic toxicity (e.g. PAHs). Nevertheless, 
it appears that there is a link between environment and dab tumourigenesis as the prevalence 
of these tumours differed between sampling sites. Overall, our study highlights the 
importance of incorporating and considering epigenetic mechanisms, especially in chronic 
exposures, for establishing acceptable levels of contaminants in marine environments which 
may subsequently impact the health of organisms, including humans. 
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Chapter 5 
 
Changes to the one-carbon cycle in dab 
liver tumours  
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5.1. Introduction 
Normal cells display a finely tuned epigenomic equilibrium (Esteller and Herman, 2002) 
regulated by a range of enzymes (Turner, 2009). However, as discussed in Chapters 1 and 4, 
the epigenome is sensitive to environmental factors (Jirtle and Skinner, 2007). In higher 
eukaryotes the immediate environment influencing cells is determined by the metabolism and 
physiology of both neighbouring cells and organs. The activities of enzymes modifying the 
epigenome, similar to most other enzymes, depend upon levels of cofactors and metabolites 
present in the intra- and extra-cellular environment (Turner, 2009). Therefore, the epigenome 
can be altered not only by environmental factors, such as exposure to chemicals like cadmium 
(Baccarelli and Bollati, 2009), but also by changes in the levels of cofactors and metabolites 
required for the activity of these enzymes (Turner, 2009; Herceg and Vaissiere, 2011). The 
interaction between methylome, transcriptome and metabolome and the influence of 
environmental factors at multiple levels is illustrated in Chapter 1, Figure 1.14 and Chapter 6, 
Figure 6.1.  
The one-carbon cycle is the main biochemical pathway regulating DNA methylation by 
altering the production of the immediate methyl donor, S-adenosylmethionine (SAM), 
through feedback regulatory mechanisms. In this pathway folate, choline and methionine are 
the primary dietary methyl donors (Herceg and Vaissiere, 2011). Following several chemical 
reactions (described in detail in Chapter 1, section 1.3.3) SAM is produced as the final methyl 
donor. SAM is used in several transmethylation reactions, such as DNA methylation (Krijt et 
al., 2009) and it is second only to ATP in the variety of reactions in which it participates 
(Kumer et al., 2008). DNA methylation is catalysed by DNA methyltransferases (DNMTs). 
DNMTs transfer a methyl group from SAM to DNA, leading to conversion of SAM to S-
adenosylhomocysteine (SAH) (Kumar et al., 2008). SAH is a potent inhibitor of 
transmethylation reactions. Accumulation of SAH, independent of SAM levels, inhibits DNA 
methylation reactions. Therefore, continuous removal of SAH is critical in regulation and 
maintenance of DNA methylation reactions (Caudill et al., 2001; James et al., 2002). Indeed, 
an increase in SAH levels and subsequent change in the SAM/SAH ratio has been associated 
with a range of clinical conditions (Krijt et al., 2009). Therefore, changes in this pathway (i.e. 
change in the transcription levels, the activity of the enzymes involved in this pathway or the 
levels of the metabolites) can influence DNA methylation. For example several studies in 
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rodents have demonstrated that diets deficient in primary methyl donors such as choline, 
folate and methionine can lead to development of tumours, especially in the liver. These 
tumours are induced through alterations of several biological pathways including the one-
carbon cycle and consequently DNA methylation levels (Poirier et al., 2001; Ghoshal and 
Farber, 1984; de Camargo et al., 1985).  
Previously (Chapter 4, section 4.4.5), it was shown that the transcription levels and DNA 
methylation of the genes involved in the methionine cycle, part of the one-carbon cycle, were 
altered in dab HCA tumours. The significance of this pathway in regulation of DNA 
methylation and tumourigenesis in mammals is evident (Krijt et al., 2009; Poirier et al., 2001; 
Ghoshal and Farber, 1984). Therefore, the main aim of the experiments described in this 
chapter was to conduct a targeted metabolomics study to investigate the differences in levels 
of the key metabolites involved in the one-carbon cycle between the three categories of 
interest, HCA, ST and healthy dab liver tissues.  
Metabolomics is the investigation of the low molecular weight metabolites within a cell, 
tissue or biofluid (Viant, 2007). Several metabolomics methods have been used to measure 
the levels of SAM and SAH and other metabolites involved in the one-carbon cycle. These 
include liquid chromatography (LC) methods with electrochemical detection (Yi et al., 2000; 
Melnyk et al., 2000), LC methods with fluorescence detection after conversion of the analytes 
to fluorescent analogues (Davis et al., 2005; Kohlmeier et al., 2005) and more recently LC 
coupled to an ionisation source attached to a triple quadrupole tandem mass spectrometric 
(MS/MS) detection method (Struys et al., 2000; Krijt et al., 2009; Jiang et al., 2009; Liang et 
al., 2009). The latter method is an extremely powerful and sensitive technique for detection 
and quantification of specified compounds (Liang et al., 2009; Cox et al., 2005; Lujan et al., 
2008). During LC a combination of mobile phases (e.g. water, acetonitrile, methanol), 
chemical modifiers (e.g. ammonium formate, ammonium acetate) and chromatography 
columns are used to achieve separation of the analytes of a complex matrix. Analytes are 
ionised at the ion source under a combination of high voltage and heat (Korfmacher, 2005) 
and directed to the mass analyser. In the triple quadrupole mass analyser, data acquisition is 
performed as multiple reaction monitoring (MRM) which creates the high sensitivity and 
selectivity of this approach (Liang et al., 2009). MRM is a method comprised of two ion 
selection stages (quadrupoles (q) 1 and 3) and a fragmentation ion stage (q2) in between the 
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two selection stages. The fragmentation of the parent ions is achieved by collision with gas 
atoms. Therefore, as a specific parent ion and specific fragment ions of the parent ion are 
selected for detection, this method is very precise. It is highly unlikely that two analytes 
would have the exact pattern of fragmentation and parent mass to charge ratio (m/z), making 
this approach ideal for analysis of complex biological matrixes (Figure 5.1) (Cox et al., 2005; 
Anderson and Hunter, 2006). Therefore, in this chapter LC combined with a triple stage 
quadrupole (TSQ) tandem mass spectrometer (MS/MS) were used to investigate the levels of 
key one-carbon metabolites in the three categories of interest, HCA, ST and healthy dab liver 
samples. Furthermore, DNA methylation and gene expression data related to the one-carbon 
cycle from the previous chapter were combined with the data from the metabolomics study 
conducted in this chapter to achieve a better understanding of the role of the one-carbon 
pathway in the development of dab HCA tumours.  
 
Figure 5.1. A schematic representation of an ion source coupled to triple quadrupole tandem 
mass spectrometer. In the ion source the analytes are ionised under a high heat and voltage. In 
quadrupole 1 (q1) or first stage selection, a specific ion of a known m/z is selected. The 
selected ion is fragmented in q2. In q3 the product ions with specific m/z that were generated 
from the fragmentation of the specified parent ion are selected (second stage selection). 
Finally, the selected parent and product ions are detected and recorded (This figure was 
modified from McLafferty, 1981). 
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5.2. Overview of the experimental approach (Methodological details are described in 
Chapter 2) 
The dab liver samples used in Chapter 4 were also used for the quantitative targeted 
metabolomics study of the one-carbon cycle. The details of the samples are presented in 
Chapter 2, Table 2.1. DNA methylation, gene expression and relative quantification of 
selected metabolites were therefore investigated in the same 32 dab liver samples (10 HCA, 
10 ST and 12 dab healthy liver). Metabolites were extracted using a modified version of 
multi-sample ceramic bead-based system described by Southam et al., (2008). In this method, 
an aliquot of the homogenised tissue (no less than 50 μl, equivalent to 5 mg of wet tissue 
mass, ideal amount 10 mg (100 μl)) as described in Chapter 2, section 2.2.2.3.2 was used for 
the extraction of metabolites. As the metabolites investigated were water soluble, only the 
polar fractions were used in this study. An aliquot of the prepared samples equivalent to 4.5 
mg of tissue and the appropriate chemical standards were analysed with liquid 
chromatography (LC)-triple stage quadrupole (TSQ) mass spectrometry as described in 
Chapter 2, section 2.8.  
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Figure 5. 2. Flowchart of the experimental procedures used in Chapter 5. The starting point of 
the diagram is the box with borders. The methods used in this chapter are described in detail 
in Chapter 2. In this flowchart, the sections where these methods are described in Chapter 2 
are shown in brackets. 
 
 
 
 
 
HCA (10), ST (10),  
non-cancerous dab liver 
(12) 
Transcriptomic analysis 
via dab 15k microarray 
(Chapter 4) 
Extraction of metabolites 
(section 2.2.2.3.2) 
Determination of the masses 
of the parent ions and the 
formed product ions using 
chemical standards 
(section 2.8) 
Quantification of the 
selected metabolites of the 
one-carbon pathway based 
on peak area 
(section 2.8) 
Re-analysis of the probes involved 
in the one-carbon pathway (P-value 
<0.05, >1.5 fold change) 
(Chapter 5, Figure 5.7) 
MeDIP-HTS of one 
HCA and matching 
ST sample  
(Chapter 4) 
DNA methylation 
levels of the probes 
involved in the one-
carbon pathway (>1.5-
fold change) 
(Chapter 5, Figure 5.7) 
Combined data (DNA methylation, 
transcriptomic, metabolomic) related 
to the one-carbon cycle 
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5.3. Results 
5.3.1. Targeted quantification of 12 metabolites involved in the one-carbon cycle using 
LC-TSQ 
The differences in the levels of 12 specific metabolites involved in the one-carbon cycle in the 
three categories of interest, HCA, ST and healthy dab liver samples, were investigated using 
LC-TSQ as described in Chapter 2, section 2.8. The metabolites quantified included: S-
adenosylhomocysteine (SAH), S-adenosyl-L-methionine (SAM), methionine, folic acid, 
adenosine, betaine, sarcosine, homocysteine, glycine, dimethylglycine, choline and 
stachydrine (proline-betaine or dimethylproline). 
As described in Chapter 2, section 2.8, analytes were detected with data acquisition performed 
as MRM. As an example one MS/MS spectrum collected from the specified 13 parent ions 
(including the internal standard, S-adenosylmethionine-d3) and product ions arising from their 
fragmentation is shown in Figure 5.3. The masses of the precursor ions and the formed 
product ions used for detection of the metabolites of interest are shown in Chapter 2, Table 
2.6. The LC-TSQ method used was not suitable for quantification of folic acid and 
homocysteine. Therefore, the data for these two metabolites have not been included. The data 
for the 10 quantifiable metabolites of interest are shown in Figure 5.4. As shown in this 
figure, methionine and SAH levels were higher and statistically significant in both HCA and 
ST samples compared to healthy dab liver while the level of choline was statistically 
significantly lower in ST and HCA samples compared to healthy dab liver samples. 
Dimethylglycine and adenosine levels were lower in ST and higher in HCA samples 
compared to healthy dab liver samples (statistically significant), respectively. As shown in 
Figure 5.5, SAM/SAH ratio was statistically significantly lower in HCA and ST samples 
compared to healthy dab liver samples. 
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Figure 5.3. Example of a MS/MS spectrum collected from the specified 13 parent ions and product ions arising from the fragmentation of 
the parent ions. The collision energy was altered according to the values indicated in Chapter 2, Table 2.6, to scan (scanning time: 27 
minutes) for the presence of the 13 parent compounds and their products. The vertical bars relate to the relative current produced by ions of 
varying m/z. Therefore, the greater the current the more abundant the ion is in the sample. For example by combining the bars related to the 
m/z of the adenosine (m/z: 267.935) and the seven formed ions after fragmentation of the adenosine, a peak relating to the metabolite 
adenosine at retention time of 5.75 was detected as shown in top right corner of the above figure. The peak area for each metabolite relates 
to the relative abundance of the metabolite. The m/z values for the seven adenosine product ions are shown in this figure.  
Parent (adenosine) m/z:
267.935
Products m/z: 
66.993, 91.976, 93.978, 118.981, 
135.993, 137.005, 137.005
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Figure 5.4. Quantification of the 10 metabolites of interest in hepatocellular adenoma (HCA), 
surrounding tissue (ST) and healthy dab liver samples. In these graphs, the relative abundance 
of each metabolite is shown, having been measured as peak area. The quantification of the 
peak area for each metabolite relates to 4.5 mg of dab liver sample. Each sample was spiked 
with the internal standard, S-adenosyl-L-methionine-d3 (0.016 mmol/ ml). The peak area for 
each metabolite was normalised to the peak area for the internal standard. The name of the 
metabolite investigated is shown at the top of each graph. Data is presented as mean ± SEM of 
12 healthy dab liver samples, 10 ST and 10 HCA samples. The same samples used in Chapter 
4 were used for the experiments conducted in Chapter 5. Samples were run in duplicate for 
technical replication. Negative controls were used to monitor the quality of the extraction 
method. A mixture of acetonitrile: water was injected in-between each biological replicate to 
prevent sample carryover. *** P<0.001, ** P<0.01, * P<0.05. Depending on the normal 
distribution of the data and homogeneity of the variance as determined by Shapiro-Wilk test 
and Levenes’ test, respectively, non-parametric test (Mann-Whitney U test) or parametric test 
(2-tailed Student’s t-test) were used for determining the P-value.  
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Figure 5.5. Quantification of SAM/SAH ratio in HCA, ST and healthy dab liver samples. 
Data are presented as mean ± SEM of 12 healthy dab liver samples, 10 HCA and 10 ST 
samples. ** P<0.01, * P<0.05. P-value was determined using 2-tailed Student’s t-test. 
 
5.3.2. Principal components analysis 
The normalised data for all the 10 metabolites investigated from the three categories of 
interest (HCA, ST and healthy dab liver) were subjected to principal component analysis 
(PCA) scores plot (Figure 5.6).  
In the PCA plot, healthy dab liver samples were separated from the HCA and ST samples 
based on disease along the PC2 axis. PC1 and PC2 accounted for 65.8% and 32.52% of the 
variance, respectively. In this PCA plot, HCA and ST were clustered together. This 
demonstrated that the metabolic profiles of the HCA and ST samples for the investigated 
metabolites are similar. This result was in agreement with the data demonstrated in Figure 5.4. 
As shown in Figure 5.4, although some metabolites had increasing or decreasing trends in 
HCA samples compared to ST samples, statistically significant differences were not observed 
between these samples and this was reflected in the results of the PCA plot (Figure 5.6). 
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Figure 5.6. Principal components analysis (PCA) scores plot for the 10 metabolites that were 
investigated in the HCA, ST and healthy dab liver samples using LC-TSQ. Dab healthy liver 
samples (green) were separated based on disease from the HCA (red) and the surrounding 
tissue (blue) samples along the PC2 axis. Numbers 1-10 represent 10 individual fish. 
Matching numbers are ST and HCA samples from the same fish. Sampling sites for each fish 
is also shown. N: North Cardigan Bay, S: South Cardigan Bay, I: Inner Cardigan Bay, B: St 
Bee’s Head, R; Red Wharf Bay, L: Lundy. 
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5.3.3. Change in the expression and DNA methylation levels of the genes involved in the 
one-carbon cycle 
The expression levels of 23 probes related to one-carbon cycle for the three tissue categories 
of interest, represented on the dab 15K microarray (described in Chapter4), were re-analysed. 
These included: S-adenosylhomocysteine hydrolase (probe ID: 18T4428314), methionine 
adenosyltransferase (probe ID: 6140736) , methionine adenosyltransferase 1 (probe ID: 
6606586), methionine adenosyltransferase 2 (probe ID: 6625279), DNA methyltransferase 1 
(probe IDs: 6355974 and 18T3383577), DNA methyltransferase 3a (probe IDs: 6396450 and 
19N4016975), DNA methyltransferase 3b (probe IDs: 6505586, 6623925 and 6185506), DNA 
methyltransferase 4, 5, 7 and 12 (probe ID: 6102058, probe ID: 6613415, probe ID: 6521192, 
probe ID: 6516262), S-adenosylmethionine dependent methyltransferase (probe ID: 
6245510), betaine-homocysteine methyltransferase (probe IDs: 18T3874626, 19N3859050, 
19N4347827, 18T4139617, 6593006), methylenetetrahydrofolate reductase (probe ID: 
6254480), methionine synthase (probe ID: 18T3885734). As comparisons were restricted to 
limited number of probes (23 probes), a p-value cut-off of less than 0.05 and a fold change 
>1.5 with no FDR correction were applied on the normalised gene expression data achieved 
in Chapter 4, section 4.3.2.3. Table 5.1 demonstrates the genes that their expressions are 
significantly changing between the three investigated tissue categories. The fold change 
differences in the transcription levels of all the 23 probes are presented in Appendix, File 16.  
 Furthermore, probes related to the one carbon cycle with DNA methylation alterations of 
greater than 1.5 fold between HCA and ST as determined by MeDIP-HTS in Chapter 4, are 
represented in Table 5.2. 
As demonstrated in Table 5.1, both over- and under-expression of members of DNMT family 
were observed in HCA samples compared to ST and healthy dab liver samples. While the 
expression of the DNA methyltransferase 3a gene and one of the probes matching to DNA 
methyltransferase 3b gene were statistically significantly lower in ST compared to healthy 
dab liver with decreasing trends in HCA samples compared to healthy dab liver samples, the 
expression of the hypomethylated DNA methyltransferase 4 was higher and statistically 
significant in HCA samples compared to ST samples. The S-adenosylhomocysteine hydrolase 
and betaine-homocysteine methyltransferase genes were statistically significantly over- and 
under-expressed, respectively in HCA compared to both ST and healthy dab liver tissues. The 
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hypomethylated methionine adenosyltransferase gene in HCA sample was statistically 
significantly over-expressed in HCA compared to ST samples with increasing trends in HCA 
compared to healthy dab liver samples. One of the probes representing the betaine-
homocysteine methyltransferase gene was lower expressed (statistically significant) in HCA 
samples compared to ST and healthy dab liver samples.  
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Category of 
comparison 
Gene Symbol Fold change 
HCA/H 
S-adenosylmethionine hydrolase SAHH +2.41** 
Betaine-homocysteine methyltransferase BMHT -2.63*** 
Methylenetetrahydrofolate reductase MTHFR +1.82*** 
ST/H 
DNA methyltransferase 3b DNMT3b -2.21* 
DNA methyltransferase 3a DNMT3a -1.61* 
HCA/ST 
methionine adenosyltransferase MAT +1.78* 
Betaine-homocysteine methyltransferase BMHT -1.77* 
DNA methyltransferase 4 DNMT4 +1.34* 
S-adenosylmethionine hydrolase SAHH +3.25* 
Table 5.1. Genes related to one-carbon pathway statistically significantly altered in expression 
between in the three categorise investigated (HCA, ST and H). *** P<0.001, ** P<0.01, * 
P<0.05. Depending on the normal distribution of the data and homogeneity of the variance as 
determined by Shapiro-Wilk test and Levenes’ test, respectively, non-parametric test (Mann-
Whitney U test) or parametric test (2-tailed Student’s t-test) were used for determining the P-
value. 
 
Gene Symbol Fold enrichment (HCA/ST) 
SAM dependent methyltransferase MT -1.75 
DNA methyltransferase 1 DNMT1 +1.50 
DNA methyltransferase 3b DNMT3b -1.67 
methionine adenosyltransferase MAT -1.54 
DNA methyltransferase 4 DNMT4 -2.56 
DNA methyltransferase 12 DNMT12 -1.72 
Table 5.2. Genes with altered DNA methylation (> 1.5-fold enrichment) involved in the one-
carbon cycle as quantified by de novo high throughput sequencing of 5-methylcytosine 
immunoprecipitated DNA.  
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5.4. Discussion  
Change in the levels of metabolites is demonstrative of the physiological, developmental and 
pathological status of a cell. Metabolomic studies in tumours have provided valuable 
information for tumour characterisation, drug therapy and diagnosis (Griffin and Shockor, 
2004). Furthermore, metabolites and nutrients that provide the primary sources of methyl 
group and by producing the final methyl donor, S-adenosylmethionine, contribute 
significantly to the regulation of DNA methylation (Ulrey et al., 2005). Therefore, not only 
disruption of the activities of epigenetic modifying enzymes, such as DNA 
methyltransferases, can have an adverse effect on health, but also changes in the levels of the 
metabolites required for the action of these enzymes can result in alterations to the epigenome 
(Turner, 2009). Therefore, in this chapter changes in the levels of a number of key metabolites 
in the one-carbon cycle were investigated. This study provided a snapshot of the relative 
levels of the metabolites of interest in the three investigated categories of tissue at a given 
time point. Therefore, although it does not directly provide information on the flux, 
nevertheless it provides valuable information regarding the changes to the one-carbon 
pathway. To achieve a better characterisation of the one-carbon pathway in dab HCA 
samples, the information on the changes in the levels of metabolites was combined with the 
changes observed in the DNA methylation and expression of the genes involved in this 
pathway. The overall changes observed in the one-carbon cycle are summarised and 
combined in the Figure 5.7.  
 
5.4.1. S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH) and DNA 
methyltransferases (DNMTs) 
SAM derived from the one-carbon pathway is the final methyl donor used in a range of 
transmethylation reactions, including methylation of DNA, RNA, phospholipids, proteins, 
histones and neurotransmitters  (Krijt et al., 2009; Mischoulon and Fava, 2002). Transfer of 
the methyl group from SAM to cytosine, catalysed by DNMTs, results in the production of 
SAH (Kumar et al., 2008).  In our experiment, the level of SAM did not differ between the 
three investigated categories of tissue. However, one of the key findings was the detection of 
a statistically significant higher level of SAH in “apparently healthy” non-cancerous 
surrounding tissue (ST) and an even higher value in HCA samples both compared to healthy 
 246 
 
dab liver samples. SAH levels were 6.9 fold higher (statistically significant) in HCA 
compared to healthy dab liver and 3.1 fold higher (statistically significant) in ST compared to 
healthy dab liver. SAH has a high binding affinity for the catalytic regions of the DNMTs 
(Melnyk et al., 2000; James et al., 2002). Therefore, it is a potent competitive inhibitor of 
DNMTs, which leads to DNA hypomethylation and alterations in the expression of specific 
genes (Krijt et al., 2009; Kumar et al., 2008; Melnyk et al., 2000; James et al., 2002). This is 
in agreement with our findings, as HCA and ST samples were significantly hypomethylated 
compared to healthy dab liver samples. Furthermore, the expression levels of several genes 
were altered in HCA samples compared to ST and completely healthy dab liver samples as 
discussed in the previous chapter.  
The level of SAM did not differ between the three tissue categories of interest. However, as 
SAH levels were significantly higher in HCA and ST samples compared to healthy dab liver 
tissues, this resulted in statistically significant 4.24 and 4.15 fold reductions in the SAM/SAH 
ratio in HCA compared to healthy dab liver samples and ST compared to healthy dab liver 
samples, respectively. This ratio, which sometimes is referred to as the “methylation index” 
(Krijt et al., 2009), has been used for the prediction of the cellular DNA methylation capacity. 
A decrease in this ratio has been linked with reduction in cellular DNA methylation capacity 
(Caudill et al., 2001; Melnyk et al., 2000). However, several studies have demonstrated that a 
decrease in SAM/SAH ratio is only predictive of reduced DNA methylation capacity if it is 
caused by an increase in SAH concentration. Therefore, an increase in SAH level, 
independent from increase or decrease in the level of SAM, will result in reduced cellular 
DNA methylation capacity and global DNA hypomethylation (Caudill et al., 2001; Yi et al., 
2000).  For example, in human lymphocytes it has been shown that 2-fold elevation of SAH is 
associated with 2.6 fold reduction in the global DNA methylation levels of lymphocytes in the 
absence of change in the levels of SAM (Yi et al., 2000). While in Min mice, a positive 
correlation was observed between increase in the levels of both cellular SAH and SAM, 
decrease in global DNA methylation levels and induction of multiple intestinal neoplasia 
(Sibani et al., 2002). This indicates that most likely SAH, independent of SAM, is the key 
metabolite that regulates the activity of DNMTs (Ulrey et al., 2005). It has been suggested 
that SAM can only negatively influence the activity of DNMTs when its level falls 
significantly below the lower limit of its physiological range (Yi et al., 2000). Therefore, 
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changes in SAH levels can be a better marker of the cellular DNA methylation capacity than 
the methylation index (Caudill et al., 2001). 
Alterations in the activities of DNMTs have a significant impact on DNA methylation and 
tumourigenesis. Changes in the activities of DNMTs can be a consequence of the interference 
of different factors with the function of DNMTs, such as an increase in SAH levels and 
inhibition of DNMTs (Krijt et al., 2009; Kumar et al., 2008; Melnyk et al., 2000), interaction 
of metals such as cadmium with DNMTs and interference by chemically-induced reactive 
oxygen species with the activity of DNMTs (Baccarelli and Bollati, 2009). However, changes 
in the expression levels of DNMTs, caused by change in their DNA methylation levels, have 
also been implicated in different stages of cancers in humans (Girault et al., 2003; Sun et al., 
1997; Laird and Jaenisch, 1994; Momparler and Bovenzi, 2000; Robertson et al., 1999, Loriot 
et al., 2006). For example decrease in the expression levels of specific DNMTs, depending on 
the type of tissue, can lead to global DNA hypomethylation and development of tumours; 
while increase in the expression of other members of the DNMT family is associated with the 
re-methylation stage and maintenance of DNA methylation in highly proliferating tumour 
cells. This is discussed in detail in Chapter 4, section 4.4.5 (Loriot et al., 2006). In humans the 
functions of various DNMTs have been well characterised. Furthermore, DNMTs have been 
separated from their paralogs, tRNA methyltransferases, which use the same methyl donor, 
SAM (Different functions of DNMTs, such as maintenance and de novo DNA methylation in 
humans are discussed in details in Chapter 1, section 1.3.1). However, DNMTs, their 
biological functions and their distinction from tRNA methyltransferases have not been well 
characterised in fish species. For example, eight different DNMTs have been identified in 
zebrafish but their biological functions are far from characterised (Shimoda, 2007). As shown 
both in the results section and in Figure 5.7, the expression and methylation of several dnmt 
genes were altered in dab liver tumours compared to ST or healthy dab liver samples. 
Although the function of each dnmt is not known in fish, these changes suggest that the 
expression of these genes may be involved in increasing the levels of SAH, global DNA 
hypomethylation and gene specific DNA methylation changes that were detected in dab 
tumours. 
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5.4.2. The inhibitory role of homocysteine and its association with SAH 
An increase in the cellular SAH level is generally recognised as a secondary effect of an 
increase in the levels of homocysteine (Melnyk et al., 2000; James et al., 2002). As shown in 
Figure 5.7, SAH is converted in a reversible reaction via SAH hydrolase (SAHH) to 
adenosine and homocysteine. However, the equilibrium constant of SAHH favours the 
production of SAH. Therefore for the continuation of the DNA methylation reaction, it is 
necessary that the homocysteine is removed from the site of production. This will induce 
further conversion of SAH to homocysteine and removal of SAH from the site of production 
(Ulrey et al., 2005). Therefore, increase in homocysteine levels will prevent the removal of 
SAH, leading to accumulation of SAH and inhibition of DNA methyltransferase reactions 
(Caudill et al., 2001). In this study, no data were available on the levels of homocysteine in 
the three investigated categorise of tissues. However, higher levels (statistically significant) of 
adenosine and sahh transcript were observed in dab HCA samples compared to ST and 
healthy dab liver samples. Considering all the above findings, the data are suggestive of a 
higher level of homocysteine in HCA samples compared to healthy dab liver samples. Higher 
levels of homocysteine in HCA samples, as discussed, could have caused a secondary 
increase in SAH levels, as observed. Furthermore, increase in the rate of SAH to 
homocysteine conversion may compensate and promote the removal of SAH for maintaining 
the lower level of DNA methylation detected in dab HCA and ST cells compared to healthy 
dab liver. However, it has to be noted that adenosine is formed both from conversion of the 
SAH to homocysteine and from dephosphorylation of adenosine monophosphate (AMP). It is 
also involved in many different pathways, including synthesis of nucleotides such as inosine 
(Fox and Kelly, 1978). Therefore, the higher level of adenosine observed in HCA samples 
compared to healthy dab liver samples could be due to alterations of several other pathways in 
dab HCA tumours.  
Removal of homocysteine is accomplished through two distinct pathways of remethylation 
and conversion to methionine (choline and folate remethylation pathways) and degradation of 
homocysteine to cysteine (number 7 in Figure 5.7). The latter is a permanent method of 
removal of homocysteine while the former will subsequently lead to regeneration of 
homocysteine as shown in the Figure 5.7 and discussed in section 5.4.3 (Caudill et al., 2001). 
Permanent degradation of homocysteine is achieved through the one-way transsulfuration 
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pathway. During the first step, cystathionine β-synthase (CBS) converts homocysteine to 
cystathionine. Cystathionine is converted to cysteine and α-ketobutyrate via cystathionine γ-
lyase (CGL). The generated cysteine will further contribute to the production of glutathione 
(Caudill et al., 2001). In humans, a positive correlation between increased levels of 
homocsyteine and increased transcription from CGL and CBS genes has been identified (Chen 
et al., 2010). This is to accelerate the removal of and inhibit the accumulation of 
homocysteine (Durand et al., 2001). However, our data showed that the expression levels of 
the cbs and cgl genes were not altered in HCA and ST samples compared to healthy dab liver 
samples (data not shown, raw data are available from the ArrayExpress at EMBL-EBI and can 
be found under accession A-MEXP-2084). This may contribute to the higher levels of 
adenosine, SAH and methionine observed in dab HCA samples and ST samples compared to 
healthy dab liver samples.  
 
5.4.3. Alterations in the levels of primary nutrient methyl donors; choline, folate and 
methionine 
Methionine levels were significantly higher in dab HCA and ST samples compared to healthy 
dab liver tissues. As mentioned above, one possibility could be insufficient degradation of and 
subsequent increase in the level of its precursor, homocysteine, which could lead to an 
increase in methionine levels in tumours. However, there are three alternative pathways that 
could also impact the level of methionine. These three pathways are highly influenced by diet. 
Diet can influence DNA methylation mainly by affecting the one-carbon cycle (Vineis et al., 
2011). In humans the three main sources of methyl groups are provided through nutrient 
intake of methionine (~10 mmol of methyl/day), folate (~5_10 mmol of methyl/day) and 
choline (~30 mmoles/day). Therefore, diet has a significant role in the regulation of the one-
carbon cycle and DNA methylation (Niculescu and Zeisel, 2002). Furthermore, it has been 
estimated that inappropriate diet accounts for more than one third of deaths caused by cancer 
(Doll and Peto, 1981; WCRF, 2007). Changes observed in the one-carbon cycle in dab 
tumours compared to healthy dab liver samples may in part, be related to differences in diet 
that could affect the development of tumours in dab, however there was no information on the 
diets of the wild fish used in this study.  
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As mentioned in section 5.4.2, methionine is regenerated in the liver from homocysteine by 
two independent pathways: 1. The betaine-homocysteine methyltransferase (BHMT) reaction 
2. Folate, vitamin B12-dependent methionine synthesis. (Emmert et al., 1996; Herceg and 
Vaissiere, 2011; the two pathways are described in details in Chapter 1, section 1.3.3). 
 
5.4.3.1. Methionine and choline  
In the first pathway, the primary source of the methyl group is provided by dietary intake of 
choline. Choline in mammals is used in three different pathways. 1. Donation of a methyl 
group and regeneration of methionine (number 2 in Figure 5.7) 2. Synthesis of 
phosphatidylcholine (PC), one of the most abundant phospholipid components of the cell 
membrane (number 8 in Figure 5.7) 3. Synthesis of the neurotransmitter acetylcholine 
(Michel et al., 2006). In the human liver, 60% of the choline is utilised in the methionine 
regeneration pathway (Delong et al., 2002). In dab tumours the levels of metabolites, such as 
dimethylglycine and choline, and the transcription level of betaine-homocysteine 
methyltransferase (bmht) gene, which converts homocysteine to methionine, were lower 
compared to healthy dab liver. This suggests an alteration in the choline-methionine metabolic 
regeneration pathway in the livers of dab containing HCA tumours. This finding agrees with 
previous published data demonstrating down-regulation of this pathway in dab liver tumours 
(Southam et al., 2008). Furthermore, choline deficiency, caused as a result of deficiency in 
uptake or reduced levels in diet and/or disruption of the choline metabolic pathway, has been 
linked with development of liver cancer in humans (Michel et al., 2006). The same effect has 
been reported in rodents. Several studies using diets deficient in choline (Locker et al., 1986), 
choline and methionine (Wilson et al., 1984; Ghoshal and Farber, 1984) or folate and choline 
(Sibani et al., 2002) have suggested a link between choline deficiency, DNA hypomethylation 
and alterations in the levels of the one-carbon metabolites such as SAM and SAH as well as 
development of liver tumours and multiple intestinal neoplasia in mice and rats. These studies 
have concluded that choline deficiency is carcinogenic in rats (Locker et al., 1986). Uptake of 
the essential nutrient methionine, in choline deficient animals, causes an increase in 
methionine and homocysteine levels (Michel et al., 2006). As mentioned in section 5.4.2 this 
will further result in accumulation of SAH, DNA hypomethylation and development of liver 
tumours. This corresponds with changes observed in the one-carbon cycle in dab tumours. 
Therefore, the higher level of methionine observed in the tumour bearing dab livers compared 
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to healthy dab liver tissues could be as a result of a decrease in choline levels and/or direct 
increase in methionine intake and increase in homocysteine levels. Furthermore, the level of 
stachydrine (proline-betaine) was investigated in the three tissue categories of interest. 
Stachydrine, synthesised in plants (Heinzmann et al., 2010), has a negative impact on the 
betaine-methinine regeneration pathway (Lever and Slow, 2010). This compound reduces the 
amount of available betaine for the betaine-methionine regeneration pathway by increasing 
excretion of betaine from the kidneys (Lever and Slow, 2010; Heinzmann et al., 2010). 
However, the level of this compound was not significantly altered in dab tumours. This 
suggests that decrease in the available amount of choline is the main cause of decrease in the 
level of dimethylglycine and down-regulation of betaine-methionine regeneration pathway 
rather than increased excretion of betaine. 
 
5.4.3.2. Folate  
A third possibility is change in the folate-methionine regeneration pathway (number 3 in 
Figure 5.7). Folate is essential in regulation of DNA repair, DNA synthesis and methylation 
reactions. As a result, folate deficiency is generally associated with reduced production of 
SAM, global DNA hypomethylation, gene specific hypermethylation and increased risk of 
several cancers, such as breast, brain, ovary, colorectum and pancreas in humans and liver 
tumours in rodents (Duthie et al., 2011; Caudill et al., 2001). However, the extent to which 
folate deficiency affects DNA methylation is less consistent between different studies. It is 
thought that the damaging effect of folate deficiency depends on a combination of factors 
such as the type of tissue and the treatment regime. Furthermore, folate deficiency is mainly 
associated with global DNA hypomethylation when it is severely limited in the diet (Duthie et 
al., 2011). In this study the HPLC running conditions could not be optimised for measurement 
of folate. However, as shown in Figure 5.6, the Methylenetetrahydrofolate reductase (mthfr) 
gene was over transcribed in HCA samples compared to healthy dab liver samples. Therefore, 
this may suggest up-regulation of the folate-methionine regeneration pathway in the livers of 
dab containing tumours.  
One possible outcome of up-regulation of folate-methionine regeneration pathway is to 
compensate for the alterations occurring in choline-methionine regeneration and 
homocysteine degradation pathways in dab tumours. Exogenous restriction of choline or 
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methionine causes an increase in synthesis of 5-methyl THF (Durand et al., 2001). The link 
between 5-methyl THF, SAM and the activity of glycine N-methyltransferase (GNMT) is 
well established. As shown in Figure 5.7, 5-methyl THF, synthesised by MTHFR from N5, 
N10-methylene THF has an inhibitory effect on GNMT. Inhibition of GNMT reduces 
conversion of SAM to SAH and increases the availability of SAM. This will lead to 
maintenance of methylation reactions (Ulrey et al., 2005; Durand et al., 2001). This is in 
agreement with: 1. Observed increase in transcription level of mthfr gene in HCA samples 
compared to ST. 2. Detection of a higher level of glycine (trend, not statistically significant) 
in dab tumour samples compared to ST and healthy dab liver samples. 3. Same global DNA 
methylation levels in ST and HCA samples. 
 
5.4.4. Production of SAM and the competition between DNMTs, GAMT and PEMT for 
consumption of SAM 
The conversion of methionine to SAM is catalysed by methionine adenosyltransferase 
(MAT). The subunits for the three MAT isoenzymes found in mammals are encoded by two 
different MAT genes, MAT1A and MAT2A (Lu, 2000). However, it is not known how many 
mat genes exist in dab. In this study, the level of the precursor compound, methionine, and the 
expression level of one of the hypomethylated probes corresponding to the mat gene were 
higher in HCA samples compared to ST samples. This implies a possible up-regulation in the 
production of SAM. However the levels of SAM did not differ between the three investigated 
tissue categories. This suggests a simultaneous and equal increase in the demand for and 
usage of SAM. Considering that: 1. SAH levels were higher in dab tumour samples compared 
to healthy dab liver samples, which inhibit DNA methylation reactions. 2. mthfr gene was 
over-expressed in dab tumours compared to healthy dab liver samples, which also inhibits 
DNA methylation reactions 3. Global DNA methylation levels were lower in tumour bearing 
dab livers compared to healthy dab liver samples; without doubt, the rate of DNA methylation 
is reduced in these tumours. Despite the evidence for reduced DNA methylation, levels of 
SAM did not differ between the different tissue types. On the basis of relatively high levels of 
methionine and mat expression in tumour and ST samples, one has to question the fate of 
SAM that is expected to be produced. As discussed in detail below, other methylation 
pathways exist (numbers 4 and 5 in Figure 5.7) that utilise SAM and hence alternative 
requirements may have been elevated. The key conclusion is that a deficiency of SAM is not 
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evident and therefore the choline deficiency (described in section 5.4.3) is not influencing 
DNA methylation through causing SAM deficiency. Choline deficiency potentially could be 
contributing to DNA hypomethylation via SAH elevation, with it being upstream of 
homocysteine production. 
There are two other main methyltransferases in the liver that use SAM as their methyl donor. 
These include guanidinoacetate methyltransferase (GAMT) and phosphatidylethanolamine N-
methyltransferase (PEMT) (Brosnan et al., 2004). In addition to the role of choline in 
regeneration of methionine, as discussed in section 5.4.3, it is used in the cytidine diphosphate 
(CDP)-choline pathway (number 8 in Figure 5.7). CDP-choline pathway is the main 
metabolic pathway in the liver for the synthesis of the membrane phospholipid, 
phosphatidylcholine (PC) (Michel et al., 2006). However, during choline deficiency, PC 
synthesis is catalysed by PEMT in a three step reaction (number 4 in Figure 5.7). In this 
reaction three SAM molecules are used as methyl donors for the production of one PC 
molecule from phosphatidylethanolamine (PE) (Michel et al., 2006; Brosnan et al., 2004). 
This leads to an increase in homocysteine levels (Michel et al., 2006). DNA 
methyltransferases and other methyltransferases such as GAMT and PEMT are in competition 
for consumption of SAM (Ulrey et al., 2005). Therefore, as discussed in section 5.4.2, 
increased homocysteine levels as a result of increase in PEMT activity could subsequently 
lead to increase in SAH and inhibition of DNA methylation. As choline and global DNA 
methylation levels were significantly lower and SAH level was significantly higher in dab 
HCA samples compared to healthy dab liver samples, this suggests that the PE-PC pathway 
could be increased in dab tumours. Increase in PC synthesis reflects the higher demand for the 
structural phospholipid, PC, by proliferating tumour cells (Southam et al., 2008). 
Furthermore, the synthesis of creatine from guanidine acid, catalysed by GAMT in the liver, 
consumes the majority of SAM (Ulrey et al., 2005; Stead et al., 2001; number 5 in Figure 
5.7). In addition, increase in the activity of GAMT causes an increase in the homocysteine 
levels and competitive inhibition of DNMTs (Brosnan et al., 2004). Therefore, in addition to 
providing another mechanism for reduction in DNA methylation levels; up-regulation of these 
pathways provides a possible explanation for the observed increase in methionine-SAM 
reaction without any change to the level of SAM in dab tumours compared to healthy dab 
liver samples (Figure 5.7).  
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Figure 5.7. Overview of the changes observed in dab HCA, ST and healthy dab liver samples 
as investigated in Chapter 5. This figure demonstrates all the significant changes detected in 
gene expression, DNA methylation and the levels of metabolites in the one-carbon cycle 
between the three investigated tissue categories of interest (HCA, ST and healthy dab liver 
(H)).  
Pathways: 1: methionine cycle, 2: betaine-methinine regeneration pathway, 3: folate pathway 
(the one-carbon cycle is comprised of pathways 1, 2 and 3), 4: PC synthesis using SAM as 
methyl donor, 5: creatine synthesis using SAM as methyl donor, 6: DNA methylation using 
SAM as methyl donor (4, 5 and 6 are three reactions catalysed by three SAM-dependent 
methyltransferases), 7: permanent removal of homocysteine, 8: cytidine diphosphate (CDP)-
choline pathway.  
Arrows: decrease or increase. Different colours are used for the arrows to indicate changes in 
metabolites, gene expression and DNA methylation as well as the compared categories of 
tissues (i.e. HCA vs. ST, HCA vs. H or ST vs. H).  
Abbreviations: ADP: adenosine diphosphate, ATP: adenosine triphosphate, BMHT: betaine-
homocysteine methyltransferase, CDP-choline: cytidine diphosphate-choline, CK: choline 
kinase, CMP: cytidine monophosphate, CPT: cholinephosphotransferase, CTP: cytidine 
triphosphate, DNMT: DNA methyltransferase, DAG: diacylglycerol, GAA: guanidinoacetate, 
GAMT: guanidinoacetate methyltransferase, GNMT: glycine N-methyltransferase, MAT: 
methionine adenosyltransferases, MS: methionine synthase, MTHFR: 
methylenetetrahydrofolate reductase, PC: phosphatidylcholine; Pcyt1: phosphocholine 
cytidylyltransferase 1, PE: phosphatidylethanolamine, PEMT: phosphatidylethanolamine N-
methyltransferase, PPi: pyrophosphate, SAH: S-adenosylhomocysteine, SAHH: S-
adenosylhomocysteine hydrolase, SAM dependent MT: S-adenosylmethionine dependent 
methyltransferase, THF: tetrahydrofolate. 
 
5.4.4. Conclusions 
In this study, it was demonstrated that levels of the components of the one-carbon cycle 
differed in tumour bearing dab livers compared to healthy dab liver samples. The two most 
apparent significant differences were detection of higher levels of SAH and lower levels of 
choline in dab HCA and ST compared to healthy dab liver. The former is a biomarker of 
reduced capacity of cellular DNA methylation (Caudill et al., 2001; Yi et al., 2000). The latter 
indicates either reduced cellular uptake of choline in the liver or choline deficiency in the diet. 
Reduction in the bioavailability of choline for the one-carbon cycle has also been linked with 
DNA hypomethylation and development of tumours (Michel et al., 2006; Locker et al., 1986; 
 256 
 
Wilson et al., 1984; Ghoshal and Farber, 1984; Sibani et al., 2002). As these tumours are 
detected in wild fish, without doubt development of these tumours is multifactorial. 
Therefore, in addition to the presence of pollutants in their environment (discussed in Chapter 
4), it is possible that dietary factors are important in higher tumour susceptibility of fish 
collected from certain sampling sites. However, further studies are required to distinguish 
between the changes in the one-carbon pathway that are involved in development of these 
tumours from the changes that are a consequence of the formed tumours. In part, this has been 
investigated by including apparently healthy tissue (ST) from tumour containing liver and 
completely healthy liver. Based on the PCA results, HCA and ST samples are metabolically 
similar in regards to the one-carbon metabolic pathway and both differed from healthy, non-
cancerous dab liver tissues. This was reflected in the graphs shown above, as no significant 
differences were observed between HCA and ST samples. Detection of similar profiles 
between HCA samples and non-cancerous ST samples, suggest that the differences observed 
in the levels of metabolites between HCA and healthy dab liver samples could be implicated 
in the development of tumours. However, further studies using pre-neoplastic lesions are 
needed before any decisive conclusions on the earlier stages of tumourigenesis could be 
made. 
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Chapter 6 
 
General discussion and future work 
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6.1. General discussion 
Assessment of the disease status of common dab (Limanda limanda), captured from the 
waters around the UK, is used in the UK Clean Seas Environmental Monitoring Programme 
(CSEMP) as an indicator of biological effects of contaminants in the marine environment. 
Surprisingly, a high prevalence of liver tumours, with some sites exceeding more than 20%, 
has been reported in this fish species (described in Chapter 1, section 1.4.1.2). However, the 
underlying causative factor/factors are not known.  
Overlaid on the genome there are layers of heritable chemical signals and markers referred to 
as epigenetic markers (Bernstein et al., 2007). As described in section 1.3.2, DNA 
methylation, as an epigenetic mechanism in connection with other epigenetic and non-
epigenetic factors, is important in control and regulation of transcription. Therefore, 
disruption of DNA methylation has been associated with development of a range of disorders 
in humans (Egger et al., 2004), including cancers (De Smet and Loriot, 2010; Feinberg et al., 
2006). It is becoming more apparent that aberrant DNA methylation is a common and early 
event during tumourigenesis and that epigenetic abnormalities increase as the tumours 
progress (Lempiainen et al., 2011; discussed in Chapter 1, section 1.3.5.3). In addition, as 
described in section 1.3.5.2, epigenetic factors are important in linking the signals received 
from the environment to phenotypic responses; hence, providing a mechanism for adaptation 
to varying environmental conditions that the genome alone cannot provide.  
As discussed in Chapter 1, section 1.3.1, Table 1.1, there is very little information on 
epigenetic changes in aquatic species as a response to exposure to model environmental 
pollutants. Epigenetic is an emerging field in aquatic biology and several aspects have been 
neglected thus far, including the role of epigenetic alterations in diseases of aquatic species. 
To our knowledge, no previous DNA methylation studies of tumours dissected from wild fish 
have been reported. Therefore, the work presented in this thesis investigated the possibility of 
alterations in DNA methylation profiles of tumours in fish and provided a comprehensive 
characterisation of liver tumours in dab in regards to changes in DNA methylation, 
transcription and the one-carbon methylation pathway, providing a hypothesis for formation 
of these tumours.  
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6.2. Main findings on global DNA methylation 
In Chapter 3, it was shown that, in agreement with the literature (Aniagu et al., 2008; Bird, 
1980), overall DNA methylation levels are two fold higher in the livers of fish (8%) compared 
to mammals (4%), including human liver. It is thought that body temperature is positively 
correlated with deamination rate of 5-methylcytosine and 5mCpG:TpG transition and 
therefore negatively correlated with overall DNA methylation levels. As a result, TpG and 
CpA dinucleotides are over-represented and 5-mCpG dinucleotide is under-represented in the 
genome of homeothermic species compared to the genome of ectothermic species (Varriable 
and Bernardi, 2006a; Varriable and Bernardi, 2006b; Jabbari and Bernardi, 2004; Bird, 1980). 
In Chapter 4, it was demonstrated that overall DNA methylation levels were significantly 
lower (~1.8 fold) in both ST and HCA samples compared to healthy dab liver. This is similar 
to the detection of severe DNA hypomethylation in human cancers (Lempiainen et al., 2011). 
The mechanism of global DNA hypomethylation and gene specific hypermethylation in 
human cancers is explained in a model referred to as demethylation-remethylation model (The 
impact of global DNA hypomethylation and its role in tumourigenesis is described in Chapter 
1, section 1.3.5.1.1). As described in Chapter 1 (section 1.3.5.1.1 and Figure 1.12) and 
Chapter 4 (section 4.4.5) in this model, tumour cells undergo an early transient stage of 
genome wide de-methylation followed by selective re-methylation and maintenance of DNA 
methylation. This model also takes into account the changes observed in the expression of 
DNMTs in different stages of tumourigenesis (Loriot et al., 2006; De Smet and Loriot, 2010). 
Furthermore, the demethylation-remethylation model describes how it is possible that both 
hypo- and hyper-methylated gene-specific regions coexist in human tumours (Loriot et al., 
2006). Although the DNA extracted from ST and HCA samples was globally 
hypomethylated, similar to cancers in humans, gene-specific hypermethylated regions were 
detected in dab tumours compared to ST and healthy dab liver. Furthermore, the expression 
and methylation of dnmt genes, as described in section 4.4.5, were altered in dab tumours. 
Therefore, it is proposed that possibly the same mechanism of demethylation-remethylation 
occurs in dab tumours as in mammalian tumours, which may explain the co-occurrence of 
both hypo- and hyper-methylated regions in dab tumours.  
 
 
 
 260 
 
6.3. Zebrafish and dab DNA methylation studies 
Dab is a non-model, un-sequenced flatfish. Therefore, any gene-specific DNA methylation 
studies at the gene level are challenging. In contrast, the zebrafish genome is sequenced and 
due to significant histopathological similarities between zebrafish tumours and corresponding 
human tumours (Lam and Gong, 2006), it is commonly used as a model for studying human 
tumourigenesis (Feitsma and Cuppen, 2008; Lawrence et al., 2009). However, there was no 
information available on the role of DNA methylation abnormalities in development of 
tumours in zebrafish. Therefore in Chapter 3, DNA methylation alterations were characterised 
in chemically induced HCC tumours in comparison with completely healthy zebrafish livers. 
The data gathered from this study not only provided the first evidence of alterations of DNA 
methylation in tumours of aquatic species but also indicated that DNA methylation alterations 
could have a significant role in the development of tumours of other fish species, such as dab. 
This strengthened the need for a methodology to study DNA methylation at the gene level in 
un-sequenced fish species. As a result in Chapter 4, MeDIP was combined for the first time 
with de novo high-throughput DNA sequencing (HTS). Gene specific studies in dab and 
zebrafish, as described in Chapters 3 and 4 (sections 3.4.2, 3.4.4 and 4.4.4), demonstrated that 
the expression and DNA methylation of genes involved in key pathways associated with 
cancer were altered in both species. For example, both Wnt-β-catenin and MAPK pathways 
were altered in dab and zebrafish tumours in regards to DNA methylation and transcription 
levels. Both pathways are associated with proliferation, apoptosis, differentiation and 
migration in cancers and are also commonly deregulated in human liver cancers (Dhillon et 
al., 2007; Firestein et al., 2008; Bikkavilli and Malbon, 2009; Lam et al., 2006). This finding 
is not unexpected as both pathways, like other parameters related to protein synthesis and 
energy production, are features that give tumour cells a selective advantage for clonal 
expansion and are required for high levels of proliferation. Furthermore, comparisons of DNA 
methylation profiles of human healthy liver and HCC with zebrafish healthy liver and HCC 
demonstrated that although at the individual gene level zebrafish and humans are different in 
regards to DNA methylation profiles, similar families of genes are altered in terms of DNA 
methylation in both species.  
Neither of the studies identified a significant overall inverse correlation between gene 
expression and DNA methylation. This is in agreement with other genome-wide methylome 
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and transcriptome studies (Lempiainen et al., 2011; Klug et al., 2010). As discussed in 
Chapter 1 (section 1.3.2.3) and Chapter 3 (section 3.4.4) this is not un-expected as the 
relationship between gene expression levels and DNA methylation is extremely complex and 
site sensitive (Van Vlodrop, 2011; Jones and Takai, 2001). As discussed in Chapter 1 (section 
1.3.2.3) several factors, such as identification of core CpG sites and the levels of methylation 
required for inactivation of transcription for each gene, are key in interpretation of the exact 
effects of DNA methylation upon transcription. Furthermore, the location of DNA 
methylation in respect to the transcription start site, the presence of core CpG sites within 
alternative promoters at intra- and intergenic CpG dinucleotides, the regulation of 
transcription of several genes by one promoter and the location of several core CpG sites 
outside the traditionally defined CGIs, are amongst many factors adding to the complexity of 
the relationship between gene expression and DNA methylation (Van Vlodrop, 2011; 
Siegfried and Simon, 2010; Jones, 1999; Jones and Takai, 2001). 
 
6.4. Hypotheses for formation of tumours in dab liver  
As discussed in Chapter 4 (section 4.4.6), several lines of evidence including; 1. Higher 
prevalence of tumours in dab sampled from sites (i.e. Cardigan Bay) with higher levels of 
pollutants such as EDCs (e.g. PCBs and PBDEs) and metals (e.g. Cd), 2. Increased expression 
of vtg, the biomarker of exposure to estrogen mimicking compounds, in tumour-bearing dab 
livers compared to healthy dab livers and 3. Detection of intersex by other research groups in 
these fish populations (Scott et al., 2007), indicated that chronic exposure to estrogenic 
pollutants may contribute to the development of liver tumours. Several studies have identified 
a link between exposure to chemicals such as EDCs (PCB, EE, E2) and heavy metals (e.g. As, 
Cd), changes in DNA methylation (Vandegehuchte and Janssen, 2011) and tumourigenesis in 
rodents and humans (Arita and Costa, 2009; Li et al., 2003; Lo and Sukumar, 2008; Skinner et 
al., 2010; Baccarelli and Bollati, 2009). For example, early postnatal exposure of rat neonates 
to environmentally relevant concentrations of the endocrine disrupters bisphenol A or 17β-
estradiol, induced DNA methylation changes in a range of genes, including genes involved in 
cell signalling, as early as postnatal day 10. Furthermore, these changes increased the risk of 
adult onset of precancerous lesions and hormonal carcinogenesis in the prostate of the 
exposed rats (Ho et al., 2006). In our study, DNA methylation and expression of several genes 
in both the non-genomic and genomic estrogenic pathways, possibly stimulated by estrogenic 
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compounds, were altered in dab tumours. These genes are involved in biological functions 
such as proliferation and growth, differentiation, cell cycle, apoptosis and oncogenesis 
(Bjornstrom and Sjoberg, 2005; Obrero et al., 2002; Safe and Kim, 2008). It is plausible that 
chronic exposure to EDCs, amongst other possible chemical contaminants, resulted in an 
initial alteration in DNA methylation. This is supported by detection of global 
hypomethylation in ST (Chapter 4, section 4.3.1) and significant alterations to the one-carbon 
cycle in ST, including a statistically significant higher level of SAH in dab tumours compared 
to healthy dab liver (Chapter 5, section 5.3.1). This suggests that the livers of these fish were 
epigenetically primed and more susceptible to development of tumours (further discussed in 
section 6.5). Additional epigenetic and genetic changes, for example in the non-genomic and 
genomic estrogenic pathway, may lead to oncogenesis in the liver of flatfish dab (as discussed 
in Chapter 4, section 4.4.6). In addition, the high occurrence of tumours in the livers of 
flatfish dab and the lack of detection of mutations in several commonly mutated genes in 
human cancers in the tumours of flatfish species (Rotchell et al., 2001a; Franklin et al., 2000), 
suggests that alterations in DNA methylation might have a key role in development of these 
tumours. 
These fish were captured from their natural habitat. Therefore, it is most likely that formation 
of liver tumours is multifactorial and elements other than exposure to pollutants are involved 
in the formation of these tumours. Indeed, the data presented in Chapter 5 as well as 
demonstrating a significant role for DNA methylation in development of liver tumours, 
showed a possible influence of diet on development of these tumours. The level of choline, 
for example, was statistically significantly lower in dab tumours compared to healthy dab 
liver. As discussed in Chapter 5 (section 5.4.3), this could be either as a result of reduced 
cellular uptake or deficiency in diet. Several studies have demonstrated a link between diets 
deficient in choline or other primary methyl donors, DNA hypomethylation and the 
development of tumours in rodents and humans (Michel et al., 2006; Locker et al., 1986; 
Wilson et al., 1984; Ghoshal and Farber, 1984; Sibani et al., 2002). However, no information 
was available on the diet of these fish (eg. stomach contents). Therefore, further research is 
required before any conclusions could be made on the effect of diet on liver tumour 
susceptibility in dab. 
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One important question is, “are the changes observed in the DNA methylation and expression 
of the genes involved in the genomic and non-genomic estrogenic pathway in dab tumours 
randomly caused or has this pathway been specifically affected due to exposure to EDCs, i.e. 
does each category of chemical compounds induce distinct DNA methylation and subsequent 
transcriptional changes upon exposure?” Phenobarbital (PB) is a non-genotoxic compound 
that can cause tumours through the constitutive androstane receptor (CAR) pathway in the 
liver of treated rodents. Lempiainen et al., (2011) demonstrated that treatment with PB (in the 
absence of a mutagenic compound) causes non-random and tissue-specific changes in DNA 
methylation and transcription. While Cyp2b10, one of the main genes affected through the 
CAR pathway, was hypomethylated and over-expressed in the liver of treated mice, it was not 
affected in non-tumour bearing kidney. Furthermore, there was no significant overlap between 
DNA methylation or transcriptional changes observed in the liver and kidney of the treated 
mice. Several other studies have also indicated that at various stages of PB-induced 
tumourigenesis DNA methylation and transcription changes are non-random (in the absence 
or presence of mutagenic compounds) (Phillips and Goodman, 2009a; Phillips et al., 2009b; 
Bachman et al., 2006). Further evidence on the dependency of DNA methylation profile on 
the causative agent comes from a study demonstrating that HCC tumours induced by hepatitis 
C virus (HCV) or hepatitis B virus (HBV) have different methylation profiles (Pei et al., 
2009). These studies all give rise to the idea that each compound has a specific DNA 
methylation “fingerprint”. This further supports our finding that DNA methylation and 
changes in gene expression observed in dab tumours were enriched in genes of particular 
pathways, for example non-genomic and genomic estrogenic pathway and pathways 
commonly associated with general hallmarks of cancer. 
However, the initial DNA methylation changes (referred to as driver methylation) should be 
separated from DNA methylation changes that occur as a consequence of tumour formation 
(referred to as passenger methylation) (Herceg and Vaissiere, 2011). As mentioned earlier, 
some DNA methylation changes (e.g. changes in genes of the energy pathways) are not 
unexpected. These changes provide tumour cells with a selective advantage for clonal 
expansion. Therefore, to identify appropriate genes with DNA methylation changes as 
biomarkers of exposure to non-genotoxic carcinogens, it is important to separate them from 
passenger methylations and DNA methylation changes that are dependent on the type of 
tumour (described in Chapter 1, Table 1.3). Furthermore, tumours are comprised of different 
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cell populations (e.g. inflammatory cells, hepatic cells, etc). Differentiation and cell 
characterisation is highly regulated by epigenetic mechanisms as described in Chapter 1 
(section 1.3.4.3). Therefore, it is possible that some of the DNA methylation changes merely 
reflect the differences in cell types. However, most likely these changes would be outweighed 
by the scale of the differences in DNA methylation between tumour and healthy cells. 
 
6.5. The importance of ST in this study and the impact of the epigenetic progenitor 
model of tumourigenesis  
As described in Chapter 1 (section 1.3.5.3), a significant change in the order of events leading 
to tumourigenesis has been proposed. This change is based on the recognition of the fact that 
epigenetic abnormalities, independent of changes in the genetic material, can cause a stable 
and sufficient change in gene expression which subsequently can lead to alteration in the 
phenotype (Moggs et al., 2004). Furthermore, it is becoming widely accepted that epigenetic 
alterations, especially the initial global DNA hypomethylation, occur at early stages of 
tumourigenesis even prior to detection of mutations. Evidence, including from our studies 
conducted in “apparently healthy” surrounding tissues as described in Chapter 1 (section 
1.3.5.3) and Chapter 4 (sections 4.4.1) supports this claim. These various studies support the 
proposal of an alternative model of tumourigenesis known as epigenetic progenitor model of 
tumourigenesis suggested by Feinberg et al (2006). It was proposed in chapter 4 (sections 
4.4.1 and 4.4.7) that development of dab HCA tumours appears to support the epigenetic 
progenitor model of tumourigenesis. This was in part based on the detection of statistically 
significant global DNA hypomethylation in ST compared to healthy dab liver and the 
detection of gene-specific differences in DNA methylation levels, in the absence of change in 
the overall DNA methylation levels, in the ST compared to HCA samples. As demonstrated 
by Ho et al (2006) in rats and described in section 6.4, early life stage exposure to epigenetic 
modifying chemicals such as EDCs can cause hormonal-dependent adult onset of tumours. 
Detection of similar lower levels of global DNA methylation in dab ST and HCA samples is 
also suggestive of the possibility of early life stage changes to the epigenome as a result of 
exposure to environmental pollutants, such as EDCs and higher susceptibly to hormonal- or 
age-dependent adult onset of liver tumours in this fish species.  
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However, one possibility that could also explain the observed global DNA hypomethylation 
in ST and contradict the epigenetic progenitor model of tumourigenesis, is that the detected 
global DNA hypomethylation is secondary to formation of tumours (i.e. the tumour has 
caused hypomethylation of the adjacent tissue). However, the tissues categorised as ST (used 
in Chapters 4 and 5), are from any histopathologically healthy section of dab liver and are not 
necessarily immediately adjacent to the tumour. This, although not entirely, minimises the 
possible secondary effects of tumours. Additionally, it was demonstrated in Chapter 5 that 
although HCA and ST are histopathologically different, their metabolic profiles within the 
one-carbon cycle are similar and both differed from healthy dab liver (while ST and 
completely healthy dab liver are histopathologically similar). This, as well as strengthening 
the theory proposed in Chapter 4 (section 4.4.7), demonstrates the importance of using both 
ST and completely healthy liver samples in any studies. For example, in the study conducted 
by Southam et al. (2008), apparently healthy tissue dissected from the tumour-containing dab 
liver was used as control tissue for characterising the metabolic changes during hepatic 
tumourigenesis in dab. However, as demonstrated in this thesis and implied by the epigenetic 
progenitor model of tumourigenesis, ST cannot be viewed as a healthy control tissue. 
Therefore, caution should be employed in the interpretation of such studies.  
As mentioned in Chapter 1 (section 1.3.5.3) and Chapter 4 (section 4.4.8), the data presented 
in this thesis and the acceptance of the epigenetic progenitor model of tumourigenesis have 
several outcomes. This model will change our understanding of the biology of cancer cells. 
Identification of appropriate epigenetic biomarkers can lead to detection of tumours earlier 
than the stage currently known as benign pre-neoplastic lesion (Feinberg et al., 2006; Herceg 
and Vaissiere, 2011). Furthermore, early epigenetic changes in cancer cells are reversible. 
This provides a suitable treatment opportunity and new targets for design of antineoplastic 
drugs (the design of HDAC inhibitors and DNA methyltransferase inhibitors are currently an 
active research area) (Moggs et al., 2004; Feinberg et al., 2006). Furthermore, in the context 
of toxicity testing, whether in laboratory animals to assess the risk to humans or in aquatic 
species relevant to the natural environment, epigenetic changes are not currently a standard 
feature of safety assessment. Part of the reason for this is the inability to interpret the findings 
in relation to potential adverse outcome without a more complete knowledge of the 
fundamental relationships between specific changes and disease. There is also the need for 
identification of suitable model systems for evaluation of chemical induction of epigenetic 
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changes as well as suitable techniques and endpoints (Goodman et al., 2010). However, the 
accumulating evidence for the contribution of DNA methylation alteration in tumourigenesis 
and adult-onset of disease produced by numerous non-genotoxic and genotoxic carcinogens 
(Goodman et al., 2010; Moggs et al., 2004; Legler, 2010; Guerrero-Bosagna et al., 2005) and 
the established carcinogenic effect of DNA methylation changes following deficiencies in 
choline and other primary methyl-donors (Michel et al., 2006; Locker et al., 1986; Wilson et 
al., 1984; Ghoshal and Farber, 1984; Sibani et al., 2002), indicates that such mechanisms 
should not be ignored. Nevertheless, this does not necessarily imply a concern in relation to 
the aquatic environment regarding methylation changes in the absence of genetic toxicity. 
Unlike the assumptions made about genotoxic carcinogens, a pragmatic threshold level of 
exposure to non-genotoxic carcinogens or dietary deficiency may be required for a clear 
impact on cancer development. However, methylation of CpG islands increases the rate of 
mutations at these sites (Discussed in Chapter 1, section 1.3.5.1.3) thereby increasing the risk 
of development of tumours. This information could potentially impact the future of regulatory 
toxicology and environmental biomonitoring. 
 
6.6. Gaps in knowledge and future work  
1. The combination of MeDIP with zebrafish CGI tiling microarray in Chapter 3 and with 
HTS in Chapter 4 provided a valuable relative measurement of DNA methylation levels. An 
alternative approach would be to achieve an absolute level of DNA methylation especially for 
normal adult zebrafish liver.  
2. In Chapter 4, it is possible that EDCs in association with other categories of compounds 
including genotoxic chemicals, such as PAHs are causing the changes observed in ST and 
HCA samples. However, in this study the existence of ample evidence strongly supported the 
role of EDCs in development of these tumours. The studies presented in this thesis provide a 
strong justification for expanding this work to chemical exposure studies in controlled 
laboratory environments. Furthermore, such studies could be used to investigate the 
possibility of transgenerational epigenetic inheritance. As mentioned in Chapter 1, gene 
expression is regulated through a highly interactive network of epigenetic and non-epigenetic 
factors. If environmental factors can cause a heritable change to the epigenome with 
phenotypic consequences in an individual organism, it is also probable that if these changes 
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occur in germ cells they could affect generations to come (Whitelaw and Whitelaw, 2008; 
Anway et al., 2005; Anway and Skinner, 2006). This is a phenomenon known as 
transgenerational epigenetic inheritance which is briefly described in Chapter 1 (section 
1.3.5.2). Therefore, it is possible that the high prevalence of liver tumours, induced by 
environmental stressors in certain populations of flatfish dab, is epigenetically transmitted 
through multiple generations (Figure 6.1, modified from Turner, 2009).    
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Figure 6.1. The complex network of epigenetic and non-epigenetic factors involved in the 
regulation of responses to environmental factors. The mechanism of response to 
environmental stimuli becomes more complex when considering that epigenetic modifications 
are not limited to modifications of histones and cytosine bases. Non-histone regulatory 
proteins such as transcription factors (TFs) undergo chemical modifications via histone 
modifying enzymes. This relationship becomes even more complex when considering that 
chemical modifications are interdependent and interactive. Furthermore, this figure 
demonstrates how a change in the epigenome induced by environmental stressors may be 
transmitted to multiple generations. This figure was modified from a review by Turner, 2009. 
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3. As mentioned in section 6.4, some of the changes observed in DNA methylation between 
various categories of samples could be due to differences in the ratios of various cell 
populations (e.g. hepatic cells, inflammatory cells, different stages of HCA tumours). A pure 
cell population can be achieved with techniques such as laser capture microdissection 
(LCMD). Furthermore, LCMD can be used to dissect cells at various stages of 
tumourigenesis. Such sampling could help to investigate the order of events (i.e. the 
occurrence of DNA hypomethylation at very early stages of tumourigenesis). The work 
presented in this thesis justifies the need for optimisation of methods for studying DNA 
methylation changes in LCMD samples. 
4. In Chapter 5, the concentrations of the metabolites involved in the one-carbon cycle were 
quantified as peak area, and the relative change between the three categories of interest (HCA, 
ST, healthy dab liver) were investigated. This work can be followed up by using chemical 
standards to measure the absolute concentrations of these metabolites in dab tissue.  
 
6.7. Concluding remarks 
The work presented in this thesis demonstrated for the first time the involvement and 
alteration of DNA methylation in liver tumours of any aquatic species and provided a suitable 
strategy for studying DNA methylation in un-sequenced species. Furthermore, this work 
provided some evidence of a link between environmental stressors, epigenetic modifications 
and phenotypic end points. The data presented in this thesis demonstrated the need for 
consideration of the role of epigenetic mechanisms in regulation of responses of aquatic 
species to environmental toxicants which could potentially have a significant impact in 
procedures currently in place for environmental toxicity safety assessments and 
biomonitoring. Above all, it has opened a new research area in the field of aquatic biology 
and with it, brings many questions.  
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